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Abstract 
Introduction and Objectives Routinely recorded clinical data held in administrative healthcare 
databases have demonstrated utility in Randomised Controlled Trials (RCTs), such as informing 
recruitment feasibility assessments, assisting with recruitment and measuring certain study 
outcomes. Furthermore, routinely recorded non-clinical data, such as data regarding employment 
and taxation have the potential to inform the measurement of outcomes including health economic 
analyses. However, limitations with accuracy, access and feasibility have been identified.   
This research systematically reviewed the use of routinely recorded data in the UK in RCTs and 
agreement of routinely recorded data compared to data collected using standard prospective 
research methods. Subsequently, the accessibility, quality, agreement and feasibility of using 
routinely recorded data compared to data collected using standard prospective methods in a UK RCT 
assessing antiepileptic drug treatments for individuals newly diagnosed with epilepsy were assessed.    
Methods A systematic review was undertaken to assess the use of routinely recorded data in the UK 
in RCTs and to compare agreement between routinely recorded data and data collected using 
standard prospective methods.  The quality of routinely recorded data was assessed according to a 
number of criteria, such as the degree of missing data. The agreement of routinely recorded data 
compared to data collected using standard methods in a UK RCT included calculation of Cohen’s 
Kappa and construction of Bland Altman Plots for categorical and continuous variables, respectively. 
Assessment of the resources required for protocol development, application for data, accessibility, 
data preparation and attributes including data coverage and agreement were included in the 
assessment of feasibility.    
Results The reviews identified few published studies using routinely recorded clinical data in the UK 
in RCTs. Mortality data were most commonly used and demonstrated the greatest agreement 
compared to data collected using standard methods. There was no evidence for the use of routinely 
recorded data from non-clinical sources, such as governmental employment and taxation data in 
clinical RCTs.  
There was a significant degree of missing routinely recorded data identified for variables and 
outcome measures relevant to the case study RCT, compared to data collected using standard 
methods. Where paired data were available, agreement was not satisfactory for the majority of 
comparisons, including the assessments of seizure occurrence and adverse events. Agreement was 
satisfactory for two comparisons; date of prescription of antiepileptic drugs and healthcare resource 
use, assessed using the dates of RCT follow-up assessments. The poor accessibility, prolonged period 
of application and cost for data access together with the poor data quality and agreement resulted 
in the limited feasibility for use of routinely recorded data in this RCT assessing antiepileptic drug 
treatments for epilepsy.   
Conclusions There is currently very limited experience of using routinely recorded data in UK RCTs 
for outcomes other than mortality and healthcare resource use for economic evaluations. In this 
research the accessibility and feasibility of use were limited and degree of missing data and 
agreement compared to data collected using standard methods unsatisfactory. The results of this 
research suggest routinely recorded data in the context of prospective clinical research could be an 
important source of additional data, for example to identify additional events such as seizures not 
recorded using standard methods. The results suggest that use of routinely recorded data as the 
primary data source or as a means of validating data collected using standard methods, would be 
limited. Recommendations include suggestions for improving the access to routinely recorded data 
for research, development of an integrated electronic health record for use in both clinical practice 
and research and further assessment of the attributes and ‘optimal mix’ of routinely recorded data 
compared to data collected using standard methods.  
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Chapter One 
Introduction: Epilepsy, Research and Routinely Recorded 
Data 
1.1 Research Overview 
In Chapter One, epilepsy and the current prospective research methods used to assess 
treatments for epilepsy will be discussed. The case study Randomised Controlled Trial 
(RCT), the Standard and New Antiepileptic Drugs II (SANAD II) RCT will be introduced. 
Routinely recorded data in the UK and the potential for use in clinical research will 
subsequently be introduced before finally the objectives of this research will be presented.  
In Chapter Two the use of routinely recorded data in RCTs in the UK will be reviewed and in 
Chapter Three the agreement between UK routinely recorded data compared to data 
collected using standard methods in prospective studies will be assessed in a systematic 
review.  
In Chapter Four, sources of routinely recorded data in the UK relevant to the outcomes of 
SANAD II will be reviewed and sources where routinely recorded data are accessible for 
individuals recruited into SANAD II will be identified.  
In Chapter Five, the methods for the assessment of the attributes of routinely recorded 
data retrieved from electronic medical records compared to data collected using standard 
prospective methods in SANAD II will be presented. The assessment of seizure occurrence, 
diagnosis and classification of epilepsy in routinely recorded datasets will be assessed in 
Chapter Six and variables and outcome measures relevant to the follow-up of participants 
in SANAD II will be assessed in Chapter Seven. The feasibility and efficiency of accessing and 
using routinely recorded data for participants in SANAD II will be assessed in Chapter Eight.  
In Chapter Nine, the results for the objectives of this research will be discussed and 
conclusions presented. Subsequently, recommendations for improving the use of routinely 
recorded data in research will be proposed and avenues for further research will be 
suggested.        
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1.2 An Introduction to Epilepsy 
 
1.2.1 Definitions 
Seizures are the manifestation of paroxysmal, uncontrolled, abnormal electrical discharge 
of neurons within the cerebral hemispheres [1, 2].  
Epilepsy is a common, chronic neurological condition with wide reaching medical and 
psychosocial implications characterised by recurrent and unprovoked seizures [1, 2].   
The annual age-adjusted incidence of epilepsy is estimated to be between 40 and 70 per 
100 000 persons [3]. The incidence rate is greatest at the extremes of life [3, 4]. 
The prevalence of epilepsy is 0.5-1%. In addition, 5% of the population, predominantly in 
the first year of life and those over 75 years of age, will experience a single unprovoked 
seizure or acute symptomatic seizure [3]. 
With no predilection for age or sex, epilepsy affects all members of society.  
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1.2.2 Classification  
1.2.2.1 Seizures 
The International League Against Epilepsy (ILAE) Classification (1981) proposed the first 
widely accepted criteria for classification of seizure type [5]. A multitude of seizure types 
were included, broadly classified as ‘partial’, originating from a focal, cortical onset in one 
hemisphere or ‘generalised’, originating in deeper midline structures and propagating to 
both hemispheres simultaneously. Where uncertainty remained, seizures were deemed 
‘unclassified’. The ILAE classification has undergone numerous iterations and the most 
recent proposal is The ILAE Operational Classification of Seizure Types (2017) [6]. Much of 
the terminology has been updated, for example ‘partial’ has been replaced with ‘focal 
onset’ seizures, but the broad classification of seizure types is consistent. Figure 1.1 
summarises the most recent classification of seizure types.  
 
Figure 1.1: The ILAE Operational Classification of Seizure Types (2017) [6] 
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1.2.2.2 Epilepsy and Epilepsy Syndromes 
Following the diagnosis of seizures, a diagnosis of epilepsy can be considered. The ILAE 
Practical Clinical Definition of Epilepsy (2014) [7] proposes the most recent criteria for 
diagnosis and updates the guidance published in 2005 [8]. The guidance proposes that at 
least two unprovoked seizures occurring greater than 24 hours apart are required for a 
diagnosis of epilepsy. Additionally, individuals experiencing a single seizure with a 
probability of subsequent seizures similar to the general recurrence risk following two 
unprovoked seizures may also qualify for a diagnosis.  However, calculating such 
probabilities is troublesome in both clinical practice and the research environment.   
The ILAE Revised Classification of the Epilepsies first included the classification of epilepsies 
and epilepsy syndromes in addition to seizures in 1989 [9]. The ILAE Classification of the 
Epilepsies (2017) is the most recently updated version [10] and the present three levels. 
Firstly, seizure type according to the 2017 ILAE Seizure Classification [6] is diagnosed. 
Subsequently epilepsy type is diagnosed and may include focal epilepsy, generalized 
epilepsy, combined generalized and focal epilepsy or unknown epilepsy. Finally, epilepsy 
syndrome is considered. The process is summarised in Figure 1.2. This recent classification 
considers aetiology at each stage as specific aetiology may influence specific treatment, 
previously discussed in Section 1.2.2.   
Figure 1.2: The ILAE Classification of the Epilepsies (2017) [10] 
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1.2.3 Pathogenesis and Epidemiology of Epilepsy   
The occurrence of seizures has been described throughout history but the recognition of 
uncontrolled discharge from cerebral neurones as the cause was not proposed until the 
19th century. The electroencephalogram (EEG) was developed to assess this abnormal 
neuronal activity and it was rapidly appreciated that specific seizure types were 
characterised by specific EEG characteristics [1].     
Despite recent advances in understanding the pathogenesis of seizures, in a large 
proportion of individuals with a diagnosis of epilepsy the aetiology cannot be defined, the 
majority of which experience generalised seizures. Aetiology in individuals with focal 
epilepsies can more readily be identified [2]. Of the individuals with newly diagnosed focal 
epilepsy enrolled in the National General Practice Study of Epilepsy (NGPSE) 32% has a 
clear aetiology and 9% a probable aetiology [11]. Cerebrovascular disease was the most 
common precipitant [11] with this aetiology also occurring in 11% of patients with adult 
onset epilepsy in the Rochester epidemiology studies [3]. Additional aetiologies included 
intracranial tumours, infection and acute or remote trauma [11]. More recently, 
understanding of the genetic architecture of specific epilepsies has resulted in a number of 
specific causes being identified. For example, Dravet’s syndrome is associated with a 
mutation in the type 1 voltage gated sodium channel-encoding SCN1A gene and an 
abnormal glucose transport protein type 1 (GLUT1) and can result in seizures and 
developmental delay in infancy [12]. However, a complex polygenic inheritance is observed 
in the majority of idiopathic and cryptogenic generalised epilepsies, as demonstrated by 
the high concordance in monozygotic twins with generalised epilepsies, reported at 65% in 
some studies [13].   
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1.2.4 Investigations  
Epilepsy is a clinical diagnosis and investigations are not mandated. However, certain 
investigations are frequently performed during the assessment of an individual with newly 
diagnosed epilepsy. Such investigations may inform the classification of seizures and 
epilepsy, assess for an underlying cause and resultantly, inform the therapeutic approach.  
Magnetic Resonance Imaging (MRI) provides information on the anatomy of the brain and 
can identify structural abnormalities, such as space-occupying lesions or cortical 
abnormalities that may require or be amenable to surgery. Computed Tomography (CT) 
may also be useful in selected cases to exclude space-occupying lesions where there is a 
low pre-test probability or in cases where MRI is contraindicated.  
Electroencephalography (EEG) provides information regarding the neuronal activity during 
the ictal (seizure) and inter-ictal (non-seizure) phases and can inform the diagnosis and 
classification as well as informing the pre-surgical evaluation, in appropriate patients.  
 
1.2.5 Impact of Epilepsy 
The World Health Organisation defines Quality of Life (QOL) as "an individual’s perception 
of their position in life, in the context of the culture and value systems in which they live, 
and in relation to their goals, expectations, standards, and concerns. It is a broad ranging 
concept, effected in a complex way by the person's physical health, psychological state, 
level of independence, social relationships and their relationships to salient features of 
their environment" [14].  
An issue of primary importance in the management of patients with epilepsy is the 
maximisation of QOL and this is the ultimate aim of treatment. Broadly, there are two 
major dimensions that impact upon patients QOL; clinical and psychosocial variables.  
Clinical variables including adverse events of antiepileptic drugs and seizure frequency and 
severity have a strong negative association with subjective health status and perception of 
QOL of patients with epilepsy [15].In the management of epilepsy, clinical issues need to be 
addressed to ensure QOL is maximised for the individual [16]. 
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Psychosocial variables including psychological distress, adjustment and coping, loneliness 
and stigma perception contribute significantly to the variance in patients self-reported 
quality of life judgements [17]. Finally, psychological co-morbidity including anxiety and 
depression occur at a higher incidence in patients with epilepsy compared to the general 
population and are associated with a reduced QOL. Therefore, addressing both anxiety and 
depression can exert a positive influence on QOL [16]. Finally, a diagnosis of epilepsy may 
have an impact on an individuals’ eligibility for specific roles in society, including roles in 
employment. For example, employment as a lifeguard would have to cease, although this 
may only be temporary. Furthermore, following a diagnosis of seizure or epilepsy in the UK, 
there are legal restrictions on driving licensing. Following an initial seizure, driving must 
cease and the Driver and Vehicle Licensing Agency (DVLA) must be informed. This applies 
for holders of both Group 1 (car and motorcycle drivers) and Group 2 (heavy goods vehicle 
drivers) licenses. The duration of suspension will depend on a number of factors including 
specific diagnosis, frequency of seizures, timing of seizures (daytime, nocturnal), treatment 
and type of license (Group 1, 2). In the majority of circumstances for Group 1 licenses, 12 
months are required free from seizures before a license can be re-issued [18].    
1.2.6 Treatment 
1.2.6.1 Prognosis 
The NGPSE identified that the prognosis of epilepsy is favourable, with 65-85% of patients 
entering long-term remission, more likely in patients with newly diagnosed epilepsy and 
receiving early treatment. Furthermore, good response to initial treatment and a prolonged 
period of remission from seizures are associated with an improved prognosis [19]. 
Mortality is highest in the initial period following diagnosis, often related to the underlying 
aetiology, although Sudden Unexpected Death in Epilepsy Patients (SUDEP) is recognised 
and raised mortality rate is observed throughout the course of epilepsy [19].   
1.2.6.2 Antiepileptic Drugs 
Antiepileptic drugs (AEDs) remain the mainstay of treatment for patients with epilepsy. 
Seventy percent of patients with epilepsy will experience sustained remission from seizures 
following initiation of AED treatment [20, 21]. The number of AEDs has increased 
dramatically in recent years and there are now over 20 AEDs licensed and available [22].  
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Traditionally, carbamazepine and sodium valproate have been the recommended first line 
AEDs for focal and generalized epilepsy, respectively and monotherapy considered the 
appropriate initial approach. However, longer term RCTs assessing clinical and cost 
effectiveness such as the Standard and New Antiepileptic Drugs Trial (SANAD) provide 
evidence to support lamotrigine as a first line treatment for focal epilepsy, whilst also 
demonstrating that gabapentin and topiramate are poor first line treatments. Similarly 
topiramate and lamotrigine were shown to be inferior to valproate as a first line treatment 
for generalized or unclassified epilepsy [23, 24].  
As a result of the number of available AEDs and complex evidence base, treatment 
guidelines have been published by national bodies such as the National Institute for Health 
and Care Excellence (NICE) [25] and medical associations such as the International League 
Against Epilepsy (ILAE) [26]. Guidelines aim to synthesise the available evidence and make 
appropriate recommendations, but the strength of recommendations is necessarily limited 
by the quality of evidence available. Due to the limited evidence available rather than 
recommend a single drug, NICE, in their most recent update of their epilepsy guidelines, 
recommend a number of AEDs that should be considered  ‘first-line’ in the treatment of a 
range of seizure types and epilepsy syndromes. AED options by seizure type are 
summarised in Box 1.1 [25]. An appropriate AED is selected following discussion between 
clinician and patient. Perhaps the most important choice being for women of child bearing 
age with genetic generalized epilepsy, where sodium valproate should be used with caution 
due to the risks of teratogenicity and greater risks of neurodevelopmental sequelae [27], 
where likely less effective but safer options such as levetiracetam and lamotrigine may be 
selected [28].  
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 Box 1.1: NICE Guidance: Antiepileptic Drug Options by Seizure Type [25] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*At the time of publication of the main NICE guidance (January 2012), this drug did not have UK marketing 
authorisation for this indication and/or population. Informed consent should be obtained and documented.  
†At the time of publication of the main NICE guidance (January 2012), this drug did not have UK marketing 
authorisation for this indication and/or population. Informed consent should be obtained and documented in 
line with normal standards in emergency care.  
  
  
Seizure type First line  Adjunctive  Others that may be 
considered on referral 
to tertiary care 
Do not offer (may worsen 
seizures) 
Generalised 
tonic-clonic 
Carbamazepine, 
lamotrigine, 
oxcarbazepine*, 
sodium valproate 
Clobazam*, lamotrigine, 
levetiracetam, sodium 
valproate, topiramate 
 If there are absence or 
myoclonic seizures, or if 
juvenile myoclonic epilepsy is 
suspected: carbamazepine, 
gabapentin, oxcarbazepine, 
phenytoin, pregabalin, 
tiagabine, vigabatrin 
Tonic or atonic Sodium valproate Lamotrigine* Rufinamide*, 
topiramate* 
Carbamazepine, gabapentin, 
oxcarbazepine, pregabalin, 
tiagabine, vigabatrin 
Absence Ethosuximide, 
lamotrigine*, sodium 
valproate 
Ethosuximide, 
lamotrigine*, sodium 
valproate 
Clobazam*, 
clonazepam, 
levetiracetam*, 
topiramate*, 
zonisamide* 
Carbamazepine, gabapentin, 
oxcarbazepine, phenytoin, 
pregabalin, tiagabine, 
vigabatrin 
Myoclonic Levetiracetam*, 
sodium valproate, 
topiramate* 
Levetiracetam, sodium 
valproate, topiramate* 
Clobazam*, 
clonazepam, 
piracetam, 
zonisamide* 
Carbamazepine, gabapentin, 
oxcarbazepine, phenytoin, 
pregabalin, tiagabine, 
vigabatrin 
Focal Carbamazepine, 
lamotrigine, 
levetiracetam, 
oxcarbazepine, 
sodium valproate 
Carbamazepine, 
clobazam*, 
gabapentin*, 
lamotrigine, 
levetiracetam, 
oxcarbazepine, sodium 
valproate, topiramate 
Eslicarbazepine 
acetate*, lacosamide, 
phenobarbital, 
phenytoin, pregabalin*, 
tiagabine, vigabatrin, 
zonisamide* 
 
Prolonged or 
repeated seizures 
and convulsive 
status epilepticus 
in the community 
Buccal midazolam, 
rectal diazepam†, 
intravenous 
lorazepam 
   
Convulsive status 
epilepticus in 
hospital 
Intravenous 
lorazepam 
Intravenous 
diazepam, buccal 
midazolam 
Intravenous 
phenobarbital 
Phenytoin 
  
Refractory 
convulsive status 
epilepticus 
Intravenous 
midazolam†, 
propofol† (not in 
children), thiopental 
sodium† 
   
 
 
10 
 
1.2.6.3 Adverse Events  
An ‘adverse event’ can be defined as the occurrence of an undesirable symptom or event 
during treatment with an AED that may or may not be caused by the AED [29]. Similar 
terms such as adverse effect and adverse drug reaction imply a more direct cause and 
effect relationship. AEDs are associated with four types of adverse events:   
- Acute Dose Related Toxicity 
- Acute Idiosyncratic Toxicity 
- Chronic Toxicity 
- Teratogenicity  
Adverse events associated with AEDs are troublesome in up to 69% of adult patients with 
epilepsy [30] and 30% of patients experience treatment failure during initial monotherapy, 
often due to the occurrence of adverse events [11]. Furthermore, adverse events resulting 
from AED therapy significantly impact on psychological and social functioning, and the 
overall patient perceived impact of epilepsy [31].   
 
1.2.6.4 Failure of First-Line Treatment 
The first line AED will fail in a significant proportion of patients due to lack of efficacy, 
intolerability or a combination of both, regardless of AED [32]. Clinical factors including 
seizure type and EEG result may be associated with treatment failure although notably, 
choice of AED is not a significant predictor of treatment failure [33]. Following a first 
treatment failure, the probability of 12 month remission remains high; overall 70% of 
patients will achieve a 12 month remission, 80% with a first treatment failure due to 
adverse events and 65% with treatment failure due to inadequate seizure control [34]. 
Inevitably, the more AEDs that a patient fails due to lack of seizure control, the less likely 
that subsequent treatment trials will be successful  [21]. The ILAE has defined 
pharmacoresistance as ’failure of adequate trials of two tolerated, appropriately chosen 
and used anti-epileptic drug schedules whether as monotherapy or in combination to 
achieve sustained seizure freedom’ [35].  A proportion of patients will achieve seizure 
control following further AED changes [34] and therefore in patients experiencing 
treatment failure an alternative AED monotherapy or rational AED polytherapy may be 
considered.   
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1.2.6.4.1 Non-Pharmacological Treatment Approaches 
Non-pharmacological treatment approaches may be considered in individuals with 
pharmacoresistant epilepsy and in some circumstances as first-line treatment. 
Neurosurgical approaches include resection of structural lesions such as space-occupying 
lesions. ‘Epilepsy surgery’ may be indicated and involves resection of a non-eloquent 
localised area of the brain, known to be the epileptogenic focus. In such cases thorough 
pre-surgical evaluation is required including but not limited to imaging, EEG and 
psychological assessment. Novel surgical approaches may also be employed and include 
vagal nerve or deep brain stimulation. In paediatric patients such as those with an 
abnormal glucose transport protein type 1 (GLUT1) the ketogenic diet may be effective.   
 
 
  
12 
 
1.3 Randomised Controlled Trials in Epilepsy  
The National Institute for Health and Care Excellence (NICE) defines the Randomised 
Controlled Trial (RCT) as ‘a study in which a number of similar people are randomly 
assigned to two (or more) groups to test a specific drug, treatment or other intervention. 
One group (the experimental group) has the intervention being tested; the other (the 
comparison or control group) has an alternative intervention, a dummy intervention 
(placebo) or no intervention. Outcomes are measured at specific intervals and the 
difference in response between groups assessed statistically’ [36].  
The Randomised Controlled Trial (RCT) is a rigorous research technique, minimising 
allocation bias and remaining the standard for regulatory approval of new treatments in 
healthcare. Consequently, the majority of RCTs assessing the effectiveness of AEDs in the 
treatment of epilepsy are undertaken to meet the requirements of regulatory authorities 
such as the Food and Drug Administration (FDA) in the United States or the European 
Medicines Agency (EMA). RCTs assessing new AEDs are usually undertaken first in adults 
with refractory focal epilepsy who have failed multiple previous AEDs and who experience 
regular seizures. The initial comparison is typically with placebo in order to demonstrate 
statistically significant superiority for efficacy. The initial regulatory licensing is frequently 
for use as an add-on treatment for refractory focal epilepsy. RCTs may then be undertaken 
in other populations including children, patients with refractory generalized seizures and 
specific epilepsy syndromes and finally as monotherapy treatment for epilepsy. However, 
such RCTs sponsored by the pharmaceutical industry primarily aim to fulfil regulatory 
requirements for licensing rather than inform the clinical treatment of epilepsy and have 
limited external validity. Typically, an eight week baseline is followed by a 16 week study 
duration, too short to provide evidence about longer term clinical and cost effectiveness 
that patients and health services require. There are few RCTs comparing different AED add 
on regimens with the majority of the RCT evidence provided through regulatory placebo 
controlled add-on RCTs. Furthermore, the outcome reported is commonly a measure of 
change in seizure frequency; the FDA preferring median reduction in seizure frequency and 
the EMA preferring the proportion of patients with a 50% or greater reduction in seizure 
frequency. Neither outcome is particularly meaningful to patients. Placebo controlled 
studies are often followed by open label extension studies which may provide longer term, 
but uncontrolled, data about AEDs. Whilst such designs may provide additional safety data, 
they are uninterpretable from the point of view of efficacy due to selection bias, 
heterogeneity, and their uncontrolled design [37].  
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Publically funded, pragmatic RCTs assessing long term clinical and cost effectiveness 
provide data more informative and directly relevant to routine clinical practice. However, 
pragmatic RCTs are expensive, time-consuming and resource intensive. 
Techniques such as network meta-analysis can usefully summarise the available data. This 
approach uses data from RCTs (placebo controlled) although is important to emphasize 
that any comparison is indirect and not randomized. Network meta-analyses make a 
number of assumptions, in particular that the population of patients recruited to RCTs is 
similar and consistent. This assumption is most likely violated in refractory epilepsy as the 
typical patient recruited to trials in the late 1980s and early 1990s is systematically 
different to a current typical patient. Current patients are likely more refractory given the 
range of treatments now available to try before considering joining a trial, and trials are 
conducted over many more centres world-wide than previously. The escalating placebo 
response rate is likely due to multiple causes, however may provide evidence for this 
change in case-mix [38].  
It is important to highlight the limitations associated with RCTs. Important safety data will 
arise from designs other than RCTs such as observational record-linkage studies. As such, 
coordinated post marketing surveillance is required to minimize risk to patients, 
particularly important for rare but life threatening events such as felbamate associated 
liver failure, long terms events such as vigabatrin retinopathy [39] and retigabine 
pigmentation and retinopathy [40], and teratogenic effects [41]. As a result of selection 
bias, RCTs may lack external validity. Significant ethical concerns have been raised such as 
using placebo controlled RCTs during the initial development of antiretroviral drugs. RCTs 
may be less appropriate or feasible in certain sectors of medicine, including RCTs assessing 
surgical or psychological interventions [42]. A major limitation associated with RCTs, is cost. 
The infrastructure required has resulted in a burgeoning corporate enterprise, where a 
phase III RCT may cost up to $30 million [43]. Contract Research Organisations have now 
become an industry worth $25 billion [44] and such high pharmaceutical development 
costs may be cited as justification for inflated prescription drug costs. As a result of high 
costs, expectation of positive results has increased and evidence suggests that industry 
funded RCTs are more likely to achieve positive results than publically funded RCTs [45].  
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Considering the clinical treatment of epilepsy with antiepileptic drugs, publically funded, 
pragmatic RCTs assessing the longer term clinical and cost effectiveness provide the most 
informative data. Published in 2007, The Standard and New Antiepileptic Drug Trial 
(SANAD) is a notable example, providing evidence to support lamotrigine as a first line 
treatment for focal epilepsy [24]. The results subsequently influencing national guidelines 
[25]. However, pragmatic RCTs are expensive, time-consuming and resource intensive. 
Routinely recorded data in administrative healthcare databases have the potential to 
address these limitations and provide an alternative, accessible and informative data 
source for clinical research [46-48].  
 
1.3.1 The Standard and New Antiepileptic Drugs II (SANAD II) Trial 
The Standard and New Antiepileptic Drugs II (SANAD II (EudraCT No: 2012-001884-64, 
ISRCTN30294119)) RCT is the successor to the SANAD RCTs published in 2007 [23, 24]. 
SANAD II is a RCT assessing the clinical and cost effectiveness of lamotrigine, levetiracetam 
and zonisamide as first line treatments for patients’ with newly diagnosed epilepsy and is 
funded by the National Institute of Health Research (NIHR) Health Technology Assessment 
(HTA) programme.   
Population: 
A total of 1510 individuals with newly diagnosed epilepsy and previously untreated with 
antiepileptic drugs were recruited between April 2013 and May 2017. Similarly to the first 
SANAD RCT, participants were recruited into one of two arms; focal onset seizures (990 
individuals) or generalised/unclassified seizures (520 individuals). The study centres 
included UK National Health Service (NHS) outpatient epilepsy, general neurology and 
paediatric clinics. Follow-up duration ranged from a minimum of two years to maximum of 
5.5 years.     
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Inclusion Criteria: 
- Aged five years or older 
- Two or more spontaneous seizures that require antiepileptic drug treatment 
- Not currently or previously treated with antiepileptic drugs 
- Antiepileptic drug monotherapy considered the most appropriate option 
- Willing to provide consent (patients parent/legal representative willing to give 
consent where the patient is aged under 16 years of age) 
Exclusion Criteria: 
- Provoked seizures (e.g. alcohol) 
- Acute symptomatic seizures (e.g. acute brain haemorrhage or brain injury) 
- Currently treated with antiepileptic drugs 
- Progressive neurological disease (e.g. known brain tumour) 
Intervention: 
Participants diagnosed with focal onset seizures were randomised to levetiracetam, 
zonisamide or the study control lamotrigine.  
Participants diagnosed with generalised or unclassifiable seizures were randomised to 
levetiracetam or the study control sodium valproate.  
Objectives: 
- Primary Objective: 
o Time to 12 month remission from seizures 
- Secondary Objectives:  
o Time to treatment failure 
▪ Time to treatment failure due to inadequate seizure control 
▪ Time to treatment failure due to adverse events 
o Time to first seizure 
o Time to 24 month remission 
o Adverse events 
o Quality of Life  
o Health Economic Outcomes 
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Methods: 
SANAD II is a pragmatic RCT and data were recorded using standard prospective methods.   
A baseline assessment was completed at the time of recruitment. Data were recorded by a 
member of the study team on a Case Report Form (CRF) including seizure history, history of 
neurological insult, febrile seizures, family history of epilepsy, EEG and imaging (CT or MRI) 
results. Eligibility was then confirmed, written consent signed and the participant was 
randomised to a study AED. Follow-up assessments were then completed at three, six, 
twelve months and annually thereafter, integrated into routine clinical practice. Data were 
recorded on CRFs during each follow-up including medication history, adverse events, 
healthcare resource use and seizure occurrence. Details of seizures were recorded for the 
time period between each follow-up. The ‘first’ and ‘last’ seizure occurrences within the 
specified time period were recorded, together with the total number of seizures. The dates 
of all seizure occurrences were not recorded as this was not practicable. Additionally, 
during the follow-up period a number of self-completed questionnaires were requested 
recording details regarding adverse events, healthcare resources use and further 
information to inform the quality of life and cost-effectiveness analyses.  
SANAD II opened in 2013, recruitment was completed in May 2017 and report is expected 
in 2019. Data are managed by the Clinical Trials Research Centre (CTRC), University of 
Liverpool.  
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1.4 Routinely Recorded Data 
 
1.4.1 Introduction 
Routinely recorded data can be defined as data that are routinely recorded for specific 
primary purposes, other than audit or research [49].  
In the UK, there is a plethora of individual-level data routinely recorded by a number of 
organisations. Broadly, data may be held for national, legal and governmental 
requirements, private industry purposes and for the benefit of the individual. Certain data 
are recorded with individual consent, for example the majority of private industry data. 
However, governmental data regarding taxation and clinical data, as examples, do not 
require individual consent. The Data Protection Act 1998 [50], to be replaced in the UK in 
May 2018 with The General Data Protection Regulation (GDPR) [51] and The Freedom of 
Information Act 2000 [52] provide the framework for data security, confidentiality and 
disclosure in the UK. Furthermore, recently the UK Department of Health has published a 
response to the National Data Guardian for Health and Care’s review of healthcare data 
security, consent and opt-outs and the Care Quality Commission’s review ‘Safe Data, Safe 
Care’ [53]. The document commits to improvements in healthcare data security, including 
sanctions following misuse and individual choice regarding data sharing. Legislation states 
data should be recorded to fulfil specific, defined purposes and the recording of excessive 
or unnecessary data should be avoided. Furthermore, legislation is in place to restrict 
access and to prevent inappropriate use of data. Where consent is required data must only 
be used for the defined purposes explicitly stated during the consent procedure. However, 
where consent is not required for certain routinely recorded data, use for secondary 
purposes may be permitted if there is a clear demonstrated ‘secondary benefit’. Secondary 
benefit may broadly include benefits to population and society. Such secondary use has 
restrictions including strict ethical and data management requirements. As an example, 
data regarding clinical care is recorded without the need for consent in electronic medical 
records in the UK to assist with healthcare delivery and the remuneration for use of 
healthcare services [48, 54]. Such data are formatted and accessible for clinical research 
through National Health Service (NHS) Digital and Hospital Episode Statistics (HES) if 
secondary benefit can be demonstrated and the application requirements are fulfilled [55].  
  
18 
 
1.4.2 Routinely Recorded Clinical Data 
Data regarding clinical care are routinely recorded in electronic medical records and stored 
in administrative healthcare databases to assist with the delivery of healthcare and the 
remuneration for use of healthcare services [48, 54].   
 Electronic medical records are in use in developed countries worldwide and in different 
healthcare settings, such as primary and secondary care. There is variation in the recorded 
data variables which depend on for example healthcare setting, with different data 
recorded for emergency care compared to inpatient care and healthcare system, where 
different variables may be recorded in a private compared to public healthcare system. 
Examples of recorded data variables include diagnoses, investigations, treatments and 
procedures, age, gender, and area of residence [48]. Data is structured by individual 
patient, with each record including data variables common to all records in the database 
[47]. Data is frequently coded and codes may differ depending on country, healthcare 
setting and individual database. For example, electronic medical records within an 
individual hospital Patient Administration System (PAS) in the UK may use a different 
coding system to data recorded in a national database, such as the Hospital Episode 
Statistics (HES) database recorded by NHS Digital [55]. However, standardised diagnostic 
coding systems exist, the most commonly used in secondary care being the World Health 
Organisation’s International Classification of Diseases system (currently in its 10th revision: 
ICD-10) [56]. In primary care in the UK, the NHS READ coding system is used in addition to 
ICD 10 [57]. Data are entered into the electronic medical records and administrative 
databases by clinicians directly or transcribed from medical records by trained clinical 
coders and administrative staff members.  
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1.4.2.1 Routinely Recorded Clinical Data and Clinical Research  
Clinical research methodologies are heterogeneous but involve the common processes of 
identifying eligible individuals and recording data to assess study outcomes. Clinical 
research can be expensive, time-consuming and resource intensive. Routinely recorded 
data in administrative healthcare databases have the potential to provide an alternative, 
accessible and informative data source for clinical research [46-48]. Furthermore, there are 
potential advantages in resource and time efficiency, impacting on the feasibility and 
funding, scope and time to study completion. Such potential advantages are applicable to a 
number of study designs, possibly resulting in a more efficient research process and 
therefore earlier results and translation into clinical practice. The potential of routinely 
recorded data to inform clinical research has been recognised for some time, together with 
the limitations of accuracy, confidentiality, ownership and access [58].  
Routinely recorded clinical data have been used in retrospective research studies including 
observational, record linkage population studies where administrative healthcare 
databases have proved an efficient means for providing study data [59]. In addition to the 
discussed advantages and relevant to retrospective studies, individual-level data may be 
available for a number of previous years resulting in the immediate availability of a study 
dataset for retrospective research. Finally, individual anonymity may be maintained more 
effectively using administrative healthcare databases where data is frequently de-
identified, resulting in a less intrusive research process [48].    
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Routinely recorded data may also be of value in prospective research studies, including 
cohort studies and RCTs [60]. Routinely recorded clinical data regarding primary and 
secondary care have demonstrated utility in informing recruitment feasibility assessments 
for RCTs. For example, the TrialViz initiative developed by Dataline provides a means to 
perform a recruitment feasibility assessment using data provided by the Clinical Practice 
Research Datalink (CPRD) [61, 62]. The identification of specific individuals in administrative 
datasets eligible for a RCT may be possible, assisting with RCT recruitment [63]. Routinely 
recorded data also have the potential to measure prospective study outcomes [64]. For 
example, death certification data from the Office of National Statistics may be accessed to 
measure mortality [65] and HES data may be accessed to inform the health economic 
analyses within RCTs [66]. In selected cases it may be feasible to conduct a pragmatic RCT 
using administrative healthcare databases, including the stages of recruitment, 
randomisation, administration of intervention and follow-up assessments. Although there 
is limited evidence of the use of routinely recorded data for this purpose and pragmatic 
RCTs with simple interventions are most appropriate, cluster RCTs have been conducted 
entirely within CPRD, including patient recruitment, randomisation, administration of 
intervention and trial assessments [67]. The Salford Lung Study is an example of a large on-
going RCT where both primary and secondary care data are accessed to measure the study 
outcomes [68, 69].  
The potential advantages of routinely recorded data in the context of clinical research have 
resulted in a political drive to increase the use of administrative healthcare databases, as 
detailed in The Plan for Growth [70]. Consequently, the NHS constitution presents research 
as a ‘core’ activity of the NHS making the link between the provision of NHS services and 
research explicit [71].   
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1.4.2.1.1 Limitations  
The limitations of routinely recorded data must be discussed when considering the use of 
data from administrative healthcare databases in clinical research. Routinely recorded data 
is by definition recorded to fulfil a specific, pre-defined primary purpose other than 
research or audit and only the data required to meet the specific purpose is recorded [49]. 
The accuracy of routinely recorded data for an alternative purpose, including clinical 
research where there may be a higher standard of scientific rigor, is therefore questionable 
[47, 72]. For example, in the UK the accuracy of routinely recorded clinical data is 
dependent upon the clinical information recorded by the clinician in the medical records 
and the accuracy of transcription by non-clinical administrative staff during the coding 
process [47]. However, using the diagnosis of epilepsy as an example, there are studies 
worldwide assessing the accuracy of algorithms using routinely recorded data to identify 
individuals with a diagnosis of epilepsy, compared to medical records. ICD-10 codes 
consistent with a diagnosis of epilepsy together with ≥1 antiepileptic drug (AED) recorded 
in the Australian National Hospital Morbidity Database resulted in a Positive Predictive 
Value (PPV) of 81.4% for diagnosis of epilepsy [73]. A similar study using multiple linked 
Canadian administrative healthcare databases found a PPV of 91.9% [74] and there are 
further studies with equivalent findings indicating algorithmic approaches using routinely 
recorded data are sensitive for identifying individuals with diagnoses of epilepsy [75-78].    
A single routinely recorded dataset may not provide sufficient data to meet the study 
objective, requiring data for study participants from multiple datasets to be retrieved. A 
number of countries have integrated healthcare systems allowing for national 
administrative healthcare databases, such as the Swedish Hospital Discharge Register, the 
Danish National Hospital Register and the Canadian Chronic Disease Surveillance System. In 
these examples it is possible to retrieve routinely recorded data from electronic medical 
records for individuals across hospital inpatient admissions and emergency care, outpatient 
clinic and primary care attendances. In the UK, healthcare administrative databases are not 
universal and to obtain all of the data required to measure a study objective, a number of 
administrative healthcare databases may need to be accessed. Individuals can frequently 
be ‘linked’ between databases to address this limitation, usually using a ‘unique identifier’ 
such as National Health Service (NHS) Number. However, the detail of the identifying 
information between sources and the different identifying data variables recorded may 
result in the ‘link’ being of reduced accuracy or in some cases not possible.  
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There are also logistical limitations when using routinely recorded data, amplified when 
accessing data from multiple administrative databases. For example, there is potentially a 
significant time interval between the time of occurrence of an event and the availability of 
the record of the event in an administrative database. This presents less of a concern to 
retrospective studies however, when considering prospective studies where prompt 
reporting is both clinically important and may be a regulatory requirement, the delay in 
availability of data may be prohibitive. Furthermore, the costs required to retrieve 
routinely recorded data can be significant, despite the majority of data holders operating 
on a not-for-profit, cost recovery basis.    
Finally, access to individual, identifiable routinely recorded data is an ethical concern [79] 
and there is the prevailing discomfort felt by professionals and the public of the use of 
routinely recorded data for secondary purposes. The belief that the ‘right to privacy’ is 
being finely balanced against the pursuit of data access for secondary purposes [80] is likely 
contributing to the difficulties reported in implementation of administrative databases in 
research due to the contradictions in the process perceived by professionals and the public 
[81]. Involving patients as important stakeholders and re-gaining their trust will be an 
essential factor in realising the individual and population healthcare benefits of analysing 
routinely recorded data [82, 83].    
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1.4.2.2 Routinely Recorded Clinical Data Sources in the UK  
Secondary Care 
National public sector organisations provide information technology and data systems for 
commissioners, analysts and clinicians in health and social care. Data is recorded to inform 
patient care, provide the data for remuneration for Hospital Trusts and is subsequently 
used to monitor and improve clinical services through research. Table 1.1 introduces the 
administrative healthcare databases where access to individual-level, secondary care 
routinely recorded data for research is possible.  
Primary Care 
Data in electronic medical records are recorded routinely by the General Practitioner to 
inform patient care and remuneration, but are not currently available for research on a 
national basis. A number of organisations represent collaborations between governmental 
bodies or academic institutions and providers of primary care information technology 
systems. Table 1.2 introduces the administrative healthcare databases where access to 
individual-level, primary care routinely recorded data for research is possible on a regional 
basis.    
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Table 1.1: Sources of Routinely Recorded Secondary Care Data 
NHS Digital [55]  
 
Data Access for Clinical Research: 
The Data Access Request Service provides a method of access to a number of routinely recorded datasets for 
England. Hospital Episode Statistics (HES) provides clinical, health and socio economic data for all secondary 
care attendances in England. Datasets include Accident and Emergency, Admitted Patient, Outpatient, Adult 
Critical Care, Maternity and selected Patient Reported Outcome Measures. 
Previous Experience in Clinical Research: 
HES data have been accessed for retrospective linkage studies [84] and to provide data for prospective studies, 
for example estimation of healthcare resource use or measuring outcomes such as long term mortality [85]. 
 
The NHS Wales Informatics Service (NWIS) [86] 
 
Data Access for Clinical Research: 
Data access can be facilitated through The NWIS Bespoke Analysis Service. The Patient Episode Database for 
Wales (PEDW) provides clinical, health and socio economic data for all secondary care attendances in Wales 
and is broadly comparable to the Admitted Patient HES dataset, with data regarding elective and emergency 
admissions and maternity care recorded. Additional datasets of relevance to this study include the Emergency 
Department and Outpatient Datasets. 
Previous Experience in Clinical Research:  
PEDW data have been accessed for retrospective analyses, for example analysis of the incidence of obstetric 
complication rates [87].  
 
The NHS National Services Scotland; Information Services Division (ISD) [88] 
 
Data Access for Clinical Research: 
The electronic Data Research and Innovation Service (eDRIS) provides a method of access to ISD datasets 
including Outpatient, General Acute / Inpatient, Emergency Department, Unscheduled Care, GP Out of Hours 
and The Prescribing Information System. Clinical, health and socio economic data are recorded and datasets are 
largely comparable to HES.   
Previous Experience in Clinical Research: 
ISD data have been accessed for retrospective linkage studies, for example analysis of the incidence of 
gastrointestinal bleeding and complications including mortality [89].  
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Table 1.2: Sources of Routinely Recorded Primary Care Data 
The Clinical Practice Research Datalink (CPRD) [90] 
 
Data Access for Clinical Research: 
CPRD is a governmental research service jointly funded by the NHS National Institute for Health Research and 
the Medicines and Healthcare products Regulatory Agency. Following approval by the Independent Scientific 
Advisory Committee, CPRD provides access to de-identified primary care clinical, health and socioeconomic data 
for a geographically representative 13 million patients in England for healthcare research. 
Previous Experience in Clinical Research: 
CPRD data have been used in retrospective studies for estimating healthcare resource use, prescription 
medicines and clinical outcomes [84]. Gulliford conducted two cluster-randomised trials using CPRD: one aimed 
to reduce inappropriate antibiotic prescribing for acute respiratory infection; the other aimed to increase 
physician adherence with secondary prevention interventions after first stroke [67].  
  
ResearchOne [91] 
 
Data Access for Clinical Research:  
ResearchOne is a collaboration between the University of Leeds and The Phoenix Partnership (TTP), developers 
of the SystmOne clinical database and IT system. De-identified clinical, health and socioeconomic data are 
available from primary, secondary and out-of-hours care settings for approximately 26 million patients in the 
UK. 
Previous Experience in Clinical Research: 
ResearchOne data have been used in public health surveillance studies, retrospective studies [91] and currently 
in combination with CPRD data to measure the outcomes of a cluster RCT [92].   
 
QResearch [93] 
 
Data Access for Clinical Research: 
QResearch is a collaboration between the University of Nottingham and the developers of the EMIS IT systems. 
De-identified clinical, health and socioeconomic data are available for approximately 18 million patents in the 
UK.  
Previous Experience in Clinical Research: 
QResearch data have been used to measure clinical outcomes in case-control and cohort studies [94].  
 
The Health Improvement Network (THIN) Database [95] 
 
Data Access for Clinical Research: 
THIN is a collaboration between IMS Health and In Practice Systems, developers of the IT software Vision. De-
identified clinical, health and socioeconomic data are available for approximately 11.1 million patients in the 
UK.  
Previous Experience in Clinical Research: 
THIN data have been accessed to measure clinical outcomes in cohort and case-control studies [96].   
 
North West eHealth (NWEH) [97] 
 
Data Access for Clinical Research: 
NWEH is a collaboration between The University of Manchester, Salford Royal Foundation Trust and Salford 
Clinical Commissioning Group. NWEH has developed the methodology and governance framework to 
implement the Salford Integrated Record, an integrated primary and secondary care electronic medical record, 
into research as part of the Salford Lung Study [69]. The infrastructure permits access to secondary care 
electronic medical records accessed through the NHS Digital Secondary Uses Service. With participant and GP 
practice enrolment and consent, the Apollo [98] and Graphnet [99] data extraction tools are employed to 
extract participant primary care electronic medical records that can then be linked to data regarding secondary 
care. NorthWest eHealth is unique in that data is not de-identified and therefore participant consent is 
required. Furthermore, GP practice enrolment and consent is required to permit the installation of third party 
software on their systems and subsequent extraction of data.  
Previous Experience in Clinical Research: 
NWEH offer a number of primary care research tools including a RCT recruitment feasibility assessment, but do 
not currently routinely provide a bespoke primary care data extraction service for research. However, the 
methodology for this process has been demonstrated [69].     
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‘Linked’ Routine Data Sources 
In order to provide a ‘complete’ dataset including all information required to meet research 
objectives, data from multiple administrative databases, both clinical and non-clinical, may 
need to be accessed and linked either on an individual or aggregate level. This is typically 
accomplished using unique identifiers such as name, date of birth, National Insurance 
Number or NHS Number. In response to the growing recognition of the potential of 
routinely recorded data, initiatives have been established to assist with the provision of 
linked, de-identified data between data sources:    
- The Secure Anonymised Information Linkage (SAIL) Databank is an initiative 
developed by Swansea University and funded by the Welsh Government. SAIL 
provides a method of access to individual-level, routinely-recorded, de-identified 
electronic data for patients across Wales to support research [100]. Access to 
clinical datasets provided by NWIS is complemented with numerous non-clinical 
administrative datasets including births, deaths and demographic data. Following 
the scoping process a formal application is submitted to the Information 
Governance Review Panel before access to data is granted. SAIL data has been 
accessed to measure clinical outcomes in retrospective research [101].  
- The Administrative Data Research Network (ADRN) is a UK-wide partnership 
between universities, government departments, national statistics authorities, 
funders and researchers, funded by the Economic and Social Research Council. 
ADRN provides a method of access to a number of non-clinical administrative 
routine datasets including employment, socioeconomic, crime and education data 
[102] in addition to clinical datasets detailed previously such as those recorded by 
NHS Digital. Following development of a project proposal a formal application is 
reviewed by the Approvals Panel.  
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1.4.3 Routinely Recorded Non-Clinical Data 
‘Non-clinical data’ includes data recorded for national, legal and governmental 
requirements, private industry purposes and for the benefit of the individual. A plethora of 
‘non-clinical data’ are routinely recorded in the UK. As previously discussed in Section 1.4.1, 
individual consent is required for certain data, for example data recorded for private 
industry purposes. Such data must only be used for the explicit purposes included in the 
consent procedure. However, there are non-clinical data recorded without the requirement 
for consent and in such circumstances there is potential for secondary use, including use 
for clinical research. For example in the UK, HM Revenue and Customs (HMRC) record 
individual-level data regarding employment status, salary, taxation and national insurance 
contributions [103]. Such routinely recorded data have the potential to inform clinical 
research.   
1.4.3.1 Routinely Recorded Non-Clinical Data Sources in the UK and Clinical Research  
Routinely recorded non-clinical data have the potential to contribute to clinical research, 
including measuring clinical study outcomes. When considering the potential 
implementation of non-clinical data in clinical research, the specific use is dependent on 
the nature of the data. Example sources of UK non-clinical routinely recorded data relevant 
to clinical research are discussed.    
The Driver and Vehicle Licensing Agency (DVLA) is responsible for the licensing of drivers 
and vehicles in the UK and issuing, reviewing and maintaining guidance regarding driver 
license status in the context of medical diagnoses [18]. The DVLA therefore record personal 
data relevant to driving and there is a legal requirement for individuals to inform the DVLA 
of relevant medical diagnoses. Using epilepsy as an example, the legal requirement for 
driving license holders to inform the DVLA of the occurrence of seizures and subsequently 
to regain normal driving privileges after a specified period of seizure freedom, raises the 
possibility of DVLA providing an accurate data source to measure clinical outcomes in 
epilepsy research. The DVLA publish limited de-identified, aggregate datasets for research, 
usually assessing driving restrictions. However, there was no evidence of individual-level 
DVLA data being accessed for clinical research in a scoping search performed in MEDLINE 
via OVID.    
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HM Revenue and Customs (HMRC) [103] is responsible for taxation including National 
Insurance and Student Loan repayments and the administration of tax credits, child benefit 
and statutory sick and maternity pay. The Department for Work and Pensions (DWP) [104] 
is responsible  for the provision of state pensions and welfare benefits. Relevant data is 
therefore routinely recorded and includes details regarding employment status, salary, tax 
and National Insurance contributions and the receipt of benefits. Such routinely recorded 
data has the potential to inform health economic analyses in clinical research, including an 
assessment of the broader societal impacts of healthcare interventions. As a result of the 
primary purpose of data collection, data routinely recorded by HMRC and DWP are likely to 
be accurate and complete compared to standard methods used in prospective clinical 
research studies. For example, data to inform health economic analyses may be obtained 
through completion of self-report questionnaires in clinical research and such data are 
frequently poorly recorded [105]. Both HMRC and DWP are involved in external research 
and following approval permit access to de-identified aggregate datasets. However, there 
are restrictions, for example the HMRC Datalab requires research to include a ‘listed 
function’ of the HMRC of which clinical research is not [103]. There is no precedent for 
individual-level HMRC [106] or DWP data being accessed for clinical research.  
The Office for National Statistics (ONS) [107] is an administrative database routinely 
recording a multitude of data including individual-level  birth and mortality data and 
aggregate economic and societal statistics. The smallest reported level is the Lower Layer 
Super Output Area (LSOA) consisting of a population of 1000-3000. Routinely recorded data 
retrieved from ONS have the potential to measure clinical study outcomes. Mortality data 
can be requested through application to the NHS Digital DARS Service and there are 
examples of mortality being measured in retrospective and prospective studies [85]. 
Additionally, aggregate data can be accessed via services provided by ONS such as NOMIS 
[108] and Data for Neighbourhoods and Regeneration [109] and have the potential to 
contribute to health economic analyses in addition to data collected using standard 
methods.   
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Routinely recorded non-clinical data share many of the potential advantages of routinely 
recorded clinical data when considering use in clinical research, including the potential for 
improved feasibility and efficiency. However, in addition, the ‘non-clinical’ data discussed 
are likely to be of improved accuracy compared to similar data recorded using standard 
methods in clinical research. For example, data to inform an assessment of the broader 
societal impacts of healthcare interventions such as employment status retrieved from 
HMRC, are likely to be of greater accuracy compared to standard research methods such as 
completion of self-report questionnaires, known to be poorly recorded [105]. Similarly, 
many of the discussed limitations are applicable. However, in the context of non-clinical 
sources the ethical concerns regarding routinely recorded data access for research [79] are 
likely to be of greater significance. Concerns have been raised regarding the ‘right to 
privacy’ when routinely recorded clinical data is accessed for clinical research. Such 
concerns are likely to be amplified when the access to non-clinical data for the purpose of 
clinical research is proposed. As is the case with clinical data, the public are an important 
stakeholder and their involvement will be essential in realising the individual and 
population healthcare benefits of routinely recorded non-clinical data [82, 83].      
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1.5 Conclusions and Research Objectives 
Publically funded, pragmatic RCTs assessing the longer term clinical and cost effectiveness 
of antiepileptic drugs in the treatment of newly diagnosed epilepsy provide the data most 
informative to the clinical treatment of epilepsy. However, pragmatic RCTs are expensive, 
time-consuming and resource intensive. Routinely recorded data in administrative 
healthcare databases have the potential to address these limitations and provide an 
alternative, accessible and informative data source for clinical research [46-48]. However, 
although the ‘accuracy’ of the diagnosis of epilepsy using routinely recorded data 
compared to medical records has been assessed [73], there is minimal evidence of the 
assessment of ‘agreement’ to standard methods of data collection employed in prospective 
research. Acknowledging the rapidly increasing use of routinely recorded data in 
prospective research including RCTs and the status of the RCT in remaining the standard for 
approval of novel treatments in healthcare [110], an assessment of the feasibility and 
agreement of routinely recorded data compared to data collected using standard 
prospective methods is pressing.  
This thesis will review the use of routinely recorded data in prospective research and 
agreement compared to standard prospective data collection methods, review accessible 
sources of routinely recorded data in the UK and assess the agreement and feasibility of 
using routinely recorded data compared to data collected in a RCT assessing treatments for 
epilepsy using standard prospective methods.   
The objectives of this thesis are as follows:   
1. Review the Use of Routinely Recorded Data in the UK to Assess Outcomes in 
Randomised Controlled Trials (Chapter Two) 
This review summarises the use of individual-level routinely recorded data from 
specified data sources in the UK to inform the assessment of outcomes of RCTs. An 
electronic database search using MEDLINE via OVID and a narrative review of 
additional relevant resources was completed.        
2. Review the Agreement of Routinely Recorded Data with Data Collected Using 
Standard Prospective Methods in UK Studies (Chapter Three) 
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This systematic review summarises the assessments of agreement between 
routinely recorded data in the UK and data collected using standard prospective 
methods to measure the outcomes in prospective clinical studies, including RCTs.     
3. Identify and Assess the Accessibility of UK Routinely Recorded Data Sources 
(Chapter Four) 
Relevant sources of routinely recorded data in the UK are presented, followed by 
an assessment of the ‘accessibility’ for the purposes of retrieving data to measure 
the outcomes in a RCT.    
4. Compare the Attributes of Data Extracted from Electronic Medical Records 
Against Data Collected Using Standard Methods, in the Randomised Controlled 
Trial (RCT), SANAD II: (Chapters Five, Six, Seven) 
 
a. Assess the Quality of Data Extracted from Electronic Medical Records 
The ‘quality’ of routinely recorded data is assessed, including an assessment of the  
‘comparability’ and ‘completeness’ compared to data collected using standard 
prospective methods in SANAD II 
b. Assess the Agreement between Data Extracted from Electronic Medical Records and 
Data Collected Using Standard Prospective Methods  
Agreement between routinely recorded data and data collected using standard 
prospective methods in SANAD II is assessed for a number of variables and 
outcome measures.  
5. Assess the Feasibility and Efficiency of Accessing and Using Routinely Recorded 
Data from Electronic Medical Records (Chapter Eight)   
The feasibility and efficiency of the process of retrieving routinely recorded data 
are assessed before recommendations for future improvement are proposed.   
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Chapter Two 
The Use of Routinely Recorded Data in the UK to Assess 
Outcomes in Randomised Controlled Trials: A Review 
2.1 Introduction 
In Chapter One, epilepsy and the current prospective research methods used to assess 
treatments for epilepsy were discussed. The case study RCT, the Standard and New 
Antiepileptic Drugs II (SANAD II) RCT was introduced. Routinely recorded data in the UK and 
the potential for use in clinical research were introduced before finally the objectives of 
this thesis were presented. In this chapter the use of routinely recorded data in RCTs in the 
UK will be reviewed.  
There is potential for use of routinely recorded data in clinical research and Health 
Technology Assessment [46] and access for ‘secondary purposes’ including clinical research 
is permitted providing there is demonstrable secondary benefit.  
There are numerous examples of retrospective observational, record linkage population 
studies where routine sources have proved to be a valid and efficient method for providing 
data for clinical research [59]. In the context of prospective clinical research such as RCTs 
routinely recorded data have been used to inform judgements about the feasibility of 
sample size and recruitment targets [62] and measuring participant outcomes [46, 64]. 
Pragmatic cluster RCTs have been coordinated through routine data sources including 
participant recruitment, randomisation, administration of intervention and trial 
assessments, such as through The Clinical Practice Research Datalink (CPRD) [67].  
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The majority of RCTs incur costs as clinicians assess participants, record outcomes and 
complete Case Report Forms - hence using routinely recorded data may provide an 
efficient alternative method for data collection in addition to reducing the burden on 
investigators and participants. Furthermore, data from non-clinical routine sources may 
inform outcomes beyond the standard RCT assessments of clinical efficacy and 
effectiveness. For example, cost data (such as use of healthcare resources) and socio-
economic data (such as employment and means-tested benefits data) may inform health 
economic analyses and the assessment of the broader societal impact of healthcare 
interventions. However, limitations with accuracy of coding, confidentiality, ownership and 
access have been identified as significant barriers to using routinely recorded data for 
research [58].  
 
2.2 Objective 
This review aims to summarise published reports of the use of individual-level routinely 
recorded data from specified data sources in the UK to inform the assessment of outcomes 
of RCTs.          
 
2.3 Methods 
This review includes a search of the electronic database, MEDLINE via OVID and a narrative 
review of additional relevant resources.  
2.3.1 Electronic Database Review 
2.3.1.1 Registration 
A protocol for this electronic database review has been prospectively developed. However, 
with the focus concerning data sources and methodological approaches to clinical research, 
the review was not eligible for registration in the PROSPERO Database. This report has been 
structured according to the PRISMA Checklist where relevant, included in Appendix A, Table 
A.3.       
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2.3.1.2 Inclusion Criteria 
Study Designs, Participants, Interventions and Outcome Measures 
Clinical RCTs were included that accessed individual-level data relevant to clinical research 
from UK routine data sources. This methodological review included studies meeting this 
criterion regardless of aim, clinical diagnosis, participants, interventions or outcome 
measures. It was therefore expected that included studies would be heterogeneous.  As a 
result of limitations in the resources required for translation and the nature of the review, 
only English language studies were included. 
Routine Data Sources 
Electronic medical records of patients’ use of secondary care services in the UK are 
routinely managed on a national basis. Each country has a governmental body that is the 
national provider of information, data and IT systems for commissioners, analysts and 
clinicians in health and social care. Data are recorded to inform patient care, provide the 
data for remuneration and subsequently used to monitor and improve clinical services 
through clinical research. Electronic medical records of patients’ use of primary care 
services in the UK are recorded routinely by the General Practitioner to inform patient care 
and for remuneration, but are not currently available for clinical research on a national 
basis. A number of organisations represent collaborations between governmental bodies or 
academic institutions and private providers of primary care IT systems. Included clinical 
routine data sources are presented in Box 2.1 and Tables 1.1 and 1.2.     
Non-clinical, individual-level data are recorded routinely by UK governmental bodies for 
specific indications. Sources routinely recording data potentially informative to prospective 
clinical research and included in this review are presented in Box 2.1 and Table 1.3.    
In response to the growing recognition of the potential of routinely recorded data, 
initiatives have been established to assist with the provision of linked, de-identified, 
aggregate data between data sources. Box 2.1 and Section 1.1.2.2 present sources included 
in this review.  
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There are a number of smaller, disease specific routinely recorded data sources, for 
example individual disease registers. In this review, we have purposively included the larger 
sources with regional or national coverage that hold clinical and non-clinical information 
potentially applicable to any disease area, in order to ensure the results are generalizable. 
RCTs using data accessed from individual disease registries and other smaller routinely 
recorded data sources have therefore not been included.  
 
Box 2.1: Included Sources of Routinely Recorded Data in the UK 
Routinely Recorded Clinical Data  
 
- NHS Digital [55]  
- The NHS Wales Informatics Service (NWIS) [86] 
- The NHS National Services Scotland; Information Services Division (ISD) [88] 
- The Office for National Statistics (ONS) [107] 
- The Clinical Practice Research Datalink (CPRD) [90] 
- The General Practice Research Database (GPRD) [90] 
- ResearchOne [91] 
- QResearch [93] 
- The Health Improvement Network (THIN) Database [95] 
- North West eHealth (NWEH) [97] 
 
Routinely Recorded Non-Clinical Data 
 
- HM Revenue and Customs (HMRC) [103] 
- The Department for Work and Pensions (DWP) [104] 
- The Driver and Vehicle Licensing Agency (DVLA) [18] 
 
Routinely Recorded Linked Data 
 
- The Secure Anonymised Information Linkage (SAIL) Databank [100] 
- The Administrative Data Research Network [102] 
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2.3.1.3 Search Strategy 
A search strategy was developed for the electronic database MEDLINE via OVID. The search 
was developed using an iterative process using Index and MeSH terms, subheadings and 
free text terms. The final search strategy is included in Appendix A, Table A.4. The search 
has been developed to ensure maximal sensitivity, with no clinical diagnoses, interventions 
or outcome measures specified. The included routine data sources have been purposively 
included together with selected generic terms and abbreviations combined using the 
Boolean operator AND with the National Institute of Health and Care Excellence (NICE) UK 
filter and Cochrane RCT Highly Sensitive Search Strategy.  
2.3.1.4 Study Identification 
The study title and abstract of all studies identified in the search were reviewed. The full 
text was retrieved for studies meeting the inclusion criteria, studies possibly meeting the 
inclusion criteria and studies where insufficient detail could be obtained from the screening 
procedure. Studies identified in multiple publications were included under the same study 
name, the source providing the richest data included in the analysis.  
2.3.1.5 Data Extraction 
Data were extracted from all included studies onto a standardised electronic data 
extraction template. Box 2.2 presents the extracted data items.  
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Box 2.2: Extracted Data Items  
 
- Study ID 
- Reference 
- Date of publication 
- RCT design 
- Routine data source 
- Clinical focus 
o Clinical speciality 
o Diagnoses 
- Implementation of routine data 
o Assessment of recruitment feasibility  
o Recruitment to RCT 
o Dataset for primary analysis 
o Dataset for secondary analysis  
- Outcome measures  
o Clinical 
▪ Efficacy 
▪ Harm 
o Mortality 
o Health Economic 
- Appraisal 
o Study reported limitations of implementing routinely 
recorded data 
o Study reported advantages of implementing routinely 
recorded data 
 
 
2.3.1.6 Data Analysis 
The objective was to review reports of the use of routinely recorded data from UK routine 
data sources in RCTs rather than appraise the individual outcomes of the RCT. We planned 
to perform a narrative assessment of the risk of bias for all studies and formal assessment 
where routinely recorded data had been used in the study and there was the potential for 
the introduction of bias, for example when routinely recorded data was used to address 
missing RCT data collected through standard methods, the risk of bias was assessed using 
the Cochrane Risk of Bias Tool. However, there was no planned routine formal risk of bias 
assessment for RCTs, assessment of heterogeneity, reporting bias, sensitivity analyses or 
meta-analyses. 
The results were analysed using simple descriptive statistics and a narrative appraisal. 
Further statistical manipulations including meta-analysis were not appropriate due to the 
heterogeneity of aims, interventions, outcomes measures and routinely recorded data 
sources accessed.  
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2.3.2 Narrative Review 
A narrative review was completed to complement the electronic database search.  
Resources that may include eligible RCTs were identified. As a result of the nature of the 
review, manual searching of journals and conference abstracts and the contact of 
researchers in the field was not feasible. This review aimed to assess methodology and 
specifically sources used to provide data for RCTs. In completed systematic reviews with a 
focus on methodology, relevant details were poorly indexed in electronic databases [111]. 
This limitation results in the requirement to potentially review ‘all’ UK RCTs if a rigorous 
systematic review is to be completed. Focussing solely on the review of RCTs included in 
specific conference proceedings or journals would not represent a valid approach. It was 
not feasible to review ‘all’ UK RCTs during this review.   
An alternative more specific approach was taken to narratively review the publically 
available data release information published by the included routinely recorded data 
sources, where available. This narrative review of published data release registers was 
completed for the included routinely recorded data sources detailed in Box 2.1.     
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2.4 Results 
2.4.1 Electronic Database Review 
The titles and abstracts of the 200 studies identified in the search, completed 03/07/2016, 
were reviewed. The full text was retrieved and reviewed for 22 studies possibly meeting 
the inclusion criteria or where insufficient detail could be obtained from the abstract. Eight 
studies were excluded from the final review. Two studies were published protocols for 
included subsequent final study reports [112, 113]. Two studies accessed non-identifiable 
data from routine sources, one to provide the general mortality rate [114] and one to 
provide general data relevant to health economic analyses [115]. One study was a review 
article involving two studies included in this review [67]. One study accessed individual 
level data from a UK routine data source but in the context of socio economic research with 
no clinical outcomes [116]. Finally, one study accessed individual level data from a routine 
data source in the Netherlands to recruit and measure the outcomes in a RCT [117].  
The process for the identification of studies is summarised in Figure 2.1.  
 
Figure 2.1: The Identification of Studies 
 
  Studies identified through MEDLINE via OVID (n=230) 
Studies identified following removal of duplicates (n=200) 
Full text reports retrieved (n=22) 
Studies excluded (n=178) 
Studies included (n=14) 
Studies excluded (n=8)  
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Fourteen studies were included in the review. A summary of the study characteristics 
including the implementation of routinely recorded data is presented in Table 2.1. Greater 
detail is provided in Appendix A, Tables A.1 and A.2. The Office of National Statistics (ONS) 
was the source of routinely recorded data most frequently accessed in the sample. Nine 
studies involved the access of ONS Mortality data to measure mortality in the short and 
long-term. The maximum duration of follow-up using ONS data was 20 years [118]. In most 
cases, follow up is reported as 98-99% complete for the sample, but the methods of 
determining participants remaining alive was only detailed in one study, and involved the 
ONS failing to identify 0.6% of participants, for example as a result of assumed emigration 
or non-specified loss to follow up [118]. Five studies included review of the International 
Classification of Diseases (ICD) information recorded on the death certificate to determine 
the cause of death. Two studies also included access to a subset of individuals’ clinical 
documentation and reported ‘good agreement’ between cause of death recorded on the 
death certificate with cause of death identified on review of clinical documentation [118, 
119]. The limitations of ONS data access are poorly recorded. One study identified the 
delay in death data being recorded in ONS [120], another identified ‘limitations associated 
with ONS data’ but with no further explanation [121]. One study protocol involved access 
to NHS Digital (The Health and Social Care Information Centre), Hospital Episode Statistics 
in addition to ONS data. During the RCT, clinical details including diagnoses and cause of 
death will be requested from NHS Digital. Participants will be prospectively flagged and the 
completion of 10 year follow up is due in 2017 [85].   
The Secure Anonymised Information Linkage Databank (SAIL) was accessed in two RCT 
recruitment feasibility assessments [62, 122]. Pragmatic RCT inclusion criteria were applied 
to the SAIL dataset in order to identify individuals meeting the inclusion criteria and their 
location by GP practice. However, SAIL records only de-identified data which results in an 
inability to re-identify such eligible individuals. Therefore individual GPs in practices with 
eligible individuals would need to participate in the recruitment process if an RCT were to 
be conducted using datasets accessed through SAIL. The Clinical Practice Research Datalink 
(CPRD) was accessed during two cluster RCTs [123, 124] and access is planned in one 
further cluster RCT, due to report in 2017 [125]. In all cases, the RCT was coordinated 
through CPRD and the consented GP practices. GPs were recruited and simple, pragmatic 
interventions were included in the RCT. For example, introduction of decision support tools 
to prompt GPs of the guidelines for secondary prevention measures for stroke [123].  
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Participants’ outcomes were recorded through CPRD and involved simple clinical measures 
such as assessment of blood pressure. The analysis of data in such studies was anonymous 
and patient consent was not required. There is a reported three month delay before data is 
available in CPRD, but the importance of this limitation is negated by the nature of the 
research question.  
There were no RCTs identified with access to data from non-clinical sources including HM 
Revenue and Customs (HMRC), The Department of Work and Pensions (DWP) and The 
Driver and Vehicle Licensing Agency (DVLA).    
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Table 2.1: Included Studies: Summary of the Use of UK Routinely Recorded Data in RCTs 
Study Reference Trial Summary Outcome Measures 
 
Office for National Statistics (ONS) (General Register Office (GRO), General Statistics Office of Ireland (GSOI)) 
 
Ashton et al: 2002 
[119] 
 
67,800 participants randomised to ultrasound abdominal 
screening or no intervention. Clinical details were recorded 
through standard prospective methods. Mortality was measured 
by accessing data from ONS.  
Primary Outcome: Aneurysm related mortality  
 
Secondary Outcomes: All-cause mortality, 
frequency of ruptured aneurysm, quality of life 
Bale et al:  2008 
[121] 
 
375 patients with moderate/severe chronic obstructive pulmonary 
disease were randomised to fluticasone or placebo for 3 years. 
Clinical details were recorded through standard prospective 
methods. Mortality was measured by accessing data from ONS. 
Primary Outcome: All-cause mortality 
Brown et al: 2012 
[120] 
 
1252 participants with abdominal aortic aneurysm (AAA) were 
randomised to EndoVascular Aneurysm Repair (EVAR) or 
laparotomy. 404 participants with AAA were randomised to EVAR 
or conservative management. Clinical details were recorded 
through standard prospective methods. Mortality was measured 
by accessing data from ONS. 
Primary Outcome: Mortality (all-cause, 
operative, aneurysm-related) 
Henderson et al: 
2015 [126] 
 
1810 patients with non-ST-segment elevation acute coronary 
syndrome were randomised to an early invasive strategy 
(coronary arteriography and myocardial revascularization) or a 
selective invasive strategy (coronary arteriography for recurrent 
ischemia only). 10 year mortality was measured in this study by 
accessing data from ONS for England and the GRO for Scotland.   
Primary Outcome: All-cause mortality 
 
Secondary Outcomes: Mortality 
(cardiovascular or non-cardiovascular) 
Molyneux et: 2015 
[127] 
 
1624 participants with ruptured cerebral aneurysm were 
randomised to neurosurgical clipping or endovascular coiling. 18 
year mortality was measured by accessing data from ONS.   
Primary Outcome: All-cause mortality 
 
Secondary Outcomes: Functional status, 
dependency 
Perera et al: 2012 
[128] 
 
301 patients with severe ventricular impairment and coronary 
artery disease were randomised to Intra-Aortic Balloon Pump 
during Percutaneous Coronary Intervention (PCI), or PCI alone. 
Clinical details were recorded through standard prospective 
methods. Mortality was measured at a median 51 months by 
accessing data from ONS and GRO.  
Primary Outcome: All-cause mortality 
Scholefield: 2012 
[118] 
 
152 850 individuals by household were randomised to biennial 
Faecal Occult Blood screening vs no intervention. Clinical details 
were recorded through standard prospective methods. Mortality 
was measured at a median 19.5 years by accessing data from ONS. 
Primary Outcomes: Mortality (all-cause, 
colorectal cancer related) 
Simmons: 2012 
[129] 
 
20 185 participants in 33 GP's were randomised, by GP to Type 2 
Diabetes Mellitus screening followed by intensive treatment, 
screening plus routine care or no-screening. Mortality was 
measured at a median 9.6 years by accessing data from ONS, GRO 
and CSOI.  
Primary Outcome: All-cause mortality 
 
Secondary Outcomes: Death from CV disease, 
cancer, DM related death 
 
NHS Digital and Office of National Statistics (ONS) 
 
Turner et al: 2014 
[85] 
 
785 GP's randomised to prostate specific antigen screening vs 
standard care in a cluster RCT. This reference reports the design 
and recruitment results. Clinical details including diagnoses and 
cause of death will be obtained through access to NHS Digital HES 
/ ONS data. Follow up at 10 years due 2017. 
Primary Outcome: 10 year ‘definite’ or 
‘probable’ prostate cancer mortality 
 
Secondary Outcomes: All-cause mortality (10 
and 15 years), cost effectiveness 
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The Secure Anonymised Information Linkage Databank (SAIL) 
 
Brooks et al: 2009 
[122] 
 
SAIL Databank was used as the data source to perform a 
recruitment feasibility assessment for two fictitious RCTs involving 
patients with diabetes mellitus and pragmatic inclusion criteria. Of 
250,086 individuals in SAIL, 284 were eligible for the first RCT and 
711 for the second. 
N/A 
McGregor et al: 
2010 [62] 
 
SAIL Databank was used as the data source to perform a 
recruitment feasibility assessment for an existing RCT assessing 
folate use in patients with depression. 867 potential participants 
were identified. 
N/A 
 
The Clinical Practice Research Datalink (CPRD) 
 
Dregan et al: 2014 
[123] 
 
106 participating GP's contributing data to CPRD were allocated to 
the intervention; installation of IT decision support tools to 
improve adherence to secondary care stroke prevention measures 
during the patient consultation or control; standard practice. RCT 
duration 12 months. Pragmatic clinical details including blood 
pressure and blood tests were recorded through CPRD to measure 
the study outcomes. 
Primary Outcome: Systolic blood pressure 
 
Secondary Outcomes: Diastolic blood pressure, 
total cholesterol, prescription of cardiovascular 
drugs 
Guilliford et al: 
2014 [124] 
 
104 participating GP's contributing data to CPRD were allocated to 
the intervention; installation of decision support tools to improve 
adherence to antibiotic prescribing guidelines during the patient 
consultation for respiratory tract infection or control; standard 
practice. RCT duration 12 months. Pragmatic clinical details 
including prescription of antibiotics and record of respiratory 
diagnoses were recorded through CPRD to measure the study 
outcomes. 
Primary Outcome: Proportion of consultations 
for respiratory tract infection with antibiotics 
prescribed 
 
Secondary Outcomes: Proportion of antibiotics 
prescribed in other respiratory infective 
diagnoses 
Horspool et al: 2013 
[125] 
 
Protocol for a cluster RCT involving 140 GP's contributing data to 
CPRD. GP’s will be allocated to the intervention; a letter informing 
parents of the importance of adherence to their child’s asthma 
treatment throughout the summer holidays or control; standard 
practice. The pragmatic clinical details will be recorded through 
CPRD to measure the study outcomes. 
Primary Outcome: Unscheduled medical 
contact in September 
 
Secondary Outcomes: Unscheduled medical 
contacts at other time points associated with 
prescriptions, respiratory diagnoses 
 
The Clinical Practice Research Datalink (CPRD) and ResearchOne 
 
Herrett et al: 2014 
[92] 
 
Protocol for a cluster RCT involving GP's contributing data to CPRD 
or ResearchOne. GP's will be randomised to the intervention; a 
text messaging campaign to increase uptake of the flu vaccine or 
control; standard practice. The pragmatic clinical outcome of flu 
vaccine administration will be recorded through CPRD and 
ResearchOne to measure the study outcome. 
Primary Outcome: Flu vaccine administration 
 
 
 
  
45 
 
2.4.2 Narrative Review 
A narrative review of the online electronic resources for each included routinely recorded 
data source was completed on 22/09/2016. Data release registers and bibliographies were 
reviewed where available, results are presented:  
2.4.2.1 NHS Digital 
NHS Digital publishes data release registers usually on a three-monthly basis and includes 
details regarding data releases in England for HES and ONS mortality data [130]. The most 
recent publication at the time of review (April-August 2016) included >1000 individual 
releases of identifiable data. Searching the ‘objective for processing’ field with the term 
‘RCT’ identified seven RCTs involving HES data with three including ONS mortality data. One 
RCT was also identified in the electronic database review [85]. Examples include a RCT 
assessing the treatment of coronary vascular disease, with the outcome of major coronary 
events, a RCT assessing the chemotherapy treatment of colon cancer with the outcome of 
cancer progression and a RCT assessing the treatment of abdominal aortic aneurysms with 
the outcome of overall and cause-specific mortality.  
The data release registers prior to and including January -March 2016 provide less detailed 
information regarding the ‘objective for processing’ resulting in difficulty in accurately 
identifying data releases for use in RCTs. In the January-March 2016 release, 809 individual 
data releases are presented. Searching for the term ‘RCT’ in the ‘purpose’ field identified 
seven data releases that are related to RCTs, two of which were also included in the April-
August 2016 release.  
NHS Digital data release registers have been published on a three-monthly basis from April 
2013 and all contain limited evidence of HES or ONS access to provide data for RCTs. Prior 
to April 2013, the study titles are presented, but there is no information presented 
regarding the ‘objective for processing’ or ‘purpose’ of the data releases. It was therefore 
not possible to identify relevant data releases prior to April 2013.  
2.4.2.2 The Clinical Practice Research Datalink (CPRD) 
Data releases for studies approved by the CPRD Independent Scientific Advisory Committee 
are presented in an online resource. This resource includes all studies approved from July 
2015 [131]. The studies have been searched using the terms ‘RCT’ and ‘trial’. No approved 
studies involving data access for use in a RCT were identified.  
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2.4.2.3 ResearchOne 
A summary of ‘current projects’ is published on the ResearchOne online electronic resource 
[132]. It is not clear if this summary includes previous data releases or completed projects, 
but this is unlikely to represent a formal data release register. One RCT is identified 
involving the release of ResearchOne data, also identified in the electronic database review 
[92]. 
2.4.2.4 QResearch 
A summary of completed studies involving the provision of QResearch data is published on 
the online electronic resource [133]. Ongoing studies are also presented on a linked 
webpage. There was no evidence of QResearch data access for use in a RCT.  
2.4.2.5 The Health Improvement Network (THIN) Database 
A bibliography including the references of all completed studies involving access to THIN 
data is published on the online electronic resource [134]. The bibliography was searched 
using the terms ‘RCT’, ‘trial’ and ‘randomised’. No data releases for a RCT were identified.  
2.4.2.6 North West eHealth (NWEH) 
A data release register for NWEH could not be identified following review of the available 
online electronic resources. However, one RCT coordinated by NWEH, the Salford Lung 
Study, being conducted using the ‘Linked Database System’ [135] is detailed.  
2.4.2.7 HM Revenue and Customs (HMRC) 
A bibliography of studies approved for the access to HMRC data is available on the online 
electronic resource [106]. No data releases for RCTs were identified and further, no data 
releases for clinical research of any methodology were identified.  
2.4.2.8 The Secure Anonymised Information Linkage (SAIL) Databank 
A bibliography of studies approved for access to SAIL data is available on the online 
electronic resource [136]. SAIL data access is planned in one RCT protocol for long term, 
anonymised follow up [137]. This RCT protocol was not identified in the electronic database 
review.  There was one further RCT protocol identified, but on full review of the publication 
the role of SAIL was unclear. This study may be requesting use of the services regarding 
linkage of data provided by SAIL.  
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2.4.2.9 The Administrative Data Research Network (ADRN) 
A bibliography of studies approved for access to ADRN data is available on the online 
electronic resource [138]. No data releases for use in a RCT were identified.  
2.4.2.10 Sources Lacking Data Release Registers 
Data release registers could not be identified for the following data sources:  
- The NHS Wales Informatics Service (NWIS) / Public Health Wales Observatory 
- The NHS National Services Scotland; Information Services Division (ISD) 
- The Department for Work and Pensions (DWP) 
- The Driver and Vehicle Licensing Agency (DVLA) 
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2.5 Discussion 
Routinely recorded data have demonstrated potential in prospective research including 
measuring the outcomes of RCTs [64] and providing additional benefits such as a method 
to address missing RCT data. Academic, political [70] and health service [71] interest in UK 
sources of routinely recorded data has resulted in expansion and improvements, notably in 
the access to linked datasets. However, in this review evidence of the use of routinely 
recorded data to assess the outcomes in UK RCTs was variable dependant on the data 
source and nature of routinely recorded data. Routinely recorded mortality and secondary 
care clinical data were most commonly accessed in RCTs. There was very limited use of 
routinely recorded primary care clinical data and no evidence of the use of data from non-
clinical sources in RCTs.  
In the electronic database review, ONS was the most frequently accessed data source, 
providing death notification and certification data. The legal requirements with regards to 
death certification and registration result in a largely complete dataset and identified 
studies reporting follow up for 98-99% of participants. However, deriving cause of death, 
based on medical certification diagnoses or clinical coding is likely to be less accurate than 
ascertaining death status, although two studies reported ‘good agreement’ between 
information derived from the ONS and clinical documentation. In one of these studies, 
there was some discrepancy between ‘certified’ and ‘verified’ causes of death, verified 
using case note review, but the overall result and significance of the primary outcome was 
unchanged [119]. The narrative review provided further evidence of the numerous RCTs 
including access to ONS mortality data. There was some discrepancy, with RCTs identified 
in the data release registers that were not included in the electronic database review. 
However, this discrepancy was more obvious with English NHS Digital HES data access, with 
only one RCT being identified in the electronic database review and numerous being 
identified in the data release registers. Similar data release registers could not be identified 
for the Welsh NWIS or Scottish ISD.  
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There was limited evidence of the use of routinely recorded primary care data. In the 
electronic database review, two recruitment feasibility assessments were performed using 
SAIL data and four cluster RCTs were conducted using CPRD data, with data from 
ResearchOne also involved in one RCT. In the narrative review, one additional RCT 
conducted through NWEH was identified. Primary care sources are limited by selective 
coverage based on General Practitioner (GP) consent and GP Patient Administration System 
and restrictions on the identification of individuals within the datasets. However, cluster 
RCTs have been conducted although simple pragmatic interventions and GP consent and 
participation to deliver the study intervention were required and notably, patient consent 
was not required. The NHS Digital General Practice Extraction Service is the only national 
record of primary care data and potentially represents the most informative data source. 
However access is currently limited to Department of Health initiatives such as national 
screening programmes [139].  
Despite the potential of non-clinical routinely recorded data to measure outcomes beyond 
the standard RCT assessments of clinical efficacy and effectiveness, such as an assessment 
of the broader societal impacts of interventions, there was no evidence of use of non-
clinical data.  
Although poorly specified in the studies included in this review, it is likely that there are a 
number of limitations when accessing routinely recorded data in the context of prospective 
research. The process of quality assurance is unclear and the level of agreement of 
routinely recorded data with data recorded through standard RCT methods remains 
uncertain and was not reported in the majority of studies, particularly when measuring 
clinical outcomes. Furthermore, the time delay before routinely recorded data becomes 
available may have implications for RCTs where prompt reporting is both clinically 
important and in some instances a regulatory requirement, such as during pharmaceutical 
trials.   
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The discrepancy between the results of the electronic database review and narrative 
review is notable. RCTs including the use of ONS mortality data were identified from the 
electronic database review with a minority identified from the narrative review of the data 
release registers, but not included in the electronic database results. However, only one 
RCT using HES data was identified from the electronic database review compared to 
evidence of numerous RCTs in the review of NHS Digital data release registers, despite a 
search strategy developed to be sensitive. Such discrepancies highlight the poor indexing of 
methodological information in electronic databases. It is likely that ONS mortality data was 
used to assess RCT primary outcomes and therefore may be more likely to be included in 
the abstract and electronic database indexing. Conversely, HES data may be accessed as an 
additional dataset to assess secondary outcomes, such as healthcare resource use and this 
may explain the poor indexing.        
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2.6 Limitations 
The nature of the objective introduces limitations into the review. The review does not 
focus on clinical diagnosis, intervention or outcome but rather on methodology. The 
alternative focus on data sources accessed resulted in the electronic database search 
strategy being inclusive of all clinical RCTs but with a purposive search of specified data 
sources and relevant generic terms filtered for the UK. There is therefore a risk that studies 
poorly indexed or poorly documenting the data source were not identified. This limitation 
was most notable for the clinical data sources such as NHS Digital HES and was addressed 
by narrative review of the registers of data releases, where available.    
It was not feasible to summarise the details of all RCTs involving the release of HES or ONS 
data from the NHS Digital data release registers. This was the result of resource and time 
limitations of the researcher during the review and the less detailed data published in the 
data release registers from earlier years, which would have necessitated reviewing ‘all’ data 
releases. However, the objective of the review was to summarise the use of routinely 
recorded data in RCTs and the identification of numerous RCTs in the data release registers 
informs this objective. Furthermore, the heterogeneity of the included studies did not 
permit any further manipulation of data and a narrative discussion is presented.    
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2.7 Conclusions 
In this chapter, the use of routinely recorded data in UK RCTs has been reviewed. Routinely 
recorded data may present benefits to prospective research including RCTs, but the overall 
experience of accessing data for this purpose remains limited. Registry mortality and 
secondary care routinely recorded data were most commonly accessed for RCTs. Primary 
care routinely recorded data were infrequently accessed but there was evidence of the 
feasibility for completing pragmatic cluster RCTs. Despite the potential for non-clinical data 
to measure outcomes beyond the standard clinical assessments, there was no evidence of 
use of data for this purpose in a RCT. Furthermore, a data release register could only be 
identified for HMRC and on review there was no evidence of data use for clinical research 
of any methodology.   
The search of the electronic database was limited by the likely poor indexing of 
methodological details in electronic databases and therefore future reviews with a focus on 
methodology should be complemented with the manual review of additional relevant 
sources.  
To further improve the use of routinely recorded data in RCTs, research is required to 
assess the accessibility, feasibility and agreement of routinely recorded data compared to 
data recorded through standard RCT methods. In the following chapter, the agreement 
between routinely recorded data and data collected using standard methods will be 
assessed in a systematic review.  
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Chapter Three 
The Agreement of Routinely Recorded Data with Data 
Collected Using Standard Prospective Methods in UK Studies: 
A Systematic Review 
 
3.1 Introduction 
In Chapter One, epilepsy and the current prospective research methods used to assess 
treatments for epilepsy were discussed. The case study RCT, the Standard and New 
Antiepileptic Drugs II (SANAD II) RCT was introduced. Routinely recorded data in the UK and 
the potential for use in clinical research were discussed. In Chapter Two the use of 
routinely recorded data in RCTs in the UK was reviewed. Mortality data and secondary care 
data were most commonly accessed, although there was relatively limited use in general. 
In this chapter the agreement between UK routinely recorded data compared to data 
collected using standard methods in prospective studies will be assessed in a systematic 
review.  
There is potential for use of routinely recorded data in prospective clinical research, 
including RCTs [46]. There are examples of studies assessing the ‘validation’ of routinely 
recorded data. Such studies compare the agreement of data within a routine source to the 
‘source’ data that is usually also ‘routinely recorded’. For example assessment of the 
agreement of diagnoses retrieved from the General Practice Research Datalink (GPRD) to 
the directly accessed primary care medical records [140]. When considering the increasing 
use of routinely recorded data in prospective research including RCTs, of greater relevance 
is an assessment of the agreement between routinely recorded data and data collected 
through ‘standard prospective methods’, such as self-reported questionnaires or 
completion of Case Report Forms (CRFs).        
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3.2 Objective 
This systematic review aims to assess the agreement of routinely recorded data in the UK 
to data collected using standard prospective methods to inform the assessment of 
outcomes in prospective clinical studies including RCTs.     
3.3 Methods    
3.3.1 Registration 
As the focus of this systematic review was on methodological approaches and the 
agreement of data from alternative sources, the protocol was not eligible for registration in 
the PROSPERO Database. This systematic review report has been structured according to 
the PRISMA Checklist where relevant, included in Appendix B, Table B.4.  
3.3.2 Inclusion Criteria 
3.3.2.1 Study Designs, Participants, Interventions and Outcome Measures 
The method of data collection rather than the study design was of primary interest in this 
review. However, following the development of the search strategy, detailed below, there 
was  justification for including only prospective study designs such as RCTs and non-
randomised studies (non-randomised controlled trials, prospective cohort studies).   
This methodological review included studies regardless of aim, diagnosis, participants, 
intervention or outcome measures and therefore heterogeneity was expected. As a result 
of resource limitations for translation and the objective of the review, only English 
language studies were included.  
3.3.2.2 UK Routine Data Sources 
Relevant clinical and non-clinical sources of routinely recorded data in the UK with the 
potential to inform prospective clinical research were identified and purposively included, 
previously presented in Box 2.1. Additionally, to ensure identification and inclusion of other 
relevant sources of routine data, generic, descriptive terms such as ‘administrative data’, 
‘medical records’, ‘routine data’ and ‘electronic data’ were included in the search strategy.     
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3.3.3 Standard Prospective Methods 
An inclusive approach was taken for the definition of ‘standard prospective methods’. This 
included data that were collected as part of any prospective study (such as RCT, non-
randomised controlled trial, prospective cohort) and included study follow up assessments 
and the completion of study documents such as CRFs as well as the completion of self, 
family or carer reported questionnaires. ‘Standard’ methods may where prospectively 
planned within the study protocol involve review of local medical records. For example, 
prospective research nurse review of individual hospital Patient Administration Systems to 
measure patient contact with secondary care services and transfer of this data to a CRF 
would reasonably represent a ‘standard prospective method’ and a comparison to 
routinely recorded data such as Hospital Episode Statistics (HES) data provided by NHS 
Digital was informative to the objective of this systematic review.     
3.3.4 Assessment of Agreement 
To ensure an inclusive approach, all comparisons between UK routinely recorded data and 
data collected using standard prospective methods were included. Matched comparisons 
on an individual level as well as a cohort level were included. Eligible methods included 
simple descriptive comparisons, assessment of statistically significant differences and 
formal statistical assessments of agreement, such as calculation of Cohens Kappa, the 
Intraclass Correlation Coefficient or construction of Bland Altman Plots. In order to 
maximise the quality of the review, studies involving only narrative comparisons, without 
the inclusion of numerical data were excluded.   
3.3.5 Search Strategy 
To ensure identification of all relevant studies, regardless of publication status (published, 
unpublished, in press, ongoing) search strategies were developed for electronic databases 
and a manual search of relevant resources was completed.    
Limitations in the specificity of the electronic database searches was expected, informed by 
the experience of published systematic reviews with a primary focus on methodology [111] 
and the previous electronic database search in Chapter Two. Acknowledging these 
expected limitations and to ensure identification of all relevant studies, search strategies 
were developed for electronic databases and additional approaches were taken to identify 
studies with a primary focus on health economic analyses, including assessment of 
healthcare resource use.   
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3.3.5.1 Development of the Electronic Database Search Strategies 
A search strategy for electronic databases was developed using an iterative process, 
initially in MEDLINE via OVID using Index and MeSH terms, subheadings and free text 
terms. The strategy was subsequently adapted to SCOPUS (including EMBASE) and the 
Cochrane Methodology Register. As a result of the primary focus on methodology, in this 
section the development of the search strategy is detailed including the total number of 
studies and total number of eligible studies identified in each iteration, summarised in 
Table 3.1. The final search strategies are presented in Appendix B, Tables B.5-B.7.  
To inform the development of the search strategy, a scoping search was completed using 
MEDLINE via OVID, SCOPUS and a manual review. Nine studies eligible for inclusion were 
identified [66, 141-148]. Generic terms to describe routinely recorded data were combined 
using the Boolean operator AND with the National Institute of Health and Care Excellence 
(NICE) filter for UK studies. Together with purposively included UK routine data sources, the 
initial search, informed by the nine studies identified in the scoping searches, included a 
number of ‘comparator’ terms. Text words such as ‘compare’, ‘agree’, or ‘valid’ adjacent to 
text words such as ‘self-report’, ‘questionnaire’ or ‘survey’ were included. Truncation and 
wildcards were used to account for variations in spelling and identify different derivations 
of search terms. This initial search, not limited by study design identified 207 studies. Six of 
the nine studies identified in the scoping searches were included, confirming the strategy 
was identifying relevant studies, although sensitivity was limited.   
In the next iteration, in an effort to increase the sensitivity, the ‘comparator terms’ were 
removed. Not limited by study design, 4423 studies were identified including seven of the 
nine eligible studies identified in the scoping searches. To improve the specificity of this 
strategy, the search was limited to prospective studies and 592 studies were identified, 
including seven of the nine eligible studies. To ensure the search for prospective studies 
was not omitting eligible studies, the 538 studies published in 2015-2016 from the search 
not limited by study design were reviewed. One additional eligible study was identified that 
was not identified in the search limited to prospective studies.  
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The final strategy included generic terms to describe routinely recorded data filtered for 
the UK and purposively included UK routinely recorded data sources, with results limited to 
studies with prospective designs. The search was identifying relevant studies, including 
seven out of the nine studies identified in the scoping searches. The two studies not 
identified in the MEDLINE search during the development of the search strategy were not 
included in the MEDLINE database and were identified in SCOPUS [66, 142].   
The search strategy was adapted to SCOPUS (including EMBASE) identifying 1911 studies, 
including eight of the nine eligible studies. Subsequently the search was adapted to the 
Cochrane Methodology Register, the most relevant database of the Cochrane Library. Forty 
eight studies were identified when limited to those with prospective designs. The final 
search, not limited by study design identified 89 studies. Four of the nine eligible studies 
were included.  
The final search strategy applied to MEDLINE, SCOPUS and the Cochrane Methodology 
Register, included the nine studies identified in the scoping review in addition to 17 eligible 
studies. A further 10 studies were also identified but excluded on subsequent review of the 
full report.  
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Table 3.1: The Development of the Electronic Database Search Strategies  
Search Strategy Total 
Studies 
Scoping 
Studies 
Included 
Scoping 
Studies 
Eligible 
Additional 
Studies 
Included 
Additional 
Studies 
Excluded 
Search Strategies: Development 
MEDLINE “All Study 
Designs with 
Comparator Terms” 
29.07.16 
207 [141, 143, 
144, 146-
148] 
9 N/A N/A 
MEDLINE 
“All Study Designs” 
1.08.16 
 
4423 [141, 143-
148] 
9 N/A N/A 
MEDLINE 
“All Study Designs 
2015 -2016”  
1.08.16 
538 Nil 2 [149] N/A 
Search Strategies: Final Iterations 
MEDLINE 
“Prospective 
Studies”  
1.10.16 
592 [141, 143-
148] 
9 [150-160] [117, 161-
165] 
SCOPUS 
“Prospective 
Studies” 
19.10.16 
1911 [66, 142-
148] 
9 [64, 65, 
152-154, 
157, 158, 
160, 166-
168] 
[117, 165, 
169-171] 
Cochrane Methods 
Register 
“All Study Designs” 
1.10.16 
89 [143, 144, 
146, 147] 
9 [46, 64, 
154, 172] 
[117] 
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3.3.5.2 Identifying ‘Health Economic’ Studies 
An additional search was completed to maximise the inclusion of studies with a primary 
focus on health economic measures, including the assessment of healthcare resource use. 
The Database of Instruments for Resource Use Measurement (DIRUM) is an open access 
database of resource use questionnaires [173]. The questionnaires and relevant 
methodological research papers are included. In the development of the database, an 
electronic search strategy was developed and MEDLINE, EMBASE and PsycINFO were 
searched (05/2012). The methodological studies included in the DIRUM database were 
reviewed in this review and in addition, the search strategy was updated in MEDLINE via 
OVID and adapted for use in SCOPUS (including EMBASE) to identify studies published 
during the period 2012-2016. The search of the DIRUM database and subsequent updates 
are detailed in Table 3.2. The updated search strategies are presented in Appendix B, 
Tables B.8-B.9.     
 
Table 3.2: The Existing and Updated DIRUM Searches 
Data Source Total Studies Eligible Studies 
Database of Instruments for 
Resource Use Measurement (DIRUM) 
1.10.16 
94 [158-160, 167, 
174-177] 
DIRUM MEDLINE 2012-2016 
21.10.16 
327 [174, 178-180] 
DIRUM SCOPUS 2012-2016 
21.10.16 
331 [180] 
 
3.3.5.3 Manual Searches 
To ensure a sensitive approach a manual search was completed and is summarised in Table 
3.3. The following resources were reviewed:  
- Health Technology Assessment (HTA) Journal 
- International Clinical Trials Methodology (ICTMC) Conference Proceedings 2015 
- Scottish Health Informatics Programme (SHIP) Conference Proceedings 2013  
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Table 3.3:  Results of the Manual Searches 
Data Source Eligible Published 
Studies 
Eligible Unpublished 
Studies 
Health Technology Assessment (HTA) 
Journal 
15.06.16 
[46, 64, 159, 177] N/A 
International Clinical Trials 
Methodology (ICTMC) Conference 
Proceedings 2015  
16.11.15 
N/A [181-183] 
Scottish Health Informatics 
Programme (SHIP) Conference 
Proceedings 2013  
28.08.13 
N/A [184] 
 
3.3.6 Study Identification 
The study title and abstract of all studies identified in the searches were reviewed. The full 
text was retrieved for studies meeting the inclusion criteria, studies possibly meeting the 
inclusion criteria and studies where insufficient detail could be obtained from the screening 
procedure. Studies identified in multiple publications were included under the same study 
name, the source providing the richest data included in the analysis.  
3.3.7 Data Extraction 
Data were extracted from all included studies onto a standardised electronic data 
extraction template. Box 3.1 presents the extracted data items.  
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Box 3.1: Extracted Data Items  
 
- Study ID 
- Reference 
- Date of publication 
- Study design 
o For non-randomised studies, specific study design 
features (Higgins and Green 2010) 
- Routinely recorded data source 
- Standard prospective method 
- Clinical focus 
o Clinical speciality 
o Diagnoses 
- Outcome measures  
o Clinical 
▪ Efficacy 
▪ Harm 
o Mortality 
o Health Economic 
- Assessment of agreement 
- Appraisal  
o Limitations 
▪ Study reported limitations of implementing 
routinely recorded data 
▪ Appraisal, bias 
o Benefits 
▪ Study reported benefits of implementing 
routinely recorded data 
▪ Appraisal, bias 
 
 
3.3.8 Data Analysis 
We planned to perform a narrative assessment of risk of bias for all studies and formal 
assessment of the risk of bias for included studies when relevant to the assessment of 
agreement. When relevant, for RCTs the Cochrane Risk of Bias Tool and for non-
Randomised Studies (NRS) the Cochrane Risk Of Bias In Non-randomized Studies - of 
Interventions (ROBINS-I) Tool would be completed. For NRS where completion of the 
ROBINS-I was not appropriate a narrative assessment of factors associated with bias and 
methodological quality would be performed. There was no planned routine formal 
assessment of reporting bias or sensitivity analyses as the aim of this review was to assess 
the agreement of data rather than appraise the outcomes of the included studies. 
The results were analysed using simple descriptive statistics and a narrative appraisal. 
Further statistical manipulations including meta-analyses were not appropriate due to the 
heterogeneity of aims, interventions, outcomes measures and routinely recorded data 
sources accessed.  
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3.4 Results 
The titles and abstracts of 2592 studies identified in the electronic database searches were 
reviewed. The full text was reviewed for 36 studies and 27 were eligible for inclusion.  
Additionally, the title and abstracts of 752 studies identified in the review of the DIRUM 
database and subsequent update were reviewed. The full text was reviewed for 11 studies 
and all were eligible for inclusion. The combined results identified 38 studies. Four exact 
duplicates were removed [158-160, 167]. Two further studies presented similar data to 
other included studies and were also removed [143, 146]. The addition of four eligible 
studies identified in the manual search and one study identified during the development of 
the search strategy [149] resulted in a total of 37 eligible, included studies. The process for 
the identification of studies is summarised in Figure 3.1.   
In addition to the two studies presenting similar data to other included studies [143, 146], a 
further nine studies were excluded from the final review, with reasoning detailed in Table 
3.4. Five studies did not present an assessment of agreement of routinely recorded data 
compared to data recorded through standard prospective methods [161-164, 171], three 
studies did not include UK routinely recorded data [117, 165, 169] and the full text for one 
study was not retrievable during the review [170].     
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Figure 3.1: The Identification of Eligible Studies 
 
  
Studies identified through electronic 
database search (n=2686) 
(MEDLINE via OVID (n=662), SCOPUS (n=1935), 
Cochrane Methodology Register (n=89)) 
Studies identified following removal of 
duplicates (n=2592) 
(MEDLINE via OVID (n=592), SCOPUS (n=1911), 
Cochrane Methodology Register (n=89)) 
 
Full text reports retrieved (n=36) 
Studies included (n=27) 
Studies included (n=38) 
Studies excluded 
(n=2556) 
Additional studies included (n=5) 
(Published (n=1), Unpublished (n=4)) 
Studies excluded 
(n=9) 
Total studies included (n=37) 
Studies identified through DIRUM database 
search (n=790) 
(DIRUM Database (n=94), MEDLINE via OVID (n=364), 
SCOPUS (n=332)) 
Studies identified following removal of 
duplicates (n=752) 
(DIRUM Database (n=94), MEDLINE via OVID (n=327), 
SCOPUS (n=331)) 
Full text reports retrieved (n=11) 
Studies Included (n=11) 
Studies excluded 
(n=741) 
Studies included following removal of duplicates (n=32) 
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Table 3.4: Excluded Studies  
Study Reference Reason for Exclusion 
Andersen et al: 2015 
[165] 
The study presents the results of source data verification of three large multinational 
RCTs, only one involving a small number of patients in the UK. Excluded as no clear 
comparison to routinely recorded data in the UK.  
Barbara et al: 2012 
[169] 
This study presents the agreement between self-reported diagnoses and those 
recorded in Canadian primary care records.  
Cornish et al: 2015 
[164] 
No comparison of routinely recorded data to data collected through standard 
prospective methods. Additionally, a non-clinical data source is accessed (National 
Pupil Database).  
Delaney et al: 2008 
[161] 
No comparison of routinely recorded data to data collected through standard 
prospective methods.  
Dobbie et al: 2015 
[162] 
The study involves analyses of questionnaire and biochemical test data that have been 
prospectively recorded. The accuracy of questionnaire data is being assessed by 
comparison to biochemical test data, although both data have been prospectively 
recorded within the same data source. There is no comparison of such prospectively 
recorded data to alternative routinely recorded data.   
Ishihara-Paul et al: 
2008 [163] 
No comparison of routinely recorded data to data collected through standard 
prospective methods. 
Lewsey et al: 1999 
[143] 
This study is an eligible reference, however the same data is presented in an included 
comprehensive HTA report [46] and therefore this study has been excluded.  
Mosis et al: 2006 
[117] 
This study involves a ‘Randomised Database Study’ using Dutch primary care routinely 
recorded data.  
Mukergee: 1999 
[170] 
This study may be eligible but there is limited detail in the abstract and the full report 
was not retrievable through the available resources during this review.  
O’Brien et al: 1992 
[171] 
No comparison of routinely recorded data to data collected through standard 
prospective methods. 
Tannen et al: 2009 
[146] 
This study is an eligible reference, however the same data is presented in previously 
published, more comprehensive reports [144, 145, 147, 148].  
 
Included studies were widely heterogeneous.  Tables 3.5 and 3.6 present a narrative 
summary of the studies including a subjective interpretation of the statistical and clinical 
significance of agreement between routinely recorded data and data collected through 
standard prospective methods. This interpretation considers if the evidence presented 
indicates an acceptable level of agreement to recommend the use of the assessed routinely 
recorded data to measure outcomes in future prospective studies such as RCTs. Extracted 
data is presented in greater detail in Appendix B, Tables B.1-B.3.    
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Table 3.5: Included Studies: Clinical Data - Assessment of Agreement 
 
Reference 
 
 
Data Sources 
 
Assessment of Agreement 
 
Acceptable Agreement?  
Barry et al 
2013 [65] 
Standard: 
RCT clinical follow up 
Routine:  
Scottish Morbidity Record 
Secondary care medical records 
Data recorded in a RCT was compared to mortality and 
secondary care medical records. The primary outcomes 
were broadly comparable. Cardiovascular death or 
myocardial infarction in the placebo compared to 
pravastatin group was 212 vs 147 (P<0.001, RR 32 
(16,45)) in the RCT dataset and 195 vs 121 (P<0.001, RR 
39 (24,51)) in the routine dataset.  
Yes: 
 
Cardiovascular mortality 
Myocardial infarction 
Britton et al 
2012 [178] 
Standard:  
Questionnaire 
Routine: 
Hospital Episode Statistics 
Inpatient Dataset (HES IP) 
Primary and secondary care 
medical records 
Patient-reported episodes of ‘stroke’ were compared to 
episodes recorded in HES, primary and secondary care 
medical records. 7.5% of self-reported strokes were not 
recorded as ‘stroke’ in routine sources. 62.3% of self-
reported strokes were validated in HES data. 15.1% were 
validated by hospital records alone and were not 
recorded in HES. 10.4% were recorded in HES alone. 
11.3% were validated by GP only. 
No 
Bryant et al 
2015 [149] 
Standard:  
Cohort study follow up 
Routine:   
Personal Child Health Record 
There were no statistically significant differences 
between research measured infant height and weight 
and routinely recorded height and weight in the 
Personal Child Health Record.  
Yes: 
 
Infant height / weight 
Cleland et al 
2007 [150] 
Standard:  
Questionnaire  
Routine: 
Primary care medical records 
The difference between ‘intervention’ and ‘control’ 
groups in a RCT assessing asthma control are narratively 
compared for standard data and routine data. Both 
methods of data collection resulted in no significant 
difference between groups but the measures are not 
adequately comparable.  
No 
Doshi et al 
2007 [152] 
Standard:  
Questionnaire  
Routine: 
Secondary care medical records 
Post-operative bleeding reported through self-report 
questionnaire was compared to secondary care medical 
records. A greater number of events were self-reported. 
It is possible events not included would be recorded in 
primary care medical records.  
No 
Embleton et 
al 2015 [183] 
Standard: 
RCT clinical follow up 
Routine:  
Secondary care medical records 
Data recorded in a RCT were compared to medical 
records. Of 253 ‘cancer progressions’ recorded in the 
RCT, 2 additional progressions were identified in medical 
records. The HR of the primary outcome and its 
significance was unchanged following the inclusion of 
the 2 additional progressions.    
Yes: 
 
‘Cancer progression’ 
Herrington et 
al 2015 [182] 
Standard: 
RCT clinical follow up 
Routine: 
‘UK Mortality Registers’ 
Data recorded in a RCT were compared to UK mortality 
registers. 2778 of 2835 deaths could be verified. The RR 
of the primary outcome, overall mortality was in 
agreement. Individual causes of death were in 
agreement (Kappa 0.78-0.86) with the exception of 
ischaemic stroke (Kappa 0.19).   
Yes: 
 
All-cause mortality 
Cardiovascular mortality 
Hutchings et 
al 2005 [154] 
Standard:  
Questionnaire  
Routine:  
Primary and secondary care 
medical records 
Assessment of medical records to substitute commonly 
used self-report questionnaires. Roughly two thirds of 
items in the SF-36 could be substituted in medical 
records, but only one third of relevant codes were ever 
used. 
No 
Iyer et al 
2013 [155] 
Standard: 
Questionnaire 
Routine:  
Secondary care medical records 
Post-operative complications were identified through 
self report questionnaires and secondary care records. 
For serious complications, all were recorded, for minor 
complications, half were recorded. Minor events may be 
alternatively recorded in primary care records.  
No 
Kingston et al 
2010 [153] 
Standard: 
Questionnaire 
Routine:  
ONS Omnibus Surveys 
The incidence of ‘unrecorded’ mammograms in the 
control arm of a RCT was assessed and compared to a 
similar cohort of women responding to the ONS 
Omnibus Survey. The populations and rates were 
comparable.  
Yes: 
 
Mammography  
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Lewsey et al 
2000 [46] 
Standard: 
RCT clinical follow up 
Routine:  
Scottish Morbidity Record 
Secondary care medical records 
A RCT assessing cardiovascular treatments was 
replicated as far as possible using a similar cohort of 
patients from routine data. The RR for the primary 
outcome was comparable.  
Yes: 
 
Cardiovascular mortality 
Myocardial infarction 
Mitchell et al 
2016 [166] 
Standard: 
Questionnaire 
Routine:  
Secondary care medical records 
Self-reported episodes of self harm were compared with 
secondary care medical records. Patients under-reported 
both the occurrence and absence of previous episodes 
of self harm. Cohen Kappa demonstrated poor 
agreement (Kappa=0.353, CI 0.287–0.419). 
No 
Pastorino et 
al 2015 [180] 
Standard: 
Questionnaire 
Routine:  
Primary care medical records 
Self-reported diagnosis of diabetes was compared to 
primary care medical records. There is good agreement 
(94.9%) for diagnosis but patients significantly over 
estimated the duration of their disease by a mean 0.6 
years.    
Yes: 
 
Diabetes mellitus  
Smith et al 
2015 [181] 
Standard: 
Research nurse review 
Routine: 
NHS Safety Thermometer 
Research nurse review of pressure ulcers compared to 
routinely recorded incidence. Reported ‘low accuracy’ 
with a calculated sensitivity of 48%.  
No 
 
Pressure ulcers 
Steward et al 
1993 [156] 
Standard: 
RCT clinical follow up  
Routine:  
Secondary care medical records 
Data recorded on CRFs in a RCT was compared to 
medical records. Data discrepancies occurred in 3-7.5%. 
20% of data recorded in the RCT could not be verified in 
the medical records.  
No 
Tannen et al 
2006 [144] 
Standard: 
RCT clinical follow up 
Routine:  
General Practice Research 
Database (GPRD) 
A RCT assessing treatments for hypertension was 
replicated as far as possible using a similar cohort of 
patients from routine data. Baseline characteristics were 
comparable. Of the 12 clinical outcomes, statistically 
significant differences between standard and routine 
data were observed in 2 outcomes.   
No 
Tannen et al 
2007 [147] 
Standard: 
RCT clinical follow up 
Routine:  
General Practice Research 
Database (GPRD) 
A RCT assessing hormone replacement therapy was 
replicated as far as possible using a similar cohort of 
patients from routine data. Notable differences were 
observed in baseline characteristics. Of the 10 clinical 
outcomes, statistically significant differences between 
standard and routine data were observed in 4 outcomes.   
No 
Tannen et al 
2007 [148] 
Standard: 
RCT clinical follow up 
Routine:  
General Practice Research 
Database (GPRD) 
A RCT assessing hormone replacement therapy was 
replicated as far as possible using a similar cohort of 
patients from routine data. Notable differences were 
observed in baseline characteristics. Of the 10 clinical 
outcomes, statistically significant differences between 
standard and routine data were observed in 5 outcomes.   
No 
Tannen et al 
2008 [145] 
Standard: 
RCT clinical follow up 
Routine:  
General Practice Research 
Database (GPRD) 
Two RCTs assessing treatments for hypertension were 
replicated as far as possible using a similar cohort of 
patients from routine data. Notable differences were 
observed in baseline characteristics. Of the 10 clinical 
outcomes, statistically significant differences between 
standard and routine data were observed in 9 outcomes.   
No 
Tudur-Smith 
et al 2012 
[141] 
Standard: 
RCT clinical follow up  
Routine:  
Secondary care medical records 
Office for National Statistics  
Data recorded in an RCT assessing chemotherapy for 
cancer were compared to medical records and ONS data. 
The primary outcome of mortality was comparable. 
Minor data discrepancies did not alter the result or 
significance of RCT outcomes.  
Yes: 
 
All-cause mortality 
Weiner et al 
2008 [157] 
Standard: 
RCT clinical follow up 
Routine:  
General Practice Research 
Database (GPRD) 
A RCT assessing treatment for hypercholesterolemia was 
replicated as far as possible using a similar cohort of 
patients from routine data. Notable differences were 
observed in baseline characteristics. Of the 3 clinical 
outcomes, a statistically significant difference between 
standard and routine data was observed in 1 primary 
outcome.  
No 
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Williams et al 
2003 [64] 
 
Standard:  
Questionnaire 
RCT clinical follow up 
Routine:  
Primary and secondary care 
medical records 
RCT 1: 9/13 outcomes on the health status questionnaire 
SF-36 could be substituted using coded terms from 
medical records. 
RCT 2, 3, 4: RCTs in different disease areas were 
replicated as far as possible using a similar cohort of 
patients from routine data. In RCT 2, out of 5 clinical 
outcomes, 4 could not be assessed. In RCT 3: out of 25 
clinical measures, 16 could not be assessed. In RCT 4: out 
of 11 outcomes, 2 could not be assessed and of the 
remaining 9 outcomes, 2 had discrepant results.       
RCT 1: No 
 
RCT 2: No 
 
RCT 3: No 
 
RCT 4: No  
 
 
Table 3.6: Included Studies: Health Economic Data - Assessment of Agreement 
 
Reference 
 
 
Data Sources 
 
Assessment of Agreement 
 
Acceptable Agreement?  
Breeman et 
al 2011 [172] 
Standard: 
Questionnaire  
Routine: 
Medical records and ‘routine 
data sources’ 
Data recorded through questionnaires for healthcare 
resource use were compared to medical records. Limited 
data were presented in the report. 15% of self-reported 
admissions could not be verified in medical records.   
No 
Byford et al 
2007 [158] 
Standard: 
Questionnaire 
Routine: 
Primary care medical records 
Data recorded through questionnaires for healthcare 
resource use were compared to medical records. At 12 
months, a mean 1.88 fewer GP appointments were self-
reported. There were greater numbers of self-reported 
appointments for services not administered in primary 
care.    
No 
Chishti et al 
2013 [174] 
Standard: 
Questionnaire 
Routine: 
Primary care medical records 
Data recorded through questionnaires for healthcare 
resource use was compared to medical records. At 12 
months, there were significantly fewer GP appointments 
self-reported (mean difference1.6, (95% CI 0.5–2.7), P = 
0.004).  
No 
Dixon et al 
2009 [151] 
Standard: 
Questionnaire  
Routine: 
Secondary care and ambulance 
medical records 
Data recorded through questionnaire for healthcare 
resource use at 28 days were compared to medical 
records. Costs derived for the intervention and control 
groups are presented. Using routinely recorded data the 
costs were; £3966 and £4166. For the questionnaire 
reported attendances were fewer; £2102 and £2641.    
No 
Ford et al 
2007 [175] 
Standard: 
Questionnaire 
Routine: 
Secondary care medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. At 2 
years, fewer appointments were self-reported (non -
significant). For appointments at the primary centre, 
there was good agreement (ICC = 0.77, 95% CI: 0.67–
0.85). 
Yes: 
 
Healthcare resource use 
Hussain et al 
2012 [179] 
Standard: 
Questionnaire: 
Routine: 
Secure Anonymised Information 
Linkage (SAIL) Databank 
(Inpatient, Outpatient, Primary 
Care, Emergency Care) 
Data recorded through questionnaires for healthcare 
resource use were compared to medical records 
accessed through SAIL. Primary care ‘visits’ were 
underreported compared to the ‘events’ recorded in 
primary care records and inpatient admissions were 
underreported compared to secondary care records. 
Outpatient visits were over-reported, the largest 
discrepancy seen in patients with high disease severity, 
reporting 2.55 vs 1.51 visits. 
No 
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Kennedy et 
al 2002 [160] 
Standard: 
Questionnaire 
Routine: 
Secondary care medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. At 12 
months a mean 5.6 attendances were self-reported 
compared to 4.3 recorded in medical records (P=0.006). 
The ICC of 0.54 indicates moderate agreement. 
No 
Mistry et al 
2005 [176] 
Standard: 
Questionnaire 
Routine: 
Primary care medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. At 12 
months, for all healthcare contacts, a mean 17.20 
attendances were self-reported compared to 12.64 
recorded in medical records (P=0.083). For GP 
appointments, there was moderate agreement (Kappa: 
0.370).  
No 
Morrell et al 
2000 [177] 
Standard: 
Questionnaire 
Routine: 
Primary care medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. At 6 
weeks, self-reported contacts were over-reported by a 
mean 0.5 of a contact (95% CI, 0.2, 0.7). At 6 months, 
self-reported contacts were underreported by a mean –
0.1 contacts (95% CI, –0.7, 0.5). 
Yes: 
 
Healthcare resource use 
Petrou et al 
2002 [159] 
Standard: 
Questionnaire: 
Routine: 
Primary and secondary care 
medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. At 4 
months 29.4% of patients recorded primary care visits in 
agreement with medical records with 56.9% 
underreporting (At 12 months; 28% and 58%) (P<0.001). 
There were no significant differences in secondary care 
attendances.  
Yes: 
 
Secondary Care: 
Healthcare resource use 
Richards et al 
2003 [167] 
Standard: 
Questionnaire: 
Routine: 
Primary, secondary and 
community medical records 
Data recorded through questionnaire for healthcare 
resource use were compared to medical records. For the 
majority of variables, there was significant under 
reporting of self-reported attendances. However, for 
certain measures there was good agreement: ‘Hospital 
Readmission’ (Kappa: 0.68) and GP surgery visits (Kappa: 
0.60).  
No 
Shaw et al 
1998 [168] 
Standard: 
Clinician report 
Routine: 
Secondary care medical records 
There was agreement between clinician report and 
medical records in 118/140 (84.3%) cases for grade of 
doctor seen and in 105/139 (76.7%) cases for the 
management decision following outpatient 
appointments.  
No 
Thorn et al 
2016 [142] 
Standard: 
RCT clinical follow up, primary 
care medical records 
Routine: 
Hospital Episode Statistics 
Outpatient Dataset (HES OP) 
Data recorded prospectively during a RCT were 
compared with HES OP data. 4088 of the total 4922 
appointments recorded in the RCT were identified in HES 
OP (83.1 %). 215/370 men (58.1 %) had at least one 
appointment that was unmatched in HES OP.  
No 
Thorn et al 
2016 [66] 
Standard: 
RCT clinical follow up, primary 
care medical records 
Routine: 
Hospital Episode Statistics 
Inpatient Dataset (HES) 
Healthcare costs derived from data recorded 
prospectively during a RCT were compared with costs 
derived using HES data. Costs associated with HES data 
were 8% lower (P=0.3). 11 men (3.8%) for whom events 
were recorded in HES had all these events missing from 
RCT data and 7 men (2.4%) with no events according to 
HES had events identified in RCT data. 
Yes: 
 
Healthcare costs 
Wright-
Hughes et al 
2013 [184] 
Standard: 
RCT clinical follow up, secondary 
care medical records 
Routine: 
Hospital Episode Statistics 
Inpatient Dataset (HES) 
Data recorded prospectively during a RCT were 
compared to HES data. Limited data presented in report. 
Narrative discussion reports comprehensive and timely 
outcome data obtained from NHS Digital, but ambiguity 
in the agreement of the outcome measures.   
No 
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Clinical Data 
Twenty two studies assessed the agreement of clinical routinely recorded data with clinical 
data collected using standard prospective methods. Comparisons included individual –level, 
paired data and matched cohort level data. The assessment of agreement was 
heterogeneous, with methods including calculation of statistically significant differences 
between outcomes and formal statistical assessments of agreement.  Comparisons ranged 
from study outcomes measured using routinely recorded data and data collected using 
standard prospective methods to comparisons of individual data items.   
Mortality data from UK mortality registers resulted in the most rigorous evidence for an 
acceptable level of agreement compared to data collected using standard prospective 
methods. In Tudur-Smith et al [141] the outcome ‘overall mortality’ calculated using RCT 
data (HR: 1.18 (95% CI: 0.99 to 1.42), secondary care medical records (1.18 (0.99 to 1.41) 
and ONS data (1.18 (0.99 to 1.40) were almost identical. Herrington et al [182] (RCT data  
(RR: 0.83, 95% CI: 0.75-0.91), Registry data (RR: 0.81, 95% CI: 0.74-0.90)) and Barry et al 
[65] (RCT data (RR 32 95% CI: 16-45), Registry data (RR 39 95% CI: 24-51)) also found 
comparable outcomes for mortality derived from RCT data and UK mortality registers.   
Four studies accessed primary care medical records for recruited individuals. Pastorino et al 
[180] found an acceptable level of agreement between self-reported diagnosis of diabetes 
and diagnosis recorded in primary care medical records, with agreement in 94.9% of cases. 
However, for a similar ‘common’ diagnosis, Britton et al [178] found that 11.3% of self-
reported episodes of stroke had no record in either primary or secondary care medical 
records. In Cleland et al [150], there was no significant difference found in ‘asthma severity’ 
between intervention and control groups in a RCT, with severity calculated using self-
reported questionnaire data or prescribing data from primary care medical records, 
although the measures are not directly comparable. Hutchings et al [154] assessed the 
potential for primary care medical records to substitute commonly used self-reported 
health status questionnaires. Although relevant codes could be identified for the majority 
of the items within the questionnaire, in practice only one third of eligible codes were ever 
used in primary care medical records. A further five studies accessed primary care data 
through the GPRD. ‘Replicated RCTs’ were performed with a cohort of patients matched as 
far as possible to the RCT cohort. Although agreement was noted in a small number of 
clinical measures and outcomes, considering all of the data, none of these studies 
produced evidence for an acceptable level of agreement.  
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For example, in Tannen et al [145], statistically significant differences were observed in 
nine of the total 10 clinical outcomes for the two replicated RCTs. However, the level of 
agreement improved in all such replicated RCTs involving GPRD data following statistical 
manipulation to address unmeasured confounding, such as prior exposure to the 
intervention treatment under study.    
Nine studies assessed agreement with data recorded in secondary care medical records, 
three of which found acceptable agreement. Embleton et al [183] recorded 253 ‘cancer 
progressions’ using standard prospective methods. Two additional progressions were 
recorded in secondary care medical records. The HR of 0.57 was unchanged and the CI 
change was minor; 0.45-0.74 to 0.44-0.73. Barry et al [65] recorded cardiovascular death or 
myocardial infarction between placebo and intervention groups identifying 212 vs 147 
events (P<0.001, RR 32 (16,45)). The outcome calculated using secondary care medical 
records was comparable (P<0.001, RR 39 (24,51)). Lewsey et al [46] recorded myocardial 
infarction or cardiac death in a meta-analysis of eight RCTs for two treatment 
interventions. The Relative Risk was 1.03 (95% CI 0.84 to 1.27) and was comparable to the 
RR calculated using routinely recorded data from secondary care and mortality records 
(1.15 (95% CI 0.90 to 1.48)). Two studies [155, 156] assessed the agreement of self-
reported post-operative complication rates to data recorded in secondary care medical 
records. In both studies a significantly greater number of events were self-reported and it is 
likely that patients either did not seek medical advice or contacted their General 
Practitioner when experiencing minor complications. In Mitchell et al [166] the opposite 
was found, with patients tending to under-report previous episodes of self-harm. Finally, of 
the additional routine data sources accessed, acceptable agreement was reported in Bryant 
et al [149] for infant height and weight recorded in the Personal Child Health Record, 
compared to measurements completed during research.      
Health Economic Data 
Healthcare resource use was self-reported in 15 studies using validated questionnaires and 
compared to primary or secondary care medical records with acceptable agreement found 
in just four studies.  Ford et al [175] assessed parent-reported healthcare use for 87 
children attending secondary care mental health services. The mean parent-reported 
number of total appointments was 5.6 compared to 7.0 retrieved from medical records 
(P=0.1) with acceptable agreement (ICC = 0.77, 95% CI: 0.67–0.85).  
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Morrel et al [177] assessed self-reported healthcare use in 623 patients compared to 
primary care medical records. At six months self-reported contacts were marginally under-
reported, the mean difference was -0.1 contacts (95% CI, –0.7, 0.5). Petrou et al [159] 
identified ‘90-100% agreement’ between self-reported healthcare attendances and 
attendances identified in secondary care medical records for women attending postpartum 
services. Two studies assessed agreement of the HES Inpatient Dataset with data collected 
during a RCT. Thorn et al [66] calculated healthcare resource use costs using data collected 
during an RCT (£11 122 (95% CI £9083 to £13 161)) and HES data (£10 223 (95% CI £8880 to 
£11 565)). Costs calculated with HES data were 8% lower but the difference was not 
significant (P=0.3). Wright-Hughes et al [184] did not present data, but altered their follow 
up method to include HES data to identify healthcare resource use in an on-going RCT, 
indicating their confidence in the level of agreement. For the studies without acceptable 
agreement, self-reported attendances were found to be both under and over-reported 
compared to medical records, with no distinguishing pattern.   
 
3.5 Discussion 
Routinely recorded data may provide an efficient alternative method for data collection in 
prospective research and inform outcomes beyond the standard RCT assessments of 
clinical efficacy and effectiveness. However, limitations with the accuracy of coding, 
confidentiality, ownership and access have been identified as significant barriers to 
accessing routinely recorded data for prospective research [58]. This systematic review 
assessed the agreement of routinely recorded data in the UK compared to data collected 
using standard prospective methods. A lack of evidence was identified, with ‘all-cause 
mortality’ being the only variable with a level of agreement sufficient to recommend use in 
outcome measurement in RCTs.   
Studies were heterogeneous in terms of the routinely recorded data sources accessed, 
outcomes assessed and methods used to assess agreement. Resultantly, further statistical 
manipulations of data including meta-analyses were inappropriate. Alternatively, a 
narrative approach was taken to summarise the assessments of agreement and propose an 
interpretation to determine if the evidence presented indicated a level of agreement that 
was acceptable and sufficient to endorse substituting data collected using standard 
prospective methods, with routinely recorded data in future prospective research.   
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For clinical outcomes, mortality data from UK Mortality Registers, such as the ONS provided 
the most rigorous evidence for an acceptable level of agreement. The occurrence of death, 
or ‘all-cause mortality’ was in agreement with data collected using standard prospective 
methods. However, cause of death, which relies on coded data recorded on the medical 
death certificate, was found to be in poor agreement in some studies. This is consistent 
with the general pattern of poor agreement for clinical outcomes from primary and 
secondary care medical records, with few studies providing evidence for acceptable 
agreement. In one example where rigorous agreement was found [183], the outcome of 
‘cancer progression’ was broad and it is likely that a host of investigations, specialist 
reviews and treatments had occurred in a secondary care setting, providing ample 
opportunity for events indicating ‘cancer progression’ to be recorded in the routine medical 
records.  
The poor agreement of data in either primary or secondary care in studies included in this 
review may be explained by the clinical event occurring in an alternative care setting. For 
example, post-operative minor complication rates were self-reported in greater numbers 
than recorded in secondary care medical records [155, 156], the likely explanation is that 
patients were attending their GP rather than re-attending the hospital for treatment. 
However, although self-reported diagnosis of diabetes was in good agreement with primary 
care medical records [180], self-reported diagnosis of stroke was in poor agreement with 
either primary or secondary care medical records [178], indicating that even for common or 
chronic diagnoses where evidence in medical records would be expected, poor agreement 
has been observed. Alternative explanations for the poor pattern of agreement noted for 
clinical outcomes include the possible limited accuracy of coded data [181] and the 
potential underutilisation of clinical codes within routinely recorded data sources [154].  
Further to the discussed assessments of agreement for individual-level, paired data, the 
GPRD was used to perform a number of ‘replicated RCTs’. Using unadjusted data, the 
replicated RCTs performed poorly in the assessment of agreement to the comparator RCT. 
The studies discuss the composite influence of unmeasured confounding as the likely 
explanation. For example, patients in GPRD fulfilling the inclusion criteria may have been 
exposed to the treatment under investigation before the commencement of the study 
period. A statistical technique to address unmeasured confounding was developed and the 
agreement between outcomes improved, although did not reach ‘acceptable’ levels [145].     
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Healthcare resource use also has a general pattern of poor agreement. Of the 15 included 
studies comparing routinely recorded data with self-reported healthcare resource use, four 
had an acceptable level of agreement compared to primary and secondary care medical 
records and the HES inpatient dataset. Patients both over and under-reported healthcare 
attendances with no distinguishing pattern evident. Recall bias is a possible explanatory 
factor. However, Ford et al [175] reported agreement with self-reported attendances over 
two years, whereas Dixon et al [151] concluded the opposite, with significantly different 
healthcare costs calculated from self-reported attendances recalled over 28 days compared 
to medical records.   
Healthcare attendances are perhaps more likely to be accurately recorded as a result of the 
nature of the method of remuneration in the UK National Health Service. In this context, 
the self-reported attendances are likely to be of reduced accuracy and have resulted in the 
general pattern of poor agreement. In contrast, although healthcare attendances are likely 
to be accurately recorded in medical records, the coded clinical details are likely to be less 
accurate [185] compared to standard prospective methods, such as research nurse 
appointments, patient recall of clinical details and research completion of CRFs. Although 
the issue of ‘accuracy’ of routinely recorded data remains limited, this review specifically 
assessed the agreement compared to data collected using standard prospective methods 
and similarly, there remains limited evidence.    
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3.6 Limitations 
The nature of the objective introduces limitations into the systematic review. The review 
does not focus on clinical diagnosis, intervention or outcome but rather on methodology. 
The alternative focus on routinely recorded data resulted in the search strategy being 
inclusive of all UK prospective studies but with a purposive search for specified data 
sources and relevant generic terms filtered for the UK. There is therefore a risk that studies 
poorly indexed or poorly documenting the data source or methodology may not have been 
identified. Additionally, although the majority of included studies are assessing ‘agreement’ 
as their primary objective, there remains a possibility that studies including relevant 
information have been omitted. For example, a RCT report may include relevant 
information regarding the agreement between data sources, but this may not be the 
primary focus of the report. To address this limitation as far as feasible and possible, a 
search of other relevant resources was completed. This included a review of the DIRUM 
database and an adaptation and extension of the electronic database searches in addition 
to a manual search of relevant resources.  
Finally, the heterogeneity of the included studies did not permit any further synthesis of 
data and results have been narratively presented.  Such a narrative presentation and 
interpretation is associated with a degree of subjectivity, particularly in the interpretation 
of ‘acceptable’ agreement.   
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3.7 Conclusions 
In this chapter, the agreement between routinely recorded data and data collected using 
standard prospective methods was assessed in a systematic review. Routinely recorded 
data has a generally poor pattern of agreement for both clinical data and healthcare 
economic data. In general, the level of agreement identified in this review is not currently 
sufficient to recommend use in place of data collected using standard methods in 
prospective studies including RCTs, with the exception of ‘all-cause mortality’. However, 
there are notable limitations with this systematic review and the lack of evidence available, 
for example no outcomes relevant to the treatment of epilepsy were identified and further 
research for outcomes relevant to this condition amongst others is needed.  
In the following chapters, the accessibility, feasibility and agreement between routinely 
recorded data compared to data collected using standard prospective methods for 
participants enrolled in SANAD II will be assessed.  
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Chapter Four 
The Identification and Accessibility of UK Routinely Recorded 
Data Sources 
 
4.1 Introduction 
In Chapter One, routinely recorded data and data sources in the UK were introduced, 
including the potential of routinely recorded data for use in clinical research. Epilepsy was 
introduced and the SANAD II RCT presented. In Chapter Two the use of routinely recorded 
data in randomised controlled trials in the UK was reviewed and in Chapter Three the 
agreement of UK routinely recorded data compared to data collected using standard 
methods in prospective studies was assessed in a systematic review. 
In this chapter, sources in the UK routinely recording data relevant to the outcomes of 
SANAD II will be reviewed. Subsequently, sources where routinely recorded data are 
accessible for individuals recruited into SANAD II are presented. In the following chapter, 
the methods for the comparison of the attributes of routinely recorded data retrieved from 
the accessible sources to data collected using standard prospective methods in SANAD II 
are presented. 
 
4.2 Routinely Recorded Data in the UK Relevant to SANAD II 
4.2.1 Introduction 
Routinely recorded data that are potentially relevant to SANAD II are recorded by a number 
of organisations in the UK. Sources routinely recording data that could potentially be used 
to directly measure the outcomes of SANAD II or contribute additional relevant data have 
previously been introduced in Chapter One, Section 1.4 and Tables 1.1 and 1.2, including a 
discussion of use in clinical research. In this section, the sources, data and datasets 
recorded within each source together with the procedures for requesting access to data for 
research, where they exist, will be reviewed. This review, together with the assessment of 
feasibility and efficiency presented in Chapter Eight has been published [186].   
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4.2.2 Secondary Care Clinical Routine Data Sources 
 
4.2.2.1 NHS Digital [55] 
NHS Digital is an executive non-departmental public body sponsored by The Department of 
Health and the national provider of information, data and IT systems for commissioners, 
analysts and clinicians in health and social care in England. NHS Digital records, analyses 
and presents English health and social care data [55]. 
NHS Digital Hospital Episode Statistics (HES) record details of all inpatient admissions 
(1989- ), outpatient appointments (2003- ) and A&E attendances (2007- ) at NHS hospitals 
in England. Data is routinely recorded in Patient Administration Systems (PAS) in all NHS 
Trusts in England, submitted to the Secondary Uses Service (SUS) for the primary purpose 
of re-imbursement and subsequently re-purposed as HES. HES includes a number of 
relevant datasets:  
- Accident and Emergency Dataset 
- Admitted Patient Care Dataset 
- Outpatient Dataset 
- Adult Critical Care Dataset 
-  Maternity Care 
- Patient Reported Outcome Measures 
HES data is published in anonymised aggregate reports annually. Bespoke individual-level 
datasets for use in clinical research are available through application to the Data Access 
and Request Service (DARS). Following approval by the Research Ethics Service and Health 
Research Authority, an application is submitted accompanied with supporting 
documentation (study protocol, patient information leaflets, approval documentation). A 
key criterion for approval is the demonstration that a study can directly (or indirectly) 
contribute to the improvement of the health and social care system in England. 
Furthermore, for individual-level identifiable data, there must be a valid legal basis for data 
release in place, such as participant consent. The Data Access Advisory Group (DAAG) 
assesses the application and will make a recommendation regarding approval. Following 
approval, payment will be required, a Data Sharing Agreement will need to be signed on a 
study level and a Data Sharing Framework Agreement will need to be signed on an 
institutional level before data is processed and securely transferred to the institution. 
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Notably, during the course of this research, the application and approval processes for 
access to data have evolved, together with the name of the organisation (formerly The 
Health and Social Care Information Centre). An online application portal now exists and the 
approval process has been revised with studies now reviewed by the Independent Group 
Advising on the Release of Data (IGARD).  
 
4.2.2.2 NHS Wales Informatics Service [86] 
The NHS Wales Informatics Service (NWIS) is an executive non-departmental public body 
sponsored by The National Assembly for Wales and is the national provider of digital 
services for commissioners, analysts and clinicians in health and social care in Wales [86]. 
The NWIS Information Services Division is responsible for the collection, management, and 
analysis of data held in a number of national databases, and the production and 
distribution of information derived from these databases [86].  NWIS record details of all 
inpatient admissions (1991- ), outpatient appointments (2003- ) and A&E attendances 
(2009- ) at NHS hospitals in Wales. Data is routinely recorded in Patient Administration 
Systems (PAS) in all NHS Trusts in Wales, submitted to NWIS for the primary purpose of re-
imbursement and subsequently re-purposed in a number of relevant datasets:  
- Emergency Department Dataset 
- Patient Episode Database for Wales 
- Outpatient Dataset 
- Critical Care Dataset 
NWIS data is published in anonymised aggregate reports annually. Bespoke individual-level 
datasets for use in clinical research are available through application to the NWIS Bespoke 
Analysis Service or Public Health Wales Observatory. Following approval by the Research 
Ethics Service and Health Research Authority, an application is submitted accompanied 
with supporting documentation (study protocol, patient information leaflets, approval 
documentation). For individual-level identifiable data, there must be a valid legal basis for 
data release such as participant consent.  
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4.2.2.3 NHS National Services Scotland: Information Services Division (ISD) [88] 
The Information Services Division (ISD) is a division of National Services Scotland, part of 
NHS Scotland. ISD provides health information, health intelligence, statistical services and 
advice that support the NHS in progressing quality improvement in health and care and 
facilitates robust planning and decision making [88].  
The Information Services Division is responsible for the collection, management, and 
analysis of data held in a number of administrative databases. ISD records details of all 
inpatient admissions, outpatient appointments and A&E attendances at NHS hospitals in 
Scotland. Data is routinely recorded in Patient Administration Systems (PAS) in all NHS 
Trusts in Scotland, submitted to ISD and re-purposed. A variety of relevant data is 
recorded:   
- Emergency Care 
- Inpatient Care 
- Outpatient Care 
- Critical Care 
- Primary Care Out-Of-Hours / Unscheduled Care 
- Prescribing Data, The Prescribing Information System 
Bespoke individual-level datasets for use in clinical research are available through 
application to the electronic Data Research and Innovation Service (eDRIS), which operates 
the Information Request Service. Following approval by the Research Ethics Service and 
Health Research Authority, an application is submitted accompanied with supporting 
documentation (study protocol, patient information leaflets, approval documentation). For 
individual-level identifiable data, there must be a valid legal basis for data release such as 
participant consent.  
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4.2.3 Primary Care Clinical Routine Data Sources  
 
4.2.3.1 The Clinical Practice Research Datalink (CPRD) [90] 
CPRD is a governmental research service jointly funded by the NHS National Institute for 
Health Research (NIHR) and the Medicines and Healthcare products Regulatory Agency 
(MHRA)  aiming to provide anonymised individual-level data to inform clinical research. The 
primary care records of 8.5% (12.6 million) of the UK population are included, distributed 
geographically [90].  
In addition to the primary care data, CPRD aims to provide linked individual-level data 
across a number of sources including primary and secondary care databases, disease 
registries, demographic and socioeconomic datasets. Linked data is provided through the 
Trusted Third Party, NHS Digital.  
- Primary Care Data 
o General Practice’s enrolled with CPRD and using a compatible IT system 
- Secondary Care Data 
o NHS Digital HES 
- Registry Data 
o Death data, Office for National Statistics (ONS) 
o Disease registries 
- Socioeconomic Data: 
o Lower Layer Super Output Area (LSOA) Level, ONS 
Bespoke individual-level datasets for use in clinical research are available through 
application to the Independent Scientific Advisory Committee (ISAC). Following approval by 
the Research Ethics Service and Health Research Authority, an application is submitted 
accompanied with supporting documentation (study protocol, patient information leaflets, 
approval documentation).  
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4.2.3.2 ResearchOne [91] 
ResearchOne is a collaboration between the University of Leeds and The Phoenix 
Partnership (TTP), developers of the SystmOne clinical database and IT system. 
ResearchOne provides de-identified individual-level data to inform clinical research. The 
primary care records of 26 million patients in the UK are included retrieved from General 
Practices’ enrolled with ResearchOne and using the SystmOne clinical database. In addition, 
health and socioeconomic data may in some circumstances be linked such as data retrieved 
from palliative care settings and secondary care settings including emergency and inpatient 
care [91]. Linked data is provided through the Trusted Third Party, NHS Digital.  
Bespoke individual-level datasets for use in clinical research can be considered on 
application. Following approval by the Research Ethics Service and Health Research 
Authority, an Expression of Interest Form is completed. If feasible, an application would 
subsequently include the supporting documentation (study protocol, patient information 
leaflets, approval documentation) and be considered by the ResearchOne Project 
Committee. 
 
4.2.3.3  QResearch [93] 
QResearch is a collaboration between the University of Nottingham and the developers of 
the EMIS IT systems. QResearch provides de-identified individual-level data to inform 
clinical research. The primary care records of 24 million patients in the UK are included 
retrieved from General Practices’ enrolled with QResearch and using the EMIS IT system 
[93]. In addition, aggregate socioeconomic data at LSOA level can be provided.  
Bespoke individual-level datasets for use in clinical research can be considered on 
application. Following approval by the Research Ethics Service and Health Research 
Authority, discussion with QResearch is required to determine feasibility. A QResearch 
Application Form is then completed and considered by the QResearch Scientific 
Committee, together with the supporting documentation (study protocol, patient 
information leaflets, approval documentation).   
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4.2.3.4 The Health Improvement Network (THIN) Database [95] 
THIN is a collaboration between IMS Health and In Practice Systems, developers of the IT 
software Vision. THIN provides de-identified individual-level data to inform clinical 
research. The primary care records of 11 million patients in the UK are included retrieved 
from General Practices’ enrolled with THIN and using the Vision IT system [95]. In addition, 
aggregate socioeconomic data at LSOA level can be provided. Data are validated by the 
Trusted Third Party, CSD Medical Research UK.  
Bespoke individual-level datasets for use in clinical research can be considered on 
application. Following approval by the Research Ethics Service and Health Research 
Authority, discussion with THIN is required to determine feasibility. The study protocol 
together with supporting documentation (study protocol, patient information leaflets, 
approval documentation) is then submitted for consideration by the THIN Scientific Review 
Committee.    
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4.2.3.5 North West eHealth (NWEH) [97] 
NWEH is a not-for-profit collaboration between The University of Manchester, Salford 
Royal Foundation Trust and Salford Clinical Commissioning Group, aiming to develop 
research in health informatics and improve the links between academic institutions and the 
NHS [69, 97]. NWEH has an established infrastructure for accessing linked primary and 
secondary care data and prescribing data. The Salford Integrated Record (SIR) is an 
integrated electronic medical record recording all primary and secondary care attendances 
in Salford. NWEH have developed the methodology and governance framework to 
implement the SIR in research to provide primary and secondary care data and additional 
data such as details regarding pharmacy dispensing. The Salford Lung Study is an ongoing 
example of the implementation of this system in research [69]. This Linked Database 
System involves access to secondary care data recorded by the Secondary Uses Service 
(SUS) and access to primary care data for consenting participants and General Practices’ 
using the Apollo [98] and Graphnet [99] data extraction tools, both used routinely for 
clinical audit and Quality and Outcome Framework (QOF) assessment. For the wider 
research community, NWEH provides services including the COCPIT and FARSITE initiatives 
to provide the facility to monitor individual patients and perform RCT recruitment 
feasibility assessments, respectively. NWEH do not currently routinely provide a bespoke 
data extraction service for research. However, the methodology and governance 
framework are in place and proof-of concept has been demonstrated [69].     
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4.2.4 ‘Linked’ Routine Data Sources 
 
4.2.4.1 The Secure Anonymised Information Linkage (SAIL) Databank [100] 
The Secure Anonymised Information Linkage Databank is an initiative developed by the 
College of Medicine, Swansea University and receives core-funding from the National 
Institute of Social Care and Health Research (NISCHR) of the Welsh Government. SAIL aims 
to provide and improve access to electronic routinely-collected, anonymised individual-
level data to support clinical research [100].  
The SAIL Primary Care GP Dataset provides primary care data for individuals registered to 
enrolled General Practices’. However, SAIL also provides the infrastructure to provide de-
identified linked individual-level data from a number of other clinical and socioeconomic 
datasets.  Linked data is provided through the Trusted Third Party, NWIS. Relevant datasets 
include: 
- Primary Care GP Dataset (SAIL) 
- Patient Episode Database for Wales (PEDW, NWIS) 
- Outpatient Dataset (NWIS) 
- Emergency Department Dataset (EDDS, NWIS) 
- Critical Care Dataset (NWIS) 
- Annual District Death Extract (NWIS) 
- Welsh Demographics Service (NWIS) 
Bespoke individual-level datasets for use in clinical research are available through 
application to the Information Governance Review Panel (IGRP). Following approval by the 
Research Ethics Service and Health Research Authority, an application is discussed with 
SAIL and a Scoping Document completed. Once the feasibility of the project, including 
funding has been confirmed the application is reviewed by the IGRP, together with 
supporting documentation (study protocol, patient information leaflets, approval 
documentation). Access to data is usually remotely, through the SAIL Gateway Platform.  
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4.2.4.2 The Administrative Data Research Network (ADRN) [102]  
The Administrative Data Research Network is a UK-wide partnership between universities, 
government departments, national statistics authorities, funders and researchers, funded 
by the Economic and Social Research Council. ADRN provides a method of access to a 
number of non-clinical administrative routine datasets including employment, 
socioeconomic, crime and education data [102] in addition to clinical datasets detailed 
previously such as those recorded by NHS Digital. 
Notably, the ADRN does not record data, but rather provides a bespoke service for 
researchers to negotiate for data access with each relevant data source. The aim is to 
provide a linked de-identified dataset to the researcher. The linking service is provided 
through a Trusted Third Party, such as NHS Digital. An important caveat is that at least a 
proportion of the data to be sought is not available through another route of access. 
Examples of potentially relevant data include:  
- Primary and Secondary Care Clinical Datasets (NHS Digital, NWIS, ISD) 
- Economic Datasets 
- Employment Datasets 
- Population Datasets, Deaths 
Bespoke individual-level datasets for use in clinical research are available through 
application to the ADRN Approvals Panel. Following approval by the Research Ethics Service 
and Health Research Authority, an application is discussed with ADRN and feasibility 
confirmed. The application is reviewed by the Approvals Panel, together with supporting 
documentation (study protocol, patient information leaflets, approval documentation). 
Access to data is usually through a dedicated Administrative Data Research Centre, for 
England this is based at University College London. 
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4.2.5 Non-Clinical Routine Data Sources 
 
4.2.5.1 The Office for National Statistics (ONS) [107]  
The Office for National Statistics is the recognised national statistics institute and the 
largest independent producer of official statistics. ONS are responsible for recording and 
publishing statistics related to the economy, population and society at national, regional 
and local levels, in addition to conducting the census in England and Wales [107].  
ONS records a limited amount of identifiable data, such as births and deaths data. 
However, the majority of statistics produced by ONS are non-identifiable, aggregate 
statistics recorded through a number of channels such as the Census and General 
Household Survey. Examples of potentially relevant data include: 
- Population, demography and migration statistics 
- Labour market Statistics (employment, unemployment and earnings) 
- Vital events statistics (births, marriages and deaths) 
- Social statistics (regarding neighbourhoods, families, crime) 
- Economic, societal and personal well-being 
Aggregate statistics are in the public domain and are available on a population level or 
presented in a Super Output Area (SOA). Clinical sources of routine data such as NHS Digital 
and NWIS record LSOA reference numbers allowing individual-level clinical data to be 
linked to LSOA level socio-economic data. Aggregate statistics can be accessed via services 
provided by ONS such as NOMIS [108] and Data for Neighbourhoods and Regeneration 
[109]. Notably, such data is non-identifiable and is in the public domain. Specific requests 
for data not published in official statistical outputs are permitted and contact via email is 
suggested in the first instance. Finally, individual data regarding deaths can be requested 
and projects are reviewed by the Microdata Release Panel. Such projects must be in the 
public interest and the researcher must attain ‘Approved Researcher Status’.  
  
88 
 
4.2.5.2 HM Revenue and Customs (HMRC) [103] 
HM Revenue and Customs is the national tax authority and was commissioned and 
established in 2005 by the Commissioners for Revenue and Customs Act, replacing the 
Inland Revenue and Customs and Excise. HMRC is a non-ministerial department responsible 
for tax policy maintenance and implementation, strategic tax policy and policy 
development [103].  
HMRC is responsible for taxation including income tax, national insurance and student loan 
repayments and the administration of tax credits, child benefit and statutory sick and 
maternity pay. HMRC records individual-level data and examples of potentially relevant 
data include: 
- Employment Data 
o Income 
o Tax contributions 
- Statutory Benefit Data 
o Tax credits 
o Statutory sick and maternity pay 
Data recorded by HMRC are likely to be accurate, complete and informative to health and 
socioeconomic analyses, including an assessment of the broader, societal impacts of 
treatments.  
HMRC are actively involved in external research with academic institutions. The ‘HMRC 
Datalab’ provides access to de-identified HMRC data for approved research. Projects must 
benefit both ‘HMRC and the wider academic community’. The Datalab is governed by the 
Commissioners for Revenue and Customs Act (CRCA) 2005 and research must serve one of 
HMRC’s functions under the CRCA 2005. Such ‘functions’ include procedures or 
responsibilities of the HMRC.  A Project Proposal Form is completed and applications are 
reviewed quarterly. Approved Researcher Status must be obtained before access to data is 
granted.   
 
  
89 
 
4.2.5.3 The Department for Work and Pensions (DWP) [104] 
The Department for Work and Pensions is a ministerial department responsible for welfare, 
pensions and child maintenance and provides its services through a number of outlets 
including Job Centre Plus, The Pension Service, Child Support Service and The Child 
Maintenance Service [104].  
DWP is responsible for the provision of the state pension and provision of benefits; 
individually assessed non-taxable monetary credits provided to support reasonable living 
costs. Benefits are numerous, frequently assessed and changes in circumstances result in 
frequent alterations to individuals’ eligibility. DWP records individual-level data and 
examples of potentially relevant data include: 
- Employment Data 
o Income 
o Tax contributions 
- Benefit Data 
o Attendance Allowance 
o Carer’s Allowance 
o Child Benefit 
o Disability Living Allowance 
o Jobseekers Allowance 
o Universal Credit 
o State Pension 
Data recorded by DWP are likely to be accurate, complete and informative to health and 
socioeconomic analyses, including an assessment of the broader, societal impacts of 
treatments. 
The DWP are actively involved in external research with academic institutions. De-
identified, aggregate data at LSOA level are available via services provided by DWP.   
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4.2.5.4 The Driver and Vehicle Licensing Authority (DVLA) [18] 
The DVLA is an executive governmental agency sponsored by the Department for Transport 
and responsible for maintaining an active register of drivers and vehicles in the UK, 
improving road safety, supporting vehicle tax, reducing vehicle related crime, and 
supporting environmental initiatives [18]. 
The DVLA is responsible for the licensing of drivers and vehicles in the UK and issuing, 
reviewing and maintaining guidance regarding driver license status in the context of 
medical diagnoses. There is a legal requirement for the individual to inform the DVLA if 
they have been diagnosed with specific diseases, including seizures and epilepsy. DVLA 
records individual-level data and examples of potentially relevant data include: 
- Driving License Status 
o Dates issued, withdrawn, re-issued 
- Diagnoses 
o Diagnosis 
o Date 
o Medical data supplied by clinician 
The DVLA have been involved in external research with academic institutions. De-
identified, aggregate data are available on application and initial discussion with the DVLA 
is advised in the first instance.   
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4.3 The Accessibility of Routinely Recorded Data Relevant to SANAD II 
 
4.3.1 Accessibility 
An objective of this research is to assess the attributes of routinely recorded data 
compared to data collected using standard prospective methods for individuals recruited 
into SANAD II. During the development of the study protocol it was necessary to identify 
data sources where routinely recorded data could be retrieved for the specific individuals 
recruited into SANAD II. This identification of accessible sources of routinely recorded data 
was required to inform the protocol and consent documentation. As a consequence of 
strict ethical and governance regulations, both nationally and within each source of 
routinely recorded data, a ‘blanket’ consent procedure requesting access to all potentially 
relevant routinely recorded data was not appropriate or permissible. Consent 
documentation needed to meet the requirements of the Research Ethics Service, Health 
Research Authority and each accessible source of routinely recorded data and therefore 
included highly specific information relevant to each organisation.  
For the purposes of this research the assessment of accessibility included the following 
criteria: 
- Access to routinely recorded data for research, including clinical research is 
possible 
- Individual-level data for specific individuals recruited into SANAD II can be retrieved 
Following a prolonged period of scoping discussions and development of the protocol and 
consent documentation, sources of routinely recorded data in the UK accessible for this 
study were identified.  
 
  
92 
 
4.3.2 Accessible Routinely Recorded Data Sources 
 
4.3.2.1 NHS Digital [55] 
The Hospital Episode Statistics datasets provide emergency, inpatient, outpatient and 
critical care clinical and socioeconomic data for participants of SANAD II resident in 
England.  
 
4.3.2.2 The Secure Anonymised Information Linkage Databank [100] 
Routinely recorded primary care, emergency, inpatient, outpatient and critical care clinical 
and socioeconomic datasets provided through SAIL for participants of SANAD II resident in 
Wales.   
 
4.3.2.3 NHS National Services Scotland: Information Services Division [88] 
Routinely recorded emergency, inpatient, outpatient and critical care clinical and 
socioeconomic data provided through ISD for participants of SANAD II resident in Scotland.   
 
4.3.2.4 The Office For National Statistics [107] 
Routinely recorded mortality data is accessible for individuals recruited into SANAD II.  
 
4.3.2.5 North West eHealth [97] 
Routinely recorded primary and secondary care clinical, prescribing and socioeconomic 
data provided through NWEH for participants of SANAD II resident in the North West of 
England.   
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4.3.3 Non-Accessible Routinely Recorded Data Sources 
A notable proportion of the available sources of routinely recorded data were non-
accessible for individuals recruited into SANAD II. Non-accessible sources are listed in this 
chapter and discussed further in the assessment of feasibility, Chapter Eight.    
 
4.3.3.1 Primary Care Clinical Routine Data Sources 
With the exception of North West eHealth, the remaining primary care sources were not 
accessible for individuals recruited into SANAD II. The Clinical Practice Research Datalink, 
ResearchOne, QResearch and The Health Improvement Network all operate on a de-
identified basis, resulting in an inability to re-identify specific individuals. Therefore, 
participants recruited into SANAD II cannot be re-identified within each database.   
 
4.3.3.2 Non-Clinical Routine Data Sources 
HM Revenue and Customs, The Department for Work and Pensions and The Driver and 
Vehicle Licensing Authority were not accessible. Enquiries for HMRC and DWP were 
directed to the ADRN, whose negotiations for data access were not successful. The DVLA 
refused permission for data access, citing ‘insufficient resources’ together with ‘security 
measures in excess of the NHS or University’ as the explanation. This outcome correlates 
with the findings in Chapters Two and Three, where no clinical studies accessing individual-
level data from these data sources were identified.   
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4.4 Conclusions 
In this chapter the accessibility of UK routinely recorded data for participants of SANAD II 
was assessed. Routinely recorded secondary care data and mortality data were accessible. 
Primary care data from the majority of sources were not accessible as a result of the de-
identified record of the data, resulting in an inability to identify the specific individuals 
recruited into SANAD II. Non-clinical data sources were not accessible, the ADRN being 
unsuccessful in negotiating access to HMRC and DWP data and the DVLA citing insufficient 
resources and stringent security measures. Streamlining the ADRN data application and 
access procedures and including the DVLA on the list of ADRN data sources to alleviate 
resource demands on this institution may result in improved access. Furthermore and 
relevant to the DVLA, utilising the ADRN who retrieve data on a de-identified basis before 
providing to the researcher, could be proposed as a method of improving data security.    
There are limitations associated with this assessment of ‘accessibility’, which involved the 
identification of relevant data sources and detailed scoping discussions to determine if 
access to data was possible. It is possible that relevant sources were not identified and 
therefore not contacted. Furthermore, the focus of the research was on large regional or 
national sources of routinely recorded data to ensure generalisability of the results, 
relevant to the UK-wide SANAD II RCT. Smaller sources, such as disease specific registers 
are likely to have different properties regarding accessibility, as well as the subsequent 
assessment of quality and agreement compared to data collected using standard 
prospective methods.   
In the following Chapter Five, the methods for the assessment of quality and agreement of 
routinely recorded data compared to data collected using standard methods in SANAD II 
will be presented.  
 
  
95 
 
Chapter Five 
Methods: The Attributes of Routinely Recorded Data 
 
5.1 Introduction 
In Chapter Two the use of routinely recorded data in randomised controlled trials in the UK 
was reviewed and in Chapter Three a systematic review of studies that have compared the 
agreement of UK routinely recorded data to data collected using standard methods in 
prospective studies was conducted. Routinely recorded data sources in the UK were 
reviewed in Chapter Four and those accessible for the purposes of this study were 
identified.   
In this chapter, the methods for the assessment of quality and agreement of routinely 
recorded data compared to data collected using standard methods in SANAD II will be 
presented. The objectives and aspects of the study design are initially presented. 
Subsequently, the methods for interrogation of the routinely recorded data, extraction of 
relevant data using an algorithmic approach and assessment of the quality and agreement 
for defined variables and outcome measures are presented.  
 
5.2 Research Objectives 
1. Compare the attributes of data extracted from electronic medical records against 
data collected using standard methods, in the randomised controlled trial (RCT), 
SANAD II: 
a. Assessment of the quality of data extracted from electronic medical records 
b. Assessment of the agreement between data extracted from electronic medical 
records and data collected using standard prospective methods  
 
2. Assess the Feasibility and Efficiency of Accessing and Using Routinely Recorded Data 
from Electronic Medical Records 
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5.3 Study Design 
This study was a retrospective, observational study assessing the attributes of data 
routinely recorded in electronic medical records and accessed through administrative 
healthcare databases, or ‘routine sources’, relevant to SANAD II. The ‘quality’ and 
agreement were assessed using descriptive statistics and quantitative measures of 
agreement for the data variables and outcome measures, where possible. Subsequently, 
the feasibility and efficiency of accessing routinely recorded data were assessed.  
 
5.4 Participants 
The inclusion criteria were as follows: 
- Individuals aged 16 years or over 
- Individuals recruited into SANAD II with a minimum of 12 months follow-up 
- Individuals with capacity to consent to the retrieval of routinely recorded data 
 
SANAD II remains in progress and participants newly recruited will have a limited follow-up 
period. Therefore, to ensure adequate follow-up duration, the inclusion of all eligible 
participants with a minimum 12 months follow-up period was specified. This pragmatic 
approach ensured sufficient data was recorded to assess the data variables and outcome 
measures relevant to SANAD II. Four hundred and seventy participants in SANAD II fulfilled 
the inclusion criteria, with 98 providing consent to participate in this study. A sample size 
calculation a priori was not meaningful or informative as a result of the limited number of 
eligible individuals; rather the impact of sample size was considered during the analyses.       
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5.5 Routinely Recorded Data Sources 
Following the assessment of accessibility presented in Chapter Four, the routinely recorded 
data sources included in this study are as follows:  
- NHS Digital [55] 
o Recording data for episodes of patient contact with NHS secondary care in 
England 
- The Secure Anonymised Information Linkage Databank (SAIL) [100] 
o Providing access to data for episodes of patient contact with NHS 
secondary care and in selected cases primary care for patients in Wales 
- General Practitioners’ (GP’s), North West England 
o Recording data for episodes of patient contact with NHS primary care in 
England 
o Access through North West eHealth (NWEH) or General Practice  
 
5.6 Ethical and Regulatory Approvals  
This study has been reviewed and approved by the North of Scotland Research Ethics 
Service (29/01/16, REC reference: 16/NS/0007, Protocol number: UOL001183, IRAS project 
ID: 189002). A substantial amendment regarding access to primary care data was 
subsequently approved (19/05/16, REC1, AM01). Regulatory approval has also been 
provided by the Health Research Authority (05/02/16 REC reference: 16/NS/0007, Protocol 
number: UOL001183, IRAS project ID: 189002). Research capacity has been confirmed by 
The Walton Centre for Neurology and Neurosurgery NHS Foundation Trust.    
SANAD II has previously been approved by the National Multi-Centre Research Ethics 
Committee (MREC Reference No: 12/NW/0361) and approved at each research site 
following independent review by local Research and Development offices.  
The University of Liverpool acted as the Sponsor for this study. Delegated responsibilities 
were assigned to The Walton Centre for Neurology and Neurosurgery NHS Foundation 
Trust. The University of Liverpool holds Indemnity and insurance cover with Marsh UK LTD, 
which apply to this study. 
This study has been completed during a Clinical Training Fellowship awarded to Dr Graham 
Powell, funded by the Medical Research Council Hubs for Trials Methodology Research.   
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5.7 Participant Recruitment 
The SANAD II Data Manager identified eligible individuals by review of data recorded for 
participants enrolled in SANAD II. Individuals’ date of birth, date of enrolment and consent 
documentation were screened and the names and addresses of eligible individuals were 
retrieved. Four hundred and seventy eligible participants were sent an ‘invitation pack’ via 
the postal services. The invitation pack contained a Participant Information Leaflet, Consent 
Form and pre-paid addressed envelope. The information leaflet detailed the rationale and 
procedures involved in the retrieval of data from electronic medical records through the 
included routine sources. Procedures included permission to transfer the identifying 
variables NHS Number and SANAD II Study Number to NHS Digital, NHS Wales Informatics 
Service and participants GP’s via NWEH, SANAD II Study Number to SAIL and permission to 
retrieve data from electronic medical records for the time period 2013 – present, matching 
the duration of SANAD II and transfer to the University of Liverpool. The information leaflet 
also explained that there was no obligation to take part, participation was entirely 
voluntary and withdrawal could occur at any time without need to provide explanation. In 
addition, individuals were assured that their involvement in SANAD II or their routine 
clinical care would not be affected by participating or not participating in this study and 
that data would only be retrieved on a single occasion. A proportion of participants in the 
North West of England were also requested to give permission for the study team and 
NWEH to approach their GP in order to request access to primary care data. A single 
‘Reminder: Letter of Invitation’ was sent via the postal services accompanied with the 
Participant Information Leaflet and Consent Form if there had been no response following 
a period of three weeks. The Participant Information Leaflet and Consent Form are 
presented in Appendix C. Ninety eight individuals (20.9%) consented to participation.  
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5.8 Routinely Recorded Data Source Applications 
NHS Digital 
An application for Hospital Episode Statistics (HES) data from the Admitted Patient, 
Outpatient, Accident and Emergency and Critical Care Datasets was submitted via the 
newly introduced Data Access Request Service Online Portal (22/04/16). Following review 
by the Data Access Advisory Group, final approval and issuing of the Data Sharing 
Agreement was completed (29/06/16) and data for 71 individuals identified by NHS 
Number was provided (13/07/16). The final cost of the data, including VAT was £10,200.   
The Secure Anonymised Information Linkage Databank (SAIL) 
An application for data from the Patient Episode Database for Wales, Outpatient, Primary 
Care and Emergency Department Datasets was submitted (01/02/16). The application was 
approved following review by the Information Governance Review Panel (26/07/16) and 
the data for 27 individuals identified by NHS Number was provided following issue of the 
Data Release Agreement (22/08/16). The final cost of the data, including VAT was £3390. 
General Practitioners’ (GP’s), North West England 
An application for primary care data from participants resident in North West England 
through North West eHealth was planned. However, of 18 patients providing consent, only 
three were registered to eligible General Practice’s enrolled with North West eHealth and 
with the required Apollo Data Extraction Tool installed. The cost was very high at £16,800 
and considered an inefficient use of resources.    
A substantial amendment was approved by the North of Scotland Research Ethics Service 
and Letter of Access provided by the National Institute of Health Research Clinical Research 
Network to permit the Principal Investigator (Dr Graham Powell) to approach the General 
Practices of participants’ resident in North West England directly. The GP was formally 
requested to provide permission and access for the Principal Investigator to attend the 
practice on a single occasion and manually review the participant’s electronic medical 
record. A Letter of Invitation was sent via the postal services accompanied with supporting 
documentation, including Research Ethics and Health Research Authority Approval 
Documents, Statement of Activities and Schedule of Events and the Data Extraction 
Procedure and Form. The data extraction procedure is detailed in Box 5.1.    
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Box 5.1: The General Practice Data Extraction Procedure 
- General Practice (GP) confirms agreement to participate in the study 
o GP returns HRA Statement of Activities and HRA Schedule of Events  
- Participant signed Consent Form will be sent to GP via postal service or secure NHS.net email address 
- Dr Graham Powell (Principal Investigator) attends GP at a pre-arranged time, presents NHS and 
University of Liverpool ID badges and NIHR Clinical Research Network Letter of Access 
o REC / HRA Approval Documents will be available 
o HRA Statement of Activities / Schedule of Events will be available 
- Dr Powell will sign a Confidentiality Agreement / Confidentiality Register, provided by the GP if 
required  
- GP staff member will provide access to a computer terminal and access to the participant’s electronic 
medical record 
- Dr Powell will review the participant’s electronic medical record 
o All information in the electronic medical record will be reviewed, including READ codes, free 
text entries, investigations requested and results and clinic letters including referral letters 
- Dr Powell transcribes information that is relevant to the study to the Data Extraction Form, pre-
labelled with the participant’s Study ID Number. Identifiable information will not be transcribed  
- On completion, the GP will have the opportunity to review the Data Extraction Form to confirm their 
agreement with the information that has been transcribed 
- Dr Powell transfers in person the Data Extraction Form to the University of Liverpool. Data is 
transcribed to the secure study database and the Data Extraction Form is destroyed 
 
The General Practices of 18 participants resident in North West England were approached. 
Two GP’s provided consent and data were extracted for the participants in accordance with 
the protocol in July 2016. Three GP’s refused participation and the remaining 13 GP’s 
provided no response despite repeated attempts at contact.   
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5.9 Data Management 
All personal data in this study has been kept strictly confidential and was handled, stored 
and destroyed in accordance with the Data Protection Act 1998. The process of 
identification and invitation of eligible individuals enrolled in SANAD II to participate in this 
study involved access to the SANAD II database. SANAD II data is managed by the University 
of Liverpool Clinical Trials Research Centre (CTRC) and existing data security standards were 
maintained during this study. The SANAD II Data Manager screened date of birth, date of 
enrolment and consent documentation and the names and addresses of eligible individuals 
were retrieved. For the 98 participants agreeing to consent to this study, the identifying 
variables NHS Number and SANAD II Study Number were transferred to NHS Digital and 
NWIS and SANAD II Study Number to SAIL using a secure electronic transfer system. 
Subsequently, participants data from electronic medical records accessed through the 
routine sources was transferred to the University of Liverpool using the NHS Digital Secure 
File Transfer (SFT) System [187] . ‘Study data’ consisted of data provided by the routine 
data sources and data extracted from the SANAD II database. The SANAD II Data Manager 
received the data from routine sources and linked to data extracted from SANAD II. These 
datasets were then pseudonymised, identified by a Unique Study Number before being 
provided to the Principal Investigator (Dr Graham Powell).   
Study data were stored using the University of Liverpool Research Data Management 
Service’s DataStore [188] and encrypted using industry standard techniques meeting the 
NHS Information Governance Toolkit standard (8HN20). The data storage location was as 
follows: livad.liv.ac.uk\rdm\projectstore\RoutineData. The Principal Investigator (Dr 
Graham Powell) acted as Data Processor. The University of Liverpool acted as Data 
Controller. The University of Liverpool Information Security Policy, informed by the 
principles set out in ISO 27001 and Research Data Management Policy were adhered to 
throughout the study.     
The participant consent forms were the only non-electronic data stored during the study. 
Consent forms were stored in a locked filing cabinet in the locked SANAD II coordinating 
centre office (2nd Floor, Clinical Sciences Centre, University of Liverpool, L9 7AL). 
Study completion is defined by the date of 31/12/18. Fully anonymised study data will be 
stored in the Research Data Management Service Archiving Repository and deleted five 
years following the date of study completion.   
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5.10 Routinely Recorded Data and Data Coding Systems 
Data routinely recorded in electronic medical records and held in administrative healthcare 
databases in the United Kingdom are routinely recorded using coding systems. In England, 
NHS Digital regulates the coding systems and in Wales the NHS Wales Informatics Service. 
The coding systems between countries are comparable. The NHS data dictionary provides 
an overview of the coding systems used in the NHS [189].   
5.10.1 NHS Digital: Hospital Episode Statistics (HES) 
NHS Digital routinely record data regarding secondary care for patients in England 
published as Hospital Episode Statistics. In this study, data from four HES datasets were 
requested:  
- Admitted Patient Care Dataset 
- Critical Care Dataset 
- Accident & Emergency Dataset 
- Outpatient Dataset 
 
NHS Digital publish data dictionaries for each dataset [190]. In each dictionary, derived 
from the NHS data dictionary, the individual data fields are presented together with the 
coded data values for interpretation. For example, from the Admitted Patient Care Dataset:  
- Data field:  Admin category at start of episode (ADMINCATST) 
- Data Values:  01 = NHS patient; 02 = Private patient 
The data fields are comparable between datasets, however the available data fields differ, 
with the Admitted Patient Care Dataset providing the most comprehensive data. The data 
fields and coded interpretation are presented in detail in the data dictionaries with the 
exception of clinical data. The Admitted Patient Care and Outpatient Datasets use the 
International Statistical Classification of Diseases and Related Health Problems (10), 
discussed in section 5.10.4. However, the Accident & Emergency Dataset records a less 
detailed diagnostic coding system, presenting diagnosis by broad disease area. For 
example, ‘CNS Disorder’ and ‘Central Nervous System Disorder – Epilepsy / Seizure’ were 
the diagnostic codes most informative to this study. The Critical Care Dataset does not 
record details regarding diagnosis.  Clinical and surgical procedures are recorded using the 
Office of Population Census and Surveys, Version 4 (OPCS 4) coding system in the Admitted 
Patient Care and Outpatient Datasets, discussed in section 5.10.4.     
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5.10.2 NHS Wales Informatics Service (NWIS): The Secure Anonymised Information 
Linkage Databank (SAIL): 
Data routinely recorded by NWIS regarding primary and secondary care for patients in 
Wales were accessed through SAIL. In this study, data from four datasets were requested:  
- Patient Episode Database for Wales 
- Emergency Department Dataset 
- Outpatient Dataset 
- Primary Care Dataset 
 
NWIS publish data dictionaries for each dataset [191]. In each dictionary, derived from the 
NHS data dictionary, the individual data fields are presented together with the coded data 
values for interpretation. Similar to HES datasets, the data fields are comparable between 
datasets but the availability of data fields differs, with the Patient Episode Database for 
Wales providing the most comprehensive data. Again similar to HES datasets, diagnostic 
information is recorded using the International Statistical Classification of Diseases and 
Related Health Problems (10), with the exception of the Emergency Department Dataset 
which uses a less detailed diagnostic coding system presenting diagnosis by broad disease 
area (‘CNS Disorder’, ‘Central Nervous System Disorder – Epilepsy / Seizure’).  Finally, clinical 
and surgical procedures are recorded using the Office of Population Census and Surveys, 
Version 4 (OPCS 4) coding system in the Patient Episode Database for Wales and 
Outpatient Datasets.     
5.10.3 Primary Care Data 
Primary care data are routinely recorded in electronic medical records by participants 
General Practitioners (GP). The GP records data both using free text entries and the UK 
READ coding system, discussed in section 5.10.4 [57]. In this study UK READ codes and free-
text entries were reviewed for the two participants in the General Practices where direct 
access was permitted. All recorded UK READ codes for the relevant time period were also 
provided for participants registered to General Practices enrolled in the SAIL Primary Care 
Dataset.     
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5.10.4 Clinical Coding 
Clinical data including diagnostic data are recorded in electronic medical records using 
clinical coding systems, differing in the routine datasets accessed during this study between 
primary and secondary care:   
Secondary Care:  
International Statistical Classification of Diseases and Related Health Problems (ICD) 10 
ICD 10 is the 10th revision of the medical classification system by the World Health 
Organization (WHO). Included are codes for diseases, signs and symptoms, abnormal 
findings, complaints, social circumstances, and external causes of injury or diseases. ICD 10 
codes are included in both HES and NWIS datasets. ICD 10 codes can be accessed in 
website form [56]. In addition, NHS Digital provide access to an eBook of ICD 10 codes 
through their Technology Reference Data Update Distribution (TRUD) service [192].  
Office of Population Census and Surveys, Version 4 (OPCS 4) 
OPCS 4 is the coding system used for procedures within NHS hospitals of England, Scotland, 
Wales and Northern Ireland. OPCS 4 includes codes for surgical operations, procedures and 
interventions performed in secondary care. NHS Digital provide access to an eBook of OPCS 
4 codes through their Technology Reference Data Update Distribution (TRUD) service [192].  
Primary Care:  
NHS UK READ Codes Clinical Terms Version 2 
UK READ codes are the standard clinical terminology coding system used in General 
Practice. The UK READ system includes codes for clinical data (signs, symptoms, 
observations, investigations, results, diagnoses and diagnostic, therapeutic or surgical 
procedures) and administrative data (occupation, social circumstances, ethnicity, religion) 
[57]. The implementation of UK READ codes in General Practice is broader, compared to 
ICD 10 in secondary care datasets which is generally used only for diagnostic data. UK READ 
Clinical Terms Version 3 is currently being implemented and may have been used in some 
of the General Practices providing data for this study. NHS Digital provide access to the UK 
READ Browser through their Technology Reference Data Update Distribution (TRUD) 
service [193].  
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The Systematized Nomenclature of Medicine--Clinical Terms (SNOMED CT) is a clinical 
coding system standardised internationally and including currently active UK READ codes.  
The UK National Informatics Board has ruled that SNOMED CT will be used as the primary 
clinical coding system across all healthcare in the UK by 2020 and it is possible that some 
General Practices included in this study were using this coding system. SNOMED CT is 
available in browser form [194] or through the NHS Digital Technology Reference Data 
Update Distribution (TRUD) service [195].  
Notably, whether Clinical Terms Version 2, Version 3 or SNOMED CT coding systems were 
used in the General Practices, the UK READ codes are consistent.  
 
5.11 The Routinely Recorded Data  
An inclusive approach to the routinely recorded data variables requested was taken to 
maximise the data available. This ensured the ‘best case’ routinely recorded data were 
available for the analyses.   
Box 5.2 presents a summary of the routinely recorded data requested.     
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Box 5.2: Summary of Data Requested from Routine Sources 
Secondary Care Data: HES / SAIL   
 
- Emergency Care Datasets: 
- All attendances for study participants during the study period: 
o Date of attendance 
o Arrival method 
o Clinical Data: 
▪ ‘Reason for attendance’ / diagnoses 
▪ Investigations 
▪ Treatment 
o Disposal method (discharge, admit) 
 
- Inpatient Care Datasets: 
- All attendances for study participants during the study period: 
o Details of Admission (‘Finished Consultant Episodes’ and ‘Hospital Spells’): 
▪ Date of admission, date of discharge, method of admission (elective, 
emergency) 
o Clinical Data: 
▪ Diagnoses, investigations, treatments, procedures 
o Socioeconomic Data 
▪ Aggregated data (LSOA), (Welsh) Index of Multiple Deprivation (IMD)  
o Health Economic Data  
▪ Cost of treatment and procedures (Healthcare Resource Groups (HRG’s)) 
o Disposal method (discharge, death)  
 
- Outpatient Care Datasets: 
- All attendances for study participants during the study period:   
o Appointment type (urgent / routine new / follow up) 
o Referral Details: 
▪ Source, urgency, waiting time 
o Clinical Data 
▪ Diagnoses, investigations, treatment 
 
- Critical Care Dataset: 
- All attendances for study participants during the study period: 
o Admission details, date, duration 
o Clinical details, support provided, Level 2, Level 3 care 
o Disposal Details, discharge destination 
 
Primary Care Data: General Practitioners’ North West England / SAIL   
 
- Primary Care Dataset:  
- All attendances for study participants during the study period: 
o Clinical Data 
▪ Consultation record, diagnoses, seizures 
▪ Adverse drug reactions / Adverse events  
o Referrals to neurology and secondary care 
o Prescriptions  
o Diagnostic testing, investigation results (MRI, CT, EEG) 
o Lifestyle information (e.g. smoking and alcohol status, employment status)  
o Socioeconomic Data 
▪ Non-identifiable, provided at the Lower Layer Super Output Area (LSOA) 
level 
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5.11.1 NHS Digital: Hospital Episode Statistics (HES) 
NHS Digital Hospital Episode Statistics (HES) [55] data were requested and retrieved. The 
cost was calculated on a not-for-profit, cost recovery basis. The total cost of HES data in 
this study, excluding VAT was £8,300. Table 5.1 presents the cost calculation using data 
provided by NHS Digital.    
 Table 5.1: NHS Digital HES Cost Calculation 
Study Element Cost (£) 
Base cost 1000 
Release fee 800 
Agreement, 3 years 500 
Data cost 6000 
Total 8300 (+VAT) 
 
The Data Protection Act [50] provides the legal framework for data release. In this study, 
participant informed written consent provided the valid legal basis for data release. Data 
minimisation principles were adhered to and therefore only the minimum data required to 
meet the research objectives were requested. However, as a result of the study objectives, 
the majority of HES data variables, with the exception of identifiable variables, were 
requested. A Data Sharing Framework Contract at institutional level and Data Sharing 
Agreement at study level were required. Data were provided via secure electronic transfer 
in SQL format. The HES Data Dictionaries [190] provided information to inform the 
interpretation of included data variables.  
Table 5.2 presents an overview of the HES datasets accessed in this study.  
 
Table 5.2: An Overview of the HES Datasets 
 APC Dataset A & E Dataset OP Dataset CC Dataset 
Number of Participants 43 65 71 1 
Number of 
Attendances 
125 230 1193 1 
Median (IQR) 2(1-4) 2(1-4) 12(7-20) N/A 
Dates Included 02/04/13 – 21/03/16 02/04/13 – 15/03/16 02/04/13 – 31/03/16 16/12/14  
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Admitted Patient Care Dataset (APC) 
The Admitted Patient Care (APC) Dataset presents data regarding inpatient admissions in 
England. Admissions are recorded as ‘Episodes’ of care under a named Consultant. Single or 
multiple episodes may be included in a single hospital admission, or ‘Spell’. A large number 
of data variables are included; both directly extracted from the SUS dataset and derived 
from the extracted data. Notable limitations include the absence of data regarding 
treatments and investigations. Data variables relevant to the objectives of this study are 
presented in Table 5.3.   
Accident & Emergency Dataset (A&E) 
The Accident & Emergency Dataset (A&E) presents data regarding emergency department 
attendances in England. A large number of data variables are included; both directly 
extracted from the SUS dataset and derived from the extracted data. Notable limitations 
include the non-specific diagnostic coding system and limited detail regarding 
investigations and treatment. Data variables relevant to the objectives of this study are 
presented in Table 5.4. 
Outpatient Dataset (OP) 
The Outpatient Dataset (OP) presents data regarding outpatient attendances in England. A 
large number of data variables are included; both directly extracted from the SUS dataset 
and derived from the extracted data. Notable limitations include the absence of data 
regarding treatments and investigations and limited completion of diagnostic information. 
Data variables relevant to the objectives of this study are presented in Table 5.5. 
Critical Care Dataset (CC) 
The Critical Care Dataset (CC) presents data regarding admission to critical care 
departments in England. Data variables are directly extracted from the SUS dataset and 
include information regarding the admission to critical care, treatment administered and 
discharge details. The limited data variables available are presented in Table 5.6.   
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Table 5.3: An Overview of HES Admitted Patient Care Data Variables 
Data Variable Description 
ACTIVAGE Age 
ADMIDATE Date of admission 
ADMIMETH Admission method 
ADMISORC Admission source 
ALCDIAG_4 Alcohol-related diagnosis 
ALCFRAC Alcohol attributable fraction, based on alcohol related diagnosis 
CLASSPAT Type of admission 
DIAG_01 - 20 ICD 10 diagnostic code 
DISDATE Date of discharge 
DISDEST Discharge destination 
DISMETH Discharge method 
ELECDATE Date decision to electively admit patient  
ELECDUR Elective admission waiting time 
EPIDUR Episode duration 
EPIEND Date of episode end  
EPIORDER Order of episode 
EPISTART Date of start of episode 
ETHNOS Ethnicity 
HRGNHS Trust generated Healthcare Resource Group code 
HRGNHSVN Healthcare Resource Group Version 
IMD04 Index of Multiple Deprivation (IMD) at Super Output Area level 
IMD04_DECILE Interpretation of IMD 
IMD04C IMD crime domain 
IMD04ED IMD education, skills and training domain 
IMD04EM IMD employment domain 
IMD04HD IMD health and disability domain 
IMD04HS IMD barriers to housing and services domain 
IMD04I IMD income domain 
IMD04IA IMD income deprivation affecting older people index 
IMD04IC IMD income deprivation affecting children index 
IMD04LE IMD living environment domain 
IMD04RK IMD overall rank 
INTMANIG Patient intended management 
LSOA11 Lower Super Output Area, 2011 Census 
MAINSPEF Main Speciality of Consultant 
MSOA11 Middle Super Output Area, 2011 Census 
OPDATE_01 - 24 Date of operation 
OPERSTAT Operation status 
OPERTN_01 - 24 OPCS4 procedure code 
POSOPDUR Postoperative duration 
POSTDIST Postcode district 
PREOPDUR Preoperative duration 
PROCODE NHS provider code 
PROTYPE Type of provider 
PURCODE Type of commissioner 
RURURB_IND Rural / urban indicator 
SEX Sex 
SPELBGIN Start of hospital spell 
SPELDUR Duration of hospital spell 
SPELEND End of hospital spell 
SUSCOREHRG SUS generated Healthcare Resource Group, spell level 
SUSHRG SUS generated Healthcare Resource Group, episode level 
TRETSPEF Treatment speciality 
WAITDAYS Duration of wait for elective admission 
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Table 5.4: An Overview of HES Accident & Emergency Data Variables 
Data Variable Description 
ACTIVAGE Age 
AEARRIVALMODE Method of arrival 
AEATTENDCAT Attendance category (planned, unplanned) 
AEATTENDDISP Disposal method 
AEDEPTTYPE Type of emergency care department 
AEPATGROUP Attendance type 
ARRIVALDATE Date of attendance 
ARRIVALTIME Time of attendance 
CONCLDUR Duration of attendance 
DIAG_01 - 12 A&E diagnostic code 
DIAGA_01 - 12 Anatomical area 
DIAGS_01 - 12 Lateralisation 
ETHNOS Ethnicity 
HRGNHS Trust generated Healthcare Resource Group code 
HRGNHSVN Healthcare Resource Group version number 
IMD04 Index of Multiple Deprivation (IMD) at Super Output Area level 
IMD04_DECILE Interpretation of IMD 
IMD04C IMD crime domain 
IMD04ED IMD education, skills and training domain 
IMD04EM IMD employment domain 
IMD04HD IMD health and disability domain 
IMD04HS IMD barriers to housing and services domain 
IMD04I IMD income domain 
IMD04IA IMD income deprivation affecting older people index 
IMD04IC IMD income deprivation affecting children index 
IMD04LE IMD living environment domain 
IMD04RK IMD overall rank 
INITDUR Duration from arrival to assessment 
INVEST_01 - 12 Investigation code 
LSOA11 Lower Super Output Area, 2011 Census 
MSOA11 Middle Super Output Area, 2011 Census 
POSTDIST Postcode district 
PROCODE NHS provider code 
PROTYPE Type of provider 
PURCODE Type of commissioner 
RURURB_IND Rural / urban indicator 
SEX Sex 
SUSHRG SUS generated Healthcare Resource Group 
SUSHRGVERS Healthcare Resource Group Version 
TREAT_01 Treatment code 
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Table 5.5: An Overview of HES Outpatient Data Variables 
Data Variable Description 
APPTAGE Age 
APPTDATE Date of attendance 
ATENTYPE Type of attendance 
DIAG_01 - 12 ICD 10 diagnostic code 
DNADATE Date of last ‘Did Not Attend’ or cancellation 
ETHNOS Ethnicity 
HRGNHS Trust generated Healthcare Resource Group code 
HRGNHSVN Healthcare Resource Group version number 
IMD04 Index of Multiple Deprivation (IMD) at Super Output Area level 
IMD04_DECILE Interpretation of IMD 
IMD04C IMD crime domain 
IMD04ED IMD education, skills and training domain 
IMD04EM IMD employment domain 
IMD04HD IMD health and disability domain 
IMD04HS IMD barriers to housing and services domain 
IMD04I IMD income domain 
IMD04IA IMD income deprivation affecting older people index 
IMD04IC IMD income deprivation affecting children index 
IMD04LE IMD living environment domain 
IMD04RK IMD overall rank 
LSOA11 Lower Super Output Area, 2011 Census 
MAINSPEF Main Speciality of Consultant 
MSOA11 Middle Super Output Area, 2011 Census 
OPERSTAT Status of operation, if pending 
OPERTN_01 - 24 OPCS4 procedure code 
OUTCOME Outcome of attendance 
POSTDIST Postcode district 
PRIORITY Priority of referral 
PROCODE NHS provider code 
PROTYPE Type of provider 
PURCODE Type of commissioner 
REFSOURC Source of referral 
REQDATE Date referral received 
RURURB_IND Rural / urban indicator 
SERVTYPE Service requested 
SEX Sex 
STAFFTYP Type of healthcare practitioner, grade 
SUSHRG SUS generated Healthcare Resource Group 
TRETSPEF Treatment speciality 
WAITDAYS Time to elective treatment 
WAITING Time from referral to OP review 
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Table 5.6: An Overview of HES Critical Care Data Variables 
Data Variable Description 
ACARDSUPDAYS Days of advanced cardiovascular support 
ARESSUPDAYS Days of advanced respiratory support 
BCARDSUPDAYS Days of basic cardiovascular support 
BRESSUPDAYS Days of basic respiratory support 
CCADMISORC Source of admission 
CCADMITYPE Type of admission 
CCDISDATE Date of discharge 
CCDISDEST Discharge destination 
CCDISLOC Discharge location 
CCDISRDYDATE Discharge ‘ready date’  
CCDISSTAT Discharge status 
CCSORCLOC Source of admission, location 
CCSTARTDATE Date of admission 
CCSTARTTIME Time of admission 
CCUNITFUN Specific critical care unit function 
DERMSUPDAYS Days of dermatological support 
GISUPDAYS Days of gastrointestinal support 
LIVERSUPDAYS Days of liver support 
NEUROSUPDAYS Days of neurological support 
ORGSUPMAX Maximum number of organs supported 
RENSUPDAYS Days of renal support 
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5.11.2 The Secure Anonymised Information Linkage Databank (SAIL) 
The NHS Wales Informatics Service (NWIS) datasets were complemented by additional 
datasets provided by The Secure Anonymised Information Linkage Databank (SAIL) [100]. 
The cost was calculated on a not-for-profit, cost recovery basis. The total cost of SAIL data 
in this study, excluding VAT was £2828. Table 5.7 presents the cost calculation using data 
provided by SAIL.    
 Table 5.7: SAIL Cost Calculation 
Study Element Timescale Effort (Days) Cost (£) 
Base cost n/a n/a 500 
Load data into SAIL  4 weeks 1 291 
Create individual level output 2 weeks 5 1455 
Data transfer 2 weeks 2 582 
Total  2828 (+VAT) 
 
The Data Protection Act [50] provides the legal framework for data release. In this study, 
participant informed written consent provided the valid legal basis for data release. Data 
minimisation principles were adhered to and therefore only the minimum data required to 
meet the research objectives were requested. However, as a result of the study objectives, 
the majority of data variables, with the exception of identifiable variables, were relevant 
and were requested. A Data Release Agreement at study level was required. Data were 
provided via secure electronic transfer in Microsoft Excel format. ‘Metadata’ files were also 
provided to inform the interpretation of data.  
Table 5.8 presents an overview of the SAIL datasets accessed in this study.  
 
Table 5.8: An Overview of the SAIL Datasets  
 PEDW Dataset EDDS Dataset OP Dataset GP Dataset 
Number of Participants 16 22 27 23 
Number of Attendances 34 54 192 5379 
Median (IQR) 2(1-3) 1.5(1-3) 7(4-8) 161(137-316)* 
Dates Included 11/05/13 – 24/02/16 10/05/13 – 04/12/15 09/05/13 – 24/12/15 30/04/13 – 23/12/15 
*READ Code Entries: may not all represent individual attendances 
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Patient Episode Database for Wales (PEDW) 
The Patient Episode Database for Wales (PEDW) presents data regarding inpatient 
admissions in Wales and is comparable to the HES APC dataset. Admissions are recorded as 
‘Episodes’ of care under a named Consultant. Single or multiple episodes may be included 
in a single hospital admission, or ‘Spell’. A large number of data variables are included; both 
directly extracted from the NHS Wales Data Warehouse and derived from the extracted 
data. Notable limitations include the absence of data regarding treatments and 
investigations. Data variables relevant to the objectives of this study are presented in Table 
5.9.   
Emergency Department Dataset (EDDS) 
The Emergency Department Dataset (EDDS) presents data regarding emergency 
department attendances in Wales and is comparable to the HES A&E dataset. A large 
number of data variables are included; both directly extracted from the NHS Wales Data 
Warehouse and derived from the extracted data. Notable limitations include the non-
specific diagnostic coding system and limited detail regarding investigations and treatment. 
Data variables relevant to the objectives of this study are presented in Table 5.10. 
Outpatient Dataset (OP) 
The Outpatient Dataset (OP) presents data regarding outpatient attendances in Wales and 
is comparable to the HES OP dataset. A large number of data variables are included; both 
directly extracted from the NHS Wales Data Warehouse and derived from the extracted 
data. Notable limitations include the absence of data regarding treatments and 
investigations and limited completion of diagnostic information. Data variables relevant to 
the objectives of this study are presented in Table 5.11. 
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Primary Care (GP) Dataset  
The Primary Care (GP) Dataset presents data regarding primary care attendances in Wales 
for General Practices enrolled within SAIL. Limited data variables are presented including 
date of event, UK READ Code, UK READ Code description and limited specific values, such 
as systolic and diastolic blood pressure measurements. Notable limitations include the 
absence of free text entries and lack of context to the recording of READ Codes. Healthcare 
events including the receipt of clinical correspondence, investigation results, medication 
prescriptions and clinical prompts may result in READ code entry, in addition to patient 
attendance. Data variables are presented in Table 5.12.   
 
Table 5.9: An Overview of SAIL Patient Episode Database for Wales Data Variables 
Data Variable Description 
 
PEDW Episode 
 
PROV_UNIT_CD NHS Provider Code 
EPI_NUM Episode number 
EPI_STR_DT Date of start of episode 
EPI_END_DT Date of end of episode 
AGE_EPI_STR_YR Age at start of episode 
CON_SPEC_MAIN_CD Main speciality of Consultant 
CON_SPEC_CD_OF_TREAT Treatment speciality 
EPI_DUR Duration of episode 
DIAG_CD_123 ICD 10 diagnostic code, 3 digits 
DIAG_CD_1234 ICD 10 diagnostic code, 4 digits 
OPER_CD_123 OPCS4 procedure code, 3 digits 
OPER_CD OPCS4 procedure code 
HRG_LOCALPAYMENT_CD Healthcare Resource Group 
HRG_LOCALPAYMENT_DESC Healthcare Resource Group description 
HRG_REFERENCECOST_CD Healthcare Resource Group reference cost 
HRG_REFERENCECOST_DESC Healthcare Resource Group reference cost description 
 
PEDW Spell 
 
SPELL_NUM_E Spell number 
GNDR_CD Gender 
ADMIS_DT Date of admission 
ADMIS_MTHD_CD Admission method 
ADMIS_SOURCE_CD Admission source  
INTENDED_MANAGEMENT_CD Patient intended management 
DISCH_DT Date of discharge 
DISCH_MTHD_CD Discharge method 
DISCH_DESTINATION_CD Discharge destination 
DUR_ELECT_WAIT Elective admission waiting time 
PAT_CLASS_CD Type of admission 
SPELL_DUR Duration of spell 
ADMIS_SPEC_CD Treatment speciality  
ADMIS_DEC_DT Date decision to electively admit patient 
LSOA_CD_2001 Lower Super Output Area, 2011 Census 
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Table 5.10: An Overview of SAIL Emergency Department Data Variables 
Data Variable Description 
ADMIN_ARR_DT Date of attendance 
ADMIN_ARR_TM Time of attendance 
AGE Age 
ARRIVAL_MODE Method of arrival 
HEALTH_EVENT_DT Date of health event  
HEALTH_EVENT_TM Time of health event 
ATTEND_GROUP Attendance type 
ATTEND_CATEGORY Attendance category (planned, unplanned) 
DIAG_CD_1 - 6 EDDS diagnostic code 
ANAT_AREA_CD_1 - 6 Anatomical area 
SIDE_CD_1 - 6 Lateralisation 
TREAT_CD_1 - 6 Treatment code 
INVEST_CD_1 - 6 Investigation code 
ADMIN_END_DT Date of end of attendance 
ADMIN_END_TM Time of end of attendance 
DISCHARGE Outcome of attendance 
LOCATION_TYPE Location of injury, where relevant 
ROAD_USER Road user status, where relevant 
MECH_OF_INJ Mechanism of injury, where relevant 
ACTIVITY Activity at time of injury, where relevant 
SPORT Sport at time of injury, where relevant 
ALCOHOL_IND Role of alcohol in injury, where relevant 
TRIAGE_CAT Triage category  
 
 
Table 5.11: An Overview of SAIL Outpatient Data Variables 
Data Variable Description 
AGE_AT_APPT Age 
REF_DT Date of patient referral 
CLINICAL_REF_DT Date of clinical referral 
PRIORITY_TYPE_CD Priority of referral 
SOURCE_OF_REF_CD Source of referral 
CON_SPEC_MAIN_CD Main speciality of Consultant 
CON_SPEC_CD_OF_TREAT Treatment speciality 
LOCAL_SPEC_CD Local sub-speciality 
ADMIN_CAT_CD Patient treatment category 
LOC_TYPE_CD Outpatient clinic location type 
MED_STAFF_TYPE_CD Type of healthcare practitioner, grade 
ATTEND_DT Date of attendance 
FIRST_ATTEND_CD Date of first attendance 
ATTEND_CD Attendance status 
OUTCOME_CD Outcome of attendance 
LAST_DNA_CANCEL_DT Date of last ‘Did Not Attend’ or cancellation 
DIAG_CD_4 ICD 10 diagnostic code 
OPER_CD_4 OPCS4 procedure code 
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Table 5.12: An Overview of SAIL Primary Care Data Variables 
Data Variable Description 
EVENT_DT Date of record 
EVENT_CD UK READ Code 
TERM_COMBINED UK READ Code – description 
EVENT_VAL ‘Number’, where relevant, for example blood pressure 
SYSTOLIC_VAL Systolic blood pressure 
DIASTOLIC_VAL Diastolic blood pressure 
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5.11.3 Primary Care Data, North West England 
Primary care data were requested directly from the General Practices for the 18 consenting 
participants’ resident in North West England. Two General Practices provided consent and 
the principal investigator attended the practices and directly extracted relevant data in July 
2016 from the EMIS IT system. Three General Practices refused participation and the 
remaining 13 General Practices provided no response despite repeated attempts at 
contact.  
Participants’ complete electronic medical records were reviewed and data extracted. Data 
reviewed included UK READ Codes, free text entries, investigation results and clinical 
correspondence. Table 5.13 presents the data included in participants’ primary care 
electronic medical records.  
 
Table 5.13: Data Included in Participants Primary Care Electronic Medical Records 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
- Demographic Details: 
o Name, Date of Birth, Address, NHS Number 
- Active Diagnoses / Problems 
- Significant Past Medical History 
- Family History 
- Medication: 
o Acute Prescriptions 
o Repeat Prescriptions 
o Past Prescriptions 
- Allergies  
- Health Status: 
o Smoking / Alcohol Status 
o Weight, Height 
- Planned Events: 
o Screening 
o Medication Reviews 
- Investigations / Results 
- Medical Record: 
o Consultations 
o Clinical Correspondence 
▪ Sent 
▪ Received 
o UK READ Codes 
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5.11.4 Study Participants 
A total of 98 individuals consented to participation in this study. Seventy one participants 
were resident in England and included in the NHS Digital Hospital Episode Statistics 
Datasets. Twenty seven participants were resident in Wales and included in the Secure 
Anonymised Information Linkage Databank Datasets. Data recorded during SANAD II were 
available for all participants. Data were available for all participants from NHS Digital or The 
Secure Anonymised Information Linkage Databank from January 2013 to the most recently 
available date, as previously detailed in sections 5.11.1, 5.11.2 and 5.11.3.    
 
5.11.4.1 Gender 
Gender was recorded for all participants in SANAD II and there were 55 males and 43 
females in the total 98 study participants.  
Gender was recorded in the Hospital Episode Statistics (HES) Admitted Patient Care (APC), 
Accident and Emergency (A&E) and Outpatient (OP) Datasets and data were present for all 
participants and consistent between datasets. In the Secure Anonymised Information 
Linkage (SAIL) Databank gender was recorded only in the Patient Episode Database for 
Wales (PEDW) Dataset. In routine datasets, data regarding gender were available in 87 
participants, 11 participants living in Wales did not have an inpatient episode recorded and 
therefore data regarding gender was missing. In the 87 participants with data available 
from both sources, gender determined from the routine datasets was compared to the 
gender recorded in SANAD II, summarised in the cross-tabulation, Table 5.14.  
Table 5.14: Gender: Cross-Tabulation 
R
C
T 
D
at
a 
Routine Data 
 Male Female Total 
Male 49 (56.3%) 0 49 
Female 0 38 (43.7%) 38 
Total 49 38 87 
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5.11.4.2 Age 
Date of birth was recorded for all participants in SANAD II and therefore age in years could 
be calculated.   
Age in years was recorded in the HES APC, A&E and OP Datasets. In the SAIL Databank age 
in years was recorded in the Emergency Department Dataset (EDDS), PEDW and OP 
Datasets and was present in routine sources for all participants. Date of birth as an 
identifiable variable was not required as a result of data minimisation principles and 
therefore age in years was provided.      
Age in years was calculated from the recorded date of birth in SANAD II and adjusted for 
the year of routine data record, matching the age recorded in routine datasets.  
The mean age of the normally distributed sample was 50 (Range: 17-89, Standard 
Deviation: 20).  
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5.12 Data Processing and Analysis 
5.12.1 Overview 
This study assessed the quality and agreement of data routinely recorded in electronic 
medical records compared with data collected using standard prospective methods in 
SANAD II. The exploratory nature of the study necessarily resulted in an iterative approach 
to the analyses. For example, prior to the data being retrieved it was unclear which data 
variables would be in a comparable format to those recorded on the SANAD II database 
suitable for a statistical assessment of agreement. A priori, the data variables and outcome 
measures where an assessment of agreement was intended were specified. For example, 
an assessment of agreement was planned for the variable ‘first follow-up seizure’ and 
subsequently outcome measure ‘time to first follow-up seizure’. Notably, assessment of 
the SANAD II outcomes stratified by treatment intervention (antiepileptic drug) under 
study would be inappropriate as a result of the on-going status of the trial. Therefore, 
throughout the analyses the included participants in this study were analysed as a 
complete cohort, without reference to antiepileptic drug or SANAD II study arm.   
5.12.2 Data Preparation 
The inherent properties of routinely recorded data resulted in a period of data preparation 
being appropriate. The process included the assessment for duplicate entries and 
formatting the data for subsequent analysis. All analyses in this study used the prepared 
datasets. Such ‘cleaned’ data is the standard for clinical research studies accessing and 
implementing routinely recorded data. The original dataset and all subsequent formatted 
datasets were stored, identified by appropriate version numbers. Furthermore, for all 
analyses data were extracted from all routinely recorded data sources to create a ‘best 
case’ dataset. For example, in the assessment of ‘total number of follow-up seizures’, all 
datasets for all participants were reviewed to ensure all occurrences of follow-up seizures 
were identified, with the dataset for each seizure occurrence also recorded. This ‘best case’ 
dataset was then used in the assessment of quality and agreement compared with the 
SANAD II dataset.     
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5.12.3 Assessment of Routinely Recorded Data Quality  
An assessment of ‘quality’ was appropriate to ensure the data provided in the routinely 
recorded datasets were comparable to the data collected in SANAD II and that the 
subsequent assessments of agreement were valid. Quality is a term used throughout this 
study and the following factors were included in its definition:  
- An assessment of the ‘comparability’ of routinely recorded data variables with data 
collected using standard prospective methods in SANAD II. This ensured data 
variables from both datasets were comparable, measuring the same underlying 
construct and ensured further analyses were valid, including the assessment of 
agreement.   
- An assessment of the ‘completeness’ of routinely recorded data.  This assessed the 
degree of missing data and resultant systematic bias, compared to data collected 
using standard prospective methods in SANAD II.  
 
5.12.4 Assessment of Agreement 
A statistical assessment of agreement was completed between routinely recorded data and 
data collected using standard prospective methods in SANAD II for comparable data 
variables and outcomes measures. Statistical and clinical differences were discussed. 
Methods for the assessment of agreement for categorical and continuous data are 
presented. All analyses were performed in SPSS (Version 22).  
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Continuous Data 
To assess agreement between paired (data from different datasets for the same individual) 
continuous data, Bland Atman methods were employed. Acceptable clinical limits of 
agreement for each variable or outcome were specified a priori. In the first instance, the 
Difference and Mean between the datasets were computed. The distribution of data was 
then assessed using the Difference variable through construction of a histogram. For 
normally distributed data a Paired T Test was performed and for non-normally distributed 
data a Wilcoxon Signed Rank Test. A P-value <0.05 was taken as indicating a significant 
difference between the means calculated from the two datasets. Subsequently, Bland 
Altman Plots were constructed, the Difference variable plotted on the Y axis and the Mean 
variable plotted on the X axis. The mean of the Difference variable was also plotted. The 
95% confidence limits of agreement were calculated by multiplying the standard deviation 
of the Difference variable by 1.96 and subsequently adding or subtracting from the mean of 
the Difference variable. The 95% confidence limits of agreement were then discussed in the 
context of the specified acceptable clinical limits of agreement [196].   
Time to Event Data  
Time to event outcomes are included in SANAD II and it was possible to calculate ‘time to 
first seizure’ and ‘time to 12 month remission’ outcomes using routinely recorded datasets. 
Kaplan Meier curves were created to estimate the survival functions using data from both 
sources. Subsequently, a Log Rank test was performed with P-value <0.05 indicating a 
statistically significant difference between the outcomes calculated from the two datasets.    
Categorical Data 
To assess agreement between paired, nominal categorical datasets, cross tabulations were 
presented followed by calculation of Cohen’s kappa. The interpretation of Cohen’s kappa 
was based on the guidelines from Altman (1999), and adapted from Landis & Koch (1977): 
0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement. Significance was examined with 
P<0.05 indicating the level of agreement defined by kappa being significant.    
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5.12.5 Assessment of Feasibility and Efficiency 
The feasibility and efficiency of accessing and using routinely recorded data was assessed. 
Factors important in the assessment of feasibility and efficiency included:  
- The resources, including financial and time required during development of the 
protocol, application and application procedures for routinely recorded data 
- The outcome of applications, including final provision of routinely recorded data 
- The resources required in data preparation, including data cleaning and formatting 
- The attributes of the data provided, including time period coverage, validity and 
agreement to data collected using standard prospective methods in SANAD II  
 
To inform the assessment of feasibility, a prospective log was recorded throughout the 
duration of the study. The log included all procedures involved in the application, retrieval 
and preparation of routinely recorded data.   
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5.13 The Data Variables and Outcome Measures 
Data variables and outcome measures relevant to the following scenarios were assessed: 
• The identification of eligible individuals and recruitment into SANAD II  
• The follow-up of participants and measurement of SANAD II outcomes 
 
5.13.1 The SANAD II Data 
5.13.1.1 The Identification of Eligible Individuals and Recruitment into SANAD II 
Individuals eligible for recruitment into SANAD II are identified by the clinician during 
routine clinical practice. During a clinical review, a diagnosis and classification of epilepsy is 
made and the decision to commence treatment with antiepileptic drugs discussed and 
agreed with the patient. Individuals agreeing to participate in SANAD II then complete a 
SANAD II ‘baseline assessment’. During this assessment, the clinician completes a Case 
Report Form (CRF). Data recorded is summarised in Box 5.3 and includes the date of first 
seizure, seizure type, total number of seizures, status and results of investigations such as 
electroencephalography, medication history, family history and personal medical history 
including previous neurological insult and occurrence of febrile seizures.  
Definite dates of seizures occurring during defined time periods are recorded in SANAD II. 
In the SANAD II baseline assessment the ‘date of first seizure’ is recorded together with the 
total number of seizures prior to the baseline assessment date. However, the dates of all 
experienced seizures are not recorded. To ensure a comparable analysis, assessments of 
agreement with routine data have been calculated using only the recorded definite dates 
of first seizure.  
The diagnosis and classification of seizure type and epilepsy syndrome are a mandatory 
requirement for enrolment in SANAD II. As such the date of ‘randomisation’, which 
correlates with the date of baseline assessment, is defined as the date of diagnosis in the 
SANAD II dataset. Participants are diagnosed based on the accepted definitions of epilepsy, 
proposed by the International League Against Epilepsy [7, 8]. In accordance with these 
guidelines, at least two unprovoked seizures occurring greater than 24 hours apart are 
required for diagnosis and enrolment in SANAD II. The guidelines also state participants 
may be diagnosed following a single seizure with a probability of subsequent seizures 
similar to the general recurrence risk following two unprovoked seizures.  
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However, calculating such probabilities is troublesome in both clinical practice and the 
research setting and as such two seizures are required for diagnosis and enrolment in 
SANAD II. During the diagnosis, participants’ seizures are classified as ‘focal’, ‘generalised’ 
or ‘unclassified’.    
The clinical investigations Magnetic Resonance Imaging (MRI) Brain, Computed 
Tomography (CT) Brain and Electroencephalography (EEG) are recorded in SANAD II at the 
baseline assessment, although there is no protocol requirement for investigations to be 
completed. Details recorded in SANAD II for each participant include the investigation, date 
and result.  
5.13.1.2 The Follow-Up of Participants and Measurement of SANAD II Outcomes 
Following recruitment and completion of the SANAD II baseline assessment, ‘follow-up 
assessments’ are completed at three, six, 12 months and annually thereafter. During each 
follow-up assessment the clinician records data onto a CRF. Data recorded is summarised in 
Box 5.3 and includes the dates of seizure occurrence and total number of seizures, 
medication history, adverse events, investigation results, personal medical history and 
details regarding healthcare resource use.  
During the follow-up assessments the ‘date of first seizure’ and ‘date of last seizure’ during 
the defined time period between SANAD II assessments are recorded together with the 
total number of seizures experienced in this time period. However, the dates of all 
experienced seizures are not recorded. To ensure a comparable analysis in this study, 
assessments of agreement with routine data have been calculated using only the recorded 
definite dates of seizures. This record of seizures permits construction and measurement of 
a number of the outcomes in SANAD II, such as ‘time to 12 month remission from seizures’.   
The prescription of Antiepileptic Drugs (AEDs), including initial randomised AED and 
subsequently prescribed AEDs are recorded during the SANAD II assessments.  The named 
AED, date of prescription and prescribed dosage are recorded together with reason for any 
dosage alteration. Participants are also requested to complete a number of self-report 
questionnaires which include details of prescribed AEDs.  
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Adverse events are recorded during the SANAD II follow-up assessments. Adverse events 
are defined as any untoward medical occurrence in a subject to whom a medicinal product 
has been administered, including occurrences which are not necessarily caused by or 
related to that product. The symptom, severity, date, AED in question, relationship to AED 
and action taken are recorded during follow-up assessments. Additional details and urgent 
reporting are required in cases of Serious Adverse Reactions (SAR) or Suspected 
Unexpected Serious Adverse Reactions (SUSAR). In addition to the assessment of adverse 
events during follow-up assessments, participants are requested at intervals to complete a 
number of self-report questionnaires including the Adverse Events Profile, providing an 
additional method for the recording of adverse events.    
Episodes of participants’ healthcare resource use are recorded in SANAD II and are 
informative to the health economic analyses, including cost effectiveness analyses. 
Healthcare resource use may be ‘planned’ or ‘unplanned’. Planned attendances (elective 
attendances) include routine outpatient follow-up attendances, for example follow-up 
attendances with the Neurologist. Unplanned attendances (emergency attendances) 
include emergency, inpatient or primary care attendances, for example, attendances as a 
result of seizure occurrence or the experience of adverse events.  
Planned attendances in SANAD II include the routine SANAD II assessments. Following the 
SANAD II baseline assessment, the follow-up assessments occur at specified intervals, 
within the context of routine clinical care. In the majority of participants, it is anticipated 
such attendances occur in the context of outpatient clinic attendances with the 
Neurologist. However, follow-up assessments may also occur in dedicated research clinics 
or opportunistically during unplanned attendances, although such methods would be 
expected to account for only a minority of SANAD II assessments.  
Unplanned attendances in SANAD II may include emergency, inpatient and primary care 
attendances. Participants are requested to complete self-report questionnaires at specified 
intervals during follow-up, indicating if they have had any healthcare attendances ‘in the 
last three months’. The healthcare setting and clinical reason for attendance are recorded 
through the options ‘epilepsy-related’ or ‘non epilepsy-related’. 
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Box 5.3 Summary: Data Recorded in SANAD II 
 
  
The Identification of Eligible Individuals and Recruitment into SANAD II 
- Identifying Variables 
o Name, DOB, NHS Number 
- Seizure History 
o Date of First Seizure, Total Number of Seizures 
- Personal History 
o Neurological Insult  
o Febrile Seizures 
- Family History, Epilepsy 
- Investigations 
o EEG and Imaging (CT or MRI) 
- Randomised Antiepileptic Drug 
The Follow-Up of Participants and Measurement of SANAD II Outcomes 
- Review of Medical History 
- Further Investigations 
o EEG and Imaging (CT or MRI) 
- Randomised Antiepileptic Drug 
o Further Antiepileptic Drug Treatment 
- Adverse Events 
o Date, Nature, Severity, Relationship to AED 
- Seizure Occurrence 
o Date of First and Last Seizures Between Follow-Up Assessments 
o Total Number of Seizures Between Follow-Up Assessments 
- Healthcare Resource Use 
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5.13.2 The Routinely Recorded Data 
To permit the assessments of agreement, relevant routinely recorded data were extracted 
for each assessed data variable and outcome measure. For each variable an algorithmic 
approach was taken for the definition of relevant clinical events, combining knowledge of 
the coding systems, clinical behaviours and organisational pathways. An approach utilising 
the clinical interpretation of routinely recorded data has previously been used in studies 
assessing seizures [197] and in other disease areas in the UK [198-200].  
5.13.3 The Identification of Seizure Occurrence in the Routinely Recorded Datasets 
The identification of the occurrence of unprovoked seizures is required for diagnosis of 
epilepsy and subsequent calculation of the outcomes in SANAD II. In order to permit an 
assessment of agreement, the occurrence of seizures must be identified and extracted 
from routinely recorded datasets. In this study an algorithmic approach was developed, 
informed by the approach taken in a published previous analysis of seizures recorded in 
NHS Digital Hospital Episode Statistics [197]. In this previous study the occurrence of 
seizures was identified in the HES Admitted Patient Care (APC) Dataset and subsequent 
specialist neurology follow-up in the HES Outpatient Dataset was examined. The 
occurrence of seizures was identified by review of the recorded ICD 10 codes, however, in 
the Admitted Patient Care Dataset; up to 15 ICD 10 codes are listed for each patient 
admission. These listed codes include the primary reason for attendance in addition to 
diagnoses included in an individual’s past medical history. This previous study developed an 
algorithmic approach with the aim of identifying emergency admissions where the 
occurrence of seizure was the primary reason for attendance, rather than a diagnosis of 
epilepsy listed as part of the past medical history. ‘Epilepsy’ and ‘seizure’ codes were 
categorised as the primary reason for attendance, meaning the occurrence of seizures, 
when listed as the first diagnosis (‘definite seizure’) or second or third diagnosis with a 
‘probable’ supportive code in the first diagnosis position (‘probable seizure’). Attendances 
with epilepsy and seizure codes listed in the second or third diagnostic position with a 
‘possible’ supportive code as the first diagnosis (‘possible seizure’) or an unrelated code as 
the first diagnosis (‘definitely not seizure’) were not categorised as the occurrence of 
seizure. Figure 5.1 details the algorithmic approach and Table 5.15 details the ICD 10 codes 
included in the definition of ‘definite seizure’ and ‘probable seizure’ in this previous study.     
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Figure 5.1: Algorithm for the Identification of Seizure Occurrence Using the HES Admitted 
Patient Care Dataset [197] 
 
 
 
 
 
 
 
 
 
 
 
 
  
Emergency Admission: 
Emergency Admission Method: 
21 Accident and emergency or dental casualty department of the Health Care Provider  
22 General Practitioner: after a request for immediate admission has been made to a Hospital Provider 
23 Bed Bureau 
24 Consultant Clinic, of this or another Health Care Provider  
28 Other means, examples: admitted from the Accident and Emergency Department of another provider where 
they had not been admitted, transfer of an admitted patient from another Hospital Provider 
 
Patient Care Assigned to Relevant Medical Treatment Speciality 
180 A&E, 192 Critical Care Medicine, 300 General Medicine, 301 Gastroenterology, 302 Endocrinology, 303 Clinical  
Haematology, 314 Rehabilitation, 315 Palliative Medicine, 320 Cardiology, 330 Dermatology, 340 Respiratory Medicine, 
361 Nephrology, 370 Medical Oncology, 400 Neurology, 410 Rheumatology, 430 Geriatric Medicine, 820 General 
Pathology, 823 Haematology 
Review ICD Codes: Detailed in Table 5.15 
 
Definite Seizure Probable Seizure Possible Seizure Not Seizure 
‘Definite’ seizure code 
listed in first diagnostic 
position 
‘Definite’ seizure code 
listed in second or third 
diagnostic position AND 
‘probable’ supportive code 
listed in the first diagnostic 
position 
‘Definite’ seizure code 
listed in a later diagnostic 
position AND ‘possible’ 
supportive code listed in 
the first diagnostic position 
‘Definite’ seizure code 
listed in later diagnostic 
position WITHOUT 
‘probable’ or ‘possible’ 
supportive code listed in 
first diagnostic position 
 
SEIZURE OCCURRENCE NO SEIZURE OCCURRENCE 
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Table 5.15: ICD Codes Included in the Definitions of ‘Definite’ and ‘Probable’ Seizure 
Occurrence [197] 
ICD 10 
Code 
ICD Code Description Definite Probable 
G400 LOCAL-RELATED (PART) IDIOPATH EPILEP/EPILEP SYND WITH SEIZURE 1 0 
G401 
LOCAL-RELATED (PART) SYMPTOM EPILEPSY/EPILEPTIC SYND WITH 
SEIZURE 
1 0 
G402 LOCAL-RELATED (PART) SYMPTOM EPILEPSY/ EPILEP SYND 1 0 
G403 GENERALIZED IDIOPATHIC EPILEPSY AND EPILEPTIC SYNDROMES 1 0 
G404 OTHER GENERALIZED EPILEPSY AND EPILEPTIC SYNDROMES 1 0 
G405 SPECIAL EPILEPTIC SYNDROMES 1 0 
G406 GRAND MAL SEIZURES, UNSPECIFIED (WITH OR WITHOUT PETIT MAL) 1 0 
G407 PETIT MAL, UNSPECIFIED, WITHOUT GRAND MAL SEIZURES 1 0 
G408 OTHER EPILEPSY 1 0 
G409 EPILEPSY, UNSPECIFIED 1 0 
G410 GRAND MAL STATUS EPILEPTICUS 1 0 
G411 PETIT MAL STATUS EPILEPTICUS 1 0 
G412 COMPLEX PARTIAL STATUS EPILEPTICUS 1 0 
G418 OTHER STATUS EPILEPTICUS 1 0 
G419 STATUS EPILEPTICUS, UNSPECIFIED 1 0 
R568 OTHER AND UNSPECIFIED CONVULSIONS 1 0 
F019 VASCULAR DEMENTIA, UNSPECIFIED 0 1 
F100 MENTAL AND BEHAVIOURAL DISORDERS DUE TO ACUTE INTOXICATION  0 1 
F101 
MENTAL AND BEHAVIOURAL DISORDERS DUE TO HARMFUL USE OF 
ALCOHOL 
0 1 
F102 
MENTAL AND BEHAVIOURAL DISORDERS DUE TO ALCOHOL 
DEPENDENCE 
0 1 
F103 
MENTAL AND BEHAVIOURAL DISORDERS DUE TO WITHDRAWAL OF 
ALCOHOL 
0 1 
F104 MENTAL AND BEHAVIOURAL DISORDERS AND DELIRIUM 0 1 
F419 ANXIETY DISORDER, UNSPECIFIED 0 1 
G439 MIGRAINE, UNSPECIFIED 0 1 
H538 OTHER VISUAL DISTURBANCES 0 1 
J690 PNEUMONITIS DUE TO FOOD AND VOMIT 0 1 
K292 ALCOHOLIC GASTRITIS 0 1 
R402 COMA, UNSPECIFIED 0 1 
R410 DISORIENTATION, UNSPECIFIED 0 1 
R418 
OTHER & UNSPEC SYMPTOMS & SIGNS INVOLVING COGNITIVE 
FUNCTION 
0 1 
R42X DIZZINESS AND GIDDINESS 0 1 
R451 RESTLESSNESS AND AGITATION 0 1 
R51X HEADACHE 0 1 
R55X SYNCOPE AND COLLAPSE 0 1 
R600 LOCALIZED OEDEMA 0 1 
R798 OTHER SPECIFIED ABNORMAL FINDINGS OF BLOOD CHEMISTRY 0 1 
S000 SUPERFICIAL INJURY OF SCALP 0 1 
S001 CONTUSION OF EYELID AND PERIOCULAR AREA 0 1 
S008 SUPERFICIAL INJURY OF OTHER PARTS OF HEAD 0 1 
S009 SUPERFICIAL INJURY OF HEAD, PART UNSPECIFIED 0 1 
S010 OPEN WOUND OF SCALP 0 1 
S018 OPEN WOUND OF OTHER PARTS OF HEAD 0 1 
S019 OPEN WOUND OF HEAD, PART UNSPECIFIED 0 1 
S099 UNSPECIFIED INJURY OF HEAD 0 1 
S308 OTHER SUPERFICIAL INJURIES OF ABDOMEN, LOWER BACK AND PELVIS 0 1 
Z038 OBSERVATION FOR OTHER SUSPECTED DISEASES AND CONDITIONS 0 1 
Z739 PROBLEM RELATED TO LIFE-MANAGEMENT DIFFICULTY, UNSPECIFIED 0 1 
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The algorithmic approach developed for this research was informed by the algorithm used 
in the discussed study yet is more complex, for the following reasons:    
Multiple Diagnostic Coding Systems are Included: 
ICD 10 codes are recorded in the HES Admitted Patient Care Dataset, HES Outpatient 
Dataset, SAIL Patient Episode Database for Wales and SAIL Outpatient Dataset and are 
comparable. However, in addition diagnostic codes using a simplified coding system are 
included in the HES Accident & Emergency Dataset and SAIL Emergency Department 
Dataset and for a proportion of patients READ codes are recorded in the SAIL Primary Care 
Dataset. The inclusion of a number of datasets and coding systems necessitated the 
inclusion of an increased number of codes to define the occurrence of seizures.   
A Single Attendance may be Recorded in More Than One Dataset: 
For example, patients may attend the emergency department and subsequently be 
admitted, with the single attendance recorded in both datasets. This necessitated a system 
for stratifying the diagnostic codes. A clinical interpretation was used with codes providing 
the ‘greatest quality’, defined as greatest diagnostic detail and specificity, contributing data 
to the routinely recorded dataset used for the analyses. For example, the ICD code G412 
(Complex Partial Status Epilepticus) provides greater diagnostic detail than the HES 
Accident and Emergency code 241 (CNS Conditions – Epilepsy). In this case the ICD code 
will be included in the dataset used for the analyses. However, the total number of relevant 
codes from all datasets for each variable was also presented.  
The Occurrence of Seizures was Identified Before and Following Diagnosis of Epilepsy: 
Routinely recorded data were available for the time periods before and following diagnosis 
of epilepsy and participant enrolment in SANAD II. The identification of the occurrence of 
seizures before diagnosis and following diagnosis must be appropriate based on the 
diagnostic codes available. Diagnostic codes specifying ‘epilepsy’ or ‘seizures’ were 
appropriate for inclusion in the identification of seizures both before and following 
diagnosis. Diagnostic codes with no specific mention of epilepsy or seizures, specifically the 
emergency codes ‘CNS Disorder’ and ‘CNS Condition – Unspecified’ are not appropriate to 
identify seizure occurrence prior to diagnosis of epilepsy. However, following clinical 
discussion and to ensure a sensitive approach, such codes would be sufficiently likely to be 
recorded and appropriate to identify the occurrence of seizures following diagnosis. The 
total numbers of seizures identified by such codes for each data variable are presented.  
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Multiple Variables Were Assessed, Including the Occurrence of Seizures and Diagnosis 
and Classification of Epilepsy and Seizures:   
Multiple variables and outcome measures were assessed using the record of ‘epilepsy’ and 
‘seizure’ codes. In addition to the occurrence of seizures, agreement was assessed for the 
date of diagnosis of epilepsy and subsequently classification of seizure type (Generalised / 
Focal / Unclassified). This necessitated development of an additional algorithm using the 
recorded codes for the identification of ‘diagnosis of epilepsy’ as a separate entity to the 
‘occurrence of seizures’. 
A Relevant Code may not Indicate the Occurrence of Seizures in some Datasets: 
This complexity refers to the Outpatient and Primary Care Datasets. An ‘epilepsy’ or 
‘seizure’ code in the Outpatient Dataset is very unlikely to indicate the occurrence of 
seizure, although was informative to the diagnosis of epilepsy and classification of seizure 
type. An ‘epilepsy’ or ‘seizure’ code in the Primary Care Dataset can be considered to 
represent occurrence of seizure, diagnosis of epilepsy and classification of seizure type. The 
exception is when the date the code is recorded correlates within one month with the date 
of a relevant attendance in a specialist outpatient clinic. In this case, the General 
Practitioner is likely to have received clinical correspondence from the specialist clinic and 
recorded the relevant codes in the patient’s electronic medical records. The date recorded 
may be the date of specialist clinic review or the date the correspondence was received. 
Such instances were informative to the diagnosis of epilepsy, but were not representative 
of the occurrence of seizures.  
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The Identification of Seizure Occurrence in the Routinely Recorded Datasets 
In this study, the identification of seizure occurrence in routinely recorded datasets 
involved the review of specified diagnostic codes, as follows:  
- Inpatient Datasets:  
HES Admitted Patient Care Dataset and SAIL Patient Episode Database for Wales 
Attendances with ICD 10 codes defined as representing ‘definite seizure’ and 
‘probable seizure’ in the HES Admitted Patient Care and SAIL Patient Episode 
Database for Wales Datasets were included as representing seizure occurrence 
- Outpatient Datasets: 
HES Outpatient and SAIL Outpatient Datasets 
ICD 10 codes recorded in the HES and SAIL Outpatient Datasets were not included 
in the assessment of seizure occurrence 
- Emergency Datasets:  
HES Accident & Emergency and SAIL Emergency Department Datasets 
Diagnostic data is recorded in only a minority of attendances and rarely exceeds a 
single diagnosis in the HES Accident & Emergency and SAIL Emergency Department 
Datasets Defined codes listed in the first diagnostic position represented seizure 
occurrence 
- Primary Care Dataset: 
SAIL Primary Care Dataset 
Specified READ codes recorded in the SAIL Primary Care Dataset represented 
seizure occurrence unless the date correlated within one month with a date of 
neurological specialist assessment in the Outpatient Datasets 
 
Figure 5.2 details the algorithmic approach used in this study. Tables 5.15 and 5.16 detail 
the diagnostic codes included in the identification of seizure occurrence for the participants 
in this study.  
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The Assessment of Seizure Occurrence Before and Following Diagnosis of Epilepsy 
 
The assessment of seizures in participants before diagnosis of epilepsy did not include the 
emergency codes ‘CNS Disorder’ and ‘CNS Condition – Unspecified’. However, following 
clinical discussion and to ensure a sensitive approach, such codes would be sufficiently 
likely to be recorded and appropriate to identify the occurrence of seizures following 
diagnosis of epilepsy. The total numbers of seizures identified by such codes for each data 
variable are presented.  
 
The Assessment of Relevant Attendances, Not Meeting the Criteria for Seizure Occurrence 
 
During the assessment of seizure occurrence, the dates of seizures recorded in the SANAD 
II dataset were used to identify attendances in the routinely recorded datasets within 48 
hours of the date of SANAD II recorded seizure. Such attendances may have been 
inadequately coded or recorded with codes not meeting the criteria for seizure occurrence. 
The total numbers of such attendances for each data variable are presented.  
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Figure 5.2: Algorithm for the Identification of Seizure Occurrence 
 INPATIENT Datasets 
Emergency Admission: 
Admission Method: 
21 Medical or Dental A&E  
22 General Practitioner 
23 Bed Bureau 
24 Consultant Clinic 
28 Other 
 
EMERGENCY Datasets PRIMARY CARE Dataset 
Relevant Medical Speciality 
180, 192, 300, 301, 302, 303, 
315, 320, 330, 340, 361, 370, 
400, 410, 430, 820, 823 
Review ICD Codes: Detailed in Table 5.15: 
 
Definite Seizure Probable Seizure 
‘Definite’ seizure code 
listed in first diagnostic 
position 
‘Definite’ seizure code 
listed in second or third 
diagnostic position AND 
‘probable’ supportive 
code listed in the first 
diagnostic position 
 
SEIZURE OCCURRENCE 
Emergency Attendance 
 
Review Seizure Codes: 
Detailed in Table 5.16: 
Seizure code listed in the 
first diagnostic position 
Review Seizure Codes: 
Detailed in Table 5.16: 
Seizure code listed  
Review Dates of Outpatient 
Neurological Appointments   
No correlating Neurology 
outpatient appointment 
within one month of date of 
primary care recorded 
seizure code 
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Table 5.16: Emergency and READ Codes Included in the Definition of Seizure Occurrence 
Code Code Description 
 
Emergency Codes 
 
HES: 241  CNS Conditions - Epilepsy 
HES: 24 CNS Disorder* 
SAIL: 17A Seizure / Convulsion 
SAIL: 17Z CNS Condition – Unspecified* 
 
Primary Care READ Codes 
 
‘Seizure’ Codes 
1B1W.00 Transient epileptic amnesia 
1B27.00 Seizures in response to acute event 
1B64.00 Had a convulsion 
1B64.11 Convulsion - symptom 
282..00 O/E - fit/convulsion 
282..11 O/E - a convulsion 
282..13 O/E - a seizure 
2828 Absence seizure 
282Z.00 O/E - fit/convulsion NOS 
667D.00 Epilepsy control poor 
667T.00 Daily seizures 
667V.00 Many seizures a day 
667W.00 Emergency epilepsy treatment since last appointment 
F132z12 Myoclonic seizure 
F250011 Epileptic absences 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251600 Grand mal seizure 
F253.11 Status epilepticus 
F254400 Epileptic automatism 
F254500 Complex partial epileptic seizure 
F255600 Simple partial epileptic seizure 
F25H.00 Generalised seizure 
F25X.00 Status epilepticus, unspecified 
F25y300 Complex partial status epilepticus 
F25z.11 Fit (in known epileptic) NOS 
Fyu5200 [X]Other status epilepticus 
Fyu5900 [X]Status epilepticus, unspecified 
R003.00 [D]Convulsions 
R003400 [D]Nocturnal seizure 
R003y00 [D]Other specified convulsion 
R003z00 [D]Convulsion NOS 
R003z11 [D]Seizure NOS 
Ryu7100 [X]Other and unspecified convulsions 
1B63.00 Had a fit 
1B63.11 Fit - had one, symptom 
282..12 O/E - a fit 
2822 O/E - grand mal fit 
2823 O/E - petit mal fit 
2824 O/E - focal (Jacksonian) fit 
2824.11 O/E - Jacksonian fit 
2824.12 O/E - focal fit 
2825 O/E - psychomotor fit 
138 
 
R003200 [D]Fit 
F252.00 Petit mal status 
F253.00 Grand mal status 
‘Epilepsy’ Codes 
1O30.00 Epilepsy confirmed 
667B.00 Nocturnal epilepsy 
F035200 Rasmussen syndrome 
F132100 Progressive myoclonic epilepsy 
F132111 Unverricht - Lundborg disease 
F25..00 Epilepsy 
F250.00 Generalised non-convulsive epilepsy 
F250000 Petit mal (minor) epilepsy 
F250100 Pykno-epilepsy 
F250400 Juvenile absence epilepsy 
F250y00 Other specified generalised non-convulsive epilepsy 
F250z00 Generalised non-convulsive epilepsy NOS 
F251.00 Generalised convulsive epilepsy 
F251000 Grand mal (major) epilepsy 
F251011 Tonic-clonic epilepsy 
F251500 Tonic-clonic epilepsy 
F251y00 Other specified generalised convulsive epilepsy 
F251z00 Generalised convulsive epilepsy NOS 
F254.00 Partial epilepsy with impairment of consciousness 
F254000 Temporal lobe epilepsy 
F254100 Psychomotor epilepsy 
F254200 Psychosensory epilepsy 
F254300 Limbic system epilepsy 
F254z00 Partial epilepsy with impairment of consciousness NOS 
F255.00 Partial epilepsy without impairment of consciousness 
F255000 Jacksonian, focal or motor epilepsy 
F255011 Focal epilepsy 
F255012 Motor epilepsy 
F255100 Sensory induced epilepsy 
F255200 Somatosensory epilepsy 
F255300 Visceral reflex epilepsy 
F255311 Partial epilepsy with autonomic symptoms 
F255400 Visual reflex epilepsy 
F255500 Unilateral epilepsy 
F255y00 Partial epilepsy without impairment of consciousness OS 
F255z00 Partial epilepsy without impairment of consciousness NOS 
F25A.00 Juvenile myoclonic epilepsy 
F25B.00 Alcohol-induced epilepsy 
F25C.00 Drug-induced epilepsy 
F25D.00 Menstrual epilepsy 
F25E.00 Stress-induced epilepsy 
F25F.00 Photosensitive epilepsy 
F25y.00 Other forms of epilepsy 
F25y000 Cursive (running) epilepsy 
F25y100 Gelastic epilepsy 
F25yz00 Other forms of epilepsy NOS 
F25z.00 Epilepsy NOS 
Fyu5000 [X]Other generalized epilepsy and epileptic syndromes 
Fyu5100 [X]Other epilepsy 
SC20000 Traumatic epilepsy 
Legend: *: Codes excluded from the assessment of seizures prior to participant diagnosis of epilepsy 
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5.13.4 Data Variables Relevant to the Identification of Eligible Individuals and 
Recruitment into SANAD II 
5.13.4.1 Seizure Occurrence: Baseline Variables 
Applicable to all variables involving dates of seizure occurrence, a one month (30 days) 
acceptable clinical limit of agreement was specified a priori. This limit was informed by 
clinical discussion and represents a level inclusive of errors in participant recall together 
with a clinically acceptable level of disagreement. The baseline variables assessed are 
detailed in Table 5.17.  
Table 5.17: Seizure Occurrence: Baseline Variables 
Variable Identification in SANAD II Identification in Routine Data 
 
Date of First Seizure 
 
Defined as the first seizure 
occurring at any time prior to 
the baseline SANAD II 
assessment date 
 
 
 
The recorded date of ‘first seizure’ 
 
The first identified seizure occurrence 
prior to the baseline SANAD II 
assessment date.  
 
Thirty six participants (36.7%) had a 
‘first seizure’ recorded in the SANAD 
II dataset occurring prior to 2013. 
This group of participants were 
excluded from this assessment due to 
the lack of availability of routine data 
coverage for the time period before 
2013.   
 
Date of First Tonic-Clonic 
Seizure 
 
Defined as the first tonic-
clonic seizure occurring at any 
time prior to the baseline 
SANAD II assessment date 
 
  
 
The recorded date of ‘first tonic-
clonic seizure’ 
 
The first identified tonic-clonic 
seizure occurrence prior to the 
baseline SANAD II assessment date.  
 
Diagnostic codes were defined a 
priori to indicate the ‘occurrence of 
tonic-clonic seizures’. Informed by 
clinical discussion and to ensure the 
approach was sensitive, non-specific 
codes such as ‘Had a Fit’ and 
‘Epilepsy Unspecified’ were included 
to represent tonic-clonic seizures. It 
was deemed more likely that patients 
seek medical attention following a 
tonic-clonic seizure and in such cases, 
non-specific codes may be recorded.  
 
Thirty six participants (36.7%) had a 
‘first seizure’ recorded in the SANAD 
II dataset occurring prior to 2013. 
This group of participants were 
excluded from this assessment due to 
the lack of availability of routine data 
coverage for the time period before 
2013. 
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5.13.4.2 The Diagnosis and Classification of Epilepsy and Seizures in the Routinely Recorded 
Datasets 
The identification of the diagnosis and subsequently classification of epilepsy and seizures 
in routinely recorded datasets involved the review of specified diagnostic ‘epilepsy’ codes 
and codes included in the identification of seizure occurrence. The diagnosis of epilepsy in 
routine datasets is defined as the recording of a single code consistent with a ‘diagnosis of 
epilepsy’ or the recording of two codes consistent with the ‘occurrence of seizures’. The 
diagnosis is identified in the routinely recorded datasets as follows:   
- Inpatient Datasets: 
HES Admitted Patient Care Dataset and SAIL Patient Episode Database for Wales 
Attendance with a single ICD 10 code representing diagnosis of epilepsy or two 
attendances with codes representing seizure occurrence (‘definite seizure’ or 
‘probable seizure’) 
- Outpatient Datasets: 
HES Outpatient and SAIL Outpatient Datasets 
Review by a neurologist with single ICD 10 code representing diagnosis of epilepsy 
- Emergency Datasets: 
HES Accident & Emergency and SAIL Emergency Department Datasets 
Two attendances with codes representing seizure occurrence 
- Primary Care Dataset: 
SAIL Primary Care Dataset 
Single READ code representing diagnosis of epilepsy or two READ codes 
representing seizure occurrence 
 
For participants meeting the criteria for a diagnosis of epilepsy, the classification of seizure 
type was determined from a clinical interpretation of the recorded codes. Where ‘focal’ or 
‘generalised’ seizures could not be specified, participants were deemed ‘unclassified’.  
Figure 5.3 details the algorithmic approach and Tables 5.18 and 5.19 detail the codes 
included in the diagnosis and classification of epilepsy and seizures relevant to the adult 
participants in this study. The codes included in the definition of seizures have been 
presented in Tables 5.15 and 5.16.     
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Figure 5.3: Algorithm for the Diagnosis of Epilepsy 
 
  
INPATIENT Datasets EMERGENCY Datasets PRIMARY CARE Dataset 
Admission: 
Any Admission Method 
Any Speciality 
 
Review ICD Codes: 
Detailed in Table 5.18 
Epilepsy code listed in 
any diagnostic position 
 
 
OR 
Emergency Admission: 
Admission Method: 
21 Medical or Dental A&E  
22 General Practitioner 
23 Bed Bureau 
24 Consultant Clinic 
28 Other 
 
Relevant Medical Speciality 
180, 192, 300, 301, 302, 303, 
315, 320, 330, 340, 361, 370, 
400, 410, 430, 820, 823 
Review ICD Codes: Detailed in Table 5.15: 
Two Seizure codes (any dataset) >24 hours apart 
 
Definite Seizure Probable Seizure 
‘Definite’ seizure code 
listed in first diagnostic 
position 
‘Definite’ seizure code 
listed in second or third 
diagnostic position AND 
‘probable’ supportive 
code listed in the first 
diagnostic position 
 
DIAGNOSIS OF EPILEPSY 
Review ICD Codes: 
Detailed in Table 5.18: 
Epilepsy code listed 
OUTPATIENT Datasets 
Review READ Codes: 
Detailed in Table 5.19: 
Epilepsy code listed 
 
 
Review READ Codes: 
Detailed in Table 5.16: 
Two Seizure codes (any 
dataset) >24 hours apart 
 
AND 
 
Review Dates of Outpatient 
Neurological Appointments   
No correlating Neurology 
outpatient appointment 
within one month of date of 
primary care recorded 
seizure code 
 
OR 
Emergency Attendance 
 
Review Seizure Codes: 
Detailed in Table 5.16: 
Two seizure codes (any 
dataset) in the first 
diagnostic position >24 
hours apart 
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Table 5.18: ICD Codes Included in the Definition of Diagnosis of Epilepsy 
ICD 10 Code ICD Code Description 
 
Focal Epilepsy 
 
G400 LOCAL-RELATED (PART) IDIOPATH EPILEP/EPILEP SYND WITH SEIZURE 
G401 LOCAL-RELATED (PART) SYMPTOM EPILEPSY/EPILEPTIC SYND WITH SEIZURE 
G402 LOCAL-RELATED (PART) SYMPTOM EPILEPSY/ EPILEP SYND 
 
Generalised Epilepsy 
 
G403 GENERALIZED IDIOPATHIC EPILEPSY AND EPILEPTIC SYNDROMES 
G404 OTHER GENERALIZED EPILEPSY AND EPILEPTIC SYNDROMES 
 
Unclassified Epilepsy 
 
G40 EPILEPSY AND RECURRENT SEIZURES 
G405 SPECIAL EPILEPTIC SYNDROMES 
G408 OTHER EPILEPSY 
G409 EPILEPSY, UNSPECIFIED 
 
Table 5.19: READ Codes Included in the Definition of Diagnosis of Epilepsy 
Code Code Description 
 
Focal Epilepsy 
 
F035200 Rasmussen syndrome 
F254.00 Partial epilepsy with impairment of consciousness 
F254000 Temporal lobe epilepsy 
F254100 Psychomotor epilepsy 
F254200 Psychosensory epilepsy 
F254300 Limbic system epilepsy 
F254z00 Partial epilepsy with impairment of consciousness NOS 
F255.00 Partial epilepsy without impairment of consciousness 
F255000 Jacksonian, focal or motor epilepsy 
F255011 Focal epilepsy 
F255200 Somatosensory epilepsy 
F255311 Partial epilepsy with autonomic symptoms 
F255500 Unilateral epilepsy 
F255y00 Partial epilepsy without impairment of consciousness OS 
F255z00 Partial epilepsy without impairment of consciousness NOS 
F25y100 Gelastic epilepsy 
F25y000 Cursive (running) epilepsy 
SC20000 Traumatic epilepsy 
 
Generalised Epilepsy 
 
F250.00 Generalised non-convulsive epilepsy 
F250100 Pykno-epilepsy 
F250400 Juvenile absence epilepsy 
F250y00 Other specified generalised non-convulsive epilepsy 
F250z00 Generalised non-convulsive epilepsy NOS 
F251.00 Generalised convulsive epilepsy 
F251y00 Other specified generalised convulsive epilepsy 
F251z00 Generalised convulsive epilepsy NOS 
F132100 Progressive myoclonic epilepsy 
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F132111 Unverricht - Lundborg disease 
F25A.00 Juvenile myoclonic epilepsy 
Fyu5000 [X]Other generalized epilepsy and epileptic syndromes 
 
Unclassified Epilepsy 
 
1O30.00 Epilepsy confirmed 
667B.00 Nocturnal epilepsy 
F250000 Petit mal (minor) epilepsy 
F251000 Grand mal (major) epilepsy 
F25..00 Epilepsy 
F251011 Tonic-clonic epilepsy 
F251500 Tonic-clonic epilepsy 
F255100 Sensory induced epilepsy 
F255300 Visceral reflex epilepsy 
F255400 Visual reflex epilepsy 
F255012 Motor epilepsy 
F25B.00 Alcohol-induced epilepsy 
F25C.00 Drug-induced epilepsy 
F25D.00 Menstrual epilepsy 
F25E.00 Stress-induced epilepsy 
F25F.00 Photosensitive epilepsy 
F25y.00 Other forms of epilepsy 
F25yz00 Other forms of epilepsy NOS 
F25z.00 Epilepsy NOS 
Fyu5100 [X]Other epilepsy 
 
 
5.13.4.3 Diagnosis and Classification of Epilepsy and Seizures: Variables  
An acceptable clinical limit of agreement for the date of diagnosis of epilepsy was specified 
a priori at one month (30 days). This limit was informed by clinical discussion and 
represents a pragmatic level inclusive of administrative procedures in clinical practice. For 
example, following a diagnosis during an outpatient assessment, the General Practitioner 
may not receive correspondence for two weeks at which time a relevant READ code may be 
recorded. This rationale also explains the one month period permitted following the 
baseline assessment date, in the ‘baseline’ diagnosis. The variables assessed are detailed in 
Table 5.20.  
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Table 5.20: Diagnosis and Classification of Epilepsy and Seizures: Variables  
Variable Identification in SANAD II Identification in Routine Data 
 
Date of Baseline Diagnosis of 
Epilepsy 
 
Defined as the first 
occurrence of a ‘diagnosis’ at 
baseline 
 
 
The recorded date of the SANAD II 
baseline assessment 
 
Defined as the first occurrence of a 
‘diagnosis’ at any time prior to the 
baseline SANAD II assessment or 
within one month subsequently.  
Thirty six participants (36.7%) had a 
‘first seizure’ recorded in the SANAD 
II dataset occurring prior to 2013. 
Twenty of this group (55.5%), not 
meeting the criteria for a diagnosis of 
epilepsy were censored from this 
assessment due to the lack of 
availability of routine data coverage 
for the time period before 2013, 
removing the potential for two 
seizures to be recorded. This 
approach ensured a fair comparison 
and the maximal inclusion of data. 
 
Date of All-Time Diagnosis of 
Epilepsy 
 
Defined as the first 
occurrence of a ‘diagnosis’ at 
any time  
 
 
 
The recorded date of the SANAD II 
baseline assessment 
 
Defined as the first occurrence of a 
‘diagnosis’ at any time.  
Thirty six participants (36.7%) had a 
‘first seizure’ recorded in the SANAD 
II dataset occurring prior to 2013. 
Seventeen of this group (47.2%), not 
meeting the criteria for a diagnosis of 
epilepsy were excluded from this 
assessment due to the lack of 
availability of routine data coverage 
for the time period before 2013, 
removing the potential for two 
seizures to be recorded. This 
approach ensured a fair comparison 
and the maximal inclusion of data. 
 
Baseline Classification of 
Seizure  
 
Defined as the ‘classification’ 
of seizure in participants 
meeting the criteria for a 
baseline diagnosis of epilepsy 
 
 
 
The classification (focal, generalised, 
unclassified) recorded in SANAD II 
 
The classification (focal, generalised, 
unclassified) derived from the 
greatest quality recorded seizure and 
epilepsy diagnostic codes in 
participants meeting the criteria for a 
baseline diagnosis of epilepsy. 
Classification is only assessed in 
participants meeting the criteria for 
diagnosis, to ensure a fair 
comparison to the data recorded in 
SANAD II.     
 
All-Time Classification of 
Seizure 
 
Defined as the ‘classification’ 
of seizure in participants 
meeting the criteria for an all-
time diagnosis of epilepsy  
 
 
 
The classification (focal, generalised, 
unclassified) recorded in SANAD II 
 
The classification (focal, generalised, 
unclassified) derived from the 
greatest quality recorded seizure and 
epilepsy diagnostic codes in 
participants meeting the criteria for 
an all-time diagnosis of epilepsy. 
Classification is only assessed in 
participants meeting the criteria for 
diagnosis, to ensure a fair 
comparison to the data recorded in 
SANAD II.     
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5.13.4.4 The Assessment of Clinical Investigations in the Routinely Recorded Datasets  
Limited data regarding clinical investigations were available in the routinely recorded 
datasets. The SAIL primary care dataset included all READ codes recorded for each 
participant for the time period 2013-present. Although MRI, CT or EEG will not be 
performed in primary care, it was reasonable to expect codes to be entered into 
participants’ electronic medical records on receipt of correspondence from secondary care. 
READ codes exist for the investigations and results and the primary care dataset had the 
greatest potential for detailed informative data. Data regarding MRI and CT were available 
from the HES Accident and Emergency and SAIL Emergency Department Datasets. The 
record of ‘MRI’ or ‘CT’ during an attendance is recorded, but the anatomical site of the 
imaging is not recorded. Additionally, the investigation results are not recorded and there 
was no available code for ‘EEG’. In both the inpatient and outpatient datasets, despite the 
availability of ICD codes for the relevant procedures, such codes were not included in the 
data fields provided in the HES and SAIL datasets.  
As a result of the limitations in the routinely recorded data, the ‘status’ of clinical 
investigations were compared in this study. Status defines whether an investigation has 
been ‘Performed’ or ‘Not Performed’. However, narrative analysis of the data regarding the 
results of the investigations has also been included where this was available.   
Identification of the status of the investigations in routinely recorded datasets involved the 
review of specified investigation codes, defined as follows: 
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CT Brain and MRI Brain: 
- Emergency Datasets: 
HES Accident & Emergency and SAIL Emergency Department Datasets 
Record of a relevant code indicating ‘MRI’ or ‘CT’ during an attendance with a 
previously defined episode of seizure occurrence 
 
Following clinical discussion and as a result of the lack of record of anatomical site, 
relevant codes recorded during attendances not meeting the criteria for seizure 
occurrence were not sufficiently likely to represent imaging of the brain  
 
- Primary Care Dataset: 
SAIL Primary Care Dataset 
READ codes representing CT Brain or MRI Brain  
 
EEG: 
- Primary Care Dataset: 
SAIL Primary Care Dataset 
READ codes representing EEG 
 
An algorithmic approach, detailed in Figure 5.4 was developed to identify the status of 
clinical investigations and data were compared to the status recorded in SANAD II. Table 
5.21 details the codes included in the assessment of the status of clinical investigations.  
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Figure 5.4: Algorithm for the Assessment of Clinical Investigations 
 
  
EMERGENCY Datasets PRIMARY CARE Dataset 
INVESTIGATION PERFORMED 
Emergency Attendance 
Consistent with an episode of 
seizure occurrence 
 
 
Review Investigation Codes: 
Detailed in Table 5.21: 
MRI or CT code listed 
Review Investigation Codes: 
Detailed in Table 5.21: 
MRI, CT or EEG code listed  
 
Non-Specific Codes: 
Codes not specifying 
anatomical site must 
correlate with a known 
episode of seizure 
occurrence 
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Table 5.21: Investigation Codes Included in the Assessment of Clinical Investigations 
Code Code Description 
 
CT Brain 
 
HES: 12 Computed Tomography 
SAIL: 201 Computed Tomography 
READ: 567 Computed Tomography 
READ: Y72JC CT Head 
READ: Y72JD CT Brain 
READ: YAYCE CT of Bone Structures and Cavities of the Head 
READ: YAYCB CT Bone Structures of the Head 
READ: YAMGZ CT Brain Normal 
READ: YAQSS CT Brain Abnormal 
READ: 5674 CT Skull 
 
MRI Brain 
 
HES: 11 Magnetic Resonance Imaging 
SAIL: 202 Magnetic Resonance Imaging 
READ: 569 Magnetic Resonance: (Imaging) or (Study) 
READ: Y7212 MRI of Head 
READ: Y7213 MRI of Brain 
READ: Y7215 MRI of Brain with Functional Imaging 
READ: YB095 MRI Scan Abnormal 
READ: YB088 MRI Scan Normal 
READ : 5692 Nuclear Magnetic Resonance Scan: Normal 
READ: 5693 Nuclear Magnetic Resonance Scan: Abnormal 
 
EEG 
 
X77i2  Scalp EEG 
X77i8 Sleep EEG 
X77iL Video EEG 
X77iM EEG telemetry 
X77JD Asymmetric EEG 
X77iI Ambulatory EEG 
X77I8 EEG observations 
X77Ir Focal EEG pattern 
X77jK Intraoperative EEG 
X77iL EEG video telemetry 
X77iI AEEG - Ambulatory EEG 
X77Ir Localised EEG pattern 
X77I9 Generalised EEG pattern 
X77iJ Continuous processed EEG 
X77i9 Sleep EEG - natural sleep 
Xa0ej Continuous EEG measurements 
X77i4 EEG with photic stimulation 
70650 EEG - Electroencephalography 
X77i6 EEG with drug administration 
X77J1 Focal episodic EEG abnormality 
X77Iz Focal reduction of EEG activity 
X77Is Focal continuous EEG abnormality 
X77iA Sleep EEG - sleep-deprived patient 
31130 EEG normal 
XM18c EEG abnormal 
X77IA EEG artefact 
X77JH Generalised EEG frequency asymmetry 
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X77JG Generalised EEG amplitude asymmetry 
X77Ig Generalised episodic EEG abnormality 
X77II EEG pattern of uncertain significance 
X77Ig Generalised paroxysmal EEG abnormality 
X77IQ Generalised continuous EEG abnormality 
X77i7 EEG during special activation procedure 
X77IQ Generalised non-paroxysmal EEG abnormality 
X77i5 EEG with over breathing and photic stimulation 
X77IM Subclinical rhythmical EEG discharges in adults 
X77IM SREDA - Subclinical rhythmical EEG discharges in adults 
70650 Electroencephalography 
XaPpX Electroencephalography NEC 
70650 EEG - Electroencephalography 
XM18c Electroencephalogram abnormal 
X77iM Electroencephalograph telemetry 
 
 
5.13.5 Data Variables and Outcomes Relevant to the Follow-Up in SANAD II 
5.13.5.1 Seizure Occurrence: Follow-Up Variables 
Applicable to all variables involving dates of seizure occurrence, a one month (30 days) 
acceptable clinical limit of agreement was specified a priori. This limit was informed by 
clinical discussion and represents a level inclusive of errors in participant recall together 
with a clinically acceptable level of disagreement. The follow-up variables assessed are 
detailed in Table 5.22.  
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Table 5.22: Seizure Occurrence: Follow-Up Variables 
Variable / Outcome Measure Identification in SANAD II Identification in Routine Data 
 
Date of First Follow-Up 
Seizure 
 
Defined as the first seizure 
occurrence for the time 
period from the date of 
SANAD II randomisation until 
the final date routine data 
from all sources was available 
(31/12/15) or the date of last 
SANAD II follow-up 
assessment if the last follow-
up assessment occurred prior 
to 31/12/15.  
 
This approach ensured the 
routine and SANAD II datasets 
were matched and permitted 
a fair comparison and the 
maximal inclusion of available 
data. 
 
The first seizure recorded following 
the date of SANAD II randomisation.  
 
 
 
The first seizure occurrence identified 
following the date of SANAD II 
randomisation.  
 
 
Time to First Follow-Up Seizure 
 
Defined as the time in days between the date of SANAD II randomisation and the date of first follow-up seizure.  
 
Time to first follow-up seizure has been constructed using the ‘date of first follow-up seizure’ recorded in the 
SANAD II and identified in the routine datasets, the difference assessed using survival analysis. Participants not 
experiencing first follow-up seizure were censored using the final date routine data from all sources was 
available (31/12/15) or the date of last follow-up assessment if the last follow-up assessment occurred prior to 
31/12/15. This approach ensured the routine and SANAD II datasets were matched and permitted a fair 
comparison and the maximal inclusion of available data.  
 
Date of First Follow-Up Tonic-
Clonic Seizure 
 
Defined as the first tonic-
clonic seizure occurrence for 
the time period from the date 
of SANAD II randomisation 
until the final date routine 
data from all sources was 
available (31/12/15) or the 
date of last SANAD II follow-
up assessment if the last 
follow-up assessment 
occurred prior to 31/12/15.  
 
This approach ensured the 
routine and SANAD II datasets 
were matched and permitted 
a fair comparison and the 
maximal inclusion of available 
data. 
 
The first tonic-clonic seizure 
recorded following the date of 
SANAD II randomisation.  
 
 
The first tonic-clonic seizure 
occurrence identified following the 
date of SANAD II randomisation.  
 
Diagnostic codes were defined a 
priori to indicate the ‘occurrence of 
tonic-clonic seizures’. Informed by 
clinical discussion and to ensure the 
approach was sensitive, non-specific 
codes such as ‘Had a Fit’ and ‘Epilepsy 
Unspecified’ were included to 
represent tonic-clonic seizures.  
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Date 12 Month Remission 
Achieved 
 
Defined as the date that 
remission from seizures has 
been achieved for a 
continuous period of 12 
months following the date of 
SANAD II randomisation.   
 
For 12 month remission to be 
achieved there must be at 
least 12 months of available 
routine data and a SANAD II 
follow-up assessment at least 
12 months after the date of 
last seizure. This approach 
ensured the routine and 
SANAD II datasets were 
matched and permitted a fair 
comparison and the maximal 
inclusion of available data.  
 
The date that remission from 
seizures has been achieved for a 
continuous period of 12 months 
following the date of SANAD II 
randomisation.   
 
In the SANAD II Dataset, for a date of 
12 month remission to be specified, 
there must be a SANAD II follow-up 
assessment at least 12 months after 
the date of last seizure.   
 
To ensure a fair comparison, 
participants in the SANAD II dataset 
achieving 12 month remission after 
31/12/15 will be deemed not to have 
achieved 12 month remission as a 
result of the lack of available routine 
data.  
 
The date that remission from seizures 
has been achieved for a continuous 
period of 12 months following the 
date of SANAD II randomisation.   
 
In the routine dataset, for a date of 
12 month remission to be specified, 
there must be at least 12 months of 
available routine data after the date 
of last seizure.  
 
To ensure a fair comparison, 
participants in the routine dataset 
achieving 12 month remission after 
the date of last SANAD II follow-up 
assessment, if this last assessment 
occurred before 31/12/15, will be 
deemed not to have achieved 
remission.    
 
Time to 12 Month Remission 
 
Defined as the time in days between the date of SANAD II randomisation and the date 12 month remission is 
achieved. 
 
Time to 12 month remission has been constructed using the ‘date 12 month remission is achieved’ calculated 
from the SANAD II and routine datasets, the difference assessed using survival analysis.  Participants not 
achieving remission were censored using the final date routine data from all sources was available (31/12/15) 
or the date of last follow-up assessment if the last follow-up assessment occurred prior to 31/12/15. This 
approach ensured the routine and SANAD II datasets were matched and permitted a fair comparison and the 
maximal inclusion of available data.  
 
Total Number of Follow-Up 
Seizures 
 
Defined as the total number 
of seizures (of any type and 
tonic-clonic) during the time 
period following the date of 
SANAD II randomisation until 
the final date routine data 
from all sources was available 
(31/12/15) or the date of last 
SANAD II follow-up 
assessment if the last follow-
up assessment occurred prior 
to 31/12/15.  
 
This approach ensured the 
routine and SANAD II datasets 
were matched and permitted 
a fair comparison and the 
maximal inclusion of available 
data. 
 
The total number of seizures 
recorded following the date of 
SANAD II randomisation.  
 
As the dates of ‘all’ seizures are not 
recorded in SANAD II, for this 
assessment only the ‘definite’ dates 
of seizures recorded in the SANAD II 
dataset have been included.  
 
The total number of seizure 
occurrences identified following the 
date of SANAD II randomisation.  
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 5.13.5.2 The Assessment of Antiepileptic Drugs in the Routinely Recorded Datasets 
Limited data regarding AEDs were available in the routinely recorded datasets. There were 
no available codes for the prescription, dose or indication in the ICD 10 or Emergency 
Dataset coding systems. Therefore, data retrieved from the Inpatient, Emergency, 
Outpatient or Critical Care datasets were not informative to the assessment of this variable. 
The SAIL Primary Care Dataset included all READ codes recorded for each participant for 
the time period 2013-present. READ codes were available for medications including AEDs 
identified by both generic and trade name including dosage of the tablet and are recorded 
in primary care electronic medical records with each prescription. However, the prescribed 
dose is not adequately recorded. For example, a participant may have a READ code 
‘Lamotrigine 25mg’ but the prescribed dosage is not recorded within the READ code system 
and could for example include 25mg once a day, 25mg twice a day, 50mg in the morning 
and 25mg at night.  
 
The Identification of the Date of AED First Prescription in the Routinely Recorded Datasets 
As a result of the limitations in the routinely recorded data, the ‘date of AED first 
prescription’ was assessed, including the initial prescription of randomised AED and 
subsequent add-on or alternative monotherapy AED prescriptions. The date of AED first 
prescription is defined as the earliest date evidence of AED prescription is identified. The 
assessment has been limited to the 23 participants where data were available in the SAIL 
Primary Care Dataset. The dates of AED first prescription identified from routinely recorded 
datasets were compared to the data regarding AEDs in SANAD II.   
Identification of the date of AED first prescription in routinely recorded datasets involved 
the review of specified READ codes: 
- Primary Care Dataset: 
SAIL Primary Care Dataset 
Date of first READ code representing prescription of an AED   
 
Recorded READ codes were reviewed and both generic and trade AED names, detailed in 
Table 5.23 were screened.   
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An acceptable clinical limit of agreement has been specified at three months (90 days). This 
time period allows for the variability in prescribing practice. For example, a possible 
scenario may include a patient receiving a prescription during the SANAD II baseline 
assessment and a two month medication supply from the hospital pharmacy. A 
prescription may not be evident until the third month in the Primary Care Dataset when 
the patient requires a re-supply of the AED and a repeat prescription is issued.  
 
Compliance 
Additionally, data regarding compliance can be inferred from the Primary Care Dataset 
based on regularity of repeat prescription (1, 2 or 3 monthly). Such data is not recorded in 
the SANAD II dataset and an interpretation of the compliance derived from the Primary 
Care Dataset is presented.   
 
Table 5.23: Antiepileptic Drugs, Generic and Trade Names 
Antiepileptic Drugs: Trade Name Antiepileptic Drugs: Generic Name 
Epilim, Epilim Chrono  Sodium Valproate 
Emeside/Zarontin Ethosuximide 
Keppra  Levetiracetam 
Lamictal Lamotrigine 
Tegretol, Tegretol Retard  Carbamazepine 
Epanutin  Phenytoin 
Frisium  Clobazam 
Fycompa  Perampanel 
Luminal  Phenobarbital 
Lyrica  Pregabalin 
Neurontin  Gabapentin 
Rivotril  Clonazepam 
Topamax  Topiramate 
Trileptal  Oxcarbazepine 
Vimpat  Lacosamide 
Zebinix  Eslicarbazepine 
Zonegran  Zonisamide 
Diacomit  Stiripentol 
Diamox Acetazolamide 
Gabitril  Tiagabine 
Inovelon  Rufinamide 
Mysoline Primidone 
Nootropil  Piracetam 
Sabril  Vigabatrin 
Trobalt  Retigabine 
Briviact Brivaracetam 
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5.13.5.3 The Assessment of Adverse Events in the Routinely Recorded Datasets 
Potentially ‘any’ clinical symptom or diagnosis may represent an adverse event. As such the 
ICD 10, emergency and READ coding systems may all contain relevant diagnostic 
information and data from the Inpatient, Outpatient, Emergency and Primary Care Datasets 
may include data informative to this assessment.   
 
The Identification of Adverse Events in the Routinely Recorded Datasets 
The occurrence of adverse events, date and clinical symptoms or diagnoses, were assessed. 
In the routinely recorded datasets, adverse events were identified with the occurrence of a 
diagnostic code consistent with ‘adverse event’ or the occurrence of a diagnostic code 
clinically consistent with an adverse event recorded in SANAD II and occurring within 90 
days of the SANAD II recorded adverse event. Diagnostic codes indicating specifically 
‘adverse events’ are detailed in Table 5.24. Diagnostic codes clinically consistent with 
adverse events recorded in SANAD II were dependent on the specific adverse event. A 
clinical interpretation of the diagnostic codes and symptoms recorded as adverse events in 
SANAD II was taken to identify consistent adverse event occurrences in the routinely 
recorded datasets. Adverse events frequently reported or serious in severity for the AEDs 
included in SANAD II are summarised in Table 5.25 and the record of such events were 
sought in the routinely recorded datasets, in addition. Furthermore, healthcare 
attendances with inadequate diagnostic information, but within 90 days of the date of 
adverse event recorded in SANAD II were noted. Finally, diagnostic data occurring at any 
time that may provide an alternative explanation for the recorded adverse event were also 
extracted.   
The acceptable clinical limit of agreement has been specified at 90 days, informed by 
clinical discussion to account for variability in healthcare attendance, recall of onset dates 
and duration of adverse events. For example, a possible scenario may include a patient 
experiencing a chronic mild symptom and reporting it to their General Practitioner who 
advises symptomatic relief, continuation of treatment and discussion with the Neurologist 
during the planned SANAD II follow-up assessment two months later where the symptom 
may be recorded as an adverse event in the SANAD II dataset. Adverse events were 
identified in routinely recorded datasets using an algorithmic approach detailed in Figure 
5.5 and compared to data collected using standard methods in SANAD II.  
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The identification of adverse events in routinely recorded datasets involved the review of 
diagnostic codes: 
- Inpatient Datasets:  
HES Admitted Patient Care Dataset and SAIL Patient Episode Database for Wales 
Attendance with an ICD 10 code defining ‘adverse event’ or attendance with an ICD 
10 code clinically consistent with an adverse event recorded in SANAD II and 
occurring within 90 days of the SANAD II recorded adverse event  
- Outpatient Datasets: 
HES Outpatient and SAIL Outpatient Datasets 
Attendance with an ICD 10 code defining ‘adverse event’ or attendance with an ICD 
10 code clinically consistent with an adverse event recorded in SANAD II and 
occurring within 90 days of the SANAD II recorded adverse event  
- Emergency Datasets:  
HES Accident & Emergency and SAIL Emergency Department Datasets 
Attendance with an emergency code defining ‘adverse event’ or attendance with 
an emergency code clinically consistent with an adverse event recorded in SANAD II 
and occurring within 90 days of the SANAD II recorded adverse event  
- Primary Care Dataset: 
SAIL Primary Care Dataset 
Attendance with a READ code defining ‘adverse event’ or attendance with a READ 
code clinically consistent with an adverse event recorded in SANAD II and occurring 
within 90 days of the SANAD II recorded adverse event  
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Figure 5.5: Algorithm for the Identification of Adverse Events  
 
  
INPATIENT Datasets EMERGENCY Datasets PRIMARY CARE Dataset 
Admission: 
Any Admission Method 
Any Speciality 
 
Review ICD Codes: 
Detailed in Table 5.24: 
‘Adverse event’ code 
listed in any diagnostic 
position 
 
 
OR 
ADVERSE EVENT 
Review ICD Codes: 
Detailed in Table 5.24: 
‘Adverse Event’ code 
listed 
OUTPATIENT Datasets 
Review READ Codes: 
Diagnostic code clinically 
consistent with adverse 
event recorded in 
SANAD II and occurring 
within 90 days of the 
SANAD II recorded 
adverse event 
 
OR 
Admission: 
Any Admission Method 
Any Speciality 
 
Review ICD Codes: 
Diagnostic code clinically 
consistent with adverse 
event recorded in 
SANAD II and occurring 
within 90 days of the 
SANAD II recorded 
adverse event 
 
 
OR 
Review ICD Codes: 
Diagnostic code clinically 
consistent with adverse 
event recorded in 
SANAD II and occurring 
within 90 days of the 
SANAD II recorded 
adverse event 
 
 
Review READ Codes: 
Detailed in Table 5.24: 
‘Adverse Event’ code 
listed 
Review Emergency 
Codes: 
Detailed in Table 5.24: 
‘Adverse Event’ code 
listed 
OR 
Review Emergency 
Codes: 
Diagnostic code clinically 
consistent with adverse 
event recorded in 
SANAD II and occurring 
within 90 days of the 
SANAD II recorded 
adverse event 
 
157 
 
Table 5.24: Diagnostic Codes Indicating ‘Adverse Events’ 
Code Code Description 
 
ICD 10 Codes 
 
T88 Other complications of surgical and medical care, not elsewhere classified 
T88.6 
Anaphylactic reaction due to adverse effect of correct drug or medicament properly 
administered 
T88.7 Unspecified adverse effect of drug or medicament 
T88.8 Other specified complications of surgical and medical care, not elsewhere classified 
T88.9 Complication of surgical and medical care, unspecified 
T42.0 Poisoning by, adverse effect of and underdosing of hydantoin derivatives 
T42.1 Poisoning by, adverse effect of and underdosing of iminostilbenes 
T42.2 Poisoning by, adverse effect of and underdosing of succinimides and oxazolidinediones 
T42.3 Poisoning by, adverse effect of and underdosing of barbiturates 
T42.4 Poisoning by, adverse effect of and underdosing of benzodiazepines 
T42.5 Poisoning by, adverse effect of and underdosing of mixed antiepileptics 
T42.6 
Poisoning by, adverse effect of and underdosing of other antiepileptic and sedative-hypnotic 
drugs 
T42.7 
Poisoning by, adverse effect of and underdosing of unspecified antiepileptic and sedative-
hypnotic drugs 
 
Emergency Code 
 
32 Allergy (anaphylaxis)  
 
READ Codes 
 
SN5 Adverse effects NEC 
SN5z Adverse effects NOS 
TJ632 Adverse reaction to carbamazepine 
TJ63 Adverse reaction to other anticonvulsant 
TJ61 Adverse reaction to hydantoin derivative 
TJHyz Adverse reaction to other drug or medicine NOS 
TJHz. Adverse reaction to drug or medicinal substance NOS 
TJ6 Adverse reaction to anticonvulsants and anti-parkinsonism drugs 
TJ6z Adverse reaction to anticonvulsant and antiparkinsonism drugs NOS 
Xa5Jh Lamotrigine adverse reaction 
TJ632 Adverse reaction to carbamazepine 
TJ633 Adverse reaction to sodium valproate 
TJ610 Adverse reaction to phenytoin 
TJ70 Adverse reaction to barbiturate 
TJ94 Adverse reaction to benzodiazepine-based tranquilliser 
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Table 5.25: Frequent or Serious Adverse Events for Antiepileptic Drugs Included in SANAD II 
Lamotrigine: 
 
- Rash 
- Stevens Johnson Syndrome / Toxic Epidermal Necrolysis 
- Dizziness / Vertigo  
- Fatigue / Drowsiness 
- Nausea / GI Disturbance 
- Headache 
- Tremor 
- Incoordination / Ataxia  
- Deranged Liver Function Tests / Enzymes 
- Behavioural Disturbance  
- Confusion / Poor Memory  
- Anaphylaxis 
Levetiracetam: 
 
- Fatigue / Drowsiness 
- Headache 
- Behavioural Disturbance 
- Suicidal Thoughts 
- Tremor 
- Incoordination / Ataxia  
- Confusion / Poor Memory 
- Nausea / GI Disturbance  
- Rash 
- Weight Gain 
- Dizziness / Vertigo  
- Anaphylaxis 
Zonisamide: 
 
- Dizziness / Vertigo  
- Fatigue / Drowsiness 
- Headache 
- Rash 
- Insomnia 
- Nausea / GI Disturbance 
- Anaphylaxis 
Sodium Valproate: 
 
- Nausea / GI Disturbance  
- Fatigue / Drowsiness  
- Weight Gain 
- Behavioural Disturbance / Aggression 
- Confusion / Poor Memory  
- Incoordination / Ataxia 
- Tremor 
- Hyperammonaemia 
- Thrombocytopenia 
- Anaphylaxis 
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5.13.5.4 The Assessment of Healthcare Resource Use in the Routinely Recorded Datasets 
Data regarding healthcare resource use for both ‘planned’ and ‘unplanned’ healthcare 
attendances were compared between the SANAD II and routinely recorded datasets.  
 
The Identification of Planned Healthcare Attendances in the Routinely Recorded Datasets 
The SANAD II baseline and follow-up assessments were representative of planned 
healthcare attendances. In the routinely recorded datasets, SANAD II assessments were 
identified as a date of relevant healthcare attendance within one month of the SANAD II 
assessment date. Where multiple relevant attendances occur within one month, the date 
in closest proximity to the SANAD II assessment date was recorded. In the first instance the 
outpatient datasets were reviewed. Subsequently, for SANAD II assessments not identified 
in the outpatient datasets, the emergency and inpatient datasets were reviewed. As the 
SANAD II assessment would occur opportunistically and not depend on clinical reason for 
attendance or admission speciality, such attendances were not restricted by diagnostic 
code or admission speciality.  
A Priori, an acceptable clinical limit of agreement has been specified at one month (30 
days). This permits time for the completion of the SANAD II documentation that may not 
always be completed at the time of the trial assessment for logistical reasons, for example 
participant assessment during a busy outpatient clinic.  
Planned healthcare attendances were identified in the routinely recorded datasets as 
follows:  
- Outpatient Datasets: 
HES Outpatient and SAIL Outpatient Datasets 
Attendance with listed medical speciality within 30 days of SANAD II assessment 
date: 
301, General Medicine, 400, Neurology, 401, Clinical Neuro-Physiology, 
420, Paediatrics, 421, Paediatric Neurology 
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For SANAD II Attendances Not Identified:  
 
- Inpatient Datasets:  
HES Admitted Patient Care Dataset and SAIL Patient Episode Database for Wales 
- Attendance within 30 days of SANAD II assessment date  
 
- Emergency Datasets:  
HES Accident & Emergency and SAIL Emergency Department Datasets 
- Attendance within 30 days of SANAD II assessment date  
 
The availability of data in the outpatient datasets for some participants extended into 2016 
and dates of outpatient attendances identified in 2016 were included. However, where 
dates of SANAD II assessment in 2016 are identified in the SANAD II dataset, but not the 
outpatient dataset and there are no other attendances in 2016 in the outpatient dataset, 
such dates were excluded from the analysis as it was likely that relevant routinely recorded 
data were not available for the time period.      
 
The Identification of Unplanned Healthcare Attendances in the Routinely Recorded Datasets 
During SANAD II participants are requested to complete self-report questionnaires at 
specified intervals during follow-up, indicating if they have had any healthcare attendances 
‘in the last three months’. Episodes of healthcare attendances reported in SANAD II for the 
specified three month time periods were sought in the routinely recorded datasets. The 
date and clinical reason for attendance were extracted.   
The exact dates of healthcare attendances are not recorded in the SANAD II dataset and 
therefore a comparison of the dates of attendance would not be valid. Therefore, the total 
numbers of healthcare attendances reported in SANAD II and extracted from routine 
datasets for the equivalent time periods were compared.   
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Unplanned healthcare attendances were identified in the routinely recorded datasets as 
follows:  
Where Emergency Department Attendances were Reported in SANAD II: 
 
- Emergency Datasets:  
HES Accident & Emergency and SAIL Emergency Department Datasets 
- Total attendances and diagnoses during the 90 days prior to the date of completion 
of the SANAD II self-report questionnaire  
 
Where Inpatient Admissions were Reported in SANAD II: 
 
- Inpatient Datasets:  
HES Admitted Patient Care Dataset and SAIL Patient Episode Database for Wales 
- Total attendances and diagnoses during the 90 days prior to the date of completion 
of the SANAD II self-report questionnaire  
 
The availability of data in selected routine datasets for some participants extended into 
2016 and dates of healthcare attendances identified in 2016 were included. However, 
where dates of SANAD II reported attendances in 2016 are not identified in the routine 
datasets and there were no other attendances in 2016, such attendances were excluded as 
it was likely that relevant routinely recorded data was not available for the equivalent time 
period.     
In addition to emergency department attendances and inpatient admissions, participants in 
SANAD II are requested to provide details regarding primary care attendances. However, 
comparable data regarding primary care attendances could not be accurately or reliably 
identified from the Primary Care Dataset. The Primary Care Dataset includes READ codes 
and date of entry, but without context. Healthcare events including the receipt of clinical 
correspondence, investigation results, medication prescriptions and clinical prompts may 
result in READ code entry, in addition to patient attendance. It is therefore not possible to 
accurately and reliably identify episodes of patient attendance.     
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5.14 Conclusions 
In this chapter the methods for the assessment of quality and agreement between 
routinely recorded data and data collected using standard prospective methods have been 
presented. In the following Chapter Six, the assessment of seizure occurrence, diagnosis 
and classification of epilepsy and seizures in routinely recorded datasets will be examined, 
relevant to the identification and recruitment of individuals eligible for inclusion in SANAD 
II. In Chapter Seven, variables and outcome measures relevant to the follow- up of 
participants in SANAD II will be examined. Finally, in Chapter Eight, the feasibility and 
efficiency of accessing and using routinely recorded data for participants in SANAD II is 
discussed and recommendations for improvement proposed.     
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Chapter Six 
Results: The Assessment of Seizures and Data Variables 
Relevant to the Identification of Eligible Individuals and 
Recruitment into SANAD II 
 
6.1 Introduction 
In this chapter, the assessment of seizure occurrence, diagnosis and classification of 
epilepsy and seizures in routinely recorded datasets is examined, relevant to the 
identification and recruitment of individuals eligible for SANAD II. Using the algorithmic 
approaches developed and presented in Chapter Five, the codes recorded for participants 
in the datasets together with an assessment of the quality of the available data is 
presented. Subsequently, an assessment of the agreement between routinely recorded 
data and data collected using standard prospective methods for variables relevant to the 
identification and recruitment of individuals was completed. Relevant variables included 
date of first seizure, date of diagnosis and classification of epilepsy and seizures. Finally, the 
record of clinical investigations was examined, including an assessment of the quality of the 
available data and agreement between datasets for the status (performed / not performed) 
of MRI Brain, CT Brain and EEG.    
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6.2 The Identification of Seizure Occurrence in the Routinely Recorded Datasets  
The identification of seizure occurrence is essential for the diagnosis of epilepsy and 
enrolment into SANAD II and subsequently calculation of the trial outcomes. 
Records of seizure occurrence were identified in the HES APC and A&E and the SAIL PEDW, 
EDDS and GP Datasets. Both ‘seizure’ codes and ‘epilepsy’ codes were recorded in the 
routine datasets and included as representing seizure occurrence in accordance with the 
developed algorithm. The codes present in the routine datasets for the participants in this 
study indicating seizure occurrence are presented in Table 6.1.  
There were a total 116 healthcare attendances using 137 diagnostic codes meeting the 
criteria for seizure occurrence identified in the routinely recorded datasets for the 98 
participants included in the study. It was possible in only a minority of cases to define 
seizure type, using the code recorded. In all coding systems and routinely recorded 
datasets, the most commonly recorded codes were non-specific ‘seizure’ and ‘epilepsy’ 
codes. The most common ICD 10 code was ‘Unspecified Convulsions (R568)’, emergency 
code ‘CNS Conditions – Epilepsy (HES 41, SAIL 17A)’ and READ code ‘Convulsion NOS 
(R003z)’ and ‘Had a Fit (IB63)’. The frequencies with which each code was recorded are 
presented in Table 6.1.  
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Table 6.1: The Occurrence of Seizures in Routinely Recorded Datasets 
Code  Description Total Records 
 
ICD Codes 
 
 
G40 EPILEPSY AND RECURRENT SEIZURES* 1 
G401 
LOCAL-RELATED (PART) SYMPTOM EPILEPSY/EPILEPTIC SYND WITH 
SEIZURE 
1 
G402 LOCAL-RELATED (PART) SYMPTOM EPILEPSY/ EPILEP SYND 1 
G403 GENERALIZED IDIOPATHIC EPILEPSY AND EPILEPTIC SYNDROMES* 5 
G409 EPILEPSY, UNSPECIFIED* 9 
G412 COMPLEX PARTIAL STATUS EPILEPTICUS 1 
R568 OTHER AND UNSPECIFIED CONVULSIONS* 27 
 
Emergency Codes 
 
 
HES: 241  CNS Conditions – Epilepsy* 25 
HES: 24 CNS Disorder* 25 
SAIL: 17A Seizure / Convulsion* 8 
SAIL: 17Z CNS Condition – Unspecified* 5 
 
Primary Care READ Codes 
 
 
2828 Absence Seizure 2 
F251600 Grand mal seizure* 2 
1B63.00 Had a fit* 7 
R003400 [D]Nocturnal seizure* 1 
R003z00 [D]Convulsion NOS* 7 
282..00 O/E - fit/convulsion* 1 
F25z.11 Fit (in known epileptic) NOS* 1 
F254500 Complex partial epileptic seizure 1 
R003200 [D]Fit* 1 
F251200 Epileptic seizures – clonic* 1 
F25..00 Epilepsy* 1 
F254000 Temporal lobe epilepsy 2 
F255000 Jacksonian, focal or motor epilepsy 1 
Fyu5100 [X]Other epilepsy* 1 
Legend: *: Codes indicating tonic-clonic seizures 
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6.3 Date of First Seizure 
Thirty six participants had a ‘first seizure’ recorded in the SANAD II dataset occurring prior 
to 2013. This group of participants were excluded from this assessment due to the lack of 
availability of routine data coverage for the time period before 2013. The remaining sixty 
two participants had a first seizure occurrence recorded in SANAD II.  
In the routine datasets a first seizure occurrence was identified in 23 of 62 participants. The 
identification of relevant participants is presented in Figure 6.1. The most common codes 
were the ICD code ‘Unspecified Convulsions (R568)’ occurring in 13 participants, and the 
emergency code ‘CNS Conditions, Epilepsy’ occurring in 10 participants. All seizure 
occurrences identified in datasets using the ICD 10 coding system were classified as 
‘definite’ using the developed algorithm.  
Sixteen participants had a relevant attendance within 48 hours of a definite seizure 
recorded in SANAD II but with inadequate or discrepant diagnostic codes not meeting the 
criteria for seizure occurrence. Codes included ‘CNS, Non-Epilepsy’ in the emergency 
datasets and ‘Disorientation’ and ‘Confusion’ in the inpatient datasets. Of the 16 
participants, six had relevant attendances inadequately coded ‘CNS Disorder’ and ‘CNS 
Condition – Unspecified’ in the emergency datasets. Following clinical discussion, it was 
deemed not appropriate to include such non-specific codes to indicate seizure occurrence 
prior to diagnosis of epilepsy.  
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Figure 6.1: The Identification of the Date of First Seizure in Routine Datasets 
 
 
 
 
 
 
 
 
 
 
  
36 Participants 
SANAD II: First seizure recorded prior to 2013 
 
 
 
98 Participants 
 
 
 
62 Participants 
 
 
 
11 Participants 
Routine: No evidence of seizure or relevant attendances with 
missing or discrepant diagnostic codes 
 
 
 
51 Participants 
 
 
 
12 Participants 
Routine: Relevant attendances, missing diagnostic code: 
- A&E / EDDS: 12 
- APC / PEDW: 0  
  
16 Participants 
Routine: Relevant attendances, inadequate or discrepant 
diagnostic code not meeting the criteria for seizure occurrence: 
- A&E / EDDS: 16  
- APC / PEDW: 5 
 
 
 
23 Participants 
Relevant attendances for dates of first seizure identified: 
- HES A&E:  12 SAIL EDDS: 8 
- HES APC:  10 SAIL PEDW: 5 
SAIL GP:  6 
Attendances recorded in 1 dataset (7 participants), 2 datasets 
(14 participants) and 3 datasets (2 participants) 
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The difference in days between the dates of first seizure from SANAD II subtracted from the 
dates from routine datasets was calculated and the assumption of normal distribution 
around the mean assessed. The distribution displays a negative skew on inspection, 
detailed in Figure 6.2. 
Figure 6.2: The Difference in Days Between the Date of First Seizure  
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P=0.002) 
indicates that the mean dates of first seizure calculated from SANAD II and routine datasets 
are significantly different. Subsequently, agreement was assessed through the construction 
of a Bland Altman Plot. Results are presented in Table 6.2 and Figure 6.3. 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates of first seizure are 145 and -313 days, clearly in excess of the 
specified 30 day clinically acceptable limit indicated by the red dashed lines. The mean of 
the difference between the dates is -84, indicating that the date of first seizure is identified 
in the SANAD II dataset a mean of 84 days earlier.  
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Figure 6.3: Date of First Seizure: Bland Altman Plot 
Mean -84.09 
Upper 95% Confidence Limit of Agreement 144.94 
Lower 95% Confidence Limit of Agreement -313.12 
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6.4 Date of First Tonic-Clonic Seizure 
Thirty six participants had a ‘first seizure’ recorded in the SANAD II dataset occurring prior 
to 2013 and were excluded. Of the remaining 62 participants, 43 had a first tonic-clonic 
seizure occurrence recorded in SANAD II.    
In the routine datasets a first tonic-clonic seizure occurrence was identified in 22 
participants. The identification of relevant participants is presented in Figure 6.4. The most 
common codes were the ICD code ‘Unspecified Convulsions (R568)’ occurring in 13 
participants, and the emergency code ‘CNS Conditions, Epilepsy’ occurring in 10 
participants. In eight participants without a first tonic-clonic seizure in the SANAD II 
dataset, a first tonic-clonic seizure occurrence was identified in routine datasets.  
Sixteen participants had a relevant attendance within 48 hours of a definite seizure 
recorded in SANAD II but with inadequate or discrepant diagnostic codes not meeting the 
criteria for seizure occurrence. Codes included ‘CNS, Non-Epilepsy’ in the emergency 
datasets and ‘Disorientation’ and ‘Confusion’ in the inpatient datasets. Of the 16 
participants, six had relevant attendances inadequately coded ‘CNS Disorder’ and ‘CNS 
Condition – Unspecified’ in the emergency datasets. Again, it was deemed not appropriate 
to include such non-specific codes to indicate seizure occurrence prior to the diagnosis of 
epilepsy.  
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Figure 6.4: The Identification of the Date of First Tonic-Clonic Seizure in Routine Datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
36 Participants 
SANAD II: First seizure recorded prior to 2013 
 
 
 
98 Participants 
 
 
 
62 Participants 
 
 
 
51 Participants 
 
 
 
22 Participants 
Relevant attendances for dates of first tonic-clonic seizure 
identified: 
- HES A&E:  12 SAIL EDDS: 8 
- HES APC:  10 SAIL PEDW: 5 
SAIL GP:  5
   
Attendances recorded in 1 dataset (6 participants), 2 datasets 
(14 participants) and 3 datasets (2 participants) 
 
 
 
11 Participants 
Routine: No evidence of seizure or relevant attendances with 
missing or discrepant diagnostic codes 
 
 
 
23 Participants 
 
 
 
12 Participants 
Routine: Relevant attendances, missing diagnostic code: 
- A&E / EDDS: 12 
- APC / PEDW: 0 
   
16 Participants 
Routine: Relevant attendances, inadequate or discrepant 
diagnostic code not meeting the criteria for seizure occurrence: 
- A&E / EDDS: 16  
- APC / PEDW: 5 
 
 
1 Participant 
Routine: Single seizure occurrence, no evidence of diagnostic 
code consistent with tonic-clonic seizure 
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The difference in days between the dates of first tonic-clonic seizure from SANAD II 
subtracted from the dates from routine datasets was calculated and the assumption of 
normal distribution around the mean assessed. The distribution displays a negative skew 
on inspection, detailed in Figure 6.5. 
Figure 6.5: The Difference in Days Between the Date of First Tonic-Clonic Seizure  
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P=0.043) 
indicates that the mean dates of first seizure calculated from SANAD II and routine datasets 
are significantly different. Subsequently, agreement was assessed through the construction 
of a Bland Altman Plot. Results are presented in Table 6.2 and Figure 6.5. 
 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates of first seizure are 68 and -124 days, clearly in excess of the 
specified 30 day clinically acceptable limit indicated by the red dashed lines although 
improved compared to the agreement for first seizures of any type. The mean of the 
difference between the dates is -28, indicating that the date of first seizure is identified in 
the SANAD II dataset a mean of 28 days earlier.          
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Figure 6.6: Date of First Tonic-Clonic Seizure: Bland Altman Plot 
Mean -28.07 
Upper 95% Confidence Limit of Agreement 67.58 
Lower 95% Confidence Limit of Agreement -123.72 
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6.5 Conclusions: Date of First Seizure and First Tonic-Clonic Seizure 
 
The quality and agreement for variables and outcome measures involving record of the 
occurrence of first seizures was poor. Dates of first tonic-clonic seizure were also poorly 
recorded, although data are more complete in the routinely recorded datasets compared 
to the analysis of first seizure of any type. Attendances as a result of seizure occurrence are 
either missing or do not include diagnostic codes consistent with seizure.  
 
For the limited number of participants where first seizures were identified, the agreement 
for the date of occurrence compared to the date collected using standard prospective 
methods in SANAD II was poor, with first seizure occurrences identified earlier in the 
SANAD II dataset. The delay in identification of first seizure occurrence has implications for 
the utility of routinely recorded data. In epilepsy research, routinely recorded data may be 
limited for the identification of eligible individuals for recruitment into prospective trials. In 
SANAD II for example, individuals must not have commenced treatment with antiepileptic 
drugs; this is less likely if there is a delay in identification. In clinical practice, the missing 
routinely recorded data is perhaps of greater importance, with impacts on the incidence 
and prevalence rates if data are used for disease monitoring purposes.  
 
Explanations for these findings may include inaccurate recording of diagnostic codes in 
routinely recorded datasets or inaccurate initial clinical diagnosis of seizure. Furthermore, 
participants may not have sought medical attention and therefore would not have 
attendances recorded in routine datasets, although following a first occurrence of seizure 
and particularly tonic-clonic seizure, it would be unlikely for an individual not to seek 
medical attention.         
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Table 6.2: The First Seizure and First Tonic-Clonic Seizure: Descriptive Statistics and 
Agreement 
  First Seizure (All Types) First Tonic-Clonic Seizure 
R
C
T 
D
at
a 
P
at
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n
ts
 Patients with Seizures 
 
62 (100%) 43 (69.4%) 
Total Eligible Patients 
 
62 62 
R
o
u
ti
n
e
 
D
at
a 
P
at
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n
ts
 Patients with Seizures 
 
23 (37.1%) 22 (35.5%) 
Total Eligible Patients 
 
62 62 
 Total Paired Patients 23 (37.1%) 14 (22.6%) 
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M
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 E
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HES: Admitted Patient 
Care 
10(10) 10(10) 
HES: Accident and 
Emergency 
12(2) 12(2) 
HES: Outpatient 
 
0(0) 0(0) 
HES: Adult Critical Care 
 
0(0) 0(0) 
SAIL: Patient Episode 
Database for Wales 
5(5) 5(5) 
SAIL: Emergency 
 
8(3) 8(3) 
SAIL: Outpatient 
 
0(0) 0(0) 
SAIL: Primary Care 
 
6(3) 5(2) 
A
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o
f 
A
gr
e
e
m
e
n
t 
R
C
T 
D
at
a 
Mean 
 
Range 
15/10/13 
 
15/02/13 – 18/08/14 
03/12/13 
 
15/03/13 – 18/08/14 
R
o
u
ti
n
e 
D
at
a 
Mean 
 
Range 
07/01/14 
 
10/05/13 – 17/11/14 
01/01/14 
 
10/05/13 – 17/11/14 
 Test for Significance Wilcoxon Signed Rank Wilcoxon Signed Rank 
Significance P=0.002 P=0.043 
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6.6 The Identification of Diagnosis and Classification of Epilepsy and Seizures in the 
Routinely Recorded Datasets 
A diagnosis of epilepsy is a mandatory requirement for enrolment in SANAD II and 
participants are diagnosed based on the accepted definitions of epilepsy, proposed by the 
International League Against Epilepsy [7, 8].  
In the routinely recorded datasets, a diagnoses of epilepsy was identified using both 
algorithmic methods; the occurrence of two episodes of seizure greater than 24 hours 
apart or the record of an ‘epilepsy’ code consistent with a diagnosis of epilepsy. Episodes of 
seizure occurrence were identified in the HES APC and A&E and the SAIL PEDW, EDDS and 
GP Datasets and have previously been presented in Table 6.1. For participants meeting the 
criteria for a diagnosis of epilepsy in the routinely recorded datasets, the classification of 
seizure type was subsequently derived through interpretation of the codes of greatest 
detail. For participants meeting the criteria for a diagnosis through record of an ‘epilepsy’ 
code, Table 6.3 presents the codes recorded for the participants in this study.     
Forty seven of the 98 participants included in this study met the criteria for diagnosis of 
epilepsy in the routinely recorded datasets using all available data. Thirteen participants 
within this group met the criteria for diagnosis through the record of two or more episodes 
of seizure occurrence.  It was possible in only a minority of cases to adequately define 
classification of seizure type, dependant on the diagnostic code recorded. In all coding 
systems and datasets, the most commonly recorded codes indicating seizure occurrence 
were non-specific codes with limited diagnostic and clinical value. The most common code 
indicating the diagnosis of epilepsy was the ICD code ‘Focal Epilepsy, Simple Partial (G401)’ 
identified in the HES OP dataset in 13 participants followed by the READ codes ‘Epilepsy 
(F25)’ and ‘Epilepsy; Jacksonian, Focal, Motor (F2550)’, occurring in the SAIL GP dataset in 
eight and four participants respectively. In the routinely recorded datasets, the codes 
indicating diagnosis and classification of epilepsy and seizures and the frequency each are 
recorded are presented in Table 6.3. 
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Table 6.3: The Diagnosis and Classification of Epilepsy and Seizures in Routinely Recorded 
Datasets 
Code Description Total Records 
 
Focal Epilepsy 
 
 
G401 
LOCAL-RELATED (PART) SYMPTOM EPILEPSY/EPILEPTIC SYND WITH 
SEIZURE 
13 
G402 LOCAL-RELATED (PART) SYMPTOM EPILEPSY/ EPILEP SYND 1 
F254000 Temporal lobe epilepsy 2 
F255000 Jacksonian, focal or motor epilepsy 4 
 
Generalised Epilepsy 
 
 
G403 GENERALIZED IDIOPATHIC EPILEPSY AND EPILEPTIC SYNDROMES 3 
 
Unclassified Epilepsy 
 
 
G40 EPILEPSY AND RECURRENT SEIZURES 3 
G409 EPILEPSY, UNSPECIFIED 2 
F25..00 Epilepsy 8 
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6.7 Diagnosis of Epilepsy (Baseline)  
Thirty six participants had a ‘first seizure’ recorded in the SANAD II dataset occurring prior 
to 2013. Within this group, in the routine datasets 20 participants did not meet the criteria 
for a baseline diagnosis of epilepsy and were excluded from further analysis due to the lack 
of availability of routine data coverage for the time period before 2013, removing the 
potential for two seizures to be recorded. Seventy eight participants were included in the 
assessment and had a diagnosis of epilepsy in the SANAD II dataset.  
In the routine datasets a baseline diagnosis of epilepsy was identified in 41 participants. 
The identification of the date of baseline diagnosis is presented in Figure 6.7. Nine 
participants met the criteria for a baseline diagnosis through the record of two episodes of 
seizure occurrence. Twenty eight participants met the criteria for a baseline diagnosis 
through the record of a code consistent with a diagnosis of epilepsy. A diagnostic code was 
recorded in the primary care dataset in 13 participants, outpatient datasets in 10 
participants, inpatient datasets in four participants and emergency care dataset in one 
participant. Notably, primary care data were available for 28 participants, in 13 of which a 
diagnosis was available. Outpatient data were available for all 98 participants yet a 
diagnostic code was recorded in only 10, all recruited from a single centre.  
As detailed in Figure 6.7, 11 participants had a relevant healthcare attendance within 48 
hours of a definite seizure recorded in SANAD II but with missing diagnostic information. All 
such attendances were recorded in the emergency datasets. Sixteen participants had a 
relevant attendance but with inadequate diagnostic information, not meeting the criteria 
for seizure occurrence. Such attendances were most commonly recorded in the emergency 
datasets and were coded ‘CNS Disorder’ and ‘CNS Condition – Unspecified’. Following 
clinical discussion, it was deemed not appropriate to include such non-specific codes to 
represent seizure occurrence prior to the diagnosis of epilepsy.  
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Figure 6.7: The Identification of the Date of Baseline Diagnosis in Routine Datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
20 Participants 
SANAD II: First seizure recorded prior to 2013 
Routine: No evidence of diagnosis  
 
 
 
98 Participants 
 
 
 
78 Participants 
 
 
 
68 Participants 
 
 
 
28 Participants 
Routine: Evidence of diagnostic code   
 
 
 
10 Participants 
Routine: No evidence of diagnostic code, seizure or relevant 
attendance with missing or discrepant diagnostic codes 
 
 
 
37 Participants 
 
 
 
8 Participants 
Routine: Single seizure occurrence 
4 Participants  
Routine: Single seizure occurrence and relevant single 
attendance, missing diagnostic code 
 
4 Participants 
Routine: Single seizure occurrence and relevant single 
attendance, inadequate diagnostic code not meeting the 
criteria for seizure occurrence 
 
2 Participants 
Routine: Relevant single attendance, missing diagnostic code 
 
1 Participant 
Routine: Two relevant attendances, missing diagnostic code 
 
8 Participants 
Routine: Relevant single attendance, discrepant diagnostic 
code not meeting the criteria for seizure occurrence 
 
4 Participants 
Routine: Two relevant attendances, one missing diagnostic 
code, one discrepant diagnostic code not meeting the criteria 
for seizure occurrence 
 
 
9 Participants 
Routine: Evidence of two episodes of seizure 
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The difference in days between the dates of diagnosis from SANAD II subtracted from the 
dates of diagnosis from routine datasets was calculated and the assumption of normal 
distribution around the mean assessed. The distribution displays a positive skew on 
inspection, detailed in Figure 6.8. 
Figure 6.8: The Difference in Days Between the Dates of Baseline Diagnosis of Epilepsy      
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P=0.004) 
indicates that the mean dates of diagnosis calculated from SANAD II and routine datasets 
are significantly different. Subsequently, agreement was assessed through the construction 
of a Bland Altman Plot. Results are presented in Table 6.4 and Figure 6.9. 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates of baseline diagnosis are 167 and -106 days, clearly in excess 
of the specified 30 day clinically acceptable limit indicated by the red dashed lines. The 
mean of the difference between the dates is 31, indicating that the date of baseline 
diagnosis is identified in the routine datasets a mean of 31 days earlier.         
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Figure 6.9: Baseline Diagnosis of Epilepsy: Bland Altman Plot 
Mean 30.54 
Upper 95% Confidence Limit of Agreement 167.25 
Lower 95% Confidence Limit of Agreement -106.17 
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6.8 Diagnosis of Epilepsy (All-Time) 
Thirty six participants had a ‘first seizure’ recorded in the SANAD II dataset occurring prior 
to 2013. Within this group, in the routine datasets 17 participants did not qualify for an all-
time diagnosis of epilepsy and were excluded from further analysis due to the lack of 
availability of routine data coverage for the time period before 2013, removing the 
potential for two seizures to be recorded. Eighty one participants were included in the 
assessment and had a diagnosis of epilepsy in the SANAD II dataset.   
In the routine datasets an all-time diagnosis of epilepsy was identified in 47 participants. 
The identification of the date of all-time diagnosis is presented in Figure 6.10. Eleven 
participants met the criteria for a diagnosis through the record of two episodes of seizure 
occurrence. Thirty six participants met the criteria for a diagnosis through the record of a 
code consistent with a diagnosis of epilepsy.  A diagnostic code was recorded in the 
primary care dataset in 14 participants, outpatient datasets in 15 participants, inpatient 
datasets in six participants and emergency care dataset in one participant. Notably, primary 
care data was available for 28 participants, in 14 of which a diagnosis was available. 
Outpatient data was available for all 98 participants yet a diagnostic code was recorded in 
only 15.  
As detailed in Figure 6.10, 10 participants have a relevant healthcare attendance within 48 
hours of a definite seizure recorded in SANAD II but with missing diagnostic information. All 
such attendances were recorded in the emergency datasets. Sixteen participants have a 
relevant attendance but with inadequate diagnostic information, not meeting the criteria 
for seizure occurrence. Such attendances were most commonly recorded in the emergency 
datasets and were coded ‘CNS Disorder’ and ‘CNS Condition – Unspecified’. These results 
are very similar to those found for diagnosis of epilepsy at baseline and similarly, it was 
deemed not appropriate to include non-specific codes to represent seizure occurrence 
prior to the diagnosis of epilepsy.  
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Figure 6.10: The Identification of the Date of All-Time Diagnosis in Routine Datasets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
17 Participants 
SANAD II: First seizure recorded prior to 2013 
Routine: No evidence of diagnosis  
 
 
 
98 Participants 
 
 
 
81 Participants 
 
 
 
75 Participants 
 
 
 
36 Participants 
Routine: Evidence of diagnostic code   
 
 
 
6 Participants 
Routine: No evidence of diagnostic code, seizure or relevant 
attendance with missing or discrepant diagnostic codes 
 
 
 
47 Participants 
 
 
 
8 Participants 
Routine: Single seizure occurrence 
 
1 Participant  
Routine: Single seizure occurrence and relevant single 
attendance, missing diagnostic code 
 
2 Participants 
Routine: Single seizure occurrence and two relevant 
attendances, missing diagnostic codes 
 
2 Participants 
Routine: Single seizure occurrence and relevant single 
attendance, inadequate diagnostic code not meeting the 
criteria for seizure occurrence 
 
2 Participants 
Routine: Single seizure occurrence, two relevant attendances, 
one missing diagnostic code, one discrepant diagnostic code 
not meeting the criteria for seizure occurrence 
 
1 Participant 
Routine: Single seizure occurrence, three relevant attendances, 
inadequate diagnostic codes not meeting the criteria for 
seizure occurrence 
 
1 Participant 
Routine: Single seizure occurrence, three relevant attendances, 
two missing diagnostic codes, one discrepant diagnostic code 
not meeting the criteria for seizure occurrence 
 
1 Participant 
Routine: Relevant single attendance, missing diagnostic code 
 
7 Participants 
Routine: Relevant single attendance, discrepant diagnostic 
code not meeting the criteria for seizure occurrence 
 
3 Participants 
Routine: Two relevant attendances, one missing diagnostic 
code, one discrepant diagnostic code not meeting the criteria 
for seizure occurrence 
 
 
11 Participants 
Routine: Evidence of two episodes of seizure 
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The difference in days between the dates of diagnosis from SANAD II subtracted from the 
dates of diagnosis from routine datasets was calculated and the assumption of normal 
distribution around the mean assessed. The distribution is normal to inspection, detailed in 
Figure 6.11.       
Figure 6.11: The Difference in Days Between the Dates of All-Time Diagnosis of Epilepsy 
 
A Paired T-Test has been performed in SPSS. The non-significant result (P=0.195) indicates 
that the mean dates of diagnosis calculated from SANAD II and routine datasets are not 
significantly different. Subsequently, agreement was assessed through the construction of 
a Bland Altman Plot. Results are presented in Table 6.4 and Figure 6.12.   
 
Despite the lack of significant difference between the means of the all-time diagnosis 
calculated using the SANAD II and routine datasets, the Bland Altman Plot demonstrates 
that agreement is poor. The 95% confidence limits of agreement between the dates of all-
time diagnosis are 242 and -294 days, clearly in excess of the specified 30 day clinically 
acceptable limit indicated by the red dashed lines. The mean of the difference between the 
dates is -26, indicating that the date of all-time diagnosis is identified in the SANAD II 
dataset a mean of 26 days earlier.            
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Figure 6.12: All-Time Diagnosis of Epilepsy: Bland Altman Plot 
Mean -26.23 
Upper 95% Confidence Limit of Agreement 241.64 
Lower 95% Confidence Limit of Agreement -294.10 
 
 
 
 
 
Table 6.4: The Diagnosis of Epilepsy: Descriptive Statistics and Agreement    
  Baseline Diagnosis All-Time Diagnosis 
R
C
T 
D
at
a 
P
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ts
 Total Diagnoses 
 
78 (100%) 81 (100%) 
Total Eligible Patients 
 
78 81 
R
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u
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n
e
 
D
at
a 
P
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ts
 Total Diagnoses 
 
37 (47.4%) 47 (58.0%) 
Total Eligible Patients 
 
78 81 
 Total Paired Diagnoses 37 (47.4%) 47 (58.0%) 
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R
C
T 
D
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a 
Mean 
 
Range 
23/04/14 
 
23/05/13 – 19/02/15 
26/04/14 
 
23/05/13 – 19/02/15 
R
o
u
ti
n
e 
D
at
a 
Mean 
 
Range 
24/03/14 
 
23/05/13 – 09/02/15 
22/05/14 
 
23/05/13 – 17/09/15 
 Test for Significance Wilcoxon Signed Rank Paired T Test 
Significance P=0.004 P=0.195 
 
  
186 
 
6.9 Classification of Seizures (Baseline) 
Thirty seven participants met the criteria for a baseline diagnosis of epilepsy in routine 
datasets. Of those, in the SANAD II dataset 33 participants were classified as focal, three 
participants as generalised and one participant unclassified. In the routine dataset, 18 
participants were unclassified, 17 participants classified as focal and two were classified as 
generalised. In the 17 participants classified as focal seizure in the routine dataset, all were 
classified as focal in the SANAD II dataset. One of the two participants classified as 
generalised in the routine dataset was classified as focal in the SANAD II dataset. The 
results have been summarised in Table 6.5.  
In the routine dataset, eight participants of the nine meeting the criteria for a baseline 
diagnosis of epilepsy through the record of two episodes of seizure occurrence had 
classifications in disagreement to the classification recorded in the SANAD II dataset. All 
such participants were deemed unclassified in the routine datasets as a result of limited 
diagnostic data. Ten of the 28 participants meeting the criteria for a baseline diagnosis of 
epilepsy through the record of a diagnostic code consistent with a diagnosis of epilepsy had 
classifications in disagreement to the classification recorded in the SANAD II dataset. Of 
these 10 participants, six diagnostic codes were recorded in the primary care dataset, one 
in the emergency care dataset and three in the inpatient datasets. Notably, in the 10 
participants with diagnostic data recorded in the outpatient dataset, all classifications were 
in agreement. As previously discussed, all such participants were recruited in a single 
centre.  
Agreement has been assessed using cross tabulation and Cohens Kappa. The value of 
Kappa is 0.151 (P=0.018) indicating ‘none to slight’ agreement between baseline 
classification of seizures determined from SANAD II and routine datasets. Results are 
presented in Table 6.7.    
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Table 6.5: Baseline Classification: Cross-Tabulation 
R
C
T 
D
at
a 
 Routine Data 
 Focal Generalised Unclassified Total 
Focal 17 (46.0%) 1 (2.7%) 15 (40.6%) 33 (89.2%) 
Generalised 0 1 (2.7%) 2 (5.4%) 3 (8.1%) 
Unclassified 0 0 1 (2.7%) 1 (2.7%) 
Total 17 (46.0%) 2 (5.4%) 18 (48.6%) 37 
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6.10 Classification of Seizures (All-Time) 
Forty seven participants met the criteria for an all-time diagnosis of epilepsy in routine 
datasets. Of those, in the SANAD II dataset 43 participants were classified as focal, three 
participants as generalised and one participant unclassified. In the routine datasets, 22 
participants were unclassified, 22 participants classified as focal and three were classified 
as generalised. In the 22 participants classified as focal seizure in the routine dataset, all 
were classified as focal in the SANAD II dataset. Two of the three participants classified as 
generalised in the routine dataset were classified as focal in the SANAD II dataset, with 
both diagnostic codes recorded in the inpatient datasets. The results have been 
summarised in Table 6.6.  
In the routine dataset, nine participants of the 11 meeting the criteria for an all-time 
diagnosis of epilepsy through the record of two episodes of seizure occurrence had 
classifications in disagreement to the classification recorded in the SANAD II dataset. All 
such participants were deemed unclassified in the routine datasets as a result of limited 
diagnostic data. Thirteen of the 36 participants meeting the criteria for an all-time 
diagnosis of epilepsy through the record of a diagnostic code consistent with a diagnosis of 
epilepsy had classifications in disagreement to the classification recorded in the SANAD II 
dataset. Of these 13 participants, eight diagnostic codes were recorded in the primary care 
dataset, one in the emergency care dataset and four in the inpatient datasets. Notably, in 
the 15 participants with diagnostic data recorded in the outpatient dataset, 13 
classifications were in agreement. The two participants not in agreement both had a record 
of the ICD code ‘Epilepsy and Recurrent Seizures (G40)’ and were therefore deemed 
unclassified.    
Agreement has been assessed using cross tabulation and Cohens Kappa. The value of 
Kappa is 0.123 (P=0.019) indicating ‘none to slight’ agreement between baseline 
classification of seizures determined from SANAD II and routine datasets. Results are 
presented in Table 6.7.    
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Table 6.6: All-Time Classification: Cross-Tabulation 
R
C
T 
D
at
a 
 Routine Data 
 Focal Generalised Unclassified Total 
Focal 22 (46.8%) 2 (4.3%) 19 (40.4%) 43 (91.5%) 
Generalised 0 1 (2.1%) 2 (4.3%) 3 (6.4%) 
Unclassified 0 0 1 (2.1%) 1 (2.1%) 
Total 22 (46.8%) 3 (6.4%) 22 (46.8%) 47 
 
 
Table 6.7: The Classification of Seizures: Agreement    
  Baseline Classification All-Time Classification 
 Total Paired Classifications 37 47 
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 Cohens Kappa 
 
0.151 0.123 
 Significance 
 
P=0.018 P=0.019 
 Interpretation 
 
‘None to Slight’ ‘None to Slight’ 
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6.11 Conclusions: Diagnosis and Classification of Epilepsy and Seizures 
 
These results indicate that the quality of routinely recorded data and agreement to data 
collected using standard prospective methods are poor for the variables date of diagnosis 
of epilepsy and classification of seizures. Diagnostic codes consistent with a ‘diagnosis of 
epilepsy’ are present in less than half of the participants. Furthermore, the poor record of 
seizure occurrence results in even fewer participants having evidence of two episodes of 
seizure occurrence required for diagnosis. Where diagnosis was possible, agreement for 
the date of diagnosis was poor with participants diagnosed at an earlier interval in the 
routine datasets at baseline, likely explained by the coding of seizure occurrence with a 
diagnostic yet non-specific ‘epilepsy’ code, either as a result of the lack of more specific 
codes, for example in the Emergency Datasets, or a result of inaccurate recording of codes 
in routinely recorded datasets or inaccurate initial clinical diagnosis by non-specialist 
physicians. In those participants meeting the criteria for diagnosis, there was poor 
agreement for the classification of seizures. This is explained by the majority of participants 
being deemed ‘unclassified’ as a result of inadequate clinical detail in the routine data. This 
has implications for the utility of routinely recorded data to identify individuals diagnosed 
with epilepsy to assist with trial recruitment in epilepsy research or identify the incidence 
and prevalence rates if data are used for disease monitoring purposes.    
 
The Outpatient Dataset had record of diagnostic ‘epilepsy’ codes but only in a small 
minority of participants. In one recruitment centre, all participants had a diagnostic code 
recorded in the Outpatient Dataset following Neurological review. This is a result of a local 
electronic proforma completed by the clinician following the clinic attendance. In the 
absence of the ability to incorporate antiepileptic drug prescribing into the algorithm to 
identify diagnosis of epilepsy, Neurological outpatient review followed by record of a 
diagnostic ‘epilepsy’ code selected by the clinician perhaps represents the most accurate 
method to identify the diagnosis of epilepsy in the included routine datasets. Furthermore, 
for the small number of participants with diagnosis identified in the Outpatient Dataset in 
this study, the diagnostic codes recorded permitted more detailed classification of seizures.     
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6.12 The Identification of Clinical Investigations in the Routinely Recorded Datasets 
The clinical investigations Magnetic Resonance Imaging (MRI) Brain, Computed 
Tomography (CT) Brain and Electroencephalography (EEG) are recorded at recruitment into 
SANAD II.  
Clinical investigations were identified in the HES A&E and the SAIL EDDS and GP datasets. 
There were 27 records of CT, nine records of MRI and eight records of EEG. The codes 
present in the routine datasets for the participants in this study indicating MRI Brain, CT 
Brain and EEG are presented in Table 6.8.  
 
Table 6.8: The Identification of Clinical Investigations in Routinely Recorded Datasets 
Code Description Total Records 
 
CT Brain 
 
HES: 12 Computed Tomography 17 
SAIL: 201 Computed Tomography 4 
READ: 567 Computed Tomography 2 
READ: Y72JD CT Brain 1 
READ: YAMGZ CT Brain Normal 2 
READ: 5674 CT Skull 1 
 
MRI Brain 
 
READ: 569 Magnetic Resonance: (Imaging) or (Study) 3 
READ: Y7213 MRI of Brain 2 
READ : 5692 Nuclear Magnetic Resonance Scan: Normal 3 
READ: 5693 Nuclear Magnetic Resonance Scan: Abnormal 1 
 
EEG 
 
X77iL Video EEG 1 
31130 EEG normal 6 
31C EEG Observations 1 
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6.13 Magnetic Resonance Imaging (MRI) 
In the SANAD II Dataset, 72 participants underwent MRI and data were missing for seven 
participants, excluded from this analysis. In the HES and SAIL Emergency Datasets no 
records of MRI were identified. In the SAIL Primary Care Dataset nine records of MRI were 
identified in seven participants. Results were available for two participants and were 
consistent with the results recorded in the SANAD II dataset. In two of the seven 
participants an MRI was recorded in the Primary Care Dataset and not the SANAD II 
Dataset. In seven of the nine records, anatomical area was not specified and the codes 
included ‘Magnetic Resonance Imaging or Study’ and ‘Nuclear Magnetic Resonance Scan: 
Normal’.     
Agreement has been assessed using cross tabulation and calculation of Cohens Kappa. The 
value of Kappa is -0.016 (P=0.602) indicating no agreement between the status of MRI 
determined from SANAD II and routine datasets. Results are presented in Table 6.9 and 
6.12.  
 
Table 6.9: MRI: Cross-Tabulation  
R
C
T 
D
at
a 
Routine Data 
 MRI 
Performed 
MRI Not 
Performed 
Total 
MRI 
Performed 
5 (5.5%) 67 (73.6%) 72 (79.1%) 
MRI Not 
Performed 
2 (2.2%) 17 (18.7%) 19 (20.9%) 
Total 7 (7.7%) 84 (92.3%) 91 
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6.14 Computed Tomography (CT)  
In the SANAD II Dataset, 33 participants underwent CT and data were missing for seven 
participants, excluded from this analysis. In the HES Emergency Dataset 17 records of CT 
were identified in 17 participants, although results were not available. In seven of the 17 
participants a CT was recorded in the HES Emergency Dataset but not the SANAD II Dataset. 
In the SAIL Datasets, 10 records of CT were identified. Four records of CT were recorded in 
four participants in the SAIL Emergency Department Dataset, of these two participants did 
not have CT recorded in the SANAD II Dataset. Six records of CT in six participants were 
recorded in the SAIL Primary Care Dataset, of these two had results available that were in 
agreement with results recorded in the SANAD II Dataset. In total, 23 of the 27 records 
anatomical area was not specified and the code ‘Computed Tomography’ was recorded. 
Agreement has been assessed using cross tabulation and calculation of Cohens Kappa. The 
value of Kappa is 0.406 (P<0.001) indicating ‘fair’ agreement between the status of CT 
determined from SANAD II and routine datasets. Results are presented in Table 6.10 and 
6.12.     
 
Table 6.10: CT: Cross-Tabulation  
R
C
T 
D
at
a 
Routine Data 
 CT 
Performed 
CT Not 
Performed 
Total 
CT 
Performed 
18 (19.8%) 15 (16.5%) 33 (36.3%) 
CT Not 
Performed 
9 (9.9%) 49 (53.8%) 58 (63.7%) 
Total 27 (29.7%) 64 (70.3%) 91 
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6.15 Electroencephalogram (EEG) 
Twenty three participants in the SANAD II Dataset were included in the SAIL Primary Care 
Dataset. 18 participants underwent EEG and data were missing for one participant, 
excluded from this analysis. In the SAIL Primary Care Dataset eight records of EEG were 
identified. In seven participants EEG was also requested in the SANAD II Dataset. In one 
participant, there was no record of EEG in the SANAD II Dataset. Results were available in 
six participants in the Primary Care Dataset and were in agreement with the results 
recorded in the SANAD II Dataset.   
Agreement has been assessed using cross tabulation and calculation of Cohens Kappa. The 
value of Kappa is 0.188 (P=0.131) indicating ‘none to slight’ agreement between the status 
of EEG determined from SANAD II and routine datasets. Results are presented in Table 6.11 
and 6.12.    
 
Table 6.11: EEG: Cross-Tabulation  
R
C
T 
D
at
a 
Routine Data 
 EEG 
Performed 
EEG Not 
Performed 
Total 
EEG 
Performed 
7 (31.8%) 11 (50%) 18 (81.8%) 
EEG Not 
Performed 
0 4 (18.2%) 4 (18.2%) 
Total 7 (31.8%) 15 (68.2%) 22 
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Table 6.12: Clinical Investigations: Descriptive Statistics and Agreement  
  MRI CT EEG 
R
C
T 
D
at
a 
P
at
ie
n
ts
 
Total Investigations 
 
72 (73.5%) 33 (33.7%) 18 (78.2%) 
Total Eligible 
Patients 
 
98 98 23 
R
o
u
ti
n
e
 
D
at
a 
P
at
ie
n
ts
 
Total Investigations 
 
9 (9.2%) 27 (27.6%) 8 (34.8%) 
Total Eligible 
Patients 
 
98 98 23 
 Total Paired Patients 91 (92.9%) 91 (92.9%) 22 (95.7%)  
R
o
u
ti
n
e
 D
a
ta
se
ts
 
To
ta
l ‘
In
ve
st
ig
at
io
n
s’
 in
 D
at
as
et
 
 
 
HES: Accident and 
Emergency 
 
0 17 N/A 
 
SAIL: Emergency 
 
 
0 4 N/A 
 
SAIL: Primary Care 
 
 
9 6 8 
A
ss
e
ss
m
e
n
t 
o
f 
A
gr
e
e
m
e
n
t 
 Cohens Kappa 
 
-0.016 0.406 0.188 
 Significance 
 
P=0.602 P<0.001 P=0.131 
 Interpretation 
 
‘None’ ‘Fair’ ‘None to Slight’ 
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6.16 Conclusions: Clinical Investigations  
 
These results indicate that the occurrence and results of clinical investigations are poorly 
recorded in routine datasets. In 10 participants across the three investigations, results were 
recorded in only the Primary Care Dataset and were in agreement with results recorded in 
SANAD II. The occurrence of investigations could be identified in the Emergency and 
Primary Care Datasets. For MRI, CT and EEG there were instances where investigations 
were recorded in the routine datasets but not SANAD II. This may be explained by the 
investigations not being recorded during the trial assessments and therefore not being 
recorded in the SANAD II dataset. However, in the majority the anatomical site was not 
recorded and therefore the assumptions necessarily made result in such data having 
limited specificity and utility for clinical practice and research.  
 
MRI Brain, EEG and to some extent CT Brain are unlikely to be performed in either the 
emergency department or primary care setting and are often performed in secondary care, 
either during an inpatient admission or on an outpatient basis. The ICD coding system used 
in secondary care includes relevant codes regarding investigations but investigations are 
not included in the Inpatient or Outpatient Datasets retrieved through NHS Digital or SAIL 
in this study. Expanding the Inpatient and Outpatient Datasets to include data regarding 
investigations would likely result in more complete data regarding the occurrence and 
results of investigations.   
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6.17 Conclusions 
 
In this chapter, the identification of seizure occurrence, diagnosis and classification of 
epilepsy and seizures and identification of the occurrence of clinical investigations in 
routinely recorded datasets compared to data collected using standard prospective 
methods have been examined, relevant to the identification and recruitment of individuals 
eligible for inclusion in SANAD II.  
A first seizure occurrence could be identified in routinely recorded datasets in 23 of the 98 
participants. For participants without a first seizure occurrence; approximately one third of 
participants had no relevant attendances, one third had a ‘relevant attendance’, defined as 
an attendance within 48 hours of the date of a definite seizure recorded in SANAD II, but 
with missing diagnostic information and one third had a relevant attendance within 48 
hours but with inadequate or discrepant diagnostic codes not meeting the criteria for 
seizure occurrence. For the limited number of participants where first seizures were 
identified, the agreement for the date of occurrence compared to the date collected using 
standard prospective methods in SANAD II was poor. Similarly, a ‘diagnosis of epilepsy’ was 
present in less than half of the participants using the routinely recorded data and 
agreement for the date of diagnosis was poor. Furthermore, there was poor agreement for 
the classification of seizures, explained by the majority of participants being deemed 
‘unclassified’ as a result of the record of codes with inadequate clinical detail. Finally, data 
regarding the occurrence of the clinical investigations MRI, CT and EEG were available only 
in the emergency and primary care datasets, with reasonably complete data and results 
available only in the primary care dataset. Additionally, there was evidence of 
investigations and results recorded in the primary care dataset that had not been recorded 
in the SANAD II dataset.  
The poor quality and agreement of routinely recorded data compared to data collected 
using standard prospective methods has implications for the utility of routinely recorded 
data. In epilepsy research, routinely recorded data may be limited for the identification of 
eligible individuals for recruitment into prospective trials. In clinical practice, the missing 
routinely recorded data is perhaps of greater importance, with impacts on the incidence 
and prevalence rates if data are used for disease monitoring purposes. Explanations for 
these findings may include inaccurate recording of codes in routinely recorded datasets or 
inaccurate initial clinical diagnosis of seizures and epilepsy. Furthermore, the events may 
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not have been ‘recordable’, for example if participants did not seek medical attention 
following seizure occurrence or if relevant codes or detail are not included in the available 
routinely recorded datasets, as with the occurrence and results of clinical investigations. 
The greatest potential of routinely recorded data may be in providing collateral clinical 
information, in addition to the primary dataset recorded using standard prospective 
methods. Considering the results thus far, the accuracy and reliability of such data must be 
questioned; however, knowledge would direct further assessment within the trial, either 
through source data verification or clarification with the individual participant.    
This assessment has notable limitations. The comparator dataset was derived from the 
SANAD II data available at the time of assessment and a minority of data entries may have 
been subject to data checking and confirmation. The pre-specified clinical limits of 
agreement were defined following clinical discussion and although not the primary 
purpose, may account for this. For example, an uncertain day of seizure, but known month 
and year would be recorded as occurring on the 15th day of the month in the SANAD II 
dataset. The one month clinical limit of agreement, whilst defined to specify the acceptable 
limit of disagreement that would be clinically acceptable, would also account for this 
uncertainty. The variables and constructed outcomes derived from the routinely recorded 
datasets were defined and extracted using algorithms developed for each comparison. 
However, there is a risk that relevant clinical events may not have been identified, if the 
diagnostic code recorded is not included in the algorithm. To address this limitation and 
explore the data further, the routinely recorded data for each participant was examined 
individually and in detail. For example, diagnostic codes recorded within 48 hours of a 
seizure recorded in the SANAD II dataset were examined. This process was feasible as a 
result of the small sample size. The assessment of clinical investigations used only ICD 10 
diagnostic codes. The omission of an assessment of OPCS-4 codes represents a 
methodological limitation, contributing to the poor quality and agreement identified. 
Finally, there were limitations with regards to the specific variables that could be 
compared, although this was more a limitation of the routinely recorded data rather than 
the methodological process.  
In the following Chapter Seven, variables and outcome measures relevant to the follow- up 
of participants in SANAD II will be examined.  
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Chapter Seven 
Results: Data Variables and Outcomes Relevant to the 
Follow-Up in SANAD II, Healthcare Resource Use and Primary 
Care Data  
 
7.1 Introduction 
In this chapter, an assessment of the quality of routinely recorded data and agreement 
between routinely recorded data and data collected using standard prospective methods 
for variables and outcome measures relevant to the follow-up of participants in SANAD II 
was completed. Relevant variables and outcome measures dependent on the assessment 
of seizure occurrence included ‘date of first seizure’, ‘time to first seizure’ and ‘time to 12 
month remission’. Subsequently, the record of antiepileptic drug prescriptions, adverse 
events and healthcare resource use were assessed.  
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7.2 Date of First Follow-Up Seizure 
In the SANAD II dataset, 61 of the 98 participants experienced a seizure occurrence 
following the date of SANAD II randomisation.   
In the routine datasets, a first follow-up seizure occurrence following the date of SANAD II 
randomisation was identified in 22 participants. The identification of relevant participants 
is presented in Figure 7.1. Of the 22 first follow-up seizure occurrences, 10 different 
diagnostic codes were recorded, although the most commonly recorded code remained the 
emergency code ‘CNS Conditions, Epilepsy’ occurring in six participants. The least specific 
emergency code ‘CNS Disorder’ occurred in three attendances, but in one a code from the 
inpatient dataset of greater quality was also recorded. In three participants without a first 
follow-up seizure in the SANAD II dataset, a first follow-up seizure occurrence was 
identified in routine datasets. In all participants, the seizures were recorded within two 
months of the baseline assessment date. All seizure occurrences identified in datasets using 
the ICD 10 coding system were classified as ‘definite’ using the developed algorithm.   
Three participants had a relevant attendance within 48 hours of the date of a definite 
seizure recorded in SANAD II but with diagnostic codes not meeting the criteria for seizure 
occurrence. All such participants had an attendance recorded in the emergency datasets. 
Codes included two records of ‘CNS, Non-Epilepsy’ and one record of ‘Fracture’ in the 
emergency datasets.   
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Figure 7.1: The Identification of the Date of First Follow-Up Seizure in Routine Datasets 
 
 
 
 
 
 
 
 
 
 
  
98 Participants 
 
 
 
28 Participants 
 
 
 
70 Participants 
Routine: No evidence of seizure or relevant attendances with 
missing or discrepant diagnostic codes 
 
 
 
22 Participants 
 
 
 
3 Participants 
Routine: Single relevant attendance, missing diagnostic code: 
- A&E / EDDS: 3 
- APC / PEDW: 0   
3 Participants 
Routine: Single relevant attendance, diagnostic code not 
meeting the criteria for seizure occurrence: 
- A&E / EDDS: 3  
- APC / PEDW: 0 
 
 
22 Participants 
Relevant attendances for dates of seizure identified: 
- HES A&E:  11 SAIL EDDS: 1 
- HES APC:  9 SAIL PEDW: 3 
SAIL GP:  4 
Attendances recorded in 1 dataset (16 participants) and 2 
datasets (6 participants)  
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The difference in days between the dates of first follow-up seizure from SANAD II 
subtracted from the dates of first follow-up seizure from routine datasets was calculated 
and the assumption of normal distribution around the mean assessed. The distribution is 
approximately normal on inspection, detailed in Figure 7.2. 
Figure 7.2: The Difference in Days Between the Date of First Follow-Up Seizure  
      
 
A Paired T Test has been performed in SPSS. The significant result (P=0.024) indicates that 
the mean dates of first follow-up seizure calculated from SANAD II and routine datasets are 
significantly different. Subsequently, agreement was assessed through the construction of 
a Bland Altman Plot. Results are presented in Table 7.1 and Figure 7.3. 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates of first follow-up seizure are 214 and -386 days, clearly in 
excess of the specified 30 day clinically acceptable limit indicated by the red dashed lines. 
The mean of the difference between the dates is -86, indicating that the date of first 
follow-up seizure is identified in the SANAD II dataset a mean of 86 days earlier.          
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Figure 7.3: Date of First Follow-Up Seizure: Bland Altman Plot 
Mean -86.26 
Upper 95% Confidence Limit of Agreement 213.89 
Lower 95% Confidence Limit of Agreement -386.41 
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7.3 Time to First Follow-Up Seizure 
Sixty one of the 98 participants experienced a seizure occurrence following the date of 
SANAD II randomisation in the SANAD II dataset. In the routine dataset, 22 participants 
experienced a seizure occurrence, of which three did not have a first follow-up seizure in 
the SANAD II dataset. Participants not experiencing a first follow-up seizure were censored 
using the final date routine data from all sources was available (31/12/15) or the date of 
last SANAD II follow-up assessment if the last follow-up assessment occurred prior to 
31/12/15. 
The 98 participants were included in a Kaplan Meier survival analysis, each with a time to 
first follow-up seizure calculated from the SANAD II and routine datasets. The mean time to 
first follow-up seizure was 325 days calculated using SANAD II data and 778 days calculated 
using routine data. The median was 111 days using the SANAD II data and could not be 
computed using the routine data. Descriptive statistics are presented in Table 7.2.  
 
Table 7.2: The Time to First Follow-Up Seizure: Descriptive Statistics  
 Total:  
Included Patients 
Total:  
Experiencing First 
Follow-Up Seizure 
Total:  
Censored (%)  
Mean  
(95% CI) 
Median 
(95% CI) 
RCT Data 98 61 37 (37.8%) 325 (258-393) 111 (38-184) 
Routine Data 98 22  76 (77.6%) 751 (680-822) N/A 
 
 
The difference in time to first follow-up seizure between datasets is statistically significant 
(Log Rank Test (Chi-Square 35.683), P<0.001, Figure 7.4).       
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Figure 7.4: Kaplan Meier Curve: The Time to First Follow-Up Seizure 
 
1 = SANAD II Dataset 
2 = Routine Dataset 
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7.4 Date of First Follow-Up Tonic-Clonic Seizure 
In the SANAD II dataset, 35 of the 98 participants experienced a tonic-clonic seizure 
occurrence following the date of SANAD II randomisation.   
In the routine datasets a first follow-up tonic-clonic seizure occurrence following the date 
of SANAD II randomisation was identified in 20 participants. The identification of relevant 
participants is presented in Figure 7.5. Of the 20 first follow-up tonic-clonic seizure 
occurrences, seven different diagnostic codes were recorded, although the most commonly 
recorded codes remained the ICD code ‘Epilepsy, Unspecified’ occurring in seven 
participants and the  emergency code ‘CNS Conditions, Epilepsy’ occurring in six 
participants. The least specific emergency code ‘CNS Disorder’ occurred in two 
attendances. In five participants without a first follow-up tonic-clonic seizure in the SANAD 
II dataset, a first follow-up tonic-clonic seizure occurrence was identified in routine 
datasets. In four cases, the ICD code ‘Epilepsy, Unspecified’ was recorded and in one case 
the READ code ‘Fit in Known Epileptic’. All seizure occurrences identified in datasets using 
the ICD 10 coding system were classified as ‘definite’ using the developed algorithm.    
Three participants had a relevant attendance within 48 hours of the date of a definite 
seizure recorded in SANAD II but with diagnostic codes not meeting the criteria for seizure 
occurrence. All such participants had an attendance recorded in the emergency datasets. 
Codes included two records of ‘CNS, Non-Epilepsy’ and one record of ‘Fracture’ in the 
emergency datasets.  
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Figure 7.5: The Identification of the Date of First Follow-Up Tonic-Clonic Seizure in Routine 
Datasets 
 
 
 
 
 
 
 
 
 
 
  
98 Participants 
 
 
 
28 Participants 
 
 
 
70 Participants 
Routine: No evidence of seizure or relevant attendances with 
missing or discrepant diagnostic codes 
 
 
 
22 Participants 
 
 
 
3 Participants 
Routine: Single relevant attendance, missing diagnostic code: 
- A&E / EDDS: 3 
- APC / PEDW: 0   
3 Participants 
Routine: Single relevant attendance, diagnostic code not 
meeting the criteria for seizure occurrence: 
- A&E / EDDS: 3  
- APC / PEDW: 0 
 
 
20 Participants 
Relevant attendances for dates of seizure identified: 
- HES A&E:  10 SAIL EDDS: 1 
- HES APC:  9 SAIL PEDW: 3 
SAIL GP:  2 
Attendances recorded in 1 dataset (15 participants) and 2 
datasets (5 participants)  
 
 
 
2 Participants 
Routine: Single follow-up seizure occurrence, no evidence of 
diagnostic codes consistent with tonic-clonic seizure 
occurrence  
 
 
 
20 Participants 
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The difference in days between the dates of first follow-up tonic-clonic seizure from SANAD 
II subtracted from the dates of first follow-up tonic-clonic seizure from routine datasets 
was calculated and the assumption of normal distribution around the mean assessed. The 
distribution displays a positive skew inspection, detailed in Figure 7.6. 
Figure 7.6: The Difference in Days Between the Date of First Follow-Up Tonic-Clonic Seizure  
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The non-significant result 
(P=0.374) indicates that the mean dates of first follow-up tonic-clonic seizure calculated 
from SANAD II and routine datasets are not significantly different. Subsequently, 
agreement was assessed through the construction of a Bland Altman Plot. Results are 
presented in Table 7.1 and Figure 7.7. 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates of first follow-up seizure are 418 and -436 days, clearly in 
excess of the specified 30 day clinically acceptable limit indicated by the red dashed lines. 
The mean of the difference between the dates is -9, indicating that the date of first follow-
up seizure is identified in the SANAD II dataset a mean of 9 days earlier.           
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Figure 7.7: Date of First Follow-Up Tonic-Clonic Seizure: Bland Altman Plot 
Mean -9.20 
Upper 95% Confidence Limit of Agreement 418.06 
Lower 95% Confidence Limit of Agreement -436.46 
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7.5 Conclusions: Date of First Follow-Up and First Tonic-Clonic Follow-Up Seizures 
Follow-up seizures are poorly recorded in the routinely recorded datasets. The limitations 
identified in the assessment of ‘first’ seizures, prior to diagnosis of epilepsy are present but 
of greater severity in this assessment of follow-up seizures.  Attendances as a result of 
follow-up seizure occurrence are either missing or present but including diagnostic codes 
not consistent with seizure.     
For the limited number of participants where follow-up seizures were identified, the 
agreement compared to data collected using standard prospective methods in SANAD II is 
poor, with seizures identified in the SANAD II dataset earlier. This is despite in some cases 
there being no significant difference identified between the means calculated using 
routinely recorded data and data collected using standard prospective methods. However, 
the limited sample size explains the lack of power to detect a significant difference for 
these variables. The degree of missing data and delay in identification of first follow-up 
seizure occurrence has implications for the utility of routinely recorded data. In research, 
routinely recorded data is not suitable for measurement of outcomes in prospective studies 
such as SANAD II. In clinical practice, routinely recorded data is not suitable for monitoring 
treatment effectiveness and the missing data may impact on the incidence and prevalence 
rates if data are used for disease monitoring purposes on a population level. 
Explanations for these results may include inaccurate recording of diagnostic codes in 
routinely recorded datasets or inaccurate clinical diagnosis of seizure. Furthermore, 
participants may not have sought medical attention following seizure occurrence. This may 
be more likely in participants with established epilepsy or those experiencing focal seizures.         
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Table 7.1: The First and First Tonic-Clonic Follow-Up Seizures: Descriptive Statistics and 
Agreement   
 
  First Follow-Up Seizure 
(All Types) 
First Follow-Up Tonic-
Clonic Seizure 
R
C
T 
D
at
a 
P
at
ie
n
ts
 Patients with Seizures 
 
61 (62.2%) 35 (35.7%) 
Total Eligible Patients 
 
98 98 
R
o
u
ti
n
e
 
D
at
a 
P
at
ie
n
ts
 Patients with Seizures 
 
22 (22.4%) 20 (20.4%) 
Total Eligible Patients 
 
98 98 
 Total Paired Patients 19 (19.3%) 15 (15.3%) 
R
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u
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e
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in
 D
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t 
(T
o
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s 
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l: 
 
M
u
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ly
 E
xc
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si
ve
) 
  
  
HES: Admitted Patient 
Care 
9(9) 9(9) 
HES: Accident and 
Emergency 
11(6) 10(6) 
HES: Outpatient 
 
0(0) 0(0) 
HES: Adult Critical Care 
 
0(0) 0(0) 
SAIL: Patient Episode 
Database for Wales 
3(3) 3(3) 
SAIL: Emergency 
 
1(0) 1(0) 
SAIL: Outpatient 
 
0(0) 0(0) 
SAIL: Primary Care 
 
4(4) 2(2) 
A
ss
e
ss
m
e
n
t 
o
f 
A
gr
e
e
m
e
n
t 
R
C
T 
D
at
a 
Mean 
 
Range 
18/05/14 
 
24/07/13 – 16/04/15 
10/07/14 
 
01/11/13 – 02/07/15 
R
o
u
ti
n
e 
D
at
a 
Mean 
 
Range 
07/08/14 
 
03/12/13 – 27/07/15 
25/08/14 
 
10/12/13 – 27/07/15 
 Test for Significance Paired T Test Wilcoxon Signed Rank 
Significance P=0.024 P=0.374 
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7.6 Date 12 Month Remission Achieved 
In the SANAD II dataset, 39 participants had episodes of seizure occurrence preventing the 
achievement of 12 month remission throughout the duration of follow-up. For participants 
without record of the occurrence of seizures, 11 participants had less than 12 months of 
SANAD II follow-up and therefore 12 month remission could not be achieved. Two 
participants had no evidence of the occurrence of seizures but with less than 12 months of 
available equivalent routine data and therefore 12 month remission could not be achieved. 
Forty six of the total 98 participants achieved 12 month remission from seizures in the 
SANAD II dataset.  
In the routine datasets, three participants had episodes of seizure occurrence preventing 
the achievement of 12 month remission throughout the duration of follow-up. For 
participants without record of the occurrence of seizures, 14 participants had less than 12 
months of equivalent SANAD II follow-up and therefore 12 month remission could not be 
achieved. Seven participants had no evidence of the occurrence of seizures but with less 
than 12 months of available routine data and therefore 12 month remission could not be 
achieved. Seventy four of the total 98 participants achieved 12 month remission from 
seizures in the routine datasets.  
For participants achieving remission in the SANAD II dataset, remission was also achieved in 
the routine datasets. However, an additional 28 participants achieved remission in the 
routine datasets. Table 7.3 summarises the identification of the date 12 month remission is 
achieved.   
 
Table 7.3: The Identification of the Date 12 Month Remission Achieved 
 SANAD II Dataset Routine Datasets 
Total Participants 98 98 
Participants Not Achieving Remission: 
 
Occurrence of Seizures 
 
No Occurrence of Seizures: 
 
- Insufficient SANAD II Follow-Up 
(<12 months SANAD II follow-up) 
 
- Insufficient Routine Data  
(‘Remission’ occurring >31/12/15) 
 
 
 
39 (39.8%) 
 
 
 
11 (11.2%) 
 
 
 
2 (2.0%) 
 
 
3 (3.1%) 
 
 
 
14 (14.3%) 
 
 
 
7 (7.1%) 
Participants Achieving Remission 46 (46.9%) 74 (75.5%)  
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The difference in days between the dates that 12 month remission is achieved identified 
from the SANAD II dataset was subtracted from the dates identified from the routine 
datasets and the assumption of normal distribution around the mean assessed. A spike-at-
zero distribution is observed, detailed in Figure 7.8. 
Figure 7.8: The Difference in Days Between the Date 12 Month Remission Achieved 
 
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P=0.004) 
indicates that the mean dates that 12 month remission is achieved calculated from the 
SANAD II and routine datasets are significantly different. Subsequently, agreement was 
assessed through the construction of a Bland Altman Plot. Results are presented in Table 
7.4 and Figure 7.9. 
The Bland Altman Plot demonstrates that agreement is poor. The 95% confidence limits of 
agreement between the dates 12 month remission is achieved are 184 and -115 days, 
clearly in excess of the specified 30 day clinically acceptable limit indicated by the red 
dashed lines. The mean of the difference between the dates is 34, indicating that the date 
12 month remission is achieved is identified in the routine datasets a mean of 34 days 
earlier.          
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Figure 7.9: The Date 12 Month Remission Achieved: Bland Altman Plot 
Mean 34.24 
Upper 95% Confidence Limit of Agreement 183.96 
Lower 95% Confidence Limit of Agreement -115.48 
 
 
 
 
Table 7.4: The Date 12 Month Remission Achieved: Descriptive Statistics and Agreement 
  Date 12 Month Remission 
Achieved 
R
C
T 
D
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a 
P
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ts
 Patients Achieving Remission 
 
46 (46.9%) 
Total Eligible Patients 
 
98 
R
o
u
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n
e
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a 
P
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 Patients Achieving Remission 
 
74 (75.5%) 
Total Eligible Patients 
 
98 
 Total Paired Patients 46 (46.9%) 
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R
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T 
D
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a 
Mean 
 
Range 
17/05/15 
 
01/06/14 – 16/12/15 
R
o
u
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n
e 
D
at
a 
Mean 
 
Range 
18/04/15 
 
23/05/14 – 27/12/15 
 Test for Significance Wilcoxon Signed Rank 
Significance P=0.004 
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7.7 Time to 12 Month Remission 
Participants not achieving 12 month remission were censored using the final date routine 
data from all sources was available (31/12/15) or the date of last follow-up assessment if 
the last follow-up assessment occurred prior to 31/12/15.  
The 98 participants were included in a Kaplan Meier survival analysis, each with a time to 
12 month remission calculated from the SANAD II and routine datasets. The mean time to 
12 month remission was 567 days calculated using SANAD II data and 393 days calculated 
using routine data. Descriptive statistics are presented in Table 7.5. 
 
Table 7.5: The Time to 12 Month Remission: Descriptive Statistics 
 Total:  
Included Patients 
Total:  
Achieving 12 
Month Remission 
Total:  
Censored (%)  
Mean  
(95% CI) 
Median 
(95% CI) 
RCT Data 98 46 52 (26.5%) 567 (515-618) 447  
Routine Data 98 74  24 (12.2%) 393 (375-410) 365 
 
 
The difference in the time to 12 month remission between datasets is statistically 
significant (Log Rank Test (Chi-Square 38.466), P<0.001, Figure 7.10).       
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Figure 7.10: Kaplan Meier Curve: The Time to 12 Month Remission 
 
1 = SANAD II Dataset 
2 = Routine Dataset 
 
 
 
7.8 Conclusions: Date 12 Month Remission is Achieved and Time to 12 Month Remission 
 
As identified, follow-up seizures are poorly recorded in the routinely recorded datasets 
with missing data and poor agreement observed. The results for these comparisons 
assessing 12 month remission reflect these earlier findings, with significantly more 
participants achieving 12 month remission using the routine datasets. These findings have 
significant implications. In research, assuming routinely recorded data alone were used to 
measure the SANAD II primary outcome of time to 12 month remission, the lack of 
recorded seizures would indicate improved treatment effectiveness for all antiepileptic 
drug interventions, constituting a type one error.  
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7.9 Total Number of Follow-Up Seizures  
7.9.1 Total Number of Follow-Up Seizures (All Seizure Types) 
In the SANAD II dataset, 61 participants experienced a total of 258 follow-up seizures 
(Range: 0-13). 
In the routine datasets, 22 participants experienced a total of 28 follow-up seizures (Range: 
0-5).  
The difference between total number of seizures from SANAD II subtracted from total 
number from routine datasets was calculated and the assumption of normal distribution 
around the mean assessed. The distribution displays a positive skew on inspection, detailed 
in Figure 7.11. 
 
Figure 7.11: The Difference in Total Number of Follow-Up Seizures  
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A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P<0.001) 
indicates that the mean total number of follow-up seizures calculated from the SANAD II 
and routine datasets are significantly different. Subsequently, agreement was assessed 
through the construction of a Bland Altman Plot. Results are presented in Table 7.6 and 
Figure 7.12.  
A positive trend is observed with an increasing mean associated with an increasing 
difference. This is explained as the majority of participants in the routinely recorded 
datasets had no evidence of seizure occurrence. Therefore, with increasing numbers of 
seizures identified in the SANAD II dataset, both the calculated mean and difference were 
greater. The 95% confidence limits of agreement between the total numbers of follow-up 
seizures are 8.3 and -3.6. The mean of the difference is 2.4, indicating that a mean 2.4 more 
follow-up seizures are identified in SANAD II. 
 
Figure 7.12: The Total Number of Follow-Up Seizures: Bland Altman Plot 
Mean 2.35 
Upper 95% Confidence Limit of Agreement 8.31 
Lower 95% Confidence Limit of Agreement -3.61 
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7.9.2 Total Number of Follow-Up Tonic-Clonic Seizures   
In the SANAD II dataset, 35 participants experienced a total of 113 follow-up tonic-clonic 
seizures (Range: 0-11).  
In the routine datasets, 20 participants experienced a total of 24 follow-up tonic-clonic 
seizures (Range: 0-3).  
The difference between total number of seizures from SANAD II subtracted from total 
number from routine datasets was calculated and the assumption of normal distribution 
around the mean assessed. A spike-at-zero distribution is observed, detailed in Figure 7.13. 
 
Figure 7.13: The Difference in Total Number of Follow-Up Tonic-Clonic Seizures  
 
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P<0.001) 
indicates that the mean total number of follow-up tonic-clonic seizures calculated from the 
SANAD II and routine datasets are significantly different. Subsequently, agreement was 
assessed through the construction of a Bland Altman Plot. Results are presented in Table 
7.6 and Figure 7.14. 
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A positive trend is again observed with an increasing mean associated with an increasing 
difference. The Bland Altman Plot demonstrates poor agreement although agreement is 
marginally improved compared to the assessment of all seizure types. The 95% confidence 
limits of agreement between the total numbers of follow-up seizures are 5.3 and -3.4. The 
mean of the difference is 0.9, indicating that a mean 0.9 more follow-up seizures are 
identified in SANAD II.  
 
Figure 7.14: The Total Number of Follow-Up Tonic-Clonic Seizures: Bland Altman Plot 
Mean 0.91 
Upper 95% Confidence Limit of Agreement 5.26 
Lower 95% Confidence Limit of Agreement -3.44 
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Table 7.6: The Total Number of Follow-Up Seizures: Descriptive Statistics and Agreement  
  Follow-Up Seizures  
(All Types) 
Follow-Up Seizures 
(Tonic-Clonic) 
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 Patients with Seizures 
 
61 (62.2%) 35 (35.7%) 
Total Eligible Patients 
 
98 98 
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 Patients with Seizures 
 
22 (22.4%) 20 (20.4%) 
Total Eligible Patients 
 
98 98 
 Total Paired Patients 98 (100%) 98 (100%) 
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Mean Number of Seizures 
 
Range 
2.63 
 
0 - 13 
1.15 
 
0 - 11 
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D
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Mean Number of Seizures 
 
Range 
0.29 
 
0 - 5 
0.24 
 
0 - 3 
 Test for Significance Wilcoxon Signed Rank Wilcoxon Signed Rank 
Significance P<0.001 P<0.001 
 
 
7.10 Conclusions: Total Number of Follow-Up Seizures 
As identified, follow-up seizures are poorly recorded in the routinely recorded datasets 
with missing data and poor agreement observed. Notably, marginally improved agreement 
was identified for tonic-clonic seizures compared to all seizure types. This would be 
expected as tonic-clonic seizures would be more likely to result in hospital attendance. 
However, the ‘true’ underlying difference is likely to be of even greater magnitude as only 
‘definite’ dates of seizures recorded in SANAD II were included in this comparison.  
These results have significant implications, reducing the utility of routinely recorded data 
for monitoring seizure occurrence in clinical practice and research. However, it is the 
identification of seizure freedom rather than the record of total number of seizures that is 
of greater importance in both clinical practice, for example influencing driving restrictions 
and research, where measures of seizure freedom represent more common prospective 
outcomes.    
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7.11 The Assessment of Antiepileptic Drug Prescribing in the Routinely Recorded Datasets 
7.11.1 The Date of AED First Prescription 
In the SANAD II dataset, 26 first AED prescriptions were recorded in 23 participants, three 
participants had a second AED prescribed following treatment failure of the initial AED.   
In the SAIL Primary Care Dataset, 25 first AED prescriptions were identified in 22 
participants. The prescribed AEDs in all cases were in agreement between the datasets and 
are summarised in Table 7.7. The first prescription of AED could not be identified in one 
participant. In this case it is evident from the subsequent SANAD II follow-up assessment 
that the AED was withdrawn shortly following the initial SANAD II prescription, which 
explains this anomaly.    
 
Table 7.7: Antiepileptic Drugs in the SANAD II and SAIL Primary Care Dataset 
Antiepileptic Drug  SANAD II Records SAIL Primary Care Records 
Lamotrigine 9 8 
Levetiracetam 9 9 
Sodium Valproate 1 1 
Zonisamide 7 7 
 
The difference in days between the dates of AED first prescription identified from SANAD II 
subtracted from the dates identified from the Primary Care Datasets was calculated and 
the assumption of normal distribution around the mean assessed. The distribution is 
approximately normal to inspection, detailed in Figure 7.15.  
A Paired T Test has been performed in SPSS. The significant result (P<0.001) indicates that 
the mean dates of first prescription of AED calculated from SANAD II and routine datasets 
are significantly different. Subsequently, agreement was assessed through the construction 
of a Bland Altman Plot. Results are presented in Table 7.8 and Figure 7.16.  
The Bland Altman Plot demonstrates that despite the significant difference between the 
mean dates of AED first prescription calculated using the Paired T Test, there is acceptable 
agreement between the calculated dates. The 95% confidence limits of agreement 
between the dates of AED first prescription are -68 and 28 days, within the specified 
acceptable clinical limit of 90 days, indicated by the red dashed lines. The mean of the 
difference between the dates is -20, indicating that the date of AED first prescription is 
identified in the SANAD II dataset a mean of 20 days earlier.          
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Figure 7.15: The Difference in Date of AED First Prescription      
 
 
 
Figure 7.16: Dates of AED First Prescription: Bland Altman Plot 
Mean -19.76 
Upper 95% Confidence Limit of Agreement 28.34 
Lower 95% Confidence Limit of Agreement -67.86 
 
 
 
  
224 
 
7.11.2 Compliance 
Data regarding compliance are not recorded in SANAD II although can be inferred from the 
Primary Care Dataset based on regularity of repeat prescription (1, 2 or 3 monthly).  In the 
SAIL Primary Care Dataset, 22 AED first prescriptions were followed by regular monthly 
repeat prescriptions. One AED first prescription was followed by regular monthly repeat 
prescriptions and subsequently, regular bi-monthly repeat prescriptions. Participants were 
‘not compliant’ with two AED prescriptions. In both cases the AED was not issued for over 
12 months yet in the SANAD II follow-up assessments the AED remained listed as 
prescribed. Explanations include poor compliance, an alternative source of the prescription 
of the AED or prescription of an alternative AED, although this was not identified in the 
available dataset. Finally, in one participant, an additional prescription of AED was 
identified in the Primary Care Dataset that was not recorded in the SANAD II dataset over a 
period of 12 months.  
 
Table 7.8: First Prescriptions of Antiepileptic Drugs: Descriptive Statistics and Agreement 
  Antiepileptic Drugs 
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 Total First Prescriptions 
 
26 
Total Patients 
 
23 
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 Total First Prescriptions 
 
25 
Total Patients 
 
23 
 Total Paired First Prescriptions 25 
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09/06/14 
 
31/05/13 – 08/09/15 
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Mean 
 
Range 
25/06/14 
 
31/05/13 – 09/09/15 
 Test for Significance Paired T Test 
Significance P<0.001 
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7.12 Conclusions: The Assessment of Antiepileptic Drugs 
Data retrieved from the Primary Care Dataset regarding AEDs in this study were complete 
and had good agreement compared to data collected using standard prospective methods 
in SANAD II. The prescriptions of AEDs and dates of prescription could be identified in the 
Primary Care Dataset, although indication was absent. Additionally, data regarding 
compliance could be inferred and are potentially informative to clinical practice; for 
example informing the management of individuals with poor seizure control associated 
with poor compliance and research; for example informing the assessment of the 
treatment effectiveness of AEDs. Finally, perhaps the greatest benefit offered by routinely 
recorded prescribing data is the ‘added information’. For example, one participant was 
prescribed a second AED for a period of over 12 months that was not recorded in SANAD II. 
Retrieving such data with potentially significant implications for confounding during the 
RCT may be informative to the analyses and interpretation of results.      
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7.13 The Assessment of Adverse Events in the Routinely Recorded Datasets 
In the SANAD II dataset, 44 participants reported 102 individual adverse events (Range: 1-
9). Four participants reporting five adverse events during the time period following 
31/12/15 were excluded from this comparison as a result of the lack of available equivalent 
routinely recorded data. The remaining 40 participants reported 97 adverse events (Range: 
1-9). During the study period, there were no reported Serious Adverse Reactions (SAR’s) or 
Suspected Unexpected Serious Adverse Reactions (SUSAR’s).  
In the routine datasets, two adverse events in two participants were identified. In the first 
participant, the adverse event ‘Poorly Controlled Epilepsy’ recorded in the SANAD II dataset 
correlated with a date of admission coded as ‘Status Epilepticus’ in the HES Inpatient 
Dataset. In the second participant, the adverse event ‘Burning Sensation - Arms , Legs’ 
correlated with a date of healthcare attendance coded as ‘Pain in Leg’ in the SAIL Primary 
Care Dataset. As a result of the limited sample size, further assessments of agreement were 
not performed. The adverse events identified and descriptive statistics are summarised in 
Tables 7.9 and 7.10.    
Seven participants had 11 attendances within three months of a date of adverse event 
recorded in SANAD II. The dates of seven adverse events recorded in the SANAD II dataset 
were in agreement with an attendance recorded in the HES Accident and Emergency 
Dataset but with missing diagnostic information, while the dates of four adverse events 
were in agreement with an attendance recorded in the HES Accident and Emergency 
Dataset but with inadequate diagnostic information. For example, one participant with the 
adverse event ‘Memory Problems’ in the SANAD II dataset was in agreement with a date of 
attendance coded as ‘CNS – other non-epilepsy’ in the Accident and Emergency Dataset.   
Potential alternative clinical explanations, other than adverse reaction to the AED, for three 
adverse events recorded in the SANAD II dataset were identified in routine datasets within 
three months of the recorded adverse event. The adverse event ‘Sedation’ was in 
agreement with a date of attendance coded as ‘Alcohol’ in the HES Accident and 
Emergency Dataset.  The adverse event ‘Nausea’ was in agreement with a date of 
attendance coded as ‘Gastritis’ in the HES Inpatient Dataset. The adverse event ‘Shortness 
of Breath’ was in agreement with a date of attendance coded as ‘Diaphragmatic Hernia’ in 
the HES Inpatient Dataset.  
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Finally, there were no recorded codes consistent with ‘adverse events’ listed in the 
routinely recorded datasets.  
     
7.14 Conclusions: The Assessment of Adverse Events 
There is a significant magnitude of missing routinely recorded data regarding adverse 
events compared to data collected using standard prospective methods in SANAD II. 
Furthermore, diagnostic codes specifically indicating ‘adverse events’ were not recorded in 
any of the routinely recorded datasets. The utility of routinely recorded data for monitoring 
of adverse events in both clinical practice and research is therefore severely limited. 
Explanatory factors include the method of ascertainment in SANAD II – completion of self-
reported questionnaires with options for free text in addition to suggested listed common 
adverse events. Such a method may encourage reporting of trivial adverse events that 
would otherwise not have resulted in a healthcare attendance. However, although trivial, 
such adverse events have the potential to exert a negative influence on quality of life. 
There were no serious adverse events recorded for the participants included in this study 
and in such cases the routinely recorded data could be expected to be more complete and 
informative.  
These results indicate that routinely recorded data are inadequate for the identification of 
adverse events and have greater potential for providing collateral data, for example 
providing alternative explanations for clinical symptoms attributed to adverse events. 
Perhaps the most pragmatic suggestion for improvement would be the utilisation of the 
diagnostic codes already available, specifically indicating ‘adverse event’.    
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Table 7.9: The Assessment of Adverse Events 
Adverse Event SANAD II Dataset: Total Events Routine Dataset: Total Events 
Weight Loss 4 0 
Poorly Controlled Epilepsy 1 1 
Dizziness 4 0 
Skin Rash 3 0 
Memory Problems 10 0 
Irritability / Anger 13 0 
Weight Gain 7 0 
Sedation / Drowsiness 15 0 
Gastro Intestinal Disturbance 10 0 
Swelling of Face / Mouth 2 0 
Chest Infection 2 0 
Tinnitus 1 0 
Deafness 1 0 
Dry Mouth 1 0 
Polydipsia 1 0 
Polyuria 1 0 
Low Mood 6 0 
Insomnia 4 0 
Headache 2 0 
Vivid Dreams 1 0 
Shortness of Breath 1 0 
Low Platelet Count 1 0 
Fever 1 0 
Cramping / Tingling Hands 1 0 
Hair Loss 1 0 
Pruritus 1 0 
Nose Bleed 1 0 
Burning sensation / Arms, Legs 1 1 
Tremor 1 0 
 
Table 7.10: Adverse Events: Descriptive Statistics 
  Adverse Events 
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97  
Total Patients 
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HES: Admitted Patient Care 1(1) 
HES: Accident and Emergency 0(0) 
HES: Outpatient 
 
0(0) 
HES: Adult Critical Care 
 
0(0) 
SAIL: Patient Episode 
Database for Wales 
0(0) 
SAIL: Emergency 
 
0(0) 
SAIL: Outpatient 
 
0(0) 
SAIL: Primary Care 
 
1(1) 
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7.15 The Assessment of Healthcare Resource Use in the Routinely Recorded Datasets 
The SANAD II baseline and follow-up assessments, occurring in the majority during routine 
outpatient appointments are examples of ‘planned’ healthcare resource use. ‘Unplanned’ 
healthcare resource use includes emergency, inpatient and primary care attendances.   
7.15.1 Planned Healthcare Attendances: The SANAD II Baseline Assessments 
All 98 participants enrolled in SANAD II have had the date of baseline assessment recorded.  
In the routinely recorded datasets, the baseline assessments were identified in 87 
participants. One baseline assessment was identified in the emergency care dataset, three 
assessments in the inpatient datasets and the remaining 83 assessments in the outpatient 
datasets. Eleven participants had no relevant healthcare attendance within the specified 
clinical limit of agreement of one month (30 days) in routine datasets. Five participants 
were resident in England and six in Wales. The missing data in these cases may be 
explained by the baseline assessment occurring out of the context of routine medical care, 
for example assessments may have taken place in dedicated research clinics that may not 
be included in routine datasets.    
The difference in days between the dates of baseline assessment from SANAD II subtracted 
from the dates from routine datasets was calculated and the assumption of normal 
distribution around the mean assessed. A spike-at-zero distribution is observed, detailed in 
Figure 7.17. 
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Figure 7.17: The Difference in Days Between the Date of Baseline Assessment 
      
A Wilcoxon Signed Rank Test has been performed in SPSS. The significant result (P<0.001) 
indicates that the mean dates of baseline assessment calculated from SANAD II and routine 
datasets are significantly different. Subsequently, agreement was assessed through the 
construction of a Bland Altman Plot. Results are presented in Table 7.11 and Figure 7.18. 
The Bland Altman Plot demonstrates that despite the significant difference between the 
mean dates of baseline assessment calculated using the Wilcoxon Signed Rank Test, there 
is acceptable agreement between the calculated dates. The 95% confidence limits of 
agreement between the dates of baseline assessment are -7 and 11 days, within the 
specified acceptable clinical limit of agreement of one month (30 days), indicated by the 
red dashed lines. The mean of the difference between the dates is 1.67, indicating that the 
date of baseline assessment is identified in routine datasets a mean 1.67 days earlier. A 
possible explanation is that the SANAD II Case Report Forms are completed and submitted 
in the days following the date of participant assessment as a result of the logistics of the 
assessment being completed in a busy outpatient clinic.         
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Figure 7.18: Date of Baseline Assessment: Bland Altman Plot 
Mean 1.67 
Upper 95% Confidence Limit of Agreement 10.55 
Lower 95% Confidence Limit of Agreement -7.21 
 
 
 
7.15.2 Planned Healthcare Attendances: The SANAD II Follow-Up Assessments 
In the SANAD II Dataset, 392 follow-up assessments were recorded in 98 participants. Forty 
two of the SANAD II follow-up assessments with no eligible attendance in routine datasets 
occurred following the date of 31/12/15. These assessments were excluded from the 
analysis as a result of lack of equivalent data coverage for this time period in the routine 
datasets. However, for participants residing in England, the Hospital Episode Statistics 
Outpatient Dataset extends into 2016 and follow-up assessments identified in the 
outpatient dataset in 2016 for this group of participants were included. Three hundred and 
fifty follow-up assessments recorded in the SANAD II dataset were included in this 
assessment. 
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In the routinely recorded datasets, 317 follow-up assessments were identified in 97 
participants. Dates for 316 follow-up assessments were identified in the outpatient 
datasets with the remaining one assessment identified in the emergency care dataset. 
Thirty three SANAD II follow-up assessments in 19 participants had no relevant healthcare 
attendance within the specified clinical limit of agreement of one month (30 days) in 
routine datasets. Thirteen participants were residing in England and six in Wales. In one 
participant no follow-up assessments were identified in routine datasets, although a 
baseline assessment was identified. In the remaining 18 participants at least one of their 
SANAD II follow-up assessments could not be identified in routine datasets. The missing 
data in these cases may be explained by the follow-up assessments occurring out of the 
context of routine medical care, for example assessments may have taken place in 
dedicated research clinics that may not be included in routine datasets.    
The difference in days between the dates of follow-up assessments from SANAD II 
subtracted from the dates from routine datasets was calculated and the assumption of 
normal distribution around the mean assessed. A spike-at-zero distribution is observed, 
detailed in Figure 7.19.  
A Wilcoxon Signed Rank Test has been performed in SPSS. The non-significant result 
(P=0.14) indicates that the mean dates of follow-up assessments calculated from SANAD II 
and routine datasets are not significantly different. Subsequently, agreement was assessed 
through the construction of a Bland Altman Plot. Results are presented in Table 7.11 and 
Figure 7.20. 
The Bland Altman Plot demonstrates that there is acceptable agreement between the 
calculated dates. The 95% confidence limits of agreement between the dates of baseline 
assessment are -4 and 4 days, within the specified acceptable clinical limit of agreement of 
one month (30 days), indicated by the red dashed line. The mean of the difference 
between the dates is 0.07, indicating that there is essentially no difference in the date of 
completion of follow-up assessments.   
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Figure 7.19: The Difference in Days Between the Date of Follow-Up Assessments 
      
 
 
Figure 7.20: Date of Follow-Up Assessments: Bland Altman Plot 
Mean 0.07 
Upper 95% Confidence Limit of Agreement 4.47 
Lower 95% Confidence Limit of Agreement -4.33 
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Table 7.11: Planned Healthcare Resource Use: Descriptive Statistics and Agreement 
  Baseline Assessment Follow-Up Assessments 
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SANAD II Assessments 
 
98 (100%) 350 (100%) 
Total Eligible Patients 
 
98 98 
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87 (88.8%) 317 (90.6%) 
Total Patients 
 
87 97 
 Total Paired Assessments 87 (88.8%)  317 (90.6%) 
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HES: Admitted Patient 
Care 
2 0 
HES: Accident and 
Emergency 
1 1 
HES: Outpatient 
 
63 240 
HES: Adult Critical Care 
 
0 0 
SAIL: Patient Episode 
Database for Wales 
0 0 
SAIL: Emergency 
 
3 0 
SAIL: Outpatient 
 
17 76 
SAIL: Primary Care 
 
0 0 
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23/05/13 – 19/02/15 
10/02/15 
 
02/08/13 – 30/03/16 
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25/05/14 
 
23/05/13 – 09/02/15 
25/02/15 
 
14/08/13 – 30/03/16 
 Test for Significance Wilcoxon Signed Rank Wilcoxon Signed Rank 
Significance P<0.001 P=0.14 
 
 
7.15.3 Conclusions: Planned Healthcare Attendances 
Planned healthcare attendances are recorded in routine datasets and data are relatively 
complete and in agreement with data collected in SANAD II. This result is not surprising as 
the record of attendance is required for NHS remuneration, the primary purpose for 
routinely recording the data in the included datasets. There is therefore potential for 
routinely recorded data to contribute to health economic analyses within prospective 
research and provide additional data, for example identification of healthcare attendances 
not forwarded to the SANAD II team.     
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7.15.4 Unplanned Healthcare Attendances  
In the SANAD II dataset, 94 participants completed 263 self-report questionnaires. 
Therefore 263 three-month time periods were examined in the routinely recorded datasets 
to identify unplanned emergency attendances and inpatient admissions.    
7.15.4.1 Emergency Department Attendances  
Thirty two participants reported 52 emergency department attendances in the SANAD II 
dataset. In the routinely recorded datasets, thirty seven emergency attendances were 
identified in 26 participants. Twelve SANAD II questionnaire responses were in agreement 
with the number of attendances identified in routine datasets. Sixteen SANAD II responses 
recorded a greater number of attendances than identified in routine datasets and eight 
SANAD II responses recorded fewer attendances than routine datasets. There is therefore a 
trend for participants to self-report a greater total number of emergency attendances than 
identified in routinely recorded datasets.  
7.15.4.2 Inpatient Admissions 
Seven participants reported 28 inpatient admissions in the SANAD II dataset. A single 
participant reported 16 admissions and this record is likely to be erroneous and has been 
excluded from the remainder of the analysis leaving six participants reporting 12 
admissions. In the routinely recorded datasets, nineteen inpatient admissions were 
identified in 18 participants. Three SANAD II questionnaire responses were in agreement 
with the number of attendances identified in routine datasets. Three SANAD II responses 
recorded a greater number of attendances than identified in routine datasets and fourteen 
SANAD II responses recorded fewer attendances than routine datasets. There is therefore a 
trend for participants to self-report a fewer total number of inpatient attendances than 
identified in routinely recorded datasets. ‘Admission’ includes transfer to any ward 
following emergency department attendance, including transfer for brief periods, for 
example same-day discharge on medical and surgical assessment units. Limited participant 
understanding of the definition of ‘admission’ may partly explain the results.   
Table 7.12 presents the unplanned healthcare attendances for each participant self-
reported in SANAD II and identified in routine datasets.    
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Table 7.12: Identified Unplanned Healthcare Attendances  
Participant SANAD II Emergency 
Attendances 
Routine Emergency 
Attendances 
Participant SANAD II Inpatient 
Admissions 
Routine Inpatient 
Admissions 
012 1 0 013 3 1 
013 1 1 013 4 0 
013 1 0 059 1 0 
043 1 1 059 1 1 
048 3 1 072 0 1 
059 1 1 084 0 1 
059 1 1 097 0 1 
059 1 1 111 1 1 
062 1 0 149 0 1 
072 3 1 170 0 1 
097 1 0 174 0 1 
111 1 0 174 0 1 
111 1 1 212 0 1 
134 2 1 231 0 1 
137 2 2 286 0 1 
137 3 1 289 0 1 
149 1 1 414 16 1 
170 3 0 478 0 1 
212 1 1 229 2 2 
227 0 1 231 0 1 
231 8 7    
286 1 0 Total 28 19 
311 1 1    
314 1 1    
351 0 1    
383 1 2    
383 1 2    
383 1 2    
384 1 1    
384 0 1    
414 1 2    
478 4 2    
227 1 0    
231 1 0    
460 1 0    
478 0 1    
      
Total 52 37    
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7.15.4.3 Emergency Department Attendances: Agreement 
The difference between the number of emergency department attendances recorded in 
SANAD II subtracted from the number recorded in routine datasets was calculated and the 
assumption of normal distribution around the mean assessed. A spike-at-zero distribution 
is observed, detailed in Figure 7.21. 
Figure 7.21: The Difference in Number of Emergency Department Attendances 
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The non-significant result 
(P=0.051) indicates that the mean number of emergency department attendances reported 
in SANAD II and identified from routine datasets are not significantly different. 
Subsequently, agreement was assessed through the construction of a Bland Altman Plot. 
Results are presented in Table 7.13 and Figure 7.22. 
The Bland Altman Plot demonstrates that there is acceptable agreement. The 95% 
confidence limits of agreement between the numbers of emergency department 
attendances are -0.7 and 0.8. The mean of the difference is 0.05, indicating that there is 
essentially no difference between the number of emergency department attendances.    
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Figure 7.22: Number of Emergency Department Attendances: Bland Altman Plot 
Mean 0.05 
Upper 95% Confidence Limit of Agreement 0.834 
Lower 95% Confidence Limit of Agreement -0.734 
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7.15.4.4 Inpatient Admissions: Agreement  
The difference between the number of inpatient admissions recorded in SANAD II 
subtracted from the number recorded in routine datasets was calculated and the 
assumption of normal distribution around the mean assessed. A spike-at-zero distribution 
is observed, detailed in Figure 7.23. 
Figure 7.23: The Difference in Number of Inpatient Admissions 
 
 
A Wilcoxon Signed Rank Test has been performed in SPSS. The non-significant result 
(P=0.098) indicates that the mean number of inpatient admissions reported in SANAD II 
and identified from routine datasets are not significantly different. Subsequently, 
agreement was assessed through the construction of a Bland Altman Plot. Results are 
presented in Table 7.13 and Figure 7.24. 
The Bland Altman Plot demonstrates that there is acceptable agreement. The 95% 
confidence limits of agreement between the numbers of inpatient admissions are -0.7 and 
0.7. The mean of the difference is -0.02, indicating that there is essentially no difference 
between the number of inpatient admissions.    
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Figure 7.24: Number of Inpatient Admissions: Bland Altman Plot 
Mean -0.02 
Upper 95% Confidence Limit of Agreement 0.68 
Lower 95% Confidence Limit of Agreement -0.72 
 
 
 
 
7.15.5 Conclusions: Unplanned Healthcare Attendances 
In the majority of the 263 comparison three-month periods, participants reported no 
unplanned attendances in SANAD II and no attendances were identified in routine datasets. 
However, in the small number of cases where attendances were reported, participants in 
SANAD II self-reported a greater number of emergency attendances and fewer inpatient 
admissions, compared to routinely recorded datasets. For emergency attendances, 23% of 
SANAD II responses were in agreement with routine data and for inpatient admissions, 
10%. Despite these differences, there was overall acceptable agreement, although this was 
as a result of the large number of responses indicating zero unplanned attendances. 
Routinely recorded data demonstrate potential to inform both routine clinical practice and 
research. The differences in reporting require further assessment and it is likely the 
greatest utility of routinely recorded data in research would be in complementing data 
collected using standard prospective methods, in line with the current status quo for the 
collection of health economic data in RCTs.  
Potential explanatory factors for the differences identified may include recall bias and 
participant misunderstanding of the constitution of ‘inpatient admission’.   
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Table 7.13: Unplanned Healthcare Resource Use: Descriptive Statistics and Agreement 
  Emergency Attendances Inpatient Admissions 
R
C
T 
D
at
a 
 
Total Eligible Patients 
 
94 94 
Total Self-Report 
Responses 
 
263 (100%) 263 (100%) 
Total Healthcare Use  
 
52 (19.8%) 12 (4.6%) 
R
o
u
ti
n
e
 
D
at
a 
 
Total Eligible Patients 94 94 
Total Healthcare Use  
 
37 (14.1%) 19 (7.2%)  
 Total Paired 263 (100%)  263 (100%) 
A
ss
e
ss
m
e
n
t 
o
f 
A
gr
e
e
m
e
n
t 
R
C
T 
D
at
a 
Mean 
 
Range 
0.20 
 
0 - 8 
0.05 
 
0 - 4 
R
o
u
ti
n
e 
D
at
a 
Mean 
 
Range 
0.15 
 
0 - 7 
0.07 
 
0 - 2 
 Test for Significance Wilcoxon Signed Rank Wilcoxon Signed Rank 
Significance P=0.051  P=0.098 
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7.16 Primary Care Data, North West England 
Primary care data were extracted directly from the General Practices for two participants 
resident in North West England. The electronic medical records including UK READ Codes, 
free text entries, investigation results and clinical correspondence were reviewed.   
As a result of the sample size a descriptive analysis was performed, summarised in Table 
7.14. The data retrieved from the primary care electronic medical records were in general, 
complete. For example, dates of seizures and prescriptions and the occurrence of adverse 
events were identified. Furthermore, additional data were available such as the result of an 
EEG that was not included in the SANAD II dataset. However, there is some variation in the 
dates recorded and this may be explained by variations in the dates recorded when 
entering information onto the electronic medical record system. For example, for 
outpatient attendances, dates may be recorded as the date of attendance or the date of 
receipt of correspondence following the outpatient attendance.   
The primary care records were informative for the assessment of prescriptions and 
unplanned healthcare resource use, for example as a result of the occurrence of adverse 
events. However, the majority of the relevant data retrieved was extracted from the clinical 
correspondence recorded on the primary care electronic medical record. Such 
correspondence included letters following emergency care attendances and Neurology 
outpatient clinic attendances.  
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Table 7.14: Primary Care Data, North West England: Descriptive Analysis 
Variable Participant 1 Participant 2 
Date of First Seizure SANAD II: 17/12/13 
 
Primary Care: 17/12/13, A&E letter 
SANAD II: 01/11/12 
 
Primary Care: N/A, pre-2013 
Diagnosis and 
Classification of 
Epilepsy 
SANAD II: 31/01/14, Focal 
 
Primary Care: 24/01/14, Focal, Neurology OP 
letter 
SANAD II: 13/08/13, Focal 
 
Primary Care: 15/08/13, Focal, Neurology OP 
letter 
Clinical Investigations SANAD II: EEG (26/03/14, abnormal), MRI 
(30/04/14, abnormal) 
 
Primary Care: EEG (15/02/14, abnormal), MRI 
(08/05/14, abnormal)  
SANAD II: MRI (17/07/13, abnormal) 
 
 
Primary Care: EEG (23/09/13, abnormal) 
Date of First Follow-
Up Seizure 
SANAD II: 19/05/14 
 
Primary Care: 29/01/14, A&E letter, attendance 
following 2 convulsive seizures 
SANAD II: 23/10/14 
 
Primary Care: 24/10/14, GP attendance 
following seizure 
Date of Last Follow-
Up Seizure 
SANAD II: 15/10/14 
 
Primary Care: Neurology letter, ‘last partial 
seizure October 2014’ 
SANAD II: No further seizures 
 
Primary Care: No further seizures 
Date 12 Month 
Remission Achieved 
SANAD II: 15/10/15 
 
Primary Care: October 2015, Neurology letter, 
‘last partial seizure October 2014’ 
SANAD II: Insufficient follow-up 
 
Primary Care: Insufficient follow-up 
Total Number of 
Follow-Up Seizures 
SANAD II: 2 
 
Primary Care: 4 
SANAD II: 1 
 
Primary Care: 3 (within 24 hours) 
Date of First 
Prescription of 
Antiepileptic Drugs 
SANAD II: 31/01/14 
 
Primary Care: 31/01/14 
SANAD II: 13/08/13 
 
Primary Care: 15/08/13 
Dates and Nature of 
Adverse Events 
SANAD II: 28/01/14 (Tiredness) 
 
 
 
 
 
Primary Care: 25/04/14 (Tiredness) Neurology 
OP letter 
SANAD II: 27/08/13 (Memory impairment), 
13/09/13 (Reduced appetite, weight loss), 
21/01/14 (Rash), 15/04/14 (Poor sleep), 
15/06/14 (Hair loss), 15/09/14 (Anger, 
aggression) 
 
Primary Care: 04/12/13 (Unpleasant taste, 
weight loss, memory impairment) Neurology OP 
letter, 11/03/14 (Rash) Neurology OP letter, 
09/10/14 (Anger, hair loss, poor sleep) 
Neurology OP letter, 30/10/14 (Blistered tongue) 
GP attendance 
Dates of SANAD II 
Assessments 
SANAD II: 31/01/14, 25/04/2014, 23/05/2014, 
01/08/2014, 25/03/2015, 17/09/2015, 
23/03/2016 
 
Primary Care: 24/01/14, 25/04/14, 23/05/14, 
01/08/14, 25/03/15, 16/09/15, 22/03/16  
 
 
SANAD II: 13/08/13,  26/11/2013, 03/03/2014, 
10/11/2014, 19/12/2014, 18/08/2015 
 
 
Primary Care: 15/08/13, 18/11/13, 11/03/14, 
10/11/14, 19/12/14, 20/08/15 
Dates of Unplanned 
Healthcare 
Attendance 
SANAD II: 02/08/14 (‘In the last 3 months’ 1 A&E 
attendance 
 
Primary Care: 1 A&E attendance, A&E letter 
SANAD II: N/A 
 
 
Primary Care: 3 GP attendances as a result of 
adverse events, 1 GP attendance as a result of 
seizure occurrence 
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7.17 Conclusions 
In this chapter, routinely recorded data have been compared to data collected using 
standard prospective methods for variables and outcome measures relevant to the follow- 
up of participants in SANAD II.  
Follow-up seizures were poorly recorded in the routinely recorded datasets, with missing 
data and poor agreement compared to data collected using standard methods.  
Resultantly, a significantly greater proportion of participants achieved the outcome 
measure ‘time to 12 month remission’ calculated using routine data, with significantly 
fewer total follow-up seizures recorded. Routinely recorded data regarding AEDs were 
complete and had good agreement compared to data collected using standard methods. 
Additionally, data regarding compliance could be inferred and further data regarding 
prescriptions were available, including prescribed AEDs not recorded in SANAD II. However, 
adverse events were not recorded, either through specific codes indicating ‘adverse events’ 
or through healthcare attendances correlating with the dates of adverse events recorded in 
SANAD II. Episodes of planned healthcare resource use could be identified, although 
participants in SANAD II self-reported a greater number of unplanned emergency 
attendances and fewer unplanned inpatient admissions, compared to routinely recorded 
datasets. 
The poor quality and agreement of routinely recorded data compared to data collected 
using standard methods has implications for the utility of routinely recorded data. In 
epilepsy research, routinely recorded data may be limited for the measurement of 
prospective seizure outcomes, adverse events and episodes of unplanned healthcare 
attendances. In clinical practice, routinely recorded data are not suitable for monitoring 
treatment effectiveness or disease monitoring including incidence and prevalence rates.  
Explanations for the poor record of seizures include inaccurate recording of codes in 
routinely recorded datasets, inaccurate clinical diagnosis of seizures or participants not 
seeking medical attention, which may also explain the poor record of adverse events. The 
poor record of unplanned healthcare resource use is likely explained by recall bias and 
limited participant understanding of the context of ‘admission’. As above, the greatest 
potential of routinely recorded data may be in providing collateral clinical information. For 
example, a first follow-up seizure was identified in three participants in the routinely 
recorded datasets, but not in the SANAD II datasets.  
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Considering the results thus far, the accuracy and reliability of such ‘seizure occurrences’ 
must be questioned, however, knowledge of such data would direct further assessment 
within the trial, either through source data verification or clarification with the individual 
participant.       
 
This assessment has notable limitations, previously discussed in Chapter Six, 6.17.  
In the following Chapter Eight, the feasibility and efficiency of accessing and using data 
routinely recorded for participants in SANAD II is discussed and recommendations for 
improvement proposed.  
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Chapter Eight  
Results: The Feasibility and Efficiency of Accessing and Using 
Routinely Recorded Data 
 
8.1 Introduction 
In Chapter Four, routinely recorded data sources ‘accessible’ for this study were identified. 
In Chapters Six and Seven the attributes of routinely recorded data compared to data 
collected using standard prospective methods in SANAD II were assessed. In this chapter, 
the feasibility and efficiency of accessing and using data routinely recorded for participants 
in SANAD II is discussed and recommendations for improvement proposed.     
 
8.2 Accessing and Using Routinely Recorded Data 
The assessment of ‘accessibility’ considered in Chapter Four is an important component of 
this assessment of feasibility and efficiency of accessing and using routinely recorded data. 
In addition, the resources, including financial and time required for applications, the 
outcome of applications, resources required for data preparation and the attributes of the 
data provided are factors also included in this assessment, as detailed in Chapter Five, 
Methods. Table D.1, Appendix D summarises the key events and timeline in the scoping and 
application processes. This assessment, together with the review of accessibility presented 
in Chapter Four has been published and is also included in Appendix D [186].    
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 8.2.1 ‘Accessible’ Routinely Recorded Data Sources 
Routinely recorded secondary care clinical data sources were accessible in this study. Data 
for participants resident in England and Wales were requested from NHS Digital and The 
Secure Anonymised Information Linkage Databank (SAIL) respectively. Data from NHS 
Services Scotland; Information Services Division (ISD) were accessible, but there was only 
limited number of eligible individuals resident in Scotland and providing consent and an 
application in this study would not have been worthwhile. Routinely recorded primary care 
clinical data was accessible from North West eHealth (NWEH) and participants General 
Practitioners directly, for individuals resident in the North West of England. Finally, 
individual-level mortality data from ONS were accessible but for this study requiring 
participant consent and assessing a retrospective period, were not required. 
8.2.1.1 NHS Digital [55] 
NHS Digital were first requested to review the Participant Information Sheet (PIS) and 
Consent Form in August 2015. Following two further requests, a discussion in person with a 
member of the Data Access Request Service (DARS) resulted in a full application being 
submitted in November 2016. Feedback from the DARS team was received in December 
2016. Following this, feedback was also received from the Data Access and Information 
Sharing (DAIS) Team, responding to the initial requests. Aware of forthcoming alterations 
to the application and approval process, NHS Digital were contacted to advise on the 
method of full application. A full application was submitted in February 2016, using the 
existing system as advised. Multiple contacts were then attempted and reassurance 
received that the application had been accepted. The first formal acknowledgement of the 
application in April 2016 advised that all applications must now be submitted via the newly 
introduced DARS Online Portal. The application was re-submitted. In May, the pre-Data 
Access Advisory Group (DAAG) and DAAG meetings recommended the application should 
be approved once minor amendments had been addressed. The Data Sharing Agreement 
was signed in June 2016 and Hospital Episode Statistics (HES) made available for download 
on 13th July 2016. The total cost of the data, based on a cost-recovery system was £10,200 
including VAT.   
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8.2.1.2 The Secure Anonymised Information Linkage Databank (SAIL) [100] 
SAIL were first contacted in April 2015 during the assessment of accessibility. SAIL 
confirmed they were affiliated with The Administrative Data Research Network (ADRN) and 
a single application to the ADRN could include access to SAIL datasets. However, 
subsequently data access through the ADRN was not possible. In June 2015, information 
regarding the application process was requested and a teleconference arranged. The SAIL 
Scoping Document was completed in July 2015. In August 2015, review of the PIS and 
Consent Form was requested and promptly received. In January 2016, further review was 
requested, following alterations at the request of the other organisations including NHS 
Digital. The full application was submitted in February 2016. Minor amendments were 
requested in March 2016 and the application was submitted to the Information 
Governance Review Panel (IGRP) in April 2016. The IGRP approved the application in July 
2016 and data were available for download in August 2016. The total cost of the data, 
based on a cost-recovery system was £3390 including VAT.   
8.2.1.3 North West eHealth (NWEH) [97] 
NWEH were first contacted in October 2015 to discuss the study outline and confirm 
feasibility in principle. In November 2015 the study protocol, PIS and Consent Form were 
reviewed. Methodological details were discussed in person, including the requirements for 
data access. Discussions with both NWEH and Apollo determined the specific requirements. 
General Practitioners already consented and involved with NWEH for the Salford Lung 
Study would be included. Such GP’s had the Apollo data extraction software already 
installed. The existing data extraction query would be used within the Apollo software. The 
total cost of the data, based on a cost-recovery system was £16,800, funding both NWEH 
and Apollo. This cost did not include third party enrolment of the GP’s as it was decided the 
researcher would be responsible for this as a cost saving measure. In May 2016, following 
recruitment of the study sample, less than five individuals were registered in GP’s enrolled 
in the Salford Lung Study. Therefore, accessing primary care data through NWEH was not 
worth the cost.   
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8.2.1.4 General Practices’, North West England 
As a result of the prohibitively expensive costs for access to primary care data through 
NWEH, an amendment was approved by the Research Ethics Committee and Health 
Research Authority for the researcher to approach the registered GP’s for participants in 
this study resident in the North West of England. The researcher requested to attend the 
GP on one occasion and transcribe the relevant data onto a de-identified Data Extraction 
Form. As detailed in the Chapter Five, Methods, a Letter of Access from the National 
Institute of Health Research Clinical Research Network was required and an invitation pack 
mailed to the GP’s of 18 participants providing consent. Two GP’s provided consent and 
data was extracted for the participants in accordance with the protocol in July 2016. Three 
GP’s refused participation and the remaining 13 GP’s provided no response despite 
repeated attempts at contact via phone call and email.  
 
8.2.2 ‘Non-Accessible’ Routinely Recorded Data Sources 
The majority of routinely recorded primary care clinical data sources were not accessible in 
this study. Additionally, The Driver and Vehicle Licensing Agency, HM Revenue and Customs 
and The Department for Work and Pensions were not accessible, either directly or through 
the Administrative Data Research Network.  
8.2.2.1 Routinely Recorded Primary Care Clinical Data Sources 
The Clinical Practice Research Datalink (CPRD) [90] was first contacted in November 2014 
and the feasibility of the study was broadly confirmed. In August 2015, CPRD were re-
contacted and reported that the CPRD Confidentiality Advisory Group, ethical and 
governance approvals needed to be updated to permit identifiable, linked data release. At 
the time of this scoping procedure, this process was in development; NHS Digital are also 
CPRD’s Trusted Third Party. However, the timelines to resolve these barriers were unclear 
resulting in CPRD not being accessible for this study. Furthermore, an estimated quote was 
received and was expensive; the total cost of the data based on a cost recovery system was 
£17,000.   
The Health Improvement Network (THIN) [95], ResearchOne [91] and QResearch [93] were 
contacted in September 2015.  
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All organisations operate on a de-identified basis, with no facility to re-identify individuals. 
Such data sources were therefore not accessible for this study.  
8.2.2.2 The Driver and Vehicle Licensing Agency (DVLA) [18] 
The DVLA was initially contacted in October 2014. Despite multiple phone calls and emails 
regarding the broad feasibility of accessing DVLA data for this study, no response was 
received. In February 2015, following discussion with a member of a DVLA expert 
committee, a DVLA medical advisor was contacted. The study was discussed with the DVLA 
Data Sharing Team and the response indicated that the DVLA would not have the capacity 
to assist with the study and the DVLA data security requirements are ‘over and above those 
in the NHS or University’.   
8.2.2.3 Department for Work and Pensions (DWP) and HM Revenue and Customs (HMRC) 
[103, 104] 
The DWP and HMRC were first contacted in November 2014. No response was received 
from the HMRC; however, the DWP directed the enquiry to the External Data Sharing and 
Advice Centre. In December 2014, the External Data Sharing Advice Centre responded and 
advised that data access directly with the DWP or HMRC would not be possible and the 
enquiry should be discussed with the Administrative Data Research Network.  
8.2.2.4 The Administrative Data Research Network (ADRN) [102] 
The ADRN were first contacted in December 2014 to discuss feasibility for this study. 
Despite multiple attempts at contact, no response was received until February 2015. 
General guidance was provided via email. In March 2015 a teleconference was arranged to 
discuss the study. ADRN confirmed that the study was eligible for their services and they 
can request access to DWP and HMRC data linked to routinely recorded clinical data such 
as HES provided by NHS Digital. ADRN agreed to begin contacting the relevant data sources 
to request access to data. In April 2015 a further teleconference revealed no significant 
progress. In May 2015 HMRC declined participation although no clear reasoning was 
provided. The discussions with DWP were on-going. Furthermore, ADRN reported that if 
the DWP do not permit access to their data, the study would not be eligible for application 
through the ADRN solely for routinely recorded clinical data and independent applications 
must be submitted to the relevant organisations. In July 2015 the ADRN Informed the 
researcher via email that the DWP have not been forthcoming but negotiations were on-
going. No further feedback was received.   
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8.3 The Feasibility and Efficiency of Accessing and Using Routinely Recorded Data 
8.3.1 Clinical Routine Data Sources 
8.3.1.1 Secondary Care Data 
Routinely recorded secondary care data were successfully requested on an individual-level, 
identifiable basis for participants resident in England and Wales through NHS Digital and 
SAIL. However, although access to data was achieved there were notable limitations.  
In England, NHS Digital has a target time to data access of 60 working days following 
submission for complex applications including bespoke data linkage from multiple datasets. 
From the date of submission of the application via the DARS Online Portal access to HES 
data was granted within this timeframe. However, this positive experience following 
submission of the application is countered by limitations in the pre-application period. 
Acknowledging the significant update to the online application and approval procedures 
that occurred during the period of application, there remained a considerable period of 
time required in the development of the application. The nature of the request for 
identifiable data necessitated participant consent as the valid legal basis. NHS Digital 
require ethical and governance approvals to be in place prior to DAAG review and to 
prevent future amendments and delays, it was rational to ensure the participant consent 
materials had been reviewed by the NHS Digital Information Governance Team, prior to 
submitting the documents for ethical and governance approval. NHS Digital publish written 
guidance regarding consent and advise that documents for individual projects should be 
reviewed. However, in our experience there is no formalised process for providing this 
review. Following significant correspondence the consent materials were reviewed by the 
Data Access and Information Sharing Team. However, this feedback was provided following 
a full application submission and review by the Data Access Request Service. This process 
was inefficient for both NHS Digital and the researcher. Furthermore, at £10,200 the data 
were expensive despite being calculated using a cost-recovery system.  
For participants in Wales, data were retrieved through SAIL Databank. SAIL provided a 
streamlined pre-application service, including promptly engaging in multiple discussions 
and completion of a scoping document, outlining the study methods and costs involved at 
an early stage. Consent materials were also promptly reviewed by a member of the 
Information Governance Team with each request.  
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Although the pre-application time period was similar to NHS Digital, it was NHS Digital who 
were primarily responsible for the prolonged duration. In contrast to NHS Digital however, 
data were provided by SAIL eight months following submission of the application, 
compared to three months for NHS Digital. The cost of SAIL data was £3390, noticeably less 
than the £10,200 required by NHS Digital despite both organisations using a cost-recovery 
system.      
Data retrieved from both NHS Digital and SAIL required a period of ‘data cleaning’. This 
involved reviewing each individual data item for each participant and extracting relevant 
data according to the developed algorithms – the total included number of ninety eight 
participants permitting this process, requiring four weeks to complete. The data from both 
sources were in similar formats although there were slight differences with naming 
conventions and the availability of specific variables. Data dictionaries were available from 
both sources, although SAIL supplied data dictionaries together with the data. Finally, as 
presented in Chapters Six and Seven, the quality and agreement of the routinely recorded 
data are poor compared to data collected using standard prospective methods.  
There are stringent Information Governance requirements that must be in place prior to 
application for both NHS Digital and SAIL. These include Information Security assessments, 
specific inclusion regarding the ‘processing of healthcare data for the subjects of research’ 
in the institutional Data Protection Act registration and in the case of NHS Digital, an 
institutional Data Sharing Framework Contract. Adequate guidance is provided by both NHS 
Digital and SAIL and if not addressed early in the pre-application process may cause delay, 
although such delay was avoided in this study.  
8.3.1.2 Primary Care Data 
Routinely recorded primary care data were successfully requested on an individual-level, 
identifiable basis for participants resident in North West England, although is noticeably 
less accessible than secondary care data.  
The majority of primary care routinely recorded data sources including The Health 
Improvement Network, ResearchOne and QResearch are collaborations between academic 
or private institutions and the developers of the Information Technology systems used in 
General Practices. Each data source records data for GP’s who have provided consent and 
who have the relevant software installed.  
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This introduces an initial limitation as individuals in a RCT may be registered to different 
GP’s using a number of different software providers and primary care data for this group of 
individuals would therefore be recorded in a number of different routine data sources. 
Furthermore, such sources record data on a de-identified basis with no facility to re-
identify individuals. Therefore, where specific individuals need to be identified as for this 
study, these sources are not accessible.  
The Clinical Practice Research Datalink is a similar data source recording data on a de-
identified basis and as a result of the required ethical and governance approvals not being 
in place, individuals could not be re-identified and data were not accessible for this study. 
Furthermore, the £17,000 quote provided for access to data was prohibitively expensive, 
when only a small proportion of the participants in SANAD II are likely to be registered in 
CPRD enrolled GP’s.   
NorthWest eHealth has an established infrastructure for accessing linked primary and 
secondary care data and prescribing data. NWEH do not routinely provide a bespoke 
primary care data extraction service for research, however following a period of discussion 
agreed to participate in this study. In order to ensure the most time and cost-effective 
methodology, GP’s already enrolled with NWEH would be included and the existing data 
extraction query used. Additionally, the usual process of using a third party to visit, recruit 
and consent the GP’s would be replaced with the researcher performing these duties. 
Despite these measures aiming to maximise cost efficiency, the quote included £11,027 for 
‘data handling’, £1575 for ‘data check’, £1326 for Project Management and £7200 for 
Apollo data query testing, totalling £21,128. If recruitment was included in addition using 
CK Aspire, the company contracted by NWEH for the Salford Lung Study an additional 
£6800 would be charged. Following recruitment of the participants in this study, just three 
were registered to GP’s enrolled with NWEH, making the cost per participant of £7042 
prohibitively expensive.  
Routinely recorded primary care data were extracted directly from participants’ electronic 
medical records at their registered GP. With the exception of research time, there was no 
additional cost and for the two participants where data were available, the attributes were 
encouraging as discussed in Chapter Seven. However, the time intensive approach for data 
extraction and preparation limited the feasibility and efficiency. Perhaps of greater 
importance, despite participant consent only two of 18 GP’s consented.  
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This may indicate a systematic limitation with this approach and explanatory factors may 
include the current demands placed on GP’s together with the lack of financial incentive to 
participate in this research.   
8.3.2 Non-Clinical Routine Data Sources 
Routinely recorded non-clinical data on an individual-level were not accessible in this study. 
Following the literature review in Chapter Two and systematic review in Chapter Three, this 
result was expected.   
The Department of Work and Pensions (DWP) and HM Revenue and Customs (HMRC) 
directed the request for data to The Administrative Data Research Network (ADRN). The 
ADRN have been unable to negotiate access to data during this study, without reasoning 
being provided. Clearly accessing and using data from HMRC and DWP during prospective 
research is not feasible, despite the potential benefits in informing health economic 
analyses.   
The Driver and Vehicle Licensing Agency (DVLA) declined the request for data access, citing 
insufficient internal resources to process the request and more stringent data protection 
requirements than those employed in the NHS or academic institutions. However, explicit 
details regarding these requirements were not provided. Again, accessing and using DVLA 
data during prospective research is not feasible, despite the potential benefits for assessing 
clinical outcomes.  
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8.4 Discussion 
 
Routinely recorded data have potential use in prospective research including measuring the 
outcomes of RCTs [64] and conducting pragmatic RCTs including the stages of recruitment, 
randomisation, administration of interventions and follow-up assessments [67]. Academic, 
political [70] and health service [71] interest in UK sources of routinely recorded data have 
resulted in expansion and improvements, notably in the access to linked datasets. However 
the experience in this study with accessing individual-level data for specific participants 
providing written consent highlights persisting limitations.  
The access and use of routinely recorded data for individuals enrolled in SANAD II was 
assessed. Including the scoping assessments of accessibility, protocol development, 
research ethics and governance approvals and submission of the applications for data 
access, a period of 18 months was required before data was provided to the researcher. 
Notably, of the total 11 identified routinely recorded data sources, excluding those not 
suitable such as the ONS and NHS ISD for individuals resident in Scotland for which there 
were insufficient participants, data was successfully retrieved from just three sources of 
routinely recorded clinical data. The data retrieved covered a retrospective period with just 
an 18 month time period common to all routine datasets. At the time of receipt of the data 
(August 2016), the most recently available data common to all datasets was recorded eight 
months previously (31/12/15). This delay in data availability potentially limits the utility of 
such sources in prospective clinical research, such as drug trials where prompt reporting is 
clinically important and a regulatory requirement. Ninety eight participants were included 
and broadly the attributes of routinely recorded data compared to data collected using 
standard prospective methods was poor, with missing data and poor agreement the 
frequent results. The total cost for the data required by NHS Digital and SAIL was £13,590. 
However, the total underlying financial cost would also include researcher salary. 
Furthermore, the 18 months of full-time equivalent time required to access the data 
indicates a significant human resource requirement.    
Routinely recorded clinical data sources are numerous and there was comprehensive 
national coverage of emergency, inpatient, outpatient and critical care, under the umbrella 
of secondary care. The experience in this study suggests that accessing individual level data 
is possible but the feasibility is limited.  
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There were notable inefficiencies in the application process, particularly during the pre-
application phase, for example requesting feedback on the Patient Information Sheet and 
Consent Form prior to Research Ethics and Governance review. The resulting inefficiencies 
and duplication of tasks negatively impacting both the data holders and the researcher.  
Access to routinely recorded individual - level primary care data has not been feasible in 
this study. The majority of primary care data sources have limited geographical coverage 
based on the Information Technology software installed and usually record data on a de-
identified basis with no facility to re-identify individuals. Data is accessible by approaching 
GP’s directly using an established infrastructure developed by NWEH, but is prohibitively 
expensive. There was poor engagement with the study when GP’s were approached 
directly, resulting in a poor response rate. The inception of the NHS Digital General Practice 
Extraction Service which routinely records primary care data nationally for England, 
represents the most optimistic national source, however access is currently restricted to 
Department of Health initiatives, such as research involving screening procedures [139]. 
Access to non-clinical data has not been possible. The ADRN has been established to act on 
behalf of the researcher in negotiating access to de-identified, linked routinely recorded 
data from a number of organisations and the study proposal was promptly re-directed to 
the ADRN. However, the decision whether to release data remains with the data holder. 
This process is therefore inefficient; an application must be submitted and approved by the 
ADRN who then subsequently approach each organisation individually. Ideologically, the 
next step would be the storage of de-identified linked data from participating organisations 
in a single repository, similar to those established for RCT data [201]. This would create a 
single point of access and remove the burden for each organisation to consider each study 
individually. This would however require significant information governance and security 
barriers to be cleared and in light of recent developments within the research climate, 
individual consent. Including the public as stakeholders in the development of such a data 
repository would be essential [82].   
Although there are examples of pragmatic RCTs being coordinated through routine data 
sources [67], in this study the process of accessing and using routinely recorded data for 
participants of SANAD II was not feasible. Perhaps the most important factor in this 
assessment is that of the attributes of the routinely recorded data.  
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The degree of missing data and results of poor agreement compared to data collected 
using standard prospective methods in SANAD II results in an inability to recommend the 
sole use of routinely recorded data in an RCT such as SANAD II. Consideration of the 
differences in cost and resource-use required to obtain routinely recorded data compared 
to data collected using standard prospective methods become less relevant. Therefore, if 
routinely recorded data is not feasible to measure the outcomes of SANAD II and 
recommendation is made for data in a future RCT to be collected using standard 
prospective methods, the relevant question then is what is the added value of retrieving 
routinely recorded data? For example, routinely recorded data may provide information 
regarding AED compliance or healthcare resource use that is not recorded or incompletely 
recorded using standard methods. The relative value of developing the application and 
retrieving such routinely recorded data in addition to data collected using standard 
prospective methods would then require assessment.  Value of Information (VOI) analysis 
is a method used to assess the return on investment in research and can be defined as the 
amount an individual would be willing to pay before making a decision [202]. VOI analysis is 
appropriate for application in this study to determine the ‘optimal mix’ of data, or the value 
of information derived from routinely recorded data compared to data collected using 
standard methods. VOI analysis however, involves calculation of the objective function, 
Incremental Net Benefit (INB) derived from the Incremental Cost Effectiveness Ratio (ICER). 
In this study we could not calculate the ICER as a result of the small sample size and the on-
going status of SANAD II – routinely recorded data from all included participants would be 
required for this assessment. In a future analysis using the complete SANAD II dataset and 
data retrieved from routine sources, a VOI analysis could be performed to quantitatively 
define the value of retrieving routinely recorded data in addition to collecting data using 
standard methods. However, as discussed previously, the degree of missing data and poor 
agreement allows prediction that the relative value of additionally retrieving routinely 
recorded data will be limited.    
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8.5 Conclusions 
The major challenge in accessing and using routinely recorded data for a purpose such as 
this study with clear secondary benefit to the public and health services seems 
inappropriate when the ‘public purse’ funds the research, the researcher and many of the 
organisations recording the data. Perhaps a significant cause or contributor to the current 
limitations is the controversy and bad publicity following the Care.Data initiative in 2014. 
The proposal to extract primary care records from all individuals in the UK was opposed 
publicly by a number of groups and for example, resulted in an internal inquiry within the 
Health and Social Care Information Centre (HSCIC). Data applications were suspended 
during this period and our current experience may be explained partly by the concurrent 
revision of the HSCIC application and approval procedures. Indeed HSCIC has also 
rebranded itself NHS Digital. However, in the medium term, of more concern is the harm in 
public perception that has resulted. Currently, more than 1.2 million individuals in the UK 
have submitted a ‘Type 2 objection’, meaning that their data will not be shared for 
purposes other than direct care [203]. Although the application procedures may improve 
and in time we may be able to access data more efficiently, the loss of 2.2% of the 
population will have implications for the routinely recorded data that will then be made 
available for research. Involving the public as important stakeholders and re-gaining their 
trust will be an essential factor in realising the individual and population healthcare 
benefits of routinely recorded data [83].    
 
8.6 Recommendations 
Recommendations are proposed to improve the access and use of routinely recorded data 
in prospective research, presented in Table 8.2.   
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Table 8.2: Recommendations to Improve the Access and Use of Routinely Recorded Data in 
Research  
 
General 
 
Routinely recorded data are being used to measure RCT outcomes with the agreement, additional benefits and 
cost-efficiency of such data compared to data collected through standard RCT methods being unknown. 
Further research in epilepsy and alternative clinical settings should be performed to assess the agreement, 
additional benefits and cost-efficiency of accessing routinely recorded data to measure RCT outcomes 
compared to data collected through standard RCT methods.  
The costs required for data access from routine data sources vary widely, although all reportedly operate on a 
cost recovery, not-for-profit basis.  
Costs should be standardised and rationalised between routine data sources.   
The time lag before data is available in routine data sources represents a significant limitation to the access of 
routinely recorded data for prospective research, including RCTs. 
The infrastructure and procedures should be developed to reduce the time lag seen in routinely recorded data 
sources.  
The requirement for linkage between sources of routinely recorded data has been observed and improvements 
are on-going, for example with the establishment of the ADRN.  
A standardised set of identifying variables could be recorded by all (clinical and non-clinical) data sources to 
improve the accuracy of data linkage, similar to a Core Outcome Set for clinical trials [204].  
The public mistrust in the sharing and linking of routinely recorded data will hamper future efforts to develop 
routinely recorded databases, despite the likely benefits to individual patients and the population. 
Further research and public engagement should be undertaken to define the issues of most importance to the 
public and develop strategies to address these.   
 
Clinical Routine Data Sources 
 
There are numerous requirements prior to application and criteria to fulfil on submission of an application, yet 
the guidance and support during development of an application remains limited.  
Formalise and improve access to guidance and review of study materials during the ‘pre-application stage’. 
There is national coverage of routinely recorded secondary care data, yet primary care coverage remains 
patchy, based on geographical area or GP IT system. 
Develop the primary care data sources to provide national coverage, either through collaboration of existing 
sources and data linkage or development of national data sources, such as the General Practice Extraction 
Service.  
 
Non-Clinical Routine Data Sources 
 
Access to non-clinical data sources to inform clinical research was not possible during this study, despite the 
significant potential to inform Health Technology Assessment and the increasing importance of such 
assessments in a healthcare system where resources are increasingly limited.   
To assist with Health Technology Assessment and particularly the analysis of health economic outcomes, 
urgent research is required to consider facilitating access to individual-level identifiable data from non-clinical 
sources. This would include:  
 
a. Research regarding the public perception and acceptability of using their personal economic data for 
clinical research. 
b. Internal review within non clinical sources such as the DWP and HMRC to assess the feasibility and 
limitations of permitting access to data for clinical research. 
c. Formalisation of the approval processes through the independent party, the ADRN for access to non –
clinical administrative data – currently, following internal approval the ADRN then negotiate access to 
administrative data on a project by project basis.   
 
  
261 
 
8.7 General Conclusions 
In this chapter, the feasibility and efficiency of accessing and using data routinely recorded 
for participants in SANAD II have been discussed and recommendations for improvements 
proposed. Limitations include the narrative assessment of feasibility and efficiency, 
although based upon pre-specified criteria. Quantitative data were presented where 
possible, such as the costs of data from each source. Methods for the assessment of the 
‘optimal mix’ of data from routine sources and data collected using standard prospective 
methods were discussed, although as a result of the sample size, inability to calculate 
Incremental Cost Effectiveness Ratios and the on-going status of SANAD II, it was not 
possible to perform these analyses.   
In the following Chapter Nine, the research in this thesis will be discussed including key 
results, implications, and recommendations for the improved implementation and use of 
routinely recorded data in both research and clinical practice.  
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Chapter Nine 
Discussion and Conclusions: An Assessment of the Use of 
Routinely Recorded Data in the UK in a Randomised 
Controlled Trial  
 
9.1 Introduction 
In Chapter One, routinely recorded data in the UK and the potential for use in clinical 
research were introduced. Epilepsy and the case study RCT SANAD II were subsequently 
introduced before finally the objectives of this research were presented. In Chapter Two 
the use of routinely recorded data in RCTs in the UK was reviewed and in Chapter Three the 
agreement between UK routinely recorded data compared to data collected using standard 
methods in prospective studies was assessed in a systematic review. In Chapter Four, 
sources of routinely recorded data in the UK relevant to the outcomes of SANAD II were 
reviewed and sources where routinely recorded data were accessible for individuals 
recruited into SANAD II were identified.  
In Chapter Five, the methods for the assessment of the attributes of routinely recorded 
data retrieved from electronic medical records compared to data collected using standard 
prospective methods in a randomised controlled trial were presented. The assessment of 
seizure occurrence, diagnosis and classification of epilepsy in routinely recorded datasets 
were assessed in Chapter Six and variables and outcome measures relevant to the follow-
up of participants in SANAD II were assessed in Chapter Seven. The feasibility and efficiency 
of accessing and using routinely recorded data for participants in SANAD II were assessed in 
Chapter Eight.  
In this chapter, the headline results and conclusions will be discussed. Recommendations 
for improving the use of routinely recorded data and suggested areas for further research 
will be proposed.       
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9.2 Discussion 
The potential use of routinely recorded data in prospective research has been recognised 
and the accuracy of routinely recorded data compared to medical records has been 
assessed for a multitude of diagnoses, including epilepsy. However, there is minimal 
evidence of the assessment of agreement between routinely recorded data and the 
standard methods of data collection employed in prospective research. Acknowledging the 
rapidly increasing use of routinely recorded data in prospective research including RCTs and 
the status of the RCT in remaining the standard for approval of novel treatments in 
healthcare [110] and to inform everyday treatment decisions, the need for an assessment 
of the feasibility and agreement of routinely recorded data compared to data collected 
using standard prospective methods is pressing.  
This research reviewed the use of routinely recorded data in prospective research and 
agreement compared to standard prospective data collection methods, reviewed 
accessible sources of routinely recorded data in the UK and assessed the attributes 
including agreement of using routinely recorded data compared to data collected using 
standard prospective methods in a RCT assessing treatments for epilepsy:  
 
9.2.1 The Use of Routinely Recorded Data in the UK to Assess Outcomes in RCTs 
The use of individual-level routinely recorded data from specified data sources in the UK to 
inform the assessment of outcomes of RCTs was reviewed.  
Routinely recorded data have potential advantages when used in prospective research but 
the overall experience of accessing data for this purpose remains limited. Registry mortality 
and secondary care routinely recorded data were the most commonly accessed. 
Explanations may include the legal requirement regarding death notification and national 
recording of secondary care data. Primary care routinely recorded data were infrequently 
accessed but there was evidence for the feasibility of completing cluster RCTs with simple 
pragmatic interventions. Despite the potential for non-clinical HMRC, DWP and DVLA data 
to measure outcomes beyond the standard clinical assessments, there was no evidence of 
use of data for this purpose in a RCT. Furthermore, a data release register could only be 
identified for HMRC and on review there was no evidence of data use for clinical research 
of any methodology.  
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Explanations for the limited use of routinely recorded data in prospective clinical research 
may include the unclear accuracy of data and agreement to data collected using standard 
prospective methods or limitations with the feasibility and efficiency of accessing and using 
routinely recorded data. Furthermore, the discrepancy in this review between the results 
of the electronic database search and manual review of published data releases was 
notable, despite the search strategy being developed to be both sensitive and non-specific. 
This highlights the likely poor indexing of methodological information in electronic 
databases.  
 
9.2.2 The Agreement of Routinely Recorded Data with Data Collected Using Standard 
Prospective Methods in UK Studies 
A systematic review was undertaken to assess the agreement between specified routinely 
recorded data in the UK and data collected using standard prospective methods to 
measure the outcomes in prospective clinical studies.  
Routinely recorded data have a generally poor pattern of agreement for both clinical data 
and healthcare economic data. In general, the level of agreement identified in this review is 
not sufficient to recommend use in place of data collected using standard methods in 
prospective studies including RCTs. ‘All-cause mortality’ identified from UK Mortality 
Registers is the exception where acceptable agreement was observed. This is consistent 
with the finding of more common use in RCTs, identified in the previous objective. 
However, cause of death, which relies on coded data recorded on the medical death 
certificate, was found to be in poor agreement in some studies. This is consistent with the 
general pattern of poor agreement for clinical outcomes from primary and secondary care 
medical records. 
In addition to the heterogeneity of identified studies and limitations stated in Section 9.2.1, 
this systematic review is limited by the lack of evidence available, particularly the lack of 
RCTs with outcomes relevant to the treatment of epilepsy.   
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9.2.3 The Identification and Accessibility of UK Routinely Recorded Data Sources 
Sources of UK routinely recorded data relevant to the outcomes of SANAD II were 
presented and the accessibility for individuals recruited into SANAD II assessed.   
Routinely recorded secondary care data and mortality data were accessible. Primary care 
data from the majority of sources were not accessible as a result of the de-identified record 
of the data, resulting in an inability to identify the specific individuals recruited into SANAD 
II. Non-clinical data sources were not accessible, the ADRN being unsuccessful in 
negotiating access to HMRC and DWP data and the DVLA citing insufficient resources and 
stringent security measures.  
There are limitations associated with this assessment of accessibility. It is possible that 
relevant sources were not identified. Furthermore, the focus of the research was on large 
regional or national sources of routinely recorded data to ensure generalisability of the 
results, relevant to the UK-wide SANAD II RCT. The accessibility of smaller sources, such as 
disease specific registers is likely to differ.   
 
9.2.4 The Attributes of Routinely Recorded Data Extracted from Electronic Medical 
Records Compared Against Data Collected Using Standard Prospective Methods in the 
RCT SANAD II 
The quality of routinely recorded data and agreement between routinely recorded data 
and data collected using standard prospective methods was assessed for the 98 included 
participants of SANAD II.  
A first seizure occurrence could be identified in routinely recorded datasets in 23 of the 98 
participants. For participants without a first seizure occurrence; approximately one third of 
participants had no relevant attendances, one third had a ‘relevant attendance’, defined as 
an attendance within 48 hours of the date of a definite seizure recorded in SANAD II, but 
with missing diagnostic information and one third had a relevant attendance within 48 
hours but with inadequate or discrepant diagnostic codes not meeting the criteria for 
seizure occurrence. For the limited number of participants where first seizures were 
identified, the agreement for the date of occurrence compared to the date collected using 
standard prospective methods in SANAD II was poor.  
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Similarly, a ‘diagnosis of epilepsy’ was present in less than half of the participants using the 
routinely recorded data and agreement for the date of diagnosis was poor. Furthermore, 
there was poor agreement for the classification of seizures, explained by the majority of 
participants being deemed ‘unclassified’ as a result of the record of codes with inadequate 
clinical detail. Similarly, follow-up seizures were poorly recorded in the routinely recorded 
datasets, with missing data and poor agreement compared to data collected using standard 
methods.  Resultantly, a significantly greater proportion of participants achieved the 
outcome measure ‘time to 12 month remission’ calculated using routine data, with 
significantly fewer total follow-up seizures recorded. 
Data regarding the occurrence of the clinical investigations MRI, CT and EEG were available 
only in the emergency and primary care datasets, with reasonably complete data and 
results available only in the primary care dataset. Data regarding AEDs recorded in the 
primary care dataset were complete and had good agreement compared to data collected 
using standard methods. However, adverse events were not recorded, either through 
specific codes indicating ‘adverse events’ or through healthcare attendances correlating 
with the dates of adverse events recorded in SANAD II. Episodes of planned healthcare 
resource use could be identified, although participants in SANAD II self-reported a greater 
number of unplanned emergency attendances and fewer unplanned inpatient admissions, 
compared to routinely recorded datasets. 
For a number of the assessed variables, data were recorded in the routinely recorded 
datasets and not recorded in SANAD II, with potentially significant implications. For 
example, seizures were identified in the routine datasets for individuals’ seizure free in the 
SANAD II dataset. Investigations such as EEG were identified in the primary care dataset, 
not recorded in the SANAD II dataset and data regarding AED prescriptions were available, 
including prescribed AEDs not recorded in the SANAD II dataset. Finally, data regarding 
compliance could be inferred from the routine datasets, although with a number of notable 
assumptions.  
Explanations for these findings may include inaccurate recording of codes in routinely 
recorded datasets or inaccurate initial clinical diagnosis of seizures and epilepsy. 
Furthermore, the events may not have been ‘recordable’, for example if participants did 
not seek medical attention following seizure occurrence or the occurrence of adverse 
events or if relevant codes or detail are not included in the available routinely recorded 
datasets.  
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The poor record of unplanned healthcare resource use is likely explained by recall bias and 
limited participant understanding of the context of ‘admission’.  
This assessment has notable limitations. The comparator dataset was derived from the 
SANAD II data available at the time of assessment and a minority of data entries may have 
been subject to data checking and confirmation. The variables and constructed outcomes 
derived from the routinely recorded datasets were defined and extracted using algorithms 
developed for each comparison. However, there is a risk that relevant clinical events may 
not have been identified, if the diagnostic code recorded is not included in the algorithm. 
To address this limitation and explore the data further, the routinely recorded data for 
each participant was examined individually and in detail. For example, diagnostic codes 
recorded within 48 hours of a seizure recorded in the SANAD II dataset were examined. 
This process was feasible as a result of the small sample size. This research has assessed 
‘agreement’ and the discussion has largely considered the RCT data as the ‘gold standard’. 
However, for selected outcomes, specifically episodes of healthcare resource use, it is likely 
that the accuracy of the routinely recorded data, recorded with the primary function of 
NHS reimbursement, is greater than the RCT data, collected using methods such as self-
report questionnaires. There were limitations with regards to the specific variables that 
could be assessed, informed by the availability of comparable data in both sources. 
Furthermore, there were limitations in certain variables that were assessed. For example, 
outcomes such as ‘date of first tonic-clonic seizure’ or an assessment of the occurrence of 
serious adverse events would be reasonably expected to result in healthcare attendance or 
admission and such events would be recorded in routinely recorded datasets. However, a 
number of the comparisons in this study have limited validity, such as the assessments of 
‘dates of follow-up seizures’ where participants may reasonably not seek healthcare 
attendance following each seizure episode. This limitation results from the post-hoc and 
retrospective design of the study and in a subsequent, prospective study, variables should 
be selected informed by the known content, strengths and limitations of the routinely 
recorded data.   
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9.2.5 The Feasibility and Efficiency of Accessing and Using Data from Electronic Medical 
Records in the Randomised Controlled Trial SANAD II  
The feasibility and efficiency of the access and use of routinely recorded data for 
individuals enrolled in SANAD II was assessed.  
Following the 18 month period of scoping discussions and protocol development, data 
were retrieved from three of the total 11 identified routinely recorded data sources.  The 
data retrieved covered a retrospective period of 18 months and the most recently available 
data were recorded eight months previously, limiting the potential utility in prospective 
clinical research. As discussed, the quality and agreement of routinely recorded data 
compared to data collected using standard prospective methods was poor and the total 
cost £13,590, excluding researcher time and remuneration. The feasibility and efficiency of 
the use of routinely recorded data in prospective clinical research including RCTs are 
therefore limited.   
The descriptive nature of the assessment, potential omission of relevant criteria and 
subjective interpretation are limitations in this assessment of feasibility and efficiency.   
 
9.2.6 Implications for Clinical Research and Practice  
The literature and systematic reviews highlight the limited experience of using clinical 
routinely recorded data in RCTs, which is more pronounced for primary care compared to 
secondary care data. Non-clinical sources of routinely recorded data had no precedent of 
use in prospective clinical research and in the cases of HMRC and DWP, no use in clinical 
research of any methodology.  
This research identified a persistent issue with missing routinely recorded data compared 
to data collected using standard prospective methods in the RCT SANAD II. Furthermore, 
poor agreement was noted for the majority of variables and outcome measures. Finally, 
the limitations with accessibility together with the poor quality and agreement result in the 
process of retrieving routinely recorded data during a RCT being of limited feasibility. In 
addition, factoring in the application time and financial resources required for data access, 
the feasibility is further limited.    
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9.2.6.1 Implications for Clinical Research 
The results of this research have potential implications for the utility of routinely recorded 
data in prospective clinical research. In the SANAD II RCT assessing antiepileptic drug 
treatments for individuals newly diagnosed with epilepsy, routinely recorded data were 
broadly unsuitable for the identification of eligible individuals for recruitment and 
measurement of prospective outcomes and adverse events, compared to data collected 
using standard prospective methods. These results were not unexpected, acknowledging 
the identified concerns regarding accuracy of routinely recorded data when used for clinical 
research [47, 72] and the results of the systematic review presented in Chapter Three.   
The limited feasibility, quality and agreement suggest that use of routinely recorded data as 
the primary data source or as a means of validating data collected using standard methods 
in prospective clinical research, would be limited for both the identification of eligible 
individuals for trial recruitment and the measurement of the trial outcomes. However, 
exceptions include data regarding prescribing and aspects of healthcare resource use, in 
both cases the routinely recorded data likely being of increased accuracy. Notably, the 
outcome most commonly measured using routinely recorded data in previous published 
research including RCTs and an exception; with acceptable evidence for agreement in the 
systematic review completed in Chapter Three, was mortality.  
As a result of the nature of this study and the requirement for participant consent, 
mortality could not be assessed. The results of this research raise concerns regarding the 
current and future use of routinely recorded data in RCTs. Excluding mortality, which has 
demonstrated acceptable agreement and healthcare resource use, which is commonly 
identified using routinely recorded data together with patient assessment and recall, the 
acceptable inclusion of routinely recorded data in RCTs seems limited. In the systematic 
review presented in Chapter Three, acceptable agreement between patient recall and 
medical records data was observed for the record of selected common, chronic medical 
diagnoses such as diabetes mellitus [180]. This would be expected, although one study did 
not find acceptable agreement between self-reported stroke and diagnosis of stroke in 
medical records [178]. In addition to common medical diagnoses, the alternative scenario 
where acceptable agreement may be expected is in the identification of complex medical 
events. For example, ‘cancer progression’ was successfully identified in medical records 
compared to physician assessment. In such cases, there may be a multitude of ‘events’ 
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including admissions, urgent specialist referrals, investigations and treatments that may be 
included in an algorithm to identify the complex outcome.  
However, the ‘middle ground’ between pragmatic, common diagnoses and complex events 
may be where the utility of routinely recorded data is most limited. The systematic review, 
for example in the identification of poor agreement for minor post-operative complications 
[155] or pressure ulcers [181] and the results of this research, for example in the 
identification of seizure occurrence, support this conclusion.  
Routinely recorded data in the context of prospective clinical research may represent an 
important source of collateral data in addition to the primary data collected using standard 
prospective methods, for example to identify additional events such as seizures not 
recorded using standard methods. Acknowledging the identified limitations, the accuracy 
and reliability of such data must be questioned. However, this additional information may 
direct further interrogation within the trial, including source data verification or 
clarification with the individual participant. Furthermore, routinely recorded data may also 
be valuable in providing additional data, for example data regarding longer-term follow-up, 
beyond the normal lifespan of a RCT and following measurement of the primary outcomes 
[205]. Lastly, informed by knowledge of the content, strengths and limitations, routinely 
recorded data alone may reasonably be used to measure specific outcomes such as 
mortality, episodes of healthcare resource use or clinical events resulting in healthcare 
attendance.  
This research also has potential implications for the use of routinely recorded data in 
retrospective research. Routinely recorded data held in administrative datasets are seen as 
a valuable resource for retrospective research and their use is established. Using the 
diagnosis of epilepsy as an example, there are studies worldwide assessing the accuracy of 
algorithms applied to routinely recorded data to identify individuals with a diagnosis of 
epilepsy. ICD-10 codes consistent with a diagnosis of epilepsy together with ≥1 AED 
recorded in the Australian National Hospital Morbidity Database resulted in a PPV of 81.4% 
[73]. A similar study using multiple linked Canadian administrative healthcare databases 
found a PPV of 91.9% [74] and there are further studies with equivalent findings indicating 
algorithmic approaches applied to routinely recorded data are sensitive for identifying 
individuals with diagnoses of epilepsy [75-78]. However, such studies providing verification 
of the use of routinely recorded data for diagnosis frequently use written medical records 
as the comparator, themselves routinely recorded.  
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This research has assessed the agreement compared to standard prospective data 
collection methods used in RCTs, which remain the gold standard for the approval of novel 
treatments in healthcare [110]. The poor agreement identified raises questions regarding 
the accuracy and methods for assessment of accuracy of routinely recorded data for use in 
retrospective, in addition to prospective research. A notable limitation of this conclusion is 
the inclusion of the prescription of AEDs in the diagnostic algorithms in these published 
studies. The inclusion of AEDs in the diagnostic algorithm was not possible in this research 
as a result of the lack of suitable data in the datasets. Furthermore, this research involved 
the identification of new diagnoses and the inclusion of AEDs in a diagnostic algorithm 
would not be appropriate.    
 
9.2.6.2 Implications for Clinical Practice  
Finally, the attributes of routinely recorded data, extracted from electronic medical records 
have potential implications for clinical practice both at the individual and population level. 
Missing or inaccurate clinical data may have negative implications on an individual patient’s 
clinical care, particularly with the increasingly central role of electronic medical records. For 
example, inaccurate diagnostic data may result in eligible individuals being missed as part 
of screening investigations and inaccurate data regarding the occurrence of seizures and 
adverse events may result in the limited utility of electronic medical records in monitoring 
treatment effectiveness.   
Furthermore, on a population level, routinely recorded data are frequently used to monitor 
the incidence and prevalence of diagnoses or associated risk factors. If such data are 
inaccurate decisions regarding the commissioning and allocation of treatment resources 
may result in inequitable clinical services.    
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9.3 Recommendations and Further Research 
Recommendations and suggestions for further research can be proposed with the aim of 
improving the quality of UK routinely recorded data and feasibility of use in clinical 
research. Table 8.2 in Chapter Eight has previously summarised a number of 
recommendations.   
 
9.3.1 General Recommendations 
Further Research to Assess and Improve the Use of Routinely Recorded Data in Clinical 
Research  
There is evidence of the inclusion of routinely recorded data in prospective clinical 
research, including all stages of a RCT being conducted using an administrative healthcare 
database [124], despite the notable limitations identified in this research. Further research 
is urgently required to assess the quality, additional benefits, feasibility and cost-efficiency 
of accessing routinely recorded data to assist with the identification of eligible individuals 
and recruitment into trials and measure RCT outcomes. Such research should include 
patients and outcomes in epilepsy together with other disease areas. To inform future 
prospective assessments, systematic reviews in individual disease areas should aim to 
identify the use of routinely recorded data in research and review assessments of the 
accuracy (compared to medical records) and agreement (compared to standard 
prospective research methods). Such reviews with a focus on methodology should include 
relevant electronic database searches and as a result of the poor recording of 
methodological information, also be complemented with a manual review of relevant 
resources.   
A proposed method to complete such methodological research assessing the quality, 
additional benefits, feasibility and cost-efficiency of accessing routinely recorded data to 
assist with the identification of eligible individuals and recruitment into trials and measure 
RCT outcomes compared to standard prospective methods is to use the ‘Studies Within A 
Trial’ (SWAT) approach. The SWAT initiative has been developed by the Medical Research 
Council Hubs for Trials Methodology Research (MRC HTMR) and proposes embedding 
methodological research within an existing prospective trial [206].  
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In the majority of current publically funded UK RCTs such as SANAD II, the retrieval of data 
from administrative healthcare databases is frequently standard, in order to inform the 
healthcare economic analyses. Using the SWAT approach, a methodological sub-study can 
be embedded within the trial and prospectively completed, for example with calculation of 
the trial outcomes using routinely recorded data and comparison to outcomes calculated 
using the data collected using standard prospective methods. This process would be 
procedurally efficient as the data would frequently be requested and examined as part of 
the trial routinely and ethically sound as no additional or subsequent request or retrieval of 
data would be necessary. It may be reasonable for such an assessment to be included in all 
future UK RCTs and including this requirement within the stipulations for funding from 
major national funders such as the National Institute for Health Research Health 
Technology Assessment (NIHR HTA) programme would ensure the inclusion of such 
methodological assessments are completed.  
As an extension to the above prospective assessments, the relative value of routinely 
recorded data and ‘optimal mix’ of routinely recorded data and data collected using 
standard methods requires assessment for specific disease areas and outcomes. Value of 
Information (VOI) analysis is a method used to assess the return on investment in research 
and can be defined as the amount an individual would be willing to pay before making a 
decision [202]. VOI analysis would be appropriate for application in future prospective 
studies to determine the ‘optimal mix’ of data, or the value of information derived from 
routinely recorded data compared to data collected using standard methods. The inclusion 
of VOI analysis prospectively and retrieval of routinely recorded data for the complete 
study sample would permit calculation of the objective function, Incremental Net Benefit 
(INB) derived from the Incremental Cost Effectiveness Ratio (ICER). As a direct extension of 
this research, using the complete SANAD II dataset and data retrieved from routine 
sources, a VOI analysis could be performed to quantitatively define the value of retrieving 
routinely recorded data in addition to collecting data using standard methods.     
Lastly, to maximise the validity of future prospective assessments, the content, strengths 
and limitations of the routinely recorded datasets must be considered and inform the 
selection of the specific variables to be assessed.  
  
275 
 
Standardisation and Rationalisation of Costs  
The costs required for data access from routine data sources where data were available in 
this research varied widely, although all reportedly operated on a cost recovery, not-for-
profit basis. For both clinical and non-clinical sources of routinely recorded data, costs for 
data access for research should be standardised and rationalised between data sources.  
The feasibility of achieving costs standardisation will be greater for publically funded data 
sources, although similar approaches to achieving standardisation could also be taken for 
privately funded sources. Proposed approaches would include the establishment of a task 
force or working group with representatives from each routine data source. Prospective 
analysis of costs should follow and would inform the definition of ‘standardised’ costs that 
each routine data source would aim to adhere to. Such an initiative may be more successful 
if government driven and medical researchers and funders lobbying relevant governmental 
departments, including the Department of Health could also be suggested. Where there 
are reasonable variations in costs, government subsidies could assist in ensuring the cost to 
the end users, including the researchers, is standardised.     
Reduction of the Time to Data Availability 
There is a time delay before data are available in all routine data sources resulting from the 
requirement to collect, transfer, clean and process data. Although less of an issue for 
retrospective research, this represents a significant limitation to the access of routinely 
recorded data for prospective research, including RCTs. This limitation will, for many RCTs, 
rule out the sole use of routinely recorded data to measure RCT outcomes, where prompt 
reporting is ethically important and frequently a regulatory requirement. The development 
of ‘real-time’ routine data recording is an unrealistic short-term aim as a result of the need 
to process, clean and format the data. However, development of the infrastructure and 
data extraction and processing procedures and increasing resources dedicated to such 
tasks should aim to reduce the time to data availability.   
Standardise and Improve Data Linkage    
Improvements in the access to linked data are on-going, for example with the 
establishment of the ADRN. However, further improvements could be suggested. To 
improve the accuracy of data linkage, a standardised set of identifying variables could be 
recorded by all (clinical and non-clinical) data sources. Suggested variables would include 
name, date of birth, National Insurance Number and NHS Number.  
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Furthermore, standardised demographic variables could also be recorded, with the 
potential to inform research. Definition of specific variables would require further research 
involving researchers, data holders and members of the public as important stakeholders, 
similar to process involved in the development of a Core Outcome Set for RCTs [204].  
The experience during this research is that the process for retrieving data through the 
ADRN is inefficient; an application must be submitted and approved by the ADRN who then 
subsequently approach each organisation individually. A recommendation for future 
improvement could include the storage of de-identified linked data from participating 
clinical and non-clinical organisations in a single repository, similar to those established for 
RCT data [201]. This would create a single point of access and remove the burden for each 
organisation to consider each study individually. Development of this repository would 
however require significant information governance and security barriers to be cleared and 
in light of recent developments in data protection regulation [51] applicable to research, 
individual consent. Including the public as stakeholders in the development of such a data 
repository would be essential [82].    
Assess Public Perceptions and Improve Public Engagement 
Finally, in the current climate the public mistrust regarding the sharing and linking of 
routinely recorded data will hamper future efforts to develop linked routinely recorded 
administrative databases, despite the likely benefits to individuals and the population. This 
issue is perhaps the most important hurdle to overcome as, despite an improved quality of 
data, feasibility of use and potential benefits, without public trust and consent, improved 
implementation and utility of routinely recorded data will not be possible. Further research 
is required with public engagement to define the issues of most importance to members of 
the public and assess perspectives with regards the routine recording of data and 
subsequent use for secondary purposes including research. Such an assessment could 
include qualitative methods including interviews and focus groups with relevant 
stakeholders and quantitative methods such as discrete choice experiments for preference 
elicitation [207].       
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9.3.2 Routinely Recorded Clinical Data 
Streamline the Process for Application Development and Provisional Review 
Access to routinely recorded secondary care data was achieved in this study, although the 
process for application development and provisional review could be improved. A number 
of requirements must be fulfilled prior to submission of the application to NHS Digital and 
SAIL, including research ethics and governance approvals. General guidance has been 
published by each source regarding the development of the consent materials.  
However guidance regarding, for example the specific phrasing required in the consent 
form was not published, and discussion with the Information Governance teams was 
suggested. However the process for requesting review of the relevant study documents 
and obtaining specific feedback was inefficient, with delays and duplication of work for 
both the researcher and data holders. To improve this period of protocol development and 
application, data sources should improve the guidance and formalise the pathway for 
requesting review of study documents prior to formal submission of the application for 
research ethics and governance approvals.  
Standardise Data Recording Between Similar Datasets 
‘Missing data’ was identified throughout this research and a contributing factor may be the 
requirements for data recording within each dataset. For example, diagnostic data in the 
inpatient datasets is mandatory. However, the record of diagnosis is not mandatory in the 
emergency care or outpatient datasets. Consequently, a high proportion of attendances 
were observed with no diagnostic information recorded. Individuals attending the 
emergency department without subsequent inpatient admission therefore, were unlikely 
to have diagnosis recorded. Significant improvements could be expected if the record of 
diagnostic data is mandatory in all datasets. This is particularly relevant for research 
involving epilepsy as patients are frequently discharged from the emergency department, 
without inpatient admission following the occurrence of a seizure. Furthermore, to 
improve the accuracy of clinical coding, clinicians could have greater involvement in the 
recording of diagnostic codes. In primary care, GP’s are frequently involved in the direct 
recording of relevant READ codes. The advent of electronic medical records and patient 
administration systems should improve the ease of this process in secondary care and 
therefore the acceptability for clinicians. For example, in the outpatient dataset, diagnostic 
codes permitting classification of epilepsy were recorded for all participants in one centre 
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and rarely recorded in all other centres. This single centre requires the clinician select a 
diagnostic code from a standardised electronic form following the clinic attendance and at 
the point of confirming follow-up arrangements, resulting in all patients having a diagnostic 
code recorded.    
Development of National Primary Care Datasets 
Access to primary care routinely recorded data was not feasible in this study. The ‘de-
identified’ nature of the data, cost and poor geographical coverage are notable limitations. 
Development of the infrastructure to record national primary care data coverage could be 
suggested. This may be achieved either through improved collaboration between existing 
routine data sources with individual-level data linkage or the development of national data 
sources, such as the NHS Digital General Practice Extraction Service [139].    
Development of an Integrated Electronic Healthcare Record 
A number of countries have integrated healthcare systems allowing for national 
administrative healthcare databases, such as the Swedish Hospital Discharge Register, the 
Danish National Hospital Register and the Canadian Chronic Disease Surveillance System. In 
these examples it is possible to retrieve routinely recorded data from electronic medical 
records for individuals across hospital inpatient admissions and emergency care, outpatient 
clinic and primary care attendances. 
An integrated electronic health record would perhaps have the greatest potential for the 
improved record of data and improved use in clinical practice and research. Such a 
proposed system would be entirely electronic and would involve the clinician recording 
free text ‘medical record’ entries, in addition to involvement in the direct selection of 
relevant clinical codes, such as diagnoses. This may result in improving the accuracy of 
routinely recorded coded data, reducing the potential for transcription errors and 
improving the efficiency of data record. In the optimal scenario, medical records from 
primary and secondary care settings, together with additional data such as pharmacy 
prescribing and dispensing data would be included in the single electronic record.  The 
electronic health record would then contribute directly to individual clinical care and 
directly provide data to the administrative databases for secondary uses, including disease 
monitoring and clinical research. The utility of such a dataset for retrospective and 
prospective research, compared to the datasets currently available in the UK is likely to be 
significantly improved.  
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For example, the most sensitive and specific algorithms used in retrospective research to 
identify individuals with a diagnosis of epilepsy include ICD 10 codes from all clinical 
settings together with data regarding the prescription of AEDs, with Positive Predictive 
Values of up to 91.9% [74]. Application of a similar algorithm in the UK would require 
linking between a number of individual datasets, which is logistically more difficult and 
introduces the potential for error. Integration of research functions, such as including RCT 
electronic CRFs [208], into the electronic health record would also improve their utility in 
prospective clinical research.  
Finally, a single integrated electronic health record may result in improved accessibility for 
individual patients. This may permit patients to view their medical records but also provide 
the facility for their contribution of certain data. For example, permitting patients to record 
their dates of seizure occurrence would inform their clinical care, such as alerting the 
clinical team to unexpected increased seizure frequency, in addition to the obvious benefits 
for clinical research.      
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9.3.3 Routinely Recorded Non-Clinical Data 
Further Research to Assess and Improve the Use of Non-Clinical Data in Research  
Further to the relevant general recommendations presented above, urgent research is 
required in the short to medium term to improve access to individual-level data from non-
clinical sources for research: 
Public Perceptions and Acceptability  
Research regarding the public perceptions and acceptability of using personal non-clinical 
data, including economic data for clinical research is needed, prior to widespread 
investment in development of the infrastructure to permit this. Such research may include 
qualitative methods such as interviews and focus groups and quantitative methods such as 
discrete choice experiments for preference elicitation.  
Formalisation of the Approval Processes through the ADRN  
In the short-term, the greatest potential for improved data access is likely to involve the 
ADRN. Formalisation of the approval processes through the independent ADRN and the 
storage of linked data in a single repository, as previously discussed, would improve 
efficiency and reduce the burden placed upon the individual data holders. Furthermore, 
utilising the ADRN who retrieve data on a de-identified basis before providing to the 
researcher could be proposed as a method of improving data security, alleviating the 
concerns raised by the DVLA during this research.     
Internal Review of Feasibility, Processes and Resource Implications 
The feasibility, methodological process and resource implications of permitting access to 
data for research requires review internally within relevant data sources such as the HMRC 
and DWP. The initiative would be best and likely only led from government and therefore 
lobbying government, once the public perceptions and acceptability are known, may be a 
suitable initial option.   
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9.4 Concluding Remarks  
In Chapter One, routinely recorded data in the UK and the potential for use in clinical 
research were introduced. Epilepsy and the case study RCT SANAD II were subsequently 
introduced before finally the objectives of this research were presented. In Chapter Two 
the use of routinely recorded data in RCTs in the UK was reviewed and in Chapter Three the 
agreement of UK routinely recorded data compared to data collected using standard 
methods in prospective studies was assessed in a systematic review. In Chapter Four, 
sources of routinely recorded data in the UK relevant to the outcomes of SANAD II were 
reviewed and sources where routinely recorded data were accessible for individuals 
recruited into SANAD II were identified.  
In Chapter Five, the methods for the assessment of the quality and agreement of routinely 
recorded data retrieved from electronic medical records compared to data collected using 
standard prospective methods in a randomised controlled trial were presented. The 
assessment of seizure occurrence, diagnosis and classification of epilepsy in routinely 
recorded datasets was assessed in Chapter Six and variables and outcome measures 
relevant to the follow-up of participants in SANAD II were assessed in Chapter Seven. The 
feasibility and efficiency of accessing and using routinely recorded data for participants in 
SANAD II was assessed in Chapter Eight.  
In this chapter, the significant results for each objective of this research and the 
implications for clinical practice and research have been discussed. Recommendations for 
improving the use of routinely recorded data have been proposed and avenues for further 
research suggested. 
This research has identified limited previous experience of using routinely recorded data in 
UK RCTs. The accessibility and feasibility of use were limited and degree of missing data 
and agreement compared to data collected using standard methods unsatisfactory. The 
results of this research suggest routinely recorded data in the context of prospective 
clinical research may be an important source of additional data, for example to identify 
additional events such as seizures not recorded using standard methods. The results 
suggest that use of routinely recorded data as the primary data source or as a means of 
validating data collected using standard methods for the variables assessed in this study, 
would be limited.  
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Although these results are potentially disappointing for immediate improvements in the 
use of routinely recorded data in RCTs, such as improvements in resource and cost-
efficiency, they enable recommendations to be proposed.  
Substantial further development is now required to improve the utility of routinely 
recorded data in clinical practice and research. Recommendations include suggestions for 
improving the access to routinely recorded data for research, development of an integrated 
electronic health record for use in both clinical practice and research, further assessment of 
the attributes and ‘optimal mix’ of routinely recorded data compared to data collected 
using standard methods. To improve the likelihood of significant progress, initiatives for 
development should be led from the government. Additionally and perhaps most 
importantly acknowledging recent controversies, involving patients and the public as 
important stakeholders and re-gaining their trust will be essential in realising the individual 
and population healthcare benefits of routinely recorded data.   
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Table A.1: Included Studies; Characteristics and Use of UK Secondary Care Routinely Recorded Data in RCTs 
Study Reference Trial Summary Outcome Measures Implementation of Routinely Collected Data Appraisal 
Office for National Statistics (ONS) (General Register Office (GRO), General Statistics Office of Ireland (GSOI)) 
Ashton et al: 2002 [119] 
 
The Multicentre 
Aneurysm Screening 
Study (MASS) into the 
effect of abdominal 
aortic aneurysm (AAA) 
screening on mortality 
in men: a randomised 
controlled trial 
 
Parallel Group RCT 
67,800 participants randomised to Ultrasound (USS) 
abdominal screening or no intervention. Those with 
normal USS had no further intervention. Abnormal USS 
had follow up scans and vascular input where indicated.  
 
Data such as investigation results and clinical follow up 
were reported through standard prospective methods.  
 
Mortality was measured by accessing data from ONS. 
Primary Outcome: 
Aneurysm related 
mortality.  
 
Secondary 
Outcomes: All-
cause mortality, 
frequency of 
ruptured aneurysm, 
quality of life 
Participants were identified by NHS Number and 
ONS requested to provide a copy of the death 
certificates.  
 
International Classification of Diseases (ICD) 
codes were used to identify relevant diagnoses 
such as 'ruptured aortic aneurysms'.  
 
‘Additional information’ was sought from 
hospital / GP records if needed although the 
information requested and participant numbers 
where this additional information was sought is 
not explicit. 
ONS Mortality follow-up was available for 67 274 
(99%) of the randomised sample. Cost and 
resources required for access not reported.  
 
Following review of all death certificates, 8% (14 
of 177) of those certified as having died from a 
AAA were considered to have died from other 
causes and 0.1% (9 of 7407) of those certified as 
having died from other causes were considered 
to have died from ruptured AAA. The study 
examined the impact of these discrepancies on 
trial results and there was no significant 
difference - HR of 0.62 compared to 0.58.   
Bale et al:  2008 [121] 
 
Long-term mortality 
follow-up of the ISOLDE 
participants: causes of 
death during 13 years 
after trial completion 
 
Parallel Group RCT 
752 patients with moderate/severe Chronic Obstructive 
Pulmonary Disease (COPD) randomised to fluticasone or 
placebo for 3 years. Mortality at 3 years examined in the 
initial trial along with lung function and COPD 
exacerbations using standard prospective methods. 
 
375 participants (inclusion dictated by ethical approval) 
were included in this long term follow up study. 
 
Mortality was measured by accessing data from ONS. 
Primary Outcome: 
All-cause mortality. 
ONS requested to provide a copy of the death 
certificates. Participant identifiers used or data 
extracted not detailed.  
 
Life status was also confirmed by the NHS 
strategic tracing service. 
Data available for 206 (98%) participants 
included. Cost and resources required for access 
not reported.  
 
No explanation of the methods for data retrieval 
or review. 
 
Study reported ‘limitations associated with ONS 
data’. No further details.  
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Brown et al: 2012 [120] 
 
The UK EndoVascular 
Aneurysm Repair 
(EVAR) trials: 
randomised trials of 
EVAR versus standard 
therapy 
 
Parallel Group RCT 
EVAR 1: EVAR vs Laparotomy, 1252 participants with 
AAA randomised to EVAR or laparotomy.  
 
EVAR 2: EVAR vs No Intervention, 404 participants with 
AAA randomised to EVAR or conservative management. 
 
Mean follow up 8 years. Data to inform clinical and cost 
effectiveness measures were reported through standard 
prospective methods. 
  
Mortality was measured by accessing data from ONS.  
Primary Outcome: 
Mortality (all-cause, 
operative, 
aneurysm-related). 
ONS requested to provide a copy of the death 
certificates. Participant identifiers used not 
detailed.  
 
ICD codes were obtained and reviewed by an 
endpoints committee. Included codes and timing 
of death were pre-specified in the protocol. No 
reported additional data sources accessed, 
including comparison to clinical sources of data 
to assess agreement.  
Mortality data available for 99% of patients. Cost 
and resources required for access not reported.  
 
No explanation of the methods for data retrieval. 
 
Study reported the 'couple of months' delay 
between death and notification of death through 
ONS. For patients where notification of death 
was not received in the last few months of the 
RCT, letters were sent to participants. Where no 
response was received, phone calls were made 
to confirm life status. No further limitations 
detailed.  
Henderson et al: 2015 
[126] 
 
10-Year Mortality 
Outcome of a Routine 
Invasive Strategy 
Versus a Selective 
Invasive Strategy in 
Non-ST-Segment 
Elevation Acute 
Coronary Syndrome 
 
Parallel Group RCT 
1810 patients with non-ST-segment elevation acute 
coronary syndrome were randomised to an early 
invasive strategy (coronary arteriography and 
myocardial revascularization) or a selective invasive 
strategy (coronary arteriography for recurrent ischemia 
only).  
 
Trial follow up for 5 years in previous paper assessed 
clinical measures and mortality (99.6% of patients) using 
standard prospective methods.  
 
10 year mortality was measured in this study by 
accessing data from ONS and the General Register Office 
(GRO) for Scotland.   
Primary Outcome: 
All-cause mortality.  
 
Secondary 
Outcomes: 
Mortality 
(cardiovascular or 
non-
cardiovascular).  
ONS for England and GRO for Scotland requested 
to provide a copy of the death certificates. 
Participant identifiers used not detailed.  
 
ICD codes were reviewed to identify relevant 
diagnoses.  
457 deaths identified at 10 years. Cost and 
resources required for access not reported.  
 
No explanation of the methods for data retrieval 
or review. 
 
Study states missing data is a possibility and 
completeness of data not reported - example 
provided of patients emigrating.   
Molyneux et: 2015 
[127] 
 
The durability of 
endovascular coiling 
versus neurosurgical 
clipping: 18 year follow-
up of the UK cohort of 
the International 
Subarachnoid 
Aneurysm Trial (ISAT) 
Parallel Group RCT 
2143 participants with ruptured cerebral aneurysm were 
randomised to neurosurgical clipping or endovascular 
coiling in the ISAT Trial.  
 
Clinical outcomes and mortality measured using 
standard prospective methods and reported in the initial 
ISAT publication.  
 
18 year mortality for 1624 participants was measured in 
this study by accessing data from ONS.  Additional 
measures included functional status, assessed by 
questionnaire.   
Primary Outcome: 
All-cause mortality.  
 
Secondary 
Outcomes: 
Functional status, 
dependency. 
ONS requested to provide a copy of the death 
certificates to determine mortality status. 
Participant identifiers used or data extracted not 
detailed.  
 
 
Follow up for 99% of cohort at 10 years, 338 
patients (24%) died. Cost and resources required 
for access not reported.  
 
No explanation of the methods for data retrieval 
or review. 
 
No limitations relating to ONS data self-reported.  
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Perera et al: 2012 [128] 
 
Long-Term Mortality 
Data From the Balloon 
Pump–Assisted 
Coronary Intervention 
Study (BCIS-1) A 
Randomized, Controlled 
Trial of Elective Balloon 
Counter-pulsation 
During High-Risk 
Percutaneous Coronary 
Intervention (PCI) 
 
Parallel Group RCT 
301 patients with severe ventricular impairment and 
coronary artery disease were randomised to Intra-Aortic 
Balloon Pump (IABP) during PCI, or PCI alone.  
 
Clinical outcomes including death, acute myocardial 
infarction, cerebrovascular event, or urgent further 
revascularization at hospital discharge and 6 month 
mortality were measured using standard prospective 
methods.  
 
This follow up study assessed long term all-cause 
mortality (median duration 51 months) through 
accessing ONS/GRO data.    
Primary Outcome: 
All-cause mortality.  
ONS requested to provide mortality status, cause 
of death not requested. Participant identifiers 
used or data extracted not detailed. 
‘100% data capture' reported, but no 
explanation as to how patients who had not 
died, were confirmed to be alive. 
 
No explanation of the methods for data retrieval 
or review.  
 
No limitations relating to ONS data self-reported.  
Scholefield: 2012 [118] 
 
Nottingham trial of 
faecal occult blood 
(FOB) testing for 
colorectal cancer: a 20-
year follow-up 
 
Parallel Group RCT 
152 850 individuals by household were randomised to 
biennial FOB screening vs no intervention.  
 
Clinical outcomes including incidence of colorectal 
cancer, incidence and complications of interventions 
(colonoscopy) and mortality were measured using 
standard prospective methods. 
 
This follow up study assessed long term (median 19.5 
years) mortality through access to ONS data.  
Primary Outcomes: 
Mortality (all-cause, 
colorectal cancer 
related).   
ONS requested to provide a copy of the death 
certificates to determine mortality status. 
Participant identifiers used or data extracted not 
detailed. 
99% follow up based on ONS flagging. 875 (0.6%) 
participants could not be traced by ONS, 
suggests patients may have emigrated. Cost and 
resources required for access not reported.  
 
No explanation of the methods for data retrieval. 
 
Reported good agreement between 'verified' 
CRC deaths and 'certified' CRC deaths on the 
ONS data, assessed by comparison to case note 
review in the initial publication.  
Simmons: 2012 [129] 
 
Screening for type 2 
diabetes and 
population mortality 
over 10 years 
(ADDITION-Cambridge) 
 
Cluster RCT 
20 185 participants in 33 GP's were randomised, by GP 
to Type 2 Diabetes Mellitus (T2DM) screening followed 
by intensive treatment for people diagnosed with 
diabetes (n=15); screening plus routine care of diabetes 
according to national guidelines (n=13); and no-
screening control group (n=5).  
 
This study reports long term (median 9.6 years) mortality 
through access to ONS/GRO and Central Statistics Office 
of Ireland (CSOI) data.  
Primary Outcome: 
All-cause mortality.  
 
Secondary 
Outcomes: Death 
from cardiovascular 
disease, cancer, DM 
related death. 
‘GP medical records’ used to screen for patients 
at risk of T2DM. No further details provided on 
the method or primary care data source.  
 
Mortality data sought from ONS/GRO/CSOI. NHS 
Number provided to each source and copy of 
death certificate requested for review.  
 
ICD codes reviewed to classify cause of death.  
99% follow up based on ONS flagging by NHS 
Number. The effect of missing data was 
examined in the study and deemed not to affect 
the result, but the data regarding this was not 
shown. Resources required for access not 
reported.  
 
Reported 'high level of agreement for cause of 
death'. However, this refers to the inter-rater 
agreement of ICD code classification, rather than 
accuracy of ONS data.  
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NHA Digital and Office of National Statistics (ONS) 
Turner et al: 2014 [85] 
 
Design and preliminary 
recruitment results of 
the Cluster randomised 
triAl of PSA testing for 
Prostate cancer (CAP) 
 
Cluster RCT 
785 GP's randomised to prostate specific antigen (PSA) 
screening vs standard care.  
 
This study reports the design and recruitment results.  
 
Clinical details including diagnoses and cause of death 
will be obtained through access to HES / ONS data. 
Follow up at 10 years due 2017.  
Primary Outcome: 
10 year ‘definite’ or 
‘probable’ prostate 
cancer mortality.  
 
Secondary 
Outcomes: All-
cause mortality (10 
and 15 years), cost 
effectiveness.  
All participants prospectively flagged with NHS 
Digital/ONS.  
 
Clinical details will be reviewed in addition to 
death certificate data through access to 
HES/ONS.   
 
Non-identifiable ONS data was also used to 
determine death rates and inform the sample 
size calculation. 
All participants (intervention and control) were 
flagged with NHS Digital prospectively.  
 
Anticipated inaccuracies with coding / 
classification of cause of death will be addressed 
with committee review and consensus of the 
available documentation - it is not clear if this 
will involve comparison to clinical / source data. 
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Table A.2: Included Studies; Characteristics and Use of UK Primary Care Routinely Recorded Data in RCTs 
 Study Reference Trial Summary Outcome Measures Implementation of Routinely Collected Data Appraisal 
The Secure Anonymised Information Linkage Databank (SAIL) 
Brooks et al: 2009 [122] 
 
Use of a patient linked 
data warehouse to 
facilitate diabetes trial 
recruitment from 
primary care 
 
RCT Recruitment 
Feasibility Assessment 
SAIL Databank was used as the data source to 
perform a recruitment feasibility assessment for 
two fictitious RCTs. Both RCTs involved diabetes 
mellitus with pragmatic inclusion criteria such as 
diagnosis of diabetes, prescription of specified 
medicines, BMI and smoking status.  
 
Of 250,086 individuals in SAIL, 284 were identified 
for the first RCT and 711 for the second.  
N/A Patients whose details were anonymously 
recorded in SAIL Databank were searched using 
specific inclusion and exclusion criteria. The total 
numbers of eligible patients in the participating 
GP’s and their location by GP were then 
determined.   
SAIL represents a useful data source to 
prospectively perform a recruitment feasibility 
assessment for selected RCTS.  
 
Pragmatic RCTs with simple inclusion criteria are 
likely most appropriate for such a feasibility 
assessment.  
 
SAIL Databank cannot routinely re-identify 
patients and therefore the transition to GP 
recruitment when the RCT opens is limited.   
McGregor et al: 2010 
[62] 
 
The Health Informatics 
Trial Enhancement 
Project (HITE): Using 
routinely collected 
primary care data to 
identify potential 
participants for a 
depression trial 
 
RCT Recruitment 
Feasibility Assessment 
SAIL Databank was used as the data source to 
perform a recruitment feasibility assessment for an 
existing RCT assessing folate use in patients with 
depression. The existing inclusion/exclusion 
criteria were translated into READ codes and a 
database query was run using Structured Query 
Language (SQL) within SAIL for 5 GP's. The 
inclusion/exclusion criteria are pragmatic and 
include variable such as prescribed drugs, 
investigation results, previous diagnoses.  
 
867 potential participants were identified.  
N/A Patients whose details were anonymously 
recorded in SAIL Databank were searched using 
specific inclusion and exclusion criteria. The total 
numbers of eligible patients in the participating 
GP’s and their location by GP were then 
determined.   
SAIL represents a useful data source to 
prospectively perform a recruitment feasibility 
assessment for selected RCTS.  
 
Pragmatic RCTs with simple inclusion criteria are 
likely most appropriate for such a feasibility 
assessment.  
 
In this study the sensitivity/specificity (>96%) of 
the SQL query was determined by manual review 
of the electronic medical record. 
SAIL Databank cannot routinely re-identify 
patients and therefore the transition to GP 
recruitment when the RCT opens is limited.   
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The Clinical Practice Research Datalink (CPRD) 
Dregan et al: 2014 [123] 
 
Point-of-Care Cluster 
Randomized Trial in 
Stroke Secondary 
Prevention Using 
Electronic Health 
Records 
 
Cluster RCT 
106 participating GP's contributing data to CPRD 
were allocated to intervention or control study 
arms. The intervention was installation of IT 
decision support tools to improve adherence to 
secondary care stroke prevention measures during 
the patient consultation. Control was standard 
practice.  
 
RCT duration 12 months. Pragmatic clinical details 
including BP and blood tests were recorded 
through CPRD to measure the study outcomes.  
Primary Outcome: 
Systolic blood pressure 
(BP).  
 
Secondary Outcomes: 
Diastolic BP, total 
cholesterol, prescription 
of cardiovascular drugs.  
GP’s contributing data to CPRD were invited to 
participate. Practices in the intervention arm 
received IT software that flagged up during the 
consultation of a suitable patient. Patient 
consent was not required.   
 
Pragmatic, commonly recorded clinical 
parameters were selected as outcome measures 
and data was collected solely through CPRD.  
BP data was available for 90% and cholesterol 
data for 84%.  
 
Data for 12 month follow up were recorded at 15 
months, to account for the delay in CPRD data 
becoming available. Baseline data regarding the 
cause of stroke (ischaemic, haemorrhagic) was 
limited with 60% classed as ‘undefined’. 
Guilliford et al: 2014 
[124] 
 
Electronic Health 
Records for 
Intervention Research: 
A Cluster Randomized 
Trial to Reduce 
Antibiotic Prescribing in 
Primary Care (eCRT 
Study) 
 
Cluster RCT 
104 participating GP's contributing data to CPRD 
were allocated to intervention or control study 
arms. The intervention was installation of decision 
support tools to improve adherence to antibiotic 
prescribing guidelines during the patient 
consultation for respiratory tract infection (RTI).  
 
RCT duration 12 months. Pragmatic clinical details 
including prescription of antibiotics and record of 
respiratory diagnoses were recorded through 
CPRD to measure the study outcomes.  
Primary Outcome: 
Proportion of 
consultations for RTI with 
antibiotics prescribed.  
 
Secondary Outcomes: 
Proportion of antibiotics 
prescribed in other 
respiratory/ENT infective 
diagnoses. 
GP’s contributing data to CPRD were invited to 
participate. Practices in the intervention arm 
received IT software that flagged up during the 
consultation of a suitable patient. Patient 
consent was not required.   
 
Pragmatic, commonly recorded clinical 
parameters were selected as outcome measures 
and data was collected solely through CPRD. 
Reported feasibility in performing large scale 
public health RCTs in a routine primary care 
database.  
 
No mention of missing data – the proportion of 
inaccurate prescription records was not 
assessed.   
Horspool et al: 2013 
[125] 
 
Preventing and 
lessening exacerbations 
of asthma in school-age 
children associated 
with a new term 
(PLEASANT): study 
protocol for a cluster 
randomised control 
trial 
 
Cluster RCT Protocol 
Protocol for a cluster RCT involving 140 GP's 
contributing data to CPRD.  
 
GP’s will be recruited, half to usual care, half to the 
intervention - a letter informing parents of the 
importance of adherence to their child’s asthma 
treatment throughout the summer holidays.  
 
The pragmatic clinical outcomes of unscheduled 
medical contact, prescriptions and respiratory 
diagnoses will be recorded through CPRD to 
measure the study outcomes.  
Primary Outcome: 
Unscheduled medical 
contact in September.  
 
Secondary Outcomes: 
Unscheduled medical 
contacts at other time 
points associated with 
prescriptions, respiratory 
diagnoses. 
GP’s contributing data to CPRD will be invited to 
participate. Practices in the intervention arm will 
receive a standard letter to be sent to eligible 
patients. Patient consent will not be required.   
 
Pragmatic outcomes that should be reliably 
recorded have been selected and data will be 
collected solely through CPRD. Committee 
review of coded data is proposed.  
N/A 
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The Clinical Practice Research Datalink (CPRD) and ResearchOne 
Herrett et al: 2014 [92] 
 
Text messaging 
reminders for influenza 
vaccine in primary care: 
protocol for a cluster 
randomised controlled 
trial 
 
Cluster RCT Protocol 
Protocol for a cluster RCT involving GP's 
contributing data to CPRD or ResearchOne.  
 
GP's will be randomised to either standard care or 
text messaging campaign to increase uptake of the 
flu vaccine. Unknown planned duration / 
completion date.  
 
The pragmatic clinical outcome of flu vaccine 
administration will be recorded through CPRD and 
ResearchOne to measure the study outcome.  
Primary Outcome: Flu 
vaccine administration. 
GP’s contributing data to CPRD and ResearchOne 
will be invited to participate. Practices in the 
intervention arm will receive software to enable 
text messages to be sent to eligible patients. 
Patient consent will not be required.   
 
A pragmatic outcome that should be reliably 
recorded has been selected as the outcome 
measure and data will be collected solely 
through CPRD and ResearchOne.  
N/A 
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Table A.3: PRISMA Checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title Page 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
Introduction 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
Methods 
The review was not 
eligible for registration 
in the PROSPERO 
database. 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Methods 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Methods 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
Methods 
Appendix II 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Methods 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
Methods 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
Methods 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
Methods 
A narrative appraisal 
was performed. Formal 
assessment was 
performed where 
routinely recorded data 
was implemented in the 
study and there was 
potential for the 
introduction of bias.   
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
Methods 
 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
Methods 
A narrative appraisal 
has been performed. 
Formal assessment has 
not been performed in 
view of the objective of 
the review.  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
N/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
Results 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
Results 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Results 
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Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Results 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
N/a 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
N/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
Discussion 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
Discussion 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
To be included in journal 
submission. 
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Table A.4: Search Strategy: Medline (OVID) 
1 Administrative Data Research Network.tw. 
2 Clinical Practi$ Research Datalink.tw. 
3 ((Driv$ adj2 Vehicle Licen?ing Agency) or (Driv$ adj2 Vehicle Licen?ing Authority)).tw. 
4 (Department adj2 "Work and Pensions").tw. 
5 General Practi$ Extraction Service.tw. 
6 (General Practi$ Research Database or General Practi$ Registry Database).tw. 
7 Hospital Episode Statistics.tw. 
8 "Revenue and Customs".tw. 
9 "Health and Social Care Information Centre".tw. 
10 NorthWest eHealth.tw. 
11 Office for National Statistics.tw. 
12 Secure Anonymised Information Linkage Databank.tw. 
13 (NHS Wales Informatics Service or Patient Episode Database for Wales).tw. 
14 "The Health Improvement Network".tw. 
15 QResearch.tw. 
16 ResearchOne.tw. 
17 Information Services Division.tw. 
18 or/1-17 
19 (ADRN or CPRD or DVLA or DWP or GPES or GPRD or HES or HMRC or HSCIC or NWEH or ONS or SAIL or PEDW).tw. 
20 ("dose-width product" or Dose width product).tw. 
21 General Practice Education$ Supervis$.tw. 
22 
(Geriatric Psychiatry Research Division or Aspergillus or gastropharyngeal reflux disease$ or (gene$ and prion 
disease$)).tw. 
23 
(balanced starch$ or hydroxyethyl starch$ or hydroxyethylstarch$ or hydroxy ethyl starch$ or Hospital Eye Service$ or 
hip extensor stretch).tw. 
24 ("Add-ons" or Oral nutri$ supplement$ or Occipital nerve stimul$).tw. 
25 
(Sheffield Assessment for Letters or Sheffield Assessment Instrument for Letters or Stimulation Assistance through 
Iterative Learning).tw. 
26 or/20-25 
27 19 not 26 
28 
((routine or clinic$ or primary or general practic$ or general practis$ or general practitioner$ or GP?) and data and 
source?).ti. 
29 ((routine or clinic$ or primary or general practic$ or general practis$ or general practitioner$ or GP?) adj2 data).ab. 
30 data source?.ab. /freq=2 
31 29 and 30 
32 27 or 28 or 31 
33 exp Great Britain/ 
34 (national health service* or nhs*).ti,ab,in. 
35 
(english not ((published or publication* or translat* or written or language* or speak* or literature or citation*) adj5 
english)).ti,ab. 
36 
(gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or united kingdom* or (england* not "new 
england") or northern ireland* or northern irish* or scotland* or scottish* or ((wales or "south wales") not "new south 
wales") or welsh*).ti,ab,jw,in. 
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37 
(bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not alabama*) or bradford or "bradford's" or 
brighton or "brighton's" or bristol or "bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or (canterbury not zealand*) or 
("canterbury's" not zealand*) or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" 
or coventry or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or ("durham's" not (carolina* or nc)) 
or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not nebraska*) or ("lincoln's" not nebraska*) 
or (liverpool not (new south wales* or nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* 
or ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or "manchester's" or (newcastle 
not (new south wales* or nsw)) or ("newcastle's" not (new south wales* or nsw)) or norwich or "norwich's" or 
nottingham or "nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or 
"plymouth's" or portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" 
or salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or stoke or 
"stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells or westminster or 
"westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or boston* or harvard*)) or (york not 
("new york*" or ny or ontario* or ont or toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))).ti,ab,in. 
38 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st davids or 
swansea or "swansea's").ti,ab,in. 
39 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or "glasgow's" or 
inverness or (perth not australia*) or ("perth's" not australia*) or stirling or "stirling's").ti,ab,in. 
40 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or derry or 
"derry's" or newry or "newry's").ti,ab,in. 
41 or/33-40 
42 
(exp africa/ or exp americas/ or exp antarctic regions/ or exp arctic regions/ or exp asia/ or exp australia/ or exp 
oceania/) not (exp great britain/ or europe/) 
43 41 not 42 
44 32 and 43 
45 18 or 44 
46 randomized controlled trial.pt. 
47 controlled clinical trial.pt.  
48 randomized.ab. 
49 placebo.ab. 
50 clinical trials as topic.sh. 
51 randomly.ab. 
52 trial.ti. 
53 Or/46-52 
54 exp animals/ not humans.sh. 
55 53 not 54 
56 45 and 55 
57 remove duplicates from 56 
i. 33-43 NICE UK Search Filter 
ii. 46-55 Cochrane RCT Highly Sensitive Search Strategy 
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Chapter Three: Systematic Review Search Strategies, PRISMA 
Checklist and Further Results 
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Table B.1: Included Studies: Agreement between Routinely Recorded Clinical Data and Data Collected through Standard Prospective Methods 
Study Reference Study Summary Data Sources Assessment of Agreement Appraisal 
Barry et al: 2013 [65] 
 
Are Routinely Collected 
NHS Administrative 
Records Suitable for 
Endpoint Identification 
in Clinical Trials? 
Evidence from the West 
of Scotland Coronary 
Prevention Study 
 
RCT 
6595 patients recruited into a 
RCT were randomised to 
pravastatin or placebo. 
Cardiovascular clinical 
outcomes and mortality were 
measured using standard RCT 
follow up.  
 
Participants were linked by the 
Information Services Division of 
the NHS National Services 
Scotland and RCT outcomes 
were identified from mortality 
and secondary care medical 
records and compared. 
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
Scottish Morbidity Record 
Secondary care medical records 
The primary outcomes were broadly comparable. 
Cardiovascular (CV) death or myocardial infarction 
(MI) in the placebo compared to pravastatin group 
was 212 vs 147 (P<0.001, RR 32 (16,45)) in the RCT 
dataset and 195 vs 121 (P<0.001, RR 39 (24,51)) in 
the routine dataset.  
 
241 deaths in the RCT dataset were matched with 
240 in the routine dataset.  
 
217/268 (81%) of the first events recorded in the RCT 
matched first recorded routine events. 217/230 
(94.3%) of the first recorded routine events matched 
first recorded RCT events.  
 
Agreement was reduced for events following the first 
recorded event and secondary outcomes, such as the 
diagnosis of stroke 44/61 (72.1%).  
There is no statistical assessment of 
agreement between patient 
completed questionnaires and 
routinely recorded data despite the 
data being comparable. 
 
There is good agreement between 
mortality and the primary outcome of 
major cardiovascular events.  
Britton et al: 2012 [178] 
 
Validating self-reported 
strokes in a longitudinal 
UK cohort study 
(Whitehall II): 
Extracting information 
from hospital medical 
records versus the 
Hospital Episode 
Statistics database 
 
Cohort Study 
10,308 patients recruited into 
the Whitehall cohort study 
completed self-report health 
questionnaires. Between 2002-
2009 self-reported episodes of 
stroke were identified.  
 
Episodes of stroke were 
identified from the Hospital 
Episode Statistics Inpatient 
Dataset (HES IP), primary and 
secondary care medical records 
and compared to patient 
reported events.   
Standard Prospective:  
Patient completed 
questionnaire 
- Interval not reported 
 
Routinely Recorded: 
Hospital Episode Statistics 
Inpatient Dataset (HES IP) 
Primary and secondary care 
medical records 
106 episodes of stroke were self-reported.  
 
8 (7.5%) self-reported strokes were recorded as ‘false 
positives’ where primary or secondary care medical 
records provided evidence the event was not a 
stroke. 4 self-reported strokes had no evidence in 
routinely recorded data.  
 
66 (62.3%) of self-reported strokes were validated in 
HES data. 16 (15.1%) were validated by hospital 
records alone and were not recorded in HES. 11 
(10.4%) were recorded in HES alone. 12 (11.3%) were 
validated by GP only. 
 
47 episodes of stroke were recorded in HES but not 
self-reported.  
There is no statistical assessment of 
agreement between patient 
completed questionnaires and 
routinely recorded data despite the 
data being comparable. 
 
There are discrepancies between self-
reported episodes of stroke and those 
routinely recorded. However, 
discrepancies are minimised if multiple 
sources of routinely recorded data are 
accessed, although this approach has 
resource limitations.  
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Bryant et al: 2015 [149] 
 
Agreement between 
routine and research 
measurement of infant 
height and weight 
 
Cohort Study 
A subgroup of patients 
recruited into the Born in 
Bradford cohort study had 
infant height and weight 
recorded in the study at 6, 12, 
18, 24 and 36 months.  
 
Height and weight, 
respectively, was measured 
routinely in the Personal Child 
Health Record at 6 months 
(n=158 and 560), 12 months 
(n=101 and 166) and 24 months 
(n=307 and 434). 
Measurements at 18 and 36 
months were excluded due to 
small sample size. Agreement 
was determined using mean 
differences and Bland Altman 
Plots.  
Standard Prospective:  
Cohort study follow up 
 
Routinely Recorded:  
Personal Child Health Record  
The mean difference in age was <1 month for all 
assessments.  
 
There was agreement, greater for weight than 
height:  
 
Routinely recorded height was underestimated at 6 
months (0.46 (−3.99 to 4.91)) and overestimated at 
12 (−0.25 (−4.50 to 4.00)) and 24 (−0.32 (−4.00 to 
3.36)) months. 
 
Routinely recorded weight was overestimated at 6 
(−0.04 (−0.67 to 0.59)), 12 (−0.06 (−1.10 to 0.98)) and 
24 (−0.14 (−1.19 to 0.91)) months.   
There is acceptable agreement 
between research and routinely 
recorded height and weight 
measurements although wide limits of 
agreement are noted.  
 
For limited numbers of individuals 
there were marked discrepancies. For 
height, the differences ranged from 
−0.4–4.91 cm and for weight −1.19–
0.98 kg. 
 
 
Cleland et al: 2007 
[150] 
 
An exploratory, 
pragmatic, cluster 
randomised trial of 
practice nurse training 
in the use of asthma 
action plans 
 
Cluster RCT 
629 patients with asthma were 
randomised to receive standard 
care or enhanced care from a 
practice nurse who had 
received advanced asthma 
training.  
 
Prescriptions of relevant 
medications were obtained 
from primary care medical 
records for all (629) patients to 
measure asthma control. 
Additionally, the Asthma 
Control Questionnaire was 
completed by 236 patients to 
provide an indirect measure of 
asthma control.   
Standard Prospective:  
Asthma Control Questionnaire 
(ACQ) 
- Baseline, 6 months 
 
Routinely Recorded: 
Primary care medical records 
The ACQ provides a summary statistic of asthma 
control and is therefore not directly comparable to 
the prescription of medications.  
 
Between intervention and control groups there was 
no difference between ACQ results (Intervention: 
2.66 (1.92-3.67), Control: 2.50 (1.67-3.67), P = 0.27).  
There was similarly no difference between 
prescription rates obtained from medical records 
(Intervention: 19 (12-32), Control: 18 (13-30), P = 
0.51).  
There is no statistical assessment of 
agreement between ACQ and primary 
care medical records and the 
measures are not directly comparable. 
However, broadly the results were 
similar and both identified no 
significant difference between 
intervention and control groups.  
 
The study also reports issues with 
missing routinely recorded data, 
despite the existence of relevant 
clinical codes.   
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Doshi et al: 2008 [152] 
 
Post-tonsillectomy 
morbidity statistics: are 
they 
underestimated? 
 
Cohort Study 
92 consecutive patients 
undergoing tonsillectomies in a 
single centre were invited to 
complete a questionnaire.  
 
Post-operative complication 
rates over a 30 day period were 
retrieved from secondary care 
medical records and compared 
to patient reported 
complication rates assessed 
through questionnaire 
completion. 
Standard Prospective:  
Patient completed 
questionnaire 
- 1 month 
 
Routinely Recorded: 
Secondary care medical records 
70 of 92 patients returned the questionnaire. 11/70 
patients reported post-operative bleeding, just 4 
patients were identified in secondary care medical 
records (Rate 15.7% versus 5.7%). The remaining 7 
patients contacted their GP and an additional 15 
contacted their GP for pain control.  
There is no statistical assessment of 
agreement between patient 
completed questionnaires and 
routinely recorded data despite the 
data being comparable. 
 
There is marked discrepancy between 
patient reported and secondary care 
routinely recorded data. However, all 
patients not contacting hospital had 
contacted their GP and therefore 
would likely be identified if primary in 
addition to secondary care medical 
records were accessed.   
Hutchings et al: 2005 
[154] 
 
Can electronic routine 
data act as a surrogate 
for patient-assessed 
outcome measures? 
 
RCT 
93 patients diagnosed with 
inflammatory bowel disease 
recruited into a RCT completed 
the UK Inflammatory Bowel 
Disease Questionnaire and 
Short Form 36.  
 
Data retrieved from primary 
and secondary care electronic 
medical records were used to 
complete the questionnaires 
and results were compared to 
the patient-reported 
responses.  
Standard Prospective:  
Patient completed UK 
Inflammatory Bowel Disease 
Questionnaire (UKIBD) and 
Short Form 36 (SF36) 
- Interval not reported 
 
Routinely Recorded: 
Primary and secondary care 
medical records 
UKIBD: 29/30 questions had a comparable READ 
(CTV3) code and 20/30 an ICD 10 code. Symptoms 
were only recorded for 10 questions. Routinely 
recorded data resulted in higher UKIBDQ subscales 
and total scores. Intraclass correlation coefficients 
were poor (0.04-0.22).  
 
SF36: 34/36 questions had a comparable READ 
(CTV3) code and 30/36 an ICD10 code. Symptoms 
were only recorded for 10 questions. Routinely 
recorded data resulted in higher SF36 subscales. 
Intraclass correlation coefficients were poor (0.00 to 
0.27).   
The ICD10 codes, more commonly 
used in secondary care, do not 
translate as well as READ (CTV3) codes 
to commonly used existing patient-
reported outcomes measures. 
 
Broadly, the patient-reported 
questions can in theory be identified 
by existing coding systems, but just 
10/30 UKIBD and 10/36 SF36 codes 
were ever used in the medical records.  
 
In this study, the under-utilisation of 
codes, rather than the lack of available 
codes resulted in the poor correlation.  
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Iyer et al: 2013 [155] 
 
Patient-reporting 
improves estimates of 
postoperative 
complication rates: a 
prospective cohort 
study in gynaecological 
oncology 
 
Cohort Study 
2152 patients undergoing 
gynaecological surgery were 
invited to complete an annual 
follow up questionnaire to 
ascertain post-operative 
complications.  
 
1462 patient completed 
questionnaire responses were 
compared to routinely 
recorded data retrieved from 
secondary care medical 
records.   
 
 
Standard Prospective: 
Patient completed 
questionnaire 
- 1 year 
 
Routinely Recorded:  
Secondary care medical records 
In total, 452 surgical Grade II-V complications were 
reported. 
 
Grade II: 158/280 (56.4%) patient reported 
complications were recorded in medical records.  
 
Grade III-V: 36/36 (100%) patient reported 
complications were recorded in medical records.  
 
The post-operative complication rate using data 
retrieved form medical records is 11.8% (172/1462; 
95% CI 11–14) and using patient completed 
questionnaires 15.8% (231/1462; 95% CI 14–17.8).  
There is a descriptive assessment of 
agreement between patient 
completed questionnaire and medical 
records.  
 
For more serious complications, 
frequently requiring hospital 
treatment such as further surgery, 
there was 100% concordance. For 
Grade II (mild) complications, the 
concordance rate was only 56.4%. This 
may be explained by the mild nature 
of symptoms and the authors suggest 
relevant details may be recorded in 
the routinely recorded primary care 
medical records.   
Kingston et al: 2010 
[153] 
 
Assessing the Amount 
of Unscheduled 
Screening 
(“Contamination”) in 
the Control Arm of the 
UK “Age” Trial 
 
RCT 
3706 patients enrolled in the 
control arm (‘standard care’) of 
a RCT assessing annual 
mammographic screening were 
sent questionnaires to assess 
the occurrence of unrecorded 
mammography.  
 
2115 patients returned 
completed questionnaires and 
data were compared to 946 
responses to the routinely 
recorded ONS Omnibus 
Surveys.  
Standard Prospective:  
Patient completed 
questionnaire 
- 1 year 
 
Routinely Recorded:  
ONS Omnibus Surveys 
2115 patients enrolled in the control arm of the RCT 
returned questionnaires. A total of 24.9% (95% 
confidence interval, 23.0-26.8) reported having a 
mammogram. A different cohort of 223 patients 
(23.6%) of similar age reported having a 
mammogram over the same time period in the ONS 
Omnibus Surveys.  
There is no statistical assessment of 
agreement between patient 
completed questionnaires and the 
routinely recorded ONS Omnibus 
Surveys despite the data being 
comparable. 
 
The methodology involves patient 
completed questionnaires either 
during a RCT or as part of a routine 
population survey. The results are 
expectedly comparable although the 
ONS Omnibus Surveys would not be a 
‘typical’ source of routinely recorded 
data.    
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Lewsey et al: 2000 [46] 
 
Using routine data to 
complement 
and enhance the results 
of randomised 
controlled trials 
 
Cohort Study 
 
Report involving a meta-
analysis of 8 RCT’s examining 
coronary artery bypass graft 
(CABG) vs percutaneous 
transluminal coronary 
angioplasty (PTCA). Data were 
compared to routinely 
recorded data retrieved from 
Scottish Morbidity Records and 
secondary care medical 
records.   
 
3371 patients enrolled in RCTs 
were compared with routinely 
recorded data regarding 12,238 
patients.  
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
Scottish Morbidity Record 
Secondary care medical records 
Baseline characteristics are broadly comparable 
between RCT and routinely recorded data.  
 
The primary outcome of the meta-analysis was 
myocardial infarction or cardiac death. The RR of 
PTCA compared to CABG was 1.03 (95% CI 0.84 to 
1.27). The RR estimated from routinely recorded data 
was 1.15 (95% CI 0.90 to 1.48).  
There is no statistical assessment of 
agreement between RCT data and 
routinely recorded data despite data 
being comparable. 
 
Acknowledging the prospective access 
to medical records during the RCT, the 
primary outcome is comparable to 
that calculated from routinely 
recorded data.     
Mitchell et al: 2016 
[166] 
 
Is there a difference 
between hospital 
verified and self-
reported self-harm? 
Implications for 
repetition 
 
Cohort Study 
774 patients presenting to a 
single emergency department 
with self harm were enrolled in 
a cohort study. Previous 
episodes of self harm were 
recorded based on patient self-
report.  
 
Self-reported self-harm was 
compared with self harm 
episodes verified in secondary 
care medical records.  
Standard Prospective: 
Patient completed 
questionnaire 
 
Routinely Recorded:  
Secondary care medical records 
774 patients were enrolled in the study.  
 
432 patients had no previous self-harm evident on 
medical records, but only 134 (31%) had no previous 
episodes on self-report.  
 
340 patients had previous self-harm evident on 
medical records but only 113 (33.2%) had previous 
self-harm on self-report.  
 
Cohen's Kappa agreement was low (Kappa=0.353, CI 
0.287–0.419, S.E. of kappa=0.034 P=not significant).  
There is a descriptive and statistical 
assessment of agreement. 
 
There is poor agreement with patients 
underreporting both the occurrence 
and absence of previous episodes of 
self harm.  
Pastorino et al: 2015 
[180] 
 
Validation of self-
reported diagnosis of 
diabetes in the 1946 
British birth cohort 
 
Cohort Study 
230 patients recruited into the 
Medical Research Council 
National Survey of Health and 
Development Study self-
reported a diagnosis of 
diabetes on questionnaire.  
 
Self-reported information 
regarding diagnosis and 
treatment of diabetes was 
compared with primary care 
medical records.  
Standard Prospective: 
Patient completed 
questionnaire 
 
Routinely Recorded:  
Primary care medical records 
230 patients reported a diagnosis of diabetes, 184 
were reviewed at the most recent study follow up 
and 172 provided consent to request primary care 
medical records.  
 
Primary care medical records were available for 157 
patients. 149 self-reported diagnoses were confirmed 
(PPV: 94.9%). Of the 8 non-confirmed, 2 patients had 
‘pre-diabetes’ (impaired fasting glucose).  
 
The mean difference in age at diagnosis is 0.6 years 
(95% CI: 0.2-1.1), with patients self-reporting earlier.    
There is a descriptive and statistical 
assessment of agreement. 
 
There is good agreement between self-
reported and recorded diagnosis of 
diabetes. However, patients 
significantly over estimated the 
duration of their disease.  
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Steward et al: 1993 
[156] 
 
Chemotherapy 
Administration and 
Data Collection in an 
EORTC Collaborative 
Group Can we Trust the 
Results? 
 
RCT 
78 (of a total 111) patients 
from 14 centres were enrolled 
in a RCT assessing 
chemotherapy for sarcoma.  
 
Information recorded 
prospectively in Case Report 
Forms was compared to local 
secondary care medical 
records.   
Standard Prospective: 
RCT clinical follow up  
 
Routinely Recorded:  
Secondary care medical records 
8776 data items entered on CRFs were compared to 
local secondary care medical records.  
 
<1% of data on CRFs was missing. Agreement, 
determined by the percentage of data items entered 
‘incorrectly’ on the CRF was <3% in 9 centres and 
between 4-7.5% in the remaining 6 centres. Drug 
dosages and patient performance status were the 
commonly incorrectly entered data items. However, 
in 7/14 centres <80% of data recorded on the CRF 
could be verified in medical records.   
There is no statistical assessment of 
agreement between RCT data and 
routinely recorded data despite data 
being comparable. 
 
The percentage of data transcribed 
‘incorrectly’ was relatively modest. 
 
However, a greater percentage of data 
recorded in the CRF could not be 
verified in the medical records. This 
may be explained as certain data items 
may not normally be routinely 
recorded in the medical records, 
although this is not discussed.  
Tannen et al: 2006 
[144] 
 
Simulation of the Syst-
Eur randomized control 
trial using a primary 
care electronic medical 
record was feasible 
 
Simulated RCT 
4695 patients were enrolled in 
a RCT assessing anti-
hypertensives vs placebo in 
patients with systolic 
hypertension.  
 
16,771 patients identified from 
the General Practice Research 
Database were identified that 
met the RCT inclusion criteria 
and were included in a 
simulated RCT, replicating all 
stages of the original RCT with 
the exception of 
randomisation.   
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
General Practice Research 
Database (GPRD) 
2815 ‘exposed’ and 13,956 ‘unexposed’ patients 
were identified in GPRD (compared to 2398 and 2297 
in the RCT). Baseline characteristics were 
comparable. The average baseline BP readings were 
similar, however, the baseline BP in the ‘exposed’ 
GPRD cohort was raised (Exposed: 176.2, Unexposed: 
171.9) compared to the RCT (173.8, 173.9). The 
difference was significant (P<0.001).   
 
The incidence rates for clinical measures were 
comparable between RCT and GPRD, except for 
incidence of heart failure and transient ischemic 
attack, that were higher (P<0.001) and cardiovascular 
death that was lower (P<0.001) in the ‘unexposed’ 
GPRD than in the RCT placebo.  
 
For clinical outcomes statistically significant 
differences between GPRD and RCT data were 
observed for 2 of the total 12 outcomes including 
death (GPRD IRR:  1.23, 95% CI: 1.00–1.50, RCT IRR: 
0.86, 95% CI: 0.67–1.09, P=0.03) and peripheral 
vascular disease (GPRD IRR: 1.13, 95% CI: 0.85–1.51, 
RCT IRR: 0.68, 95% CI: 0.46–1.02, P=0.04).  
Baseline characteristics were 
comparable with the exception of 
baseline BP – likely explained by the 
greater probability of patients with 
higher BP readings being commenced 
on treatment.  
 
There were some statistically 
significant differences in the incidence 
rates of clinical measures and 2 of 12 
clinical outcomes. However, broadly 
the results of the GPRD study and RCT 
were comparable.  
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Tannen et al: 2007 
[147] 
 
A simulation using data 
from a primary care 
practice database 
closely replicated the 
women’s health 
initiative trial 
 
Simulated RCT 
17,407 patients were enrolled 
in a RCT assessing the risks and 
benefits of oestrogen plus 
progestin hormone 
replacement therapy vs 
placebo in postmenopausal 
women.  
 
51,388 patients identified from 
the General Practice Research 
Database were identified that 
met the RCT inclusion criteria 
and were included in a 
simulated RCT, replicating all 
stages of the original RCT with 
the exception of 
randomisation.   
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
General Practice Research 
Database (GPRD) 
13,658 ‘exposed’ and 37,730 ‘unexposed’ patients 
were identified in GPRD (compared to 8506 and 8902 
in the RCT). Baseline characteristics were broadly 
comparable. However, patients in the GPRD study 
were younger, less obese, more were current 
smokers and had a lower incidence of diabetes, 
hypercholesterolemia and hypertension. Prior use of 
HRT was greater in the GPRD exposed group than the 
RCT treated group, lower in the GPRD Unexposed 
than RCT placebo. In the RCT baseline characteristics 
between treated and placebo groups were identical. 
Between exposed and unexposed groups in GPRD, 
significant differences were observed in BMI, 
diabetes, hypertension, smoking status, prior 
cardiovascular disease and prior HRT use (P<0.01). 
 
The incidence rates for clinical measures were 
broadly comparable with the exception of GPRD 
adjusted hazard ratios for cancer (increased) and 
death (decreased) which were not significant in the 
RCT. In addition, myocardial infarction was 
significantly increased in the RCT and unchanged in 
GPRD.  
 
For clinical outcomes statistically significant 
differences between GPRD and RCT data were 
observed in the ITT HR’s (95% CI) for 4 of the total 10 
outcomes including myocardial infarction (RCT: 1.32 
1.02-1.72, GPRD: 0.79 0.65-0.95, P=0.05), pulmonary 
embolus (RCT: 2.13 1.39-3.25, GPRD: 1.26 0.90-1.76, 
P=0.04), breast cancer (RCT: 1.26 1.00-1.59, GPRD: 
1.67 1.45-1.93, P=0.05) and death (RCT: 0.98 0.82-
1.18, GPRD: 0.64 0.57-0.73, P=0.02).  
Baseline characteristics differ in some 
variables and are potentially important 
to the agreement between study 
results. For example the RCT inclusion 
criteria could not be rigidly applied 
with regards to prior HRT use, 
medication and HRT doses were 
different and the GPRD study included 
a significantly younger population.  
 
Resultantly, statistically significant 
differences were observed for clinical 
outcomes including myocardial 
infarction, cancer and death. An 
‘adjusted’ analysis, using multiple 
imputation or propensity scores to 
account for missing data, mediated 
some of these differences.    
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Tannen et al: 2007 
[148] 
 
Estrogen affects post-
menopausal women 
differently than 
estrogen plus progestin 
replacement therapy 
 
Simulated RCT 
10,739 patients were enrolled 
in a RCT assessing the risks and 
benefits of oestrogen 
monotherapy hormone 
replacement therapy vs 
placebo in postmenopausal 
women.  
 
18,462 patients from the 
General Practice Research 
Database were identified that 
met the RCT inclusion criteria 
and were included in a 
simulated RCT, replicating all 
stages of the original RCT with 
the exception of 
randomisation.   
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
General Practice Research 
Database (GPRD) 
6890 ‘exposed’ and 11,572 ‘unexposed’ patients 
were identified in GPRD (compared to 5310 and 5429 
in the RCT). Baseline characteristics were broadly 
comparable. However, patients in the GPRD study 
were younger, weighed less and had fewer 
cardiovascular risk factors. Current oestrogen use 
was higher in the exposed and lower in the 
unexposed GPRD groups compared to the RCT and 
women in the RCT had earlier hysterectomy. 
 
In the RCT baseline characteristics between treated 
and placebo groups were identical. Between exposed 
and unexposed groups in GPRD, significant 
differences were observed in cardiovascular risk 
factors (reduced in exposed) and prior use of HRT 
(increased in exposed) (P<0.001).  
 
For clinical outcomes statistically significant 
differences between GPRD and RCT data were 
observed in the ITT HR’s (95% CI) for 5 of the 10 total 
outcomes including myocardial infarction (RCT: 0.89 
(0.7–1.12) , GPRD: 0.42 (0.31–0.55), P=0.002), stroke 
(RCT: 1.39 (1.1–1.77), GPRD: 0.82 (0.64–1.05), 
P=0.032), DVT (RCT: 1.47 (1.04–2.08), GPRD: 0.84 
(0.71–1.00), P=0.008), breast cancer (RCT: 0.77 
(0.59–1.01), GPRD: 1.15 (0.92–1.42), P=0.031) and 
death (RCT: 1.04 (0.88–1.22), GPRD: 0.62 (0.52–0.74), 
P<0.001).  
Baseline characteristics differ between 
RCT and GPRD cohorts and GPRD 
exposed and unexposed cohorts. 
These differences are likely important 
to the disagreements between 
selected study outcomes.  
 
For selected clinical outcomes there 
are statistically significant and clinically 
important differences between RCT 
and GPRD studies, for example death 
is significantly reduced in the GPRD 
study.  
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Tannen et al: 2008 
[145] 
 
Replicated studies of 
two randomized trials 
of angiotensin 
converting enzyme 
inhibitors: further 
empiric validation of 
the ‘prior event rate 
ratio’ to adjust for 
unmeasured 
confounding by 
indication 
 
Simulated RCT 
RCT1: 
9297 patients were enrolled in 
a RCT assessing Ramipril vs 
placebo in preventing 
cardiovascular outcomes 
including heart failure in 
patients with stable 
cardiovascular disease.  
 
35,521 patients identified from 
the General Practice Research 
Database were included in a 
simulated RCT, replicating all 
stages of the original RCT with 
the exception of 
randomisation.  
 
RCT2: 
9297 patients were enrolled in 
a RCT assessing Perindopril vs 
placebo in preventing 
cardiovascular outcomes 
including heart failure in 
patients with stable 
cardiovascular disease.  
 
19,958 patients identified from 
the General Practice Research 
Database were included in a 
simulated RCT, replicating all 
stages of the original RCT with 
the exception of 
randomisation. 
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded:  
General Practice Research 
Database (GPRD) 
Baseline Characteristics:  
Both the intervention and placebo groups of the RCTs 
were comparable. In both GPRD studies, there were 
statistically significant differences in the majority of 
variables including cardiovascular risk factors and 
prior medication use both between the RCT groups 
and between GPRD exposed and unexposed groups.   
 
RCT1:  
For clinical outcomes statistically significant 
differences between GPRD and RCT data were 
observed in the ITT RR’s (HR’s for GPRD  data) (95% 
CI) for all 5 outcomes including myocardial infarction 
(RCT: 0.79 (0.70–0.89), GPRD: 1.61 (1.47–1.76), 
P<0.001), stroke (RCT: 0.68 (0.56–0.84), GPRD 1.30 
(1.18–1.43), P<0.001), death (RCT: 0.84 (0.75–0.95), 
GPRD: 1.23 (1.17–1.30), P<0.001), congestive heart 
failure (RCT: 0.77 (0.67–0.87), GPRD: 4.26 (3.98–
4.56), P<0.001) and coronary revascularisation (RCT: 
0.82 0.74–0.92 GPRD: 1.90 (1.66–2.68), P<0.001).  
 
RCT 2:  
For clinical outcomes statistically significant 
differences between GPRD and RCT data were 
observed in the ITT RR’s (HR’s for GPRD  data) (95% 
CI) for 4 of the total 5 outcomes including myocardial 
infarction (RCT: 0.76 (0.66–0.89), GPRD: 1.55 (1.39–
1.73), P<0.001), death (RCT: 0.89 (0.77–1.02), GPRD: 
1.34 (1.25–1.45), P<0.001), congestive heart failure 
(RCT: 0.61 (0.44–0.84), GPRD: 3.92 (3.60–4.26), 
P<0.001) and coronary revascularisation (RCT: 0.96 
(0.85–1.08), GPRD: 1.93 (1.69–2.20), P<0.001). 
Baseline characteristics differ between 
RCT and GPRD cohorts and GPRD 
exposed and unexposed cohorts. 
These differences are likely important 
to the statistically significant 
differences between RCT and GPRD 
study outcomes. 
 
Further analysis used the Prior Event 
Rate Ratio (PERR) technique which 
assumes that the ratio of an 
outcome event rate in the exposed to 
unexposed cohorts preceding the 
study reflects the composite effect of 
all ‘unmeasured’ confounders on that 
specific outcome so long as neither the 
exposed or unexposed groups received 
the intervention prior to the 
commencement of the study. 
Repeating the analysis using only the 
‘no prior intervention’ patients, 
produced results more comparable to 
the RCT.  
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Tudur-Smith et al: 2012 
[141]  
 
The Value of Source 
Data Verification in a 
Cancer Clinical 
Trial 
 
RCT 
533 patients were enrolled in a 
RCT to assess control and 
experimental treatments for 
advanced cancer.  
 
Information recorded 
prospectively in Case Report 
Forms was compared to local 
secondary care medical records 
and data retrieved from the 
Office for National Statistics. 
Standard Prospective: 
RCT clinical follow up  
 
Routinely Recorded:  
Secondary care medical records 
and Office for National 
Statistics (ONS) data 
Results for the primary outcome (overall survival) are 
comparable between RCT data (HR: 1.18 (95% CI: 
0.99 to 1.42), secondary care medical records (1.18 
(0.99 to 1.41) and ONS data (1.18 (0.99 to 1.40). 
There were discrepancies for 13 patients with date of 
death ranging 1-366 days.  
 
When assessing response rates there was some 
discrepancy between RCT and routine data, with 
routine data likely picking up additional investigation 
results. For overall response, the OR (95% CI) in the 
RCT was 2.45 (1.49 to 4.04) versus 1.67 (1.04 to 2.68) 
in the routine data. Both were significant (P=0.003 vs 
P=0.03).  
 
There were discrepancies between reported Serious 
Adverse Events (SAE’s). 20 patients reported 
additional SAE’s in the RCT data and 33 in the 
secondary care medical records.  
Data regarding the primary outcome 
of mortality are comparable.  
 
However, data for other clinical 
outcomes including ‘overall response’ 
and SAE’s demonstrated some 
discrepancy. However, the overall 
results and significance of the RCT 
outcomes are consistent whether 
using RCT or routinely recorded data.   
Weiner et al: 2008 
[157] 
 
Replication of the 
Scandinavian 
Simvastatin Survival 
Study using a primary 
care medical record 
database prompted 
exploration of a new 
method to address 
unmeasured 
confounding 
 
Cohort Study 
A RCT recruited 4444 patients 
and involved the prescription of 
simvastatin, assessing cardiac 
outcomes and mortality. The 
study was replicated in all 
aspects except randomisation 
in 4151 similar patients present 
in the GPRD.   
 
Patient characteristics and 
study outcomes were 
compared between RCT and 
GPRD studies.  
Standard Prospective: 
RCT clinical follow up  
 
Routinely Recorded:  
General Practice Research 
Database (GPRD) 
There were significant baseline differences between 
the 4151 GRPD patients and the 4444 RCT patients, 
including a higher rate of prior coronary 
revascularisation, BMI, diabetes mellitus and lower 
rate of aspirin therapy.  
 
Outcomes were similar for mortality (RR 0.70 95% CI: 
58-0.85 vs HR 0.66 95% CI: 0.49-0.89 P = 0.94) and 
myocardial infarction (RR 0.67 95% CI: 0.58-0.77 vs 
HR 0.78 95% CI: 0.61-1.01 P = 0.28) between RCT and 
GRPD respectively. However, coronary 
revascularisation increased in the GPRD cohort (HR 
2.17 95% CI: 1.76-2.68) and decreased in the RCT (RR 
0.63 95% CI: 0.54-0.74), differing significantly (P < 
0.001).  
There were significant baseline 
differences between the RCT and 
GPRD cohorts.  
 
Outcomes calculated using the GPRD 
cohort are not significantly different to 
those calculated in the RCT, with the 
exception of coronary 
revascularisation, which was 
aberrantly higher in the statin treated 
group in the GRPD cohort. However 
following further analyses, involving 
only a subgroup of GPRD patients that 
had not taken cholesterol lowering 
medications prior to the pre-study 
period and using Prior Event Rate Ratio 
analysis to address unmeasured 
confounding and described in the 
summary of Tannen et al 2008 , the 
outcomes were similar to the RCT.     
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Williams et al: 2003 
[64] 
 
Can randomised trials 
rely on existing 
electronic data? A 
feasibility study to 
explore the value of 
routine data in health 
technology assessment 
 
Simulated RCTs 
RCT1:  
Open access vs routine follow 
up for inflammatory bowel 
disease 
 
 
 
 
 
 
 
 
RCT 2: 
Community vs inpatient 
diagnosis of obstructive sleep 
apnoea 
 
 
 
 
 
 
 
 
RCT 3: 
Comparison of two surgical 
techniques for the treatment of 
urinary stress incontinence 
 
 
 
 
 
 
 
 
 
 
 
 
RCT1: 
Standard Prospective: 
Patient completed 
questionnaire: 
- 0,6,12,18,24 months 
RCT clinical follow up 
 
Routinely Recorded:  
Primary and secondary care 
medical records 
 
 
RCT 2: 
Standard Prospective: 
Patient completed 
questionnaire 
RCT clinical follow up 
 
Routinely Recorded:  
Primary and secondary care 
medical records 
 
 
 
RCT 3: 
Standard Prospective: 
Patient completed 
questionnaire: 
- 0,3,6,12 months 
RCT clinical follow up 
 
Routinely Recorded:  
Secondary care medical records 
 
 
 
 
 
 
 
RCT1: 
Surrogate coded terms in routine data were 
identified to substitute data collected during the RCT. 
This was available for 9/13 outcomes. There is 
similarity in calculated outcomes and no significant 
differences were identified between groups using 
either dataset. The biggest mean difference between 
groups was for SF-36 ‘Vitality’ (RCT data –3.72 (–
10.72 to 3.27) ‘Tired all the time’ –0.01 (–0.17 to 
0.14). Similarly the outcomes regarding healthcare 
resource use were comparable.  
 
RCT 2:  
Data was available for only 90/102 patients from the 
individual hospital’s medical records. Primary care 
data was available for only 34/102 due to refusal of 
consent. Only 19/102 patients had 2 episodes of care 
routinely recorded and therefore met the RCT 
inclusion criteria. Only 1/5 outcomes could be 
calculated – positive diagnosis and results were 
comparable to RCT data with no significant difference 
identified. Data assessing healthcare resource use 
were comparable.  
 
RCT3 : 
Data for enrolled patients was missing from all 
routine sources, most pronounced on a single 
hospital’s records where only 39 of 95 patients could 
be identified. Of the 25 clinical measures, 14 could be 
determined from routine data. Broadly, results were 
comparable including the primary outcome (no 
significant difference between surgical techniques). 
For outcome (post-op pain at 5 days) the significant 
difference or site of pain could not be determined 
using routine data.  
 
 
 
 
 
RCT 1:  
Routinely recorded data was broadly 
comparable to RCT data and similar 
study results were concluded.  
 
 
 
 
 
 
 
 
RCT 2: 
Routinely recorded data was limited 
with data available for only a 
proportion of the RCT sample. 
Furthermore, although data regarding 
healthcare resource use were 
comparable, these data were 
extracted from the same source. Just 
1/5 clinical outcomes could be 
assessed.   
 
 
RCT 3:  
Routinely recorded data was limited 
with data available for only a 
proportion of the RCT sample. With 
the exception of one outcome 
involving the assessment of post-
operative pain, clinical outcomes were 
comparable.  
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RCT 4: 
Autologous blood transfusion 
vs donor blood transfusion in 
total knee replacement surgery 
RCT 4: 
Standard Prospective: 
Patient completed 
questionnaire: 
- 0, 7D, 4W, 3M 
RCT clinical follow up 
 
Routinely Recorded:  
Secondary care medical records 
RCT 4: 
223/231 patients could be identified from the 
hospital medical records. 2 out of 11 clinical 
outcomes could not be calculated. For 9/11 the 
results were comparable but one significant 
difference was not found (post-operative infection 
rates) and one was found (increased post-operative 
circulatory disorders) in comparison to the RCT 
results. For the assessment of QOL (EuroQol) only 1/5 
variables could be calculated from routine data, the 
result was comparable. Data assessing healthcare 
resource use were comparable. 
RCT 4:  
Routinely recorded data were 
relatively complete and broadly data 
were comparable. However, unlike the 
previous RCTs, significantly different 
results were obtained for 2/11 
outcome measures.  
 
There were extremely limited 
surrogate routinely recorded measures 
in the assessment of QOL, compared 
to standard self-report questionnaires.  
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Table B.2: Included Studies: Agreement between Routinely Recorded Health Economic Data and Data Collected through Standard Prospective Methods 
Study Reference Study Summary Data Sources Assessment of Agreement Appraisal 
Byford et al: 2007 [158] 
 
Comparison of 
alternative methods of 
collection of service use 
data for the economic 
evaluation of health 
care interventions   
 
RCT 
397 patients recruited into a 
RCT assessing treatments for 
deliberate self harm completed 
a questionnaire (Client Services 
Receipt Inventory (CSRI)) 
assessing healthcare resource 
use.  
 
Primary care medical record 
data was retrieved for 272/397 
patients for GP and allied 
health service resource use and 
compared to data from the 
completed CSRI.   
Standard Prospective: 
Patient completed 
questionnaire (Client Services 
Receipt Inventory) 
- 6, 12 months 
 
Routinely Recorded: 
Primary care medical records 
A mean 8.78 GP contacts were reported on the CSRI 
compared to 10.66 from medical records (95% limits 
of agreement: 13.71 to 16.94, Mean Difference: 1.88, 
95% CI: 0.96 to 2.81), representing an 
underreporting.  
 
Broadly, the record of services not administered in 
primary care was under recorded in primary care 
medical records. This includes a mean difference of-
2.27 (95% CI: 3.39 to –1.15) for total outpatient 
appointments and -2.47 (95% CI: 4.70 to 0.23) for 
total inpatient days.  
There is under-reporting of the 
number of GP contacts and ‘over-
reporting’ of contacts with other 
health services although it is likely that 
these services are poorly recorded on 
primary care records.  
 
Wide limits of agreement are noted 
indicating the presence of outliers 
where there is likely marked 
discrepancy.  
Chishti et al: 2013 [174] 
 
How reliable are stroke 
patients’ reports of 
their numbers 
of general practice 
consultations over 12 
months? 
 
RCT 
115 patients enrolled in a RCT 
assessing home blood pressure 
monitoring completed a 
questionnaire assessing 
healthcare resource use.  
 
Primary care medical record 
data was retrieved for 87 
patients and compared to data 
from the patient completed 
questionnaires.   
Standard Prospective: 
Patient completed 
questionnaire  
- 12 months 
 
Routinely Recorded: 
Primary care medical records 
For the patient completed questionnaires, a mean 
5.7 (SD: 5.4, Range: 0 to 24, n=83) GP appointments 
were reported compared to 7.2 (SD: 5.9, Range: 0 to 
28, n=73) in the medical record. The mean difference 
is 1.6 (95% CI 0.5–2.7); P = 0.004, representing an 
under reporting of 22%. 
 
For consultations with a nurse, a patient reported 
mean of 1.4 (SD: 2.5, Range: 0 to 12, n=73) compared 
to 1.9 (SD: 2.3, Range: 0 to 14, n=73) determined 
from medical records. The mean difference was not 
significant 0.5 (95% CI: −0.2 to 1.2; P = 0.12).  
There is significant patient under 
reporting of healthcare utilisation 
compared to medical record data.  
 
Recall bias may be responsible with 
the questionnaire completed at 12 
months.   
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Dixon et al: 2009 [151] 
 
Is it cost effective to 
introduce paramedic 
practitioners for older 
people to the 
ambulance 
service? Results of a 
cluster randomised 
controlled 
trial 
 
Cluster RCT 
2854 elderly patients were 
randomised to receive 
intervention from a paramedic 
practitioner compared to 
standard care.  
 
Healthcare resource use was 
determined through routinely 
recorded secondary care 
medical records and ambulance 
records. Additionally, to 
examine quality of life and 
healthcare resource use, a 
patient completed 
questionnaire including the EQ-
5D was administered.  
Standard Prospective: 
Patient completed 
questionnaire including EQ-5D 
- 28 days 
 
Routinely Recorded: 
Secondary care and ambulance 
medical records 
The questionnaire regarding healthcare resource use 
provides is directly comparable to routinely recorded 
data.  
 
However, routinely recorded data was available for 
2854 patients and questionnaire data available for a 
subset of 938. For the intervention and control 
groups respectively, the total costs of healthcare 
resource use using routinely recorded data were 
£3966 and £4166. For the subset completing the 
questionnaire costs were £2102 and £2641.    
There is no statistical assessment of 
agreement between patient 
completed questionnaires and 
routinely recorded data despite the 
data being comparable.  
 
There is marked discrepancy between 
costs derived from questionnaires and 
routinely recorded data and the study 
provides explanation in the likely 
existence of bias with patients 
returning questionnaires less unwell at 
baseline.  
Ford et al: 2007 [175] 
 
The children’s services 
interview: validity and 
reliability 
 
Cross Sectional Study 
The parents of 87 children 
attending a complex mental 
health service completed the 
Children’s Services Interview, a 
parent-completed 
questionnaire assessing mental 
healthcare resource use. 25 
parents completed a second 
questionnaire.   
 
Parent reported healthcare 
resource use was compared 
with local secondary care 
medical records.  
Standard Prospective: 
Parent completed Children’s 
Services Interview: 
- 2 years - present 
 
Routinely Recorded: 
Secondary care medical records 
The mean parent reported number of total 
appointments was 5.6 (Range 1-30) compared to 7.0 
(Range 1-50) retrieved from the medical records 
(P=0.1). For appointments at the primary mental 
health trust, there was good agreement (ICC = 0.77, 
95% CI: 0.67–0.85). 
 
There was good agreement for the type of 
intervention received (e.g. Cognitive Behavioural 
Therapy, Kappa: 0.81 (SE: 0.07)) but poor agreement 
for type of professional seen (e.g. Psychiatrist, Kappa: 
0.07 (SE: 0.12) and healthcare resource use other 
than the primary mental health trust (e.g. Primary 
Care and Contact with Teachers, respectively, Kappa 
0.30 (SE: 0.08) and 0.03 (SE: 0.03)). 
Parents’ under-reported healthcare 
resource use compared to data 
retrieved from medical records 
although the difference was non-
significant.  
 
Data is presented regarding agreement 
for other variables. Parents reported 
type of intervention received in 
agreement to medical records but 
reported greater resource use for care 
received outside of the primary mental 
health trust, most evident for primary 
care and contact involving the 
educational sector.   
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Hussain et al: 2012 
[179] 
 
HERALD (Health 
Economics using 
Routine Anonymised 
Linked Data) 
 
Cohort Study 
500 patients diagnosed with 
ankylosing spondylitis and 
enrolled in a cohort study were 
invited to complete 
questionnaires reporting 
attendance at healthcare 
services.  
 
Patient reported healthcare use 
was compared to routinely 
recorded datasets accessed 
through the Secure 
Anonymised Information 
Linkage (SAIL) Databank.   
Standard Prospective: 
Patient completed 
questionnaire: 
- 3 months 
 
Routinely Recorded: 
Secure Anonymised 
Information Linkage (SAIL) 
Databank (Inpatient, 
Outpatient, Primary Care, 
Emergency Care) 
Primary care data was available for 183 patients. In 
all cases, self-reported ‘visits’ were underreported 
compared to the ‘events’ recorded in the primary 
care records. ‘Events’ also includes non-visits. E.g. 
Patients with high disease severity 1.78 (95% CI: 1.32-
2.21) visits compared to 4.25 (3.22-5.28) events.  
 
Outpatient data was available for 236 patients. In all 
cases, self-reported visits were over-reported. Most 
evident in patients with high disease severity, 
reporting 2.55 (1.54-3.55) visits compared to 1.51 
(1.06-1.97) over the previous 3 month period.  
 
Inpatient data was available for 296 patients. 
Patients tended to under-report admissions. Most 
evident in young patients, reporting 0.05 (0.01-0.09) 
admissions compared to 0.16 (0.08-0.25) recorded.   
There is no statistical assessment of 
agreement between patient 
completed questionnaires and 
routinely recorded data. 
 
GP data were not comparable for 
assessing ‘visits’.   
 
Outpatient attendances were over-
reported and inpatient attendances 
under-reported by patients compared 
to medical records over the 3 month 
recall period.  
Kennedy et al: 2002 
[160] 
 
Resource use data by 
patient report or 
hospital records: Do 
they agree? 
 
RCT 
315 patients enrolled in an 
orthopaedic RCT, receiving care 
from an orthopaedic surgeon 
or orthopaedic medical 
specialist, were invited to 
complete a self-report 
questionnaire assessing 
healthcare resource use at 3 
months and 1 year.  
 
243 patients completed the 
questionnaire. Patient reported 
healthcare resource use was 
compared with local secondary 
care medical records.   
Standard Prospective: 
Patient completed 
questionnaire: 
- 3 months, 1 year 
 
Routinely Recorded: 
Secondary care medical records 
The questionnaire regarding healthcare resource use 
provides a direct comparator to routinely recorded 
data. 
 
Overall the intraclass correlation coefficient was 0.54 
(95% Cl 0.31 to 0.70), indicating moderate 
agreement. 
 
The mean patient reported hospital attendance was 
5.6 compared to 4.3 recorded in medical records 
(P=0.006).  
 
21% of patients who had been referred but did not 
report attendance, had attended based on medical 
records.   
The intraclass correlation coefficient 
indicates moderate agreement. 
However, there are a significantly 
increased number of patient reported 
attendances compared to hospital 
records. The authors suggest this is 
likely explained by attendance at other 
centres where medical records have 
not been accessed as part of this 
study. 
 
Furthermore, a subgroup of patients 
did not report attendance when this 
was evident from the medical records.  
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Mistry et al: 2005 [176] 
 
Comparison of general 
practitioner records 
and patient self-report 
questionnaires for 
estimation of costs 
 
RCT 
324 patients enrolled in a RCT 
assessing the cost-effectiveness 
of antidepressant treatments 
had primary care medical 
record data available for a 12 
month period.  
 
85 patients completed 6 
questionnaires regarding 
healthcare resource use and 82 
patients completed 4 or 5 
questionnaires. Healthcare 
resource use was compared 
between patient completed 
questionnaires and primary 
care medical records.  
Standard Prospective: 
Patient completed 
questionnaire: 
- 1, 2, 3, 6, 9 and 12 
months 
 
Routinely Recorded: 
Primary care medical records 
The total mean patient reported number of 
healthcare contacts was 17.20 (SD: 30.24) compared 
to 12.64 (SD: 10.11) determined from medical 
records for patients completing all 6 questionnaires. 
This difference was not significant (paired t test: 
t=−1.755, P=0.083).  
 
Patients reported a mean 9.94 (SD: 6.11) contacts 
with the GP which moderately agreed with data from 
medical records (9.79 SD: 5.06, Kappa: 0.370). 
However, for contact with services not delivered by 
the GP, patient reported contact was greater (e.g. 
patient reported social services 3.27 SD: 21.45 
compared to data from medical records 0.09SD: 0.77, 
Kappa: 0.021).  
 
The total costs of healthcare resource use using 
patient reported data was 680.04 (SD: 1,634.63) 
compared to 545.75 (SD: 1,260.20) calculated form 
medical records. The difference was not significant 
(P=0.549).  
There was agreement between patient 
reported GP contact and data 
retrieved from medical records.  
 
Although the total numbers of 
healthcare contacts were not 
statistically significantly different, 
patients reported greater contact with 
healthcare resources not delivered by 
the GP. This may indicate primary care 
medical records poorly record data on 
the access of allied healthcare 
services.  
Morrell et al: 2000 
[177] 
 
Costs and benefits of 
community postnatal 
support workers: a 
randomised controlled 
trial 
 
RCT 
623 women enrolled in a RCT 
assessing the clinical and cost-
effectiveness of providing 
community postnatal support 
completed self-report 
questionnaires at 6 weeks and 
6 months postnatally.  
 
Self-reported healthcare 
resource use in 266 women 
was compared to data 
retrieved from primary care 
medical records.   
Standard Prospective: 
Patient completed 
questionnaire: 
- 6 weeks, 6 months 
 
Routinely Recorded: 
Primary care medical records 
At 6 weeks: There was a total mean 3.8 (SD, 2.6) self-
reported GP contacts, compared with 3.4 (SD, 2.3) 
recorded in the medical records. Self-reported 
contacts were over-reported by a mean 0.5 of a 
contact (95% CI, 0.2, 0.7). There was no difference 
between ‘over-reporting’ between intervention and 
control groups (mean difference, 0.2; 95% CI, –0.4, 
0.7; t = 0.67 on 1 df; p = 0.51). 
 
At 6 months: There was under-reporting, the 
difference between medical records and self-reports 
was –0.1 contacts (95% CI, –0.7, 0.5). 
In the short term (6 weeks), self-
reported healthcare contacts were 
significantly over-reported by a mean 
of 0.5 of 1 contact.   
 
However, at 6 months, there was a 
non-significant modest under-
reporting.  
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Petrou et al: 2002 [159] 
 
The Accuracy of Self-
Reported Healthcare 
Resource Utilisation in 
Health Economic 
Studies 
 
RCT 
82 women enrolled in a RCT 
assessing a preventative 
intervention for women at risk 
of postpartum depression 
completed self-report 
questionnaires at 4 and 12 
months postpartum, 
retrospectively detailing 
healthcare contacts.   
 
Patient reported healthcare 
resource use was compared to 
data retrieved from primary 
and secondary care medical 
records.  
 
Standard Prospective: 
Patient completed 
questionnaire: 
- 4, 12 months 
 
Routinely Recorded: 
Primary and secondary care 
medical records  
For primary care visits, at months 1-4 29.4% of 
patients recorded visits accurately with 56.9% 
underreporting. At months 5-12, the proportions 
were 28.0% and 58.0%. Community midwifery was 
accurately reported in 21.1% and underreported in 
49.3%. The differences between self-reported 
primary care attendances and medical record review 
were significant in all cases (Wilcoxon Sign-Rank Test 
P<0.001).  
 
The accuracy of other healthcare contacts including 
secondary care attendances ranged 90.8%-100%, 
differences were non-significant.  
 
Multivariate linear regression identified a reduced 
absolute number of GP visits, the presence of 
postnatal depression and accommodation problems 
were significantly associated with reduced under-
reporting. The presence of financial difficulties and 
reduced years spent with current partner were 
significantly associated with over-reporting.  
Significant differences were identified 
between self-reported primary care 
visits and primary care medical 
records, with the majority of patients 
under-reporting.  
 
Notably, the differences remain very 
similar between 4 and 12 months, 
indicating a potentially static effect of 
recall bias. 
 
There were no significant differences 
between self-reported and medical 
record data regarding other healthcare 
contacts including secondary care.    
Richards et al: 2003 
[167] 
 
Patient-reported use of 
health service 
resources compared 
with information 
from health providers 
 
RCT 
185 elderly patients enrolled in 
a RCT assessing a ‘hospital-at-
home’ service with routine care 
completed questionnaires at 4 
and 12 weeks post admission 
assessing healthcare resource 
use.  
 
Patient reported healthcare 
resource use was compared to 
data retrieved from primary, 
secondary and community 
medical records.  
Standard Prospective: 
Patient completed 
questionnaire: 
- 4, 12 weeks 
 
Routinely Recorded: 
Primary, secondary and 
community medical records 
Agreement was greatest for ‘Hospital Readmission’ 
(90.6%, Kappa: 0.68 (95% CI: 0.54–0.82)) and GP 
surgery visits (88.0%, Kappa: 0.60 (0.44–0.76)) and 
weakest for ‘Physiotherapy’ (72.1%, Kappa: 0.23 
(0.13–0.33)).  
 
Patients under-reported primary and secondary care 
attendances. Medical records indicated a greater 
number of hospital admissions in 
the previous 12 weeks (McNemar χ2 = 4.8, d.f.=1, P = 
0.03), and a greater number than that reported by 
patients (Stuart–Maxwell χ2 = 6.8, d.f. =2, P = 0.03).  
GPs reported a greater number of visits than patients 
(Stuart–Maxwell χ2 = 6.5, d.f. =2, P = 0.04).  
Agreement was ‘Good’ or ‘Moderate’ 
for the majority of healthcare settings 
including hospital admissions and GP 
visits.  
 
However, patients under reported 
contact with all healthcare services 
with the exception of ‘Requesting GP 
Visit’.  
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Thorn et al: 2016 [142] 
 
Validation of the 
Hospital Episode 
Statistics Outpatient 
Dataset 
in England 
 
RCT 
370 men enrolled in a RCT 
assessing PSA testing vs 
standard care for prostate 
cancer were flagged and had 
their data prospectively 
extracted from medical 
records.  
 
Healthcare resource use was 
compared to data retrieved 
from the Hospital Episode 
Statistics Outpatient dataset. 
Standard Prospective: 
RCT clinical follow up, primary 
care medical records 
 
Routinely Recorded: 
Hospital Episode Statistics 
Outpatient Dataset (HES OP) 
4922 outpatient appointments with urology services 
were identified from primary care medical records. 
12,154 appointments were identified in the HES OP 
dataset (all specialities). 0.4% of appointments did 
not record speciality. 7452 appointments occurred 
with a relevant speciality and 4088/4922 
appointments recorded in medical records were 
identified in HES OP (83.1 %; 95 % CI 82.0–84.1).  
Diagnosis codes were present in only 0.9% and 
operation codes in 6.7%. 215/370 men (58.1 %) had 
at least one appointment that was unmatched in HES 
OP.  
2195/2755 (79.7 %; 95 % CI 78.2–81.2) matches were 
observed pre-2008, while 1893/2167 
(87.4 %; 95 % CI 86.0–88.9) matches were observed 
post-2008 (P<0.001).  
There is moderate agreement of clinic 
appointments that were recorded in 
the RCT. However, there are significant 
numbers of ‘additional’ appointments 
identified and also ‘missing’ 
appointments.  
 
Routinely recorded data has improved 
since 2008 and for assessing 
healthcare resource use currently 
represents a useful data source. 
However, clinical data such as 
diagnostic details is extremely poorly 
recorded.  
Thorn et al: 2016 [66] 
 
Validating the use of 
Hospital Episode 
Statistics data and 
comparison of costing 
methodologies for 
economic evaluation: 
an end-of-life case 
study from the Cluster 
randomised triAl of PSA 
testing for Prostate 
cancer (CAP) 
 
RCT 
282 men enrolled in a RCT 
assessing PSA testing vs 
standard care for prostate 
cancer were included in this 
methodological study.   
 
Healthcare resource use costs 
derived from data collected 
during the RCT from medical 
record review were compared 
to costs derived from data 
retrieved from the Hospital 
Episode Statistics Inpatient 
dataset. 
Standard Prospective: 
RCT clinical follow up, primary 
care medical records 
 
Routinely Recorded: 
Hospital Episode Statistics 
Inpatient Dataset (HES)  
The inpatient cost profiles derived from RCT and HES 
were comparable, the 95% CIs overlapped at each 
month, and values were not significantly different at 
the 1% significance level.  
The mean resource use per man over the final year of 
life was £11 122 (95% CI £9083 to £13 161) using 
RCT data and national reference costs, and £10 223 
(95% CI £8880 to £11 565) using HES data with 
reference costs. Costs associated with HES data were 
slightly lower (about 8%) than those associated with 
RCT data, but the difference was not significant 
(p=0.3).  
The definition of a ‘single event’ was not consistent 
between the two sets of resource use, with some 
episodes recorded as single events in RCT data 
appearing as multiple events in HES and vice versa. 
11 men (3.8%) for whom events were recorded in 
HES had all these events missing from RCT data and 7 
men (2.4%) with no events according to HES had 
events identified in RCT data. 
There was good agreement between 
the inpatient cost profiles derived 
from HES compared to RCT data and 
between the cost per patient.  
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Table B.3: Included Abstracts: Agreement between Routinely Recorded Data and Data Collected through Standard Prospective Methods 
Study Reference Study Summary Data Sources Assessment of Agreement Appraisal 
Breeman et al: 2011 
[172] 
 
Patient reported clinical 
outcomes: the 
challenges 
and implications for 
randomised controlled 
trials 
 
RCT 
Four RCTs assessing knee 
surgery included the collection 
of data to measure outcomes 
through patient completion of 
questionnaires.  
 
Self-reported data was 
compared to data from ‘routine 
sources’ including medical 
records.   
Standard Prospective: 
Patient completed 
questionnaire  
- Interval not reported 
 
Routinely Recorded: 
Medical records and ‘routine 
data sources’ 
The questionnaires potentially provide a direct 
comparator to routinely recorded data. 
 
‘15% of patient reported knee-related hospital re-
admission could not be verified through routine data 
sources or medical records.’ 
There is no statistical assessment of 
agreement presented between patient 
completed questionnaires and 
routinely recorded data despite the 
data being comparable. 
 
There is marked discrepancy between 
patient-reported outcomes and 
outcomes retrieved from medical 
records. The authors propose the 
underlying reasons are a result of 
patient misunderstanding and 
inaccuracies of routine data.  
Embleton et al: 2015 
[183] 
 
Impact of retrospective 
data verification on the 
results of the academic 
led ICON6 trial 
 
RCT 
282 patients were enrolled in a 
RCT assessing novel 
chemotherapy + standard 
treatment vs placebo + 
standard treatment. Standard 
prospective methods including 
Case Report Forms were 
completed to measure the 
primary outcome of 
progression free survival.  
 
RCT data was compared to 
secondary care medical records 
for all patients during source 
data verification.   
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded: 
Secondary care medical records 
There were 253 ‘progressions’. Source data 
verification identified 2 additional progressions, 1 in 
each trial arm.  
 
The result of the log-rank test changed marginally, 
remaining P<0.001. The HR of 0.57 was unchanged, 
but the CI changed from 0.45-0.74 to 0.44-0.73. 
Median time to event remained at 8.7 months.  
There is good agreement for the 
primary outcome based on the 
descriptive comparison presented.  
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Herrington et al: 2015 
[182] 
 
Can vascular mortality 
be reliably ascertained 
from the underlying 
cause of death 
recorded on a medical 
death certificate? 
Evidence from the 2800 
adjudicated Heart 
Protection Study deaths 
 
RCT 
2835 of total 20,536 
participants of the Heart 
Protection Study died during 
study follow up.  
 
Data retrieved from UK 
mortality registers was 
compared with data collected 
using standard prospective 
methods (‘clinically 
adjudicated’ data).  
Standard Prospective: 
RCT clinical follow up 
 
Routinely Recorded: 
‘UK Mortality Registers’ 
2778/2835 deaths were recorded in UK mortality 
registers.  
 
1152 certified compared to 1260 adjudicated 
coronary heart disease (CHD) deaths. 108 
adjudicated CHD deaths were wrongly certified to 
another cause and 81 non-CHD deaths were wrongly 
certified as CHD (Kappa: 0.86, 95% CI: 0.84-0.88).  
 
161 certified compared to 214 adjudicated stroke 
deaths. 53 were certified as other causes and 26 non-
stroke deaths were wrongly certified as stroke 
(Kappa: 0.78, 95% CI: 0.74-0.83).  
 
7 certified did not compare to 60 adjudicated 
ischaemic stroke deaths (K: 0.19, 95% CI: 0.07-0.31).  
 
The allocation to intervention vs control in HPS 
reduced vascular deaths (RR: 0.83, 95% CI: 0.75-
0.91). Using only certified deaths the outcome is 
comparable (RR: 0.81, 95% CI: 0.74-0.90).     
There is good agreement for all clinical 
measures with the exception of 
‘ischaemic stroke’.  
 
The primary trial outcomes are almost 
identical whether using ‘adjudicated’ 
or certified deaths.  
 
The authors conclude that using 
routinely recorded data from the UK 
Mortality Registers is likely to be 
sufficiently reliable to assess vascular 
deaths.  
Shaw et al: 1998 [168] 
 
Can we trust the quality 
of routine hospital 
outpatient information 
in the UK? Validating 
outpatient data from 
the patient 
administration system 
 
Cohort Study 
Attendance details for 140 
patients at 4 NHS hospitals 
were examined.  
 
The grade of doctor seen and 
management decision were 
recorded by clinician report 
immediately following the 
appointment and compared to 
the information recorded in the 
Patient Administration System 
(PAS).  
Standard Prospective: 
Clinician report 
 
Routinely Recorded: 
Secondary care medical records 
There was agreement between the clinician report 
and the PAS data in 118/140 (84.3%) cases for grade 
of doctor seen and in 105/139 (76.7%) cases for the 
management decision. There was complete 
agreement for both items in 88/139 (62.6%) cases. 
 
Kappa values indicated ‘good’ agreement between 
the two data sources. However, sensitivity statistics 
suggested that the likely accuracy of each data item 
varied. 
There is a descriptive and statistical 
assessment of agreement.  
 
Data extraction is limited as the full 
report was not retrievable through 
available resources during this review. 
Smith et al: 2015 [181] 
 
Assessing the accuracy 
of routinely collected 
data and their use in 
pressure ulcer trials. 
Cross Sectional Study 
A cross sectional study 
compared routinely recorded 
data on the incidence of 
pressure ulcers, recorded 
through the English NHS Safety 
Thermometer, to research 
nurse review.  
Standard Prospective: 
Research nurse review 
 
Routinely Recorded: 
English NHS Safety 
Thermometer 
Reported low accuracy of routinely recorded data. 
 
Weighted sensitivity estimate: 48.2% (95% CI: 35.4%-
56.7%).  
There is marked discrepancy between 
routinely recorded data and research 
nurse review. The study concludes 
routinely recorded data is not 
satisfactory for measuring the 
outcomes of pressure ulcer RCTs.  
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Wright-Hughes et al: 
2013 [184] 
 
Can the use of routine 
data enhance collection 
of the primary outcome 
in the SHIFT trial? 
 
RCT 
The SHIFT RCT involved 
randomising adolescents 
following an episode of self 
harm to family therapy vs 
standard care. The primary 
outcome of ‘repetition, leading 
to hospital attendance’ 
involved research nurse 
prospective review of local 
hospital record data.  
 
Data was also retrieved from 
secondary care medical records 
and agreement compared.    
Standard Prospective: 
RCT clinical follow up, 
secondary care medical records 
 
Routinely Recorded: 
Hospital Episode Statistics 
Inpatient Dataset (HES) 
‘Our comparison found advantages of data collection 
via NHS Digital to include the acquisition of more 
comprehensive and timely trial outcome data, 
potentially at a reduced cost, whilst disadvantages 
included ambiguity in the classification of self-harm 
relatedness for a proportion of episodes.’ 
There is no presented data regarding 
the assessment of agreement 
performed.  
 
However, as a result of this analysis, 
the researchers altered the RCT 
methodology to access HES data as the 
primary dataset for measuring RCT 
outcomes.  
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Table B.4: PRISMA Checklist  
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title Page 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
Introduction 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
Methods 
The review was not 
eligible for registration in 
the PROSPERO 
database.  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Methods 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors 
to identify additional studies) in the search and date last searched.  
Methods 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that 
it could be repeated.  
Methods 
Appendix II 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, 
if applicable, included in the meta-analysis).  
Methods 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
Methods 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
Methods 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
Methods 
A narrative appraisal was 
performed. Formal 
assessment was 
performed where relevant 
to the assessment of 
agreement and when 
possible considering the 
methods used in the 
included study.   
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
Methods 
 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
Methods 
A narrative appraisal has 
been performed. Formal 
assessment has not been 
performed due to the 
heterogeneity of included 
studies.  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
N/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
Results 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
Results 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Results 
Presented in tables where 
relevant.  
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Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Results 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
N/a 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
N/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
Discussion 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
Discussion 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role 
of funders for the systematic review.  
To be included in journal 
submission.  
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Table B.5: Search Strategy: MEDLINE (OVID) “Prospective Studies” 1.10.16  
1 Administrative Data Research Network.tw. 
2 Clinical Practi$ Research Datalink.tw. 
3 ((Driv$ adj2 Vehicle Licen?ing Agency) or (Driv$ adj2 Vehicle Licen?ing Authority)).tw. 
4 (Department adj2 "Work and Pensions").tw. 
5 General Practi$ Extraction Service.tw. 
6 (General Practi$ Research Database or General Practi$ Registry Database).tw. 
7 Hospital Episode Statistics.tw. 
8 "Revenue and Customs".tw. 
9 "Health and Social Care Information Centre".tw. 
10 NorthWest eHealth.tw. 
11 Office for National Statistics.tw. 
12 Secure Anonymised Information Linkage Databank.tw. 
13 (NHS Wales Informatics Service or Patient Episode Database for Wales).tw. 
14 "The Health Improvement Network".tw. 
15 QResearch.tw. 
16 ResearchOne.tw. 
17 Information Services Division.tw. 
18 or/1-17 
19 (ADRN or CPRD or DVLA or DWP or GPES or GPRD or HES or HMRC or HSCIC or NWEH or ONS or SAIL or PEDW).tw. 
20 ("dose-width product" or Dose width product).tw. 
21 General Practice Education$ Supervis$.tw. 
22 
(Geriatric Psychiatry Research Division or Aspergillus or gastropharyngeal reflux disease$ or (gene$ and prion 
disease$)).tw. 
23 
(balanced starch$ or hydroxyethyl starch$ or hydroxyethylstarch$ or hydroxy ethyl starch$ or Hospital Eye Service$ or 
hip extensor stretch).tw. 
24 ("Add-ons" or Oral nutri$ supplement$ or Occipital nerve stimul$).tw. 
25 
(Sheffield Assessment for Letters or Sheffield Assessment Instrument for Letters or Stimulation Assistance through 
Iterative Learning).tw. 
26 or/20-25 
27 19 not 26 
28 
((routine or clinic$ or primary or general practic$ or general practis$ or general practitioner$ or GP?) and data and 
source?).ti. 
29 ((routine or clinic$ or primary or general practic$ or general practis$ or general practitioner$ or GP?) adj2 data).ab. 
30 data source?.ab. /freq=2 
31 29 and 30 
32 27 or 28 or 31 
33 ((Electronic or Routine or Administrative) adj (health or medical or recor$ or data)).tw. 
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34 ((Regist$ or Hospital) adj (data or recor$)).tw. 
35 33 or 34 
36 32 or 35 
37 exp Great Britain/ 
38 (national health service* or nhs*).ti,ab,in. 
39 
(english not ((published or publication* or translat* or written or language* or speak* or literature or citation*) adj5 
english)).ti,ab. 
40 
(gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or united kingdom* or (england* not "new 
england") or northern ireland* or northern irish* or scotland* or scottish* or ((wales or "south wales") not "new south 
wales") or welsh*).ti,ab,jw,in. 
41 
(bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not alabama*) or bradford or "bradford's" or 
brighton or "brighton's" or bristol or "bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or (canterbury not zealand*) or 
("canterbury's" not zealand*) or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" 
or coventry or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or ("durham's" not (carolina* or nc)) 
or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not nebraska*) or ("lincoln's" not nebraska*) 
or (liverpool not (new south wales* or nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* 
or ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or "manchester's" or (newcastle 
not (new south wales* or nsw)) or ("newcastle's" not (new south wales* or nsw)) or norwich or "norwich's" or 
nottingham or "nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or 
"plymouth's" or portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" 
or salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or stoke or 
"stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells or westminster or 
"westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or boston* or harvard*)) or (york not 
("new york*" or ny or ontario* or ont or toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))).ti,ab,in. 
42 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st davids or 
swansea or "swansea's").ti,ab,in. 
43 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or "glasgow's" or 
inverness or (perth not australia*) or ("perth's" not australia*) or stirling or "stirling's").ti,ab,in. 
44 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or derry or 
"derry's" or newry or "newry's").ti,ab,in. 
45 or/37-44 
46 
(exp africa/ or exp americas/ or exp antarctic regions/ or exp arctic regions/ or exp asia/ or exp australia/ or exp 
oceania/) not (exp great britain/ or europe/) 
47 45 not 46 
48 36 and 47 
49 18 or 48 
50 randomized controlled trial.pt. 
51 controlled clinical trial.pt.  
52 randomized.ab. 
53 placebo.ab. 
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54 clinical trials as topic.sh. 
55 randomly.ab. 
56 trial.ti. 
57 Or/50-56 
58 cohort studies/ or longitudinal studies/ or follow-up studies/ or cohort.ti,ab. or longitudinal.ti,ab. 
59 exp prospective studies/ 
60 
exp case-control studies/ or exp retrospective studies/ or exp cross-sectional studies/ or (case control or case-control 
or case series or cross?section$ or "cross section$" or retrospective).ti. or case reports.pt. 
61 Retrospective adj cohort.ti,ab.   
62 58 and 59 
63 62 not 60 
64 63 not 61 
65 57 or 64 
66 exp animals/ not humans.sh. 
67 65 not 66 
68 49 and 67  
69 Remove duplicates from 68 
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Table B.6: Search Strategy: SCOPUS “Prospective Studies” 19.10.16 
1 
TITLE-ABS-KEY (“Administrative Data Research Network” OR “Clinical Practi* Research Datalink” OR “Driv* W/1 Vehicle 
Licen?ing Agency” OR “Driv* W/1 Vehicle Licen?ing Authority” OR “Department W/1 Work and Pensions” OR “General 
Practi* Extraction Service” OR “General Practi* Research Database” OR “General Practi* Registry Database” OR 
“Hospital Episode Statistics” OR "Revenue and Customs" OR "Health and Social Care Information Centre" OR 
“NorthWest eHealth” OR “Office for National Statistics” OR “Secure Anonymised Information Linkage Databank” OR 
“NHS Wales Informatics Service” OR “Patient Episode Database for Wales” OR "The Health Improvement Network" OR 
QResearch OR ResearchOne OR “Information Services Division”) 
2 
TITLE-ABS-KEY (ADRN OR CPRD OR DVLA OR DWP OR GPES OR GPRD OR HES OR HMRC OR HSCIC OR NWEH OR ONS 
OR SAIL OR PEDW) 
3 TITLE-ABS-KEY ("dose-width product" OR “Dose width product”) 
4 TITLE-ABS-KEY (“General Practice Education Supervis*”) 
5 
TITLE-ABS-KEY (“Geriatric Psychiatry Research Division” OR Aspergillus OR “gastropharyngeal reflux disease*” OR 
(“gene* AND prion disease*”))  
6 
TITLE-ABS-KEY (“balanced starch*” OR “hydroxyethyl starch*” OR “hydroxyethyl starch*” OR “hydroxy ethyl starch*” 
OR “Hospital Eye Service*” OR “hip extensor stretch”) 
7 TITLE-ABS-KEY ("Add-ons" OR “Oral nutri* supplement*” OR “Occipital nerve stimul*”)  
8 
TITLE-ABS-KEY (“Sheffield Assessment for Letters” OR “Sheffield Assessment Instrument for Letters” OR “Stimulation 
Assistance through Iterative Learning”)  
9 #3 OR #4 OR #5 OR #6 OR #7 OR #8 
10 #2 AND NOT #9 
11 
TITLE-ABS-KEY (routine OR clinic* OR primary OR “general practice*” OR “general practis*” OR “general practitioner*” 
OR GP) AND (“data source”) 
12 TITLE-ABS-KEY ((Electronic OR Routine OR Administrative) W/0 health OR medical OR recor* OR data) 
13 TITLE-ABS-KEY ((Regist* OR Hospital) W/0 data OR recor*) 
14 #10 OR #11 OR #12 OR #13 
15 TITLE-ABS-KEY (Great Britain) 
16 
TITLE-ABS-KEY (“national health service*” OR nhs* OR (english AND NOT (published OR publication* OR translat* OR 
written OR language* OR speak* OR literature OR citation*) W/5 english)) 
17 
TITLE-ABS-KEY (gb OR "g.b." OR britain* OR (british* AND NOT "british columbia") OR uk OR "u.k." OR “united 
kingdom*” OR (england* AND NOT "new england") OR “northern ireland*” OR “northern irish*” OR scotland* OR 
scottish* OR ((wales OR "south wales") AND NOT "new south wales") OR welsh*) 
18 
TITLE-ABS-KEY (bath OR "bath's" OR ((birmingham AND NOT alabama*) OR ("birmingham's" AND NOT alabama*) OR 
bradford OR "bradford's" OR brighton OR "brighton's" OR bristol OR "bristol's" OR carlisle* OR "carlisle's" OR 
(cambridge AND NOT (massachusetts* OR boston* OR harvard*)) OR ("cambridge's" AND NOT (massachusetts* OR 
boston* OR harvard*)) OR (canterbury AND NOT zealand*) OR ("canterbury's" AND NOT zealand*) OR chelmsford OR 
"chelmsford's" OR chester OR "chester's" OR chichester OR "chichester's" OR coventry OR "coventry's" OR derby OR 
"derby's" OR (durham AND NOT (carolina* OR nc)) OR ("durham's" AND NOT (carolina* OR nc)) OR ely OR "ely's" OR 
exeter OR "exeter's" OR gloucester OR "gloucester's" OR hereford OR "hereford's" OR hull OR "hull's" OR lancaster OR 
"lancaster's" OR leeds* OR leicester OR "leicester's" OR (lincoln AND NOT nebraska*) OR ("lincoln's" AND NOT 
nebraska*) OR (liverpool AND NOT (new south wales* OR nsw)) OR ("liverpool's" AND NOT (new south wales* OR 
nsw)) OR ((london AND NOT (ontario* OR ont OR toronto*)) OR ("london's" AND NOT (ontario* OR ont OR toronto*)) 
OR manchester OR "manchester's" OR (newcastle AND NOT (new south wales* OR nsw)) OR ("newcastle's" AND NOT 
(new south wales* OR nsw)) OR norwich OR "norwich's" OR nottingham OR "nottingham's" OR oxford OR "oxford's" 
OR peterborough OR "peterborough's" OR plymouth OR "plymouth's" OR portsmouth OR "portsmouth's" OR preston 
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OR "preston's" OR ripon OR "ripon's" OR salford OR "salford's" OR salisbury OR "salisbury's" OR sheffield OR 
"sheffield's" OR southampton OR "southampton's" OR st albans OR stoke OR "stoke's" OR sunderland OR 
"sunderland's" OR truro OR "truro's" OR wakefield OR "wakefield's" OR wells OR westminster OR "westminster's" OR 
winchester OR "winchester's" OR wolverhampton OR "wolverhampton's" OR (worcester AND NOT (massachusetts* OR 
boston* OR harvard*)) OR ("worcester's" AND NOT (massachusetts* OR boston* OR harvard*)) OR (york AND NOT 
("new york*" OR ny OR ontario* OR ont OR toronto*)) OR ("york's" AND NOT ("new york*" OR ny OR ontario* OR ont 
OR toronto*))))) 
19 
TITLE-ABS-KEY (bangor OR "bangor's" OR cardiff OR "cardiff's" OR newport OR "newport's" OR st asaph OR "st asaph's" 
OR st davids OR swansea OR "swansea's" OR aberdeen OR "aberdeen's" OR dundee OR "dundee's" OR edinburgh OR 
"edinburgh's" OR glasgow OR "glasgow's" OR inverness OR (perth AND NOT australia*) OR ("perth's" AND NOT 
australia*) OR stirling OR "stirling's" OR armagh OR "armagh's" OR belfast OR "belfast's" OR lisburn OR "lisburn's" OR 
londonderry OR "londonderry's" OR derry OR "derry's" OR newry OR "newry's")  
20 #15 OR #16 OR #17 OR #18 OR #19 
21 ALL ((Africa OR Americas OR Antarctic OR arctic OR Asia OR Australia OR Oceania) AND NOT Great Britain OR Europe) 
22 #20 AND NOT #21 
23 #14 AND #22 
24 #1 OR #23 
25 TITLE-ABS-KEY (“randomized controlled trial” OR “controlled clinical trial” OR “clinical tria*”) 
26 TITLE (trial) 
27 ABS (randomized OR placebo OR randomly)  
28 #25 OR #26 OR #27  
29 TITLE-ABS-KEY (cohort OR longitudinal OR “follow-up”) 
30 TITLE-ABS-KEY (prospective) 
31 
TITLE-ABS-KEY (case-control OR retrospective OR cross-sectional OR “case control” OR case series OR cross?section* 
OR "cross section*" OR retrospective OR case report*) 
32 TITLE-ABS-KEY (Retrospective W/0 cohort)   
33 #29 AND #30 
34 #33 AND NOT #31 
35 #34 AND NOT #32 
36 #28 OR #35 
37 ALL (anima* AND NOT huma*) 
38 #36 AND NOT #37 
39 #24 AND #38  
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Table B.7: Search Strategy: Cochrane Methodology Register “No Study Filter” 1.10.16 
1 “Administrative Data Research Network”:ti,ab 
2 “Clinical Practi* Research Datalink”:ti,ab 
3 ((Driv* and Vehicle Licen?ing Agency) or (Driv* and Vehicle Licen?ing Authority)):ti,ab 
4 (Department of "Work and Pensions"):ti,ab 
5 “General Practi* Extraction Service”:ti,ab 
6 (“General Practi* Research Database” or “General Practi* Registry Database”):ti,ab 
7 “Hospital Episode Statistics”:ti,ab 
8 "Revenue and Customs":ti,ab 
9 "Health and Social Care Information Centre":ti,ab 
10 “NorthWest eHealth”:ti,ab 
11 “Office for National Statistics”:ti,ab 
12 “Secure Anonymised Information Linkage Databank”:ti,ab 
13 (“NHS Wales Informatics Service” or “Patient Episode Database for Wales”):ti,ab 
14 "The Health Improvement Network":ti,ab 
15 QResearch:ti,ab 
16 ResearchOne:ti,ab 
17 “Information Services Division”:ti,ab 
18 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 
19 (ADRN or CPRD or DVLA or DWP or GPES or GPRD or HES or HMRC or HSCIC or NWEH or ONS or SAIL or PEDW):ti,ab 
20 ("dose-width product" or Dose width product):ti,ab 
21 “General Practice Education* Supervis*”:ti,ab 
22 
(Geriatric Psychiatry Research Division or Aspergillus or gastropharyngeal reflux disease* or (gene* and prion 
disease*)):ti,ab 
23 
(balanced starch* or hydroxyethyl starch* or hydroxyethylstarch* or hydroxy ethyl starch* or Hospital Eye Service* or 
hip extensor stretch):ti,ab 
24 ("Add-ons" or Oral nutri* supplement* or Occipital nerve stimul*):ti,ab 
25 
(Sheffield Assessment for Letters or Sheffield Assessment Instrument for Letters or Stimulation Assistance through 
Iterative Learning):ti,ab 
26 #20 or #21 or #22 or #23 or #24 or #25 
27 #19 not #26 
28 
((routine or clinic* or primary or general practice* or general practis* or general practitioner* or GP?) and data and 
source?):ti,ab 
29 #27 or #28 
30 ((Electronic or Routine or Administrative) NEXT (health or medical or recor* or data)):ti,ab 
31 ((Regist* or Hospital) NEXT (data or recor*)):ti,ab 
32 #30 or #31 
33 #29 or #32 
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34 “Great Britain” 
35 (national health service* or nhs*):ti,ab 
36 
(english not ((published or publication* or translat* or written or language* or speak* or literature or citation*) near 
english)):ti,ab 
37 
(gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or united kingdom* or (england* not "new 
england") or northern ireland* or northern irish* or scotland* or scottish* or ((wales or "south wales") not "new south 
wales") or welsh*):ti,ab 
38 
(bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not alabama*) or bradford or "bradford's" or 
brighton or "brighton's" or bristol or "bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or (canterbury not zealand*) or 
("canterbury's" not zealand*) or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" 
or coventry or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or ("durham's" not (carolina* or nc)) 
or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not nebraska*) or ("lincoln's" not nebraska*) 
or (liverpool not (new south wales* or nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* 
or ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or "manchester's" or (newcastle 
not (new south wales* or nsw)) or ("newcastle's" not (new south wales* or nsw)) or norwich or "norwich's" or 
nottingham or "nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or 
"plymouth's" or portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" 
or salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or stoke or 
"stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells or westminster or 
"westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or boston* or harvard*)) or (york not 
("new york*" or ny or ontario* or ont or toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))):ti,ab 
39 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st davids or 
swansea or "swansea's"):ti,ab 
40 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or "glasgow's" or 
inverness or (perth not australia*) or ("perth's" not australia*) or stirling or "stirling's"):ti,ab 
41 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or derry or 
"derry's" or newry or "newry's"):ti,ab 
42 #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 
43 
(africa or americas or antarctic regions or arctic regions or asia or australia or oceania) not (great britain or 
europe):ti,ab 
44 #42 not #43 
45 #33 and #44 
46 #18 or #45 
 
  
341 
 
Table B.8: Search Strategy: DIRUM MEDLINE 2012-2016 21.10.16  
1 Patient Readmission/  
2 Office Visits/  
3 House Calls/ 
4 "Referral and Consultation"/ 
5 Remote Consultation/ 
6 Patient Admission/ 
7 Hospitalization/ 
8 exp Ambulatory Care Facilities/ 
9 exp mass screening/ 
10 exp Diagnostic Imaging/ 
11 visits.tw. 
12 appointment$.tw. 
13 hospitali?ation$.tw. 
14 exp Health Services/ 
15 Health Resources/ 
16 "episode of care"/ 
17 exp General Practice/ 
18 exp Drug Therapy/ 
19 Outpatients/ 
20 exp therapeutics/ 
21 or/1-20 
22 ut.fs. 
23 utili?ation.tw. 
24 (valid$ adj5 self report$).tw. 
25 or/22-24 
26 21 and 25 
27 exp Drug Utilization/ 
28 ((medicine$ or medication$ or hospital$) adj1 "use").tw. 
29 ("health care use" or "healthcare use").tw. 
30 ("medical care use" or "use of medical care").tw. 
31 ("use of health care" or "use of healthcare").tw. 
32 ("health service$ use" or "use of health service$").tw. 
33 ("clinic use" or "use of clinic#").tw. 
34 ("hospital$ use" or "use of hospital$" or "emergency use" or "use of emergency").tw. 
35 "resource use".tw. 
36 "use of resource$".tw. 
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37 ((health care or healthcare) adj1 visit$).tw. 
38 (utili?ation adj3 (resource$ or healthcare or health care or medical care or hospital$ or emergency or service$)).tw. 
39 (usage adj3 (resource$ or healthcare or health care or medical care or hospital$ or emergency or service$)).tw. 
40 or/27-39 
41 26 or 40  
42 exp Questionnaires/ 
43 exp Interviews as Topic/ 
44 Health Care Surveys/ 
45 Data Collection/ 
46 Self Disclosure/ 
47 Self-Assessment/ 
48 Self Report/ 
49 Mental Recall/ 
50 Self Care/ 
51 (self adj1 (report$ or disclos$ or record$)).tw. 
52 (patient$ adj1 (report$ or disclos$ or recorded or recall)).tw. 
53 (patient completed or completed by patient$).tw. 
54 self assess$.tw. 
55 (patient assess$ or assess$ by patient$).tw. 
56 (questionnaire$ or survey$ or interview$ or diary or diaries).tw. 
57 or/42-56 
58 57 and 41  
59 "reproducibility of results"/ 
60 accuracy.tw. 
61 reliability.tw. 
62 reliable.tw. 
63 valid$.tw. 
64 exp utilization review/ 
65 recall bias.tw. 
66 internal consisten$.tw. 
67 precision.tw. 
68 test-retest.tw. 
69 missing data.tw. 
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70 "Bias (Epidemiology)"/ 
71 gold standard.tw. 
72 exp medical records/ 
73 records as topic/ 
74 registries/ 
75 or/59-74  
76 58 and 75 
77 limit 76 to english language 
78 77 and 2012:2016.(sa_year).   
79 exp Great Britain/ 
80 (national health service* or nhs*).ti,ab,in. 
81 
(english not ((published or publication* or translat* or written or language* or speak* or literature or citation*) adj5 
english)).ti,ab. 
82 
(gb or "g.b." or britain* or (british* not "british columbia") or uk or "u.k." or united kingdom* or (england* not "new 
england") or northern ireland* or northern irish* or scotland* or scottish* or ((wales or "south wales") not "new south 
wales") or welsh*).ti,ab,jw,in. 
83 
(bath or "bath's" or ((birmingham not alabama*) or ("birmingham's" not alabama*) or bradford or "bradford's" or 
brighton or "brighton's" or bristol or "bristol's" or carlisle* or "carlisle's" or (cambridge not (massachusetts* or boston* 
or harvard*)) or ("cambridge's" not (massachusetts* or boston* or harvard*)) or (canterbury not zealand*) or 
("canterbury's" not zealand*) or chelmsford or "chelmsford's" or chester or "chester's" or chichester or "chichester's" 
or coventry or "coventry's" or derby or "derby's" or (durham not (carolina* or nc)) or ("durham's" not (carolina* or nc)) 
or ely or "ely's" or exeter or "exeter's" or gloucester or "gloucester's" or hereford or "hereford's" or hull or "hull's" or 
lancaster or "lancaster's" or leeds* or leicester or "leicester's" or (lincoln not nebraska*) or ("lincoln's" not nebraska*) 
or (liverpool not (new south wales* or nsw)) or ("liverpool's" not (new south wales* or nsw)) or ((london not (ontario* 
or ont or toronto*)) or ("london's" not (ontario* or ont or toronto*)) or manchester or "manchester's" or (newcastle 
not (new south wales* or nsw)) or ("newcastle's" not (new south wales* or nsw)) or norwich or "norwich's" or 
nottingham or "nottingham's" or oxford or "oxford's" or peterborough or "peterborough's" or plymouth or 
"plymouth's" or portsmouth or "portsmouth's" or preston or "preston's" or ripon or "ripon's" or salford or "salford's" 
or salisbury or "salisbury's" or sheffield or "sheffield's" or southampton or "southampton's" or st albans or stoke or 
"stoke's" or sunderland or "sunderland's" or truro or "truro's" or wakefield or "wakefield's" or wells or westminster or 
"westminster's" or winchester or "winchester's" or wolverhampton or "wolverhampton's" or (worcester not 
(massachusetts* or boston* or harvard*)) or ("worcester's" not (massachusetts* or boston* or harvard*)) or (york not 
("new york*" or ny or ontario* or ont or toronto*)) or ("york's" not ("new york*" or ny or ontario* or ont or 
toronto*))))).ti,ab,in. 
84 
(bangor or "bangor's" or cardiff or "cardiff's" or newport or "newport's" or st asaph or "st asaph's" or st davids or 
swansea or "swansea's").ti,ab,in. 
85 
(aberdeen or "aberdeen's" or dundee or "dundee's" or edinburgh or "edinburgh's" or glasgow or "glasgow's" or 
inverness or (perth not australia*) or ("perth's" not australia*) or stirling or "stirling's").ti,ab,in. 
86 
(armagh or "armagh's" or belfast or "belfast's" or lisburn or "lisburn's" or londonderry or "londonderry's" or derry or 
"derry's" or newry or "newry's").ti,ab,in. 
87 or/79-86 
88 (exp africa/ or exp americas/ or exp antarctic regions/ or exp arctic regions/ or exp asia/ or exp australia/ or exp 
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oceania/) not (exp great britain/ or europe/) 
89 87 not 88 
90 78 and 89 
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Table B.9: Search Strategy: DIRUM SCOPUS 2012-2016 21.10.16 
1 
TITLE-ABS-KEY (visits OR appointment* OR hospitali?ation* OR “Health Services/” OR “Drug Therapy/” OR Outpatients 
OR hospital readmission OR “ambulatory care” OR “professional practice” OR “patient referral” OR teleconsultation OR 
“hospital admission” OR hospitalization OR “outpatient department” OR “mass screening” OR “diagnostic imaging” OR 
“health service/” OR “health care delivery” OR “general practice” OR therapy/) 
2 TITLE-ABS-KEY (utili?ation OR utili?ation OR (“valid* W/5 self report*”)) 
3 #1 AND #2 
4 
TITLE-ABS-KEY (“Drug Utilization/” OR ((medicine* OR medication* OR hospital*) W/1 use) OR ("health care use" OR 
"healthcare use") OR ("medical care use" OR "use of medical care") OR ("use of health care" OR "use of healthcare") 
OR ("health service* use" OR "use of health service*") OR ("clinic use" OR "use of clinic*") OR ("hospital* use" OR "use 
of hospital*") OR ("emergency use" OR "use of emergency") OR ((“health care” OR healthcare) W/1 visit*) OR 
"resource use" OR "use of resource*" OR (utili?ation W/3 (resource* OR healthcare OR “health care” OR “medical 
care” OR hospital* OR emergency OR service*)) OR (usage W/3 (resource* OR healthcare OR “health care” OR 
“medical care” OR hospital* OR emergency OR service*)) OR “health care utilization” OR “hospital utilization” OR 
utilization OR (valid* W/5 “self report*”)) 
5 #3 OR #4  
6 
TITLE-ABS-KEY (“Questionnaires/” OR “Health Care Surveys/” OR “Self Disclosure/” OR “Self Report/” OR “Mental 
Recall/” OR “Self Care/” OR (self W/1 (report* OR disclos* OR record*)) OR (patient* W/1 (report* OR disclos* OR 
recorded)) OR (“patient completed” OR “completed by patient*”) OR “self assess*” OR (“patient assess*” OR “assess* 
by patient*”) OR (questionnaire* OR survey* OR diary OR diaries OR interview*) OR “self evaluation/” OR “recall/” OR 
“self repor*” OR “patient report*”) 
7 
TITLE-ABS-KEY (accuracy OR reliability OR reliable OR valid* OR “utilization review/” OR “recall bias” OR “reliability/” 
OR “reproducibility/” OR “accuracy/” OR “validity/” OR “recall bias/” OR “information processing/” OR “medical 
record/” OR “register/” OR "medical record review/” OR (accura* OR reliab* OR reproduce* OR valid*) OR precision 
OR “test retest” OR “missing data” OR “gold standard”) 
8 #5 AND #6 AND #7 
9 TITLE-ABS-KEY (“conference abstract”) 
10 #8 AND NOT #9 
11 TITLE-ABS-KEY (Great Britain) 
12 
TITLE-ABS-KEY (“national health service*” OR nhs* OR (english AND NOT (published OR publication* OR translat* OR 
written OR language* OR speak* OR literature OR citation*) W/5 english)) 
13 
TITLE-ABS-KEY (gb OR "g.b." OR britain* OR (british* AND NOT "british columbia") OR uk OR "u.k." OR “united 
kingdom*” OR (england* AND NOT "new england") OR “northern ireland*” OR “northern irish*” OR scotland* OR 
scottish* OR ((wales OR "south wales") AND NOT "new south wales") OR welsh*) 
14 
TITLE-ABS-KEY (bath OR "bath's" OR ((birmingham AND NOT alabama*) OR ("birmingham's" AND NOT alabama*) OR 
bradford OR "bradford's" OR brighton OR "brighton's" OR bristol OR "bristol's" OR carlisle* OR "carlisle's" OR 
(cambridge AND NOT (massachusetts* OR boston* OR harvard*)) OR ("cambridge's" AND NOT (massachusetts* OR 
boston* OR harvard*)) OR (canterbury AND NOT zealand*) OR ("canterbury's" AND NOT zealand*) OR chelmsford OR 
"chelmsford's" OR chester OR "chester's" OR chichester OR "chichester's" OR coventry OR "coventry's" OR derby OR 
"derby's" OR (durham AND NOT (carolina* OR nc)) OR ("durham's" AND NOT (carolina* OR nc)) OR ely OR "ely's" OR 
exeter OR "exeter's" OR gloucester OR "gloucester's" OR hereford OR "hereford's" OR hull OR "hull's" OR lancaster OR 
"lancaster's" OR leeds* OR leicester OR "leicester's" OR (lincoln AND NOT nebraska*) OR ("lincoln's" AND NOT 
nebraska*) OR (liverpool AND NOT (new south wales* OR nsw)) OR ("liverpool's" AND NOT (new south wales* OR 
nsw)) OR ((london AND NOT (ontario* OR ont OR toronto*)) OR ("london's" AND NOT (ontario* OR ont OR toronto*)) 
OR manchester OR "manchester's" OR (newcastle AND NOT (new south wales* OR nsw)) OR ("newcastle's" AND NOT 
(new south wales* OR nsw)) OR norwich OR "norwich's" OR nottingham OR "nottingham's" OR oxford OR "oxford's" 
OR peterborough OR "peterborough's" OR plymouth OR "plymouth's" OR portsmouth OR "portsmouth's" OR preston 
OR "preston's" OR ripon OR "ripon's" OR salford OR "salford's" OR salisbury OR "salisbury's" OR sheffield OR 
"sheffield's" OR southampton OR "southampton's" OR st albans OR stoke OR "stoke's" OR sunderland OR 
"sunderland's" OR truro OR "truro's" OR wakefield OR "wakefield's" OR wells OR westminster OR "westminster's" OR 
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winchester OR "winchester's" OR wolverhampton OR "wolverhampton's" OR (worcester AND NOT (massachusetts* OR 
boston* OR harvard*)) OR ("worcester's" AND NOT (massachusetts* OR boston* OR harvard*)) OR (york AND NOT 
("new york*" OR ny OR ontario* OR ont OR toronto*)) OR ("york's" AND NOT ("new york*" OR ny OR ontario* OR ont 
OR toronto*))))) 
15 
TITLE-ABS-KEY (bangor OR "bangor's" OR cardiff OR "cardiff's" OR newport OR "newport's" OR st asaph OR "st asaph's" 
OR st davids OR swansea OR "swansea's" OR aberdeen OR "aberdeen's" OR dundee OR "dundee's" OR edinburgh OR 
"edinburgh's" OR glasgow OR "glasgow's" OR inverness OR (perth AND NOT australia*) OR ("perth's" AND NOT 
australia*) OR stirling OR "stirling's" OR armagh OR "armagh's" OR belfast OR "belfast's" OR lisburn OR "lisburn's" OR 
londonderry OR "londonderry's" OR derry OR "derry's" OR newry OR "newry's")  
16 #11 OR #12 OR #13 OR #14 OR #15 
17 ALL ((Africa OR Americas OR Antarctic OR arctic OR Asia OR Australia OR Oceania) AND NOT Great Britain OR Europe) 
18 #16 AND NOT #17 
19 #10 AND #18 
20 INDEX(embase) 
21 #19 AND #20 
22 Results limited manually to 2012-2016 
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An Assessment of Data from Routine Sources Applied to a 
Randomised Controlled Trial 
Information Leaflet 
 
 
We would like to invite you to take part in a research study. Before you decide we would like 
you to understand why the research is being done and what it would involve.  
This information leaflet will introduce the study. Please contact us to discuss any questions 
you may have or clarify anything that is not clear.  
 
What is the purpose of the study? 
All new medical treatments need to be studied to see how they compare to standard 
treatments for intended benefits and risks of side effects. The Study of Standard and New 
Antiepileptic Drugs (SANAD II) is an example of a medical study in which people with newly 
diagnosed epilepsy are given different treatments and followed over time to see which 
treatment is best.  
In studies such as SANAD II the way in which we measure benefits and side effects of 
treatment can be time-consuming for participants and expensive. For example, participants 
may be asked to come back to hospital for a clinic appointment, be telephoned by the study 
team or asked to fill in questionnaires.  
We plan to find out whether information routinely collected by the NHS and other 
organisations in the UK can be used to assess the benefits and side effects of treatments for 
epilepsy. When any patient attends their GP or hospital, information regarding this visit is 
recorded on NHS computers forming your electronic medical record. These records are 
stored securely but shared between a number of organisations to inform your care and the 
wider functions of the NHS. In this research study we will compare the information collected 
during the SANAD II study with information recorded in your GP and hospital electronic 
medical records. This will help us assess if routinely recorded information from electronic 
medical records is useful when measuring the effects of the different treatments in the 
SANAD II study.  
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Why have I been invited to take part in this study? 
We would like to invite you to participate in this study as you are currently taking part in 
SANAD II. 
 
What will happen during the study? 
If you are willing to take part in this study, we ask that you complete and return the 
attached consent form. Following this, you would not be asked to do anything else.  
The study team will then retrieve information from your GP and hospital electronic medical 
records. The time period covered will be the date you entered SANAD II until the most 
recently available date. We will not be obtaining information for any time you are not taking 
part in SANAD II or retrieving information from your electronic medical records on an 
ongoing basis in the future. We will extract information on only one occasion.   
We will assess if information from your electronic medical records can accurately measure 
seizures, possible side effects of treatment, hospital attendances and admissions and other 
factors relevant to patients with epilepsy. We will compare the information from electronic 
medical records to the information obtained in SANAD II to see if it is useful. In order to 
provide a thorough assessment of information in electronic medical records we will retrieve 
all of the information that may be relevant to SANAD II. This information is collected 
routinely in both GP and hospital electronic medical records for all patients in the UK and 
includes:  
- Clinical Information such as details about any hospital attendances and admissions, 
results of tests, other medical conditions you may have or treatments that are 
prescribed 
- Information about Patients’ such as your age and lifestyle factors 
- Administrative Information such as waiting times, details of any hospital referrals 
and methods of admission 
- Geographical Information such as details about where you are treated and the area 
where you live  
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For Patients in England:  
The study team will retrieve information from your electronic medical records from:  
- The Health and Social Care Information Centre (www.hscic.gov.uk)   
Who collect information in electronic medical records about your hospital care 
(Hospital Episode Statistics) recorded by hospital care providers via The Secondary 
Uses Service, on behalf of the NHS 
- For patients’ living in the North West of England, your General Practice Surgery 
Who record information in electronic medical records about your GP care on behalf 
of the NHS 
The study team will retrieve information from your hospital electronic medical records from 
the Hospital Episode Statistics recorded by The Health and Social Care Information Centre 
for the time period you have been taking part in SANAD II.   
For patients living in the North West of England, the study team are working with North 
West EHealth (www.nweh.org.uk) an organisation sponsored by Salford Royal NHS Hospital, 
Salford Clinical Commissioning Group and the University of Manchester. North West 
EHealth, on behalf of the study team will approach your GP to retrieve information from 
your GP electronic medical records and retrieve information from your hospital electronic 
medical records from the Secondary Uses Service for the time period you have been taking 
part in SANAD II.   
To retrieve your electronic medical records, information to identify you, including your 
name, date of birth, NHS Number and SANAD II Study Number will be securely transferred 
to The Health and Social Care Information Centre. For patients living in the North West of 
England, your details will also be securely transferred to the Secondary Uses Service and 
North West EHealth.     
For Patients in Wales:  
The study team will retrieve information from your electronic medical records from:  
- The Secure Anonymised Information Linkage (SAIL) Databank 
(www.saildatabank.com) an organisation based in Swansea University and funded by 
the Welsh government to make GP and hospital electronic medical records 
accessible for research  
SAIL holds information from electronic medical records provided by the The NHS Wales 
Informatics Service (www.wales.nhs.uk/nwis), who record information about your GP and 
hospital care on behalf of the NHS. All information held by SAIL is de-identified, meaning 
SAIL will not know the identity of individuals.      
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To allow the study team to obtain information from electronic medical records in 
identifiable form for this study, your name, date of birth, NHS Number and SANAD II Study 
Number will be securely transferred to The NHS Wales Informatics Service who then 
transfer your SAIL Code Number and the SANAD II Study Number to SAIL. This allows SAIL to 
securely transfer your electronic medical records to the study team, identified by SANAD II 
Study Number, without knowing the identity of individuals.    
For All Patients: 
Information from your GP and hospital electronic medical records will be securely 
transferred to the University of Liverpool using an encrypted electronic transfer system.  
Your electronic medical records will be stored on secure University of Liverpool computer 
servers which meet NHS data security standards. The SANAD II data team will receive the 
electronic medical records and then link all the information collected about you from your 
GP and hospital electronic medical records and information collected about you for the 
SANAD II study. Information from your electronic medical records will then be compared to 
the information collected about you for the SANAD II study. The SANAD II data team will 
remove your identifying details (name, date of birth, address, NHS Number) from your 
medical records before the members of the study team who will be making this comparison 
have access to the information.     
Data protection and security is of paramount importance and all information collected 
about you during this study will be used in accordance with the Data Protection Act 1998. 
Personally identifiable information collected for this study will be deleted by 31/12/18, 
within 12 months of study completion. All of the organisations involved in this study have 
established systems in place for securely retrieving and transferring information from 
electronic medical records for research.   
If you would like to discuss any aspect of this study with the research team, we would be 
pleased if you would contact us on the details listed below.  
 
What are the possible disadvantages of taking part in this study? 
There are no significant, direct disadvantages or risks to participants during this study. 
This study involves the collection of information from your electronic medical records that 
can identify you (personally identifiable information). As with all research studies, data 
security and confidentiality is of paramount importance and will be protected at all times, 
meeting NHS data security standards.    
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What are the possible benefits of taking part in this study? 
There are no expected significant, direct benefits to the participants of this study.  
However, the information collected from electronic medical records may be found to 
contribute to the information collected as part of the SANAD II study and inform the 
analyses at the end of the SANAD II study.      
What if there is a problem during the study?  
If you have any questions or concerns about any aspect of this study, we would encourage 
you to contact the study team. Should you wish to submit a formal complaint, we 
recommend following the NHS Complaints Procedure. Details can be obtained from the NHS 
Patient Advice and Liaison Services:  
PALS Office, The Walton Centre for Neurology and Neurosurgery NHS Trust  
Liverpool 
L9 7LJ 
Telephone: 0151 529 6100 
 
The University of Liverpool is the sponsor for this study and the professional indemnity 
insurance will apply as appropriate. If you are harmed by taking part in this research study, 
there are no special compensation arrangements in place. If harm occurs to you and is due 
to someone’s negligence, you may have grounds for legal action for compensation against 
the treating NHS Trust or Hospital. 
Will my taking part in this study be kept confidential? 
Yes, data security and confidentiality will be protected throughout the study. Only 
authorised members of the study team and authorised persons directly supporting the 
study from The Health and Social Care Information Centre and Secondary Uses Service, 
NorthWest EHealth, NHS Wales Informatics Service and The Secure Anonymised Information 
Linkage Databank will have access to information from your electronic medical records. 
Data protection and security is of paramount importance and all information collected 
about you during this study will be used in accordance with the Data Protection Act 1998. 
What will happen to the results of this study?  
We hope to present the results of this study at academic conferences and publish in the 
medical and scientific literature in order to inform other researchers of our findings and 
help them perform medical studies more efficiently. Your confidentiality will be ensured at 
all times and individual participants will not be identified in any presentation or publication.  
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What will happen if I don’t want to carry on with this study? 
Taking part in this study is voluntary. You may decide not to take part, or after an original 
decision to take part you may decide to withdraw from the study. You do not have to give a 
reason and it will not affect your participation in SANAD II or the standard of medical care 
you receive now or in the future.   
If you initially decide to take part and then change your mind in the future no more 
information from your electronic medical records will be collected. All information collected 
up until this time will be included in the study unless you specifically request that it is not 
included. If you decide in the future you would not like to continue with the study we would 
ask that you contact the study team using the contact details provided below.  
Who is performing this study? 
This study is funded by the Medical Research Council Hubs for Trials Methodology Research 
(www.methodologyhubs.mrc.ac.uk/research), a governmental body aiming to improve the 
way in which medical studies are performed to benefit patients, the public and researchers. 
The research is being led by the University of Liverpool and The Walton Centre NHS 
Foundation Trust, by the same research team that are leading the SANAD II study.  
Who has reviewed this study? 
The aims, methods and ethics of this study have been reviewed and approved by the Health 
Research Authority and The North of Scotland Research Ethics Committee.   
Contact Details 
For further information about the study, please contact the principal researcher:  
Dr Graham Powell 
The Department of Molecular and Clinical Pharmacology 
University of Liverpool 
Telephone: 0151 529 5464 
 
Thank you for taking the time to read this information leaflet. 
If you would be willing to take part in this study, please complete the consent form and 
return to the research team in the enclosed pre-paid, addressed envelope.  
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An Assessment of Data from Routine Sources Applied to a Randomised 
Controlled Trial: Consent Form 
If you are willing to take part in this study, please consider each statement below and sign 
with your initials. Please return one copy of the consent form in the enclosed pre-paid, 
addressed envelope and keep one copy for your records.     
I confirm I have read and understood the information leaflet (version 2.7, dated 28/01/16), had 
the opportunity to ask questions and if asked, had them answered satisfactorily. 
Please Initial: 
 
 
I understand that my taking part is voluntary and that I am free to withdraw from the study at any 
time without giving a reason and without my care or legal rights being affected. 
Please Initial: 
 
 
I understand and give permission for personally identifiable information relevant to this study to 
be collected from my GP and hospital electronic medical records held by my General Practice and 
held and maintained by The Health and Social Care Information Centre, Secondary Uses Service 
and The NHS Wales Informatics Service for the time I have been taking part in SANAD II. I give 
permission for the secure transfer of my name, date of birth and NHS Number to allow 
information from my electronic medical records to be collected.  
Please Initial: 
 
 
I understand and give permission for authorised persons from The Secure Anonymised 
Information Linkage Databank, North West E-Health and the study team at the University of 
Liverpool to access information collected from my GP and hospital electronic medical records 
where it is relevant to taking part in this study.   
Please Initial: 
 
 
I understand and give permission for members of the SANAD II study team in the University of 
Liverpool to link information from my GP and hospital electronic medical records and information 
collected during SANAD II. I give permission for the secure electronic transfer of information in my 
electronic medical records to the University of Liverpool.  
Please Initial: 
 
 
I agree to take part in this study.    Please Initial: 
 
 
 
Name:              
Date of Birth:          
Signature:   
           
Date:           
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Table D.1: Summary of Key Application Milestones 
Routine Data Source Summary of Key Application Milestones Cost Structure  
NHS Digital August 2015: First request to review Participant Information Sheet (PIS) and Consent Form. Directed by enquiries desk to a member 
of the Data Access Request Service (DARS) and subsequently reportedly forwarded to the Information Governance Team.  
4th November 2015: No feedback received. Second request to review PIS and Consent Form. Forwarded by enquiries desk to Data 
Access and Information Sharing Team (DAIS).   
23rd November 2015: No feedback received. Third request. PIS and Consent Form discussed with a member of the DARS Team in 
person at a NHS Digital Engagement Event. Informed that a full application would be required in order for NHS Digital to provide 
feedback on the PIS and Consent Form. This was completed and submitted on 26th November.  
7th December 2015: Response regarding PIS and Consent Form following a further email. Informative and useful teleconference with 
a member of the DARS Team, informing development of the PIS / Consent Form.  
22nd December 2015: Feedback received via email form the DAIS Team, in response to the second request on 4th November. 
Subsequent teleconference arranged to discuss. Useful feedback received, largely in agreement with that received from the DARS 
Team on the 7th December. 
25th January 2016: Final review requested from DARS Team prior to ethics and governance application, prompt feedback received.  
8th February 2016: NHS Digital requested completion of a new application using the existing application process. 
29th February 2016: Submission of full application.  
1st March 2016: Informed via automated email that there will be a 2 week suspension of applications whilst the system is updated.  
March 2016: Enquires desk contacted on multiple occasions, repeatedly reassured that application has been accepted.  
18th April 2016: First formal acknowledgment of submission of application. NHS Digital advised that they are no longer accepting 
applications using the previous system and the DARS Online Portal application must be used.   
22nd April 2016: Third full application submitted, via DARS Online portal. 
28th April 2016: Application acknowledged.  
16th May 2016: Review at ‘pre-DAAG’ meeting. Recommended for full review at DAAG meeting. 
24th May 2016: DAAG meeting. Recommended for approval once caveats addressed. 
26th May 2016: Caveats addressed, application updated and re-submitted to NHS Digital. 
7th June 2016: DAAG Approved. Data Sharing Agreement provided.  
13th July 2016: Hospital Episode Statistics (HES) data available for download. 
Standard cost recovery 
structure applied: 
 
£1000 New application 
£900 Release fee 
£500 3 year agreement 
£300 Per dataset per year 
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The Secure Anonymised 
Information Linkage 
Databank 
(SAIL) 
22nd April 2015: First contact regarding application process and association with ADRN. Prompt response confirming a single ADRN 
application would also include access to SAIL datasets if required.  
June 2015: Request for information regarding application process. Teleconference arranged. Request by SAIL for protocol to inform 
scoping procedure. 
7th July 2015: SAIL protocol submitted, specific points clarified by SAIL.   
August 2015: Request to review PIS and Consent Form. Forwarded to Information Governance officer for review.  
September 2015: Response from Information Governance Officer with feedback on PIS and Consent Form. Scoping document 
received and verified.  
October 2015: Further advice requested and received regarding PIS / Consent Form. 
January 2016: Final review of PIS / Consent Form requested following alterations required for the other organisations, received.  
February 2016: Submission of full application. 
March 2016: Feedback received regarding application following internal review, alterations suggested prior to submission for formal 
review. Re-emailed with alterations.  
April 2016: Application re-submitted for formal IGRP review.  
21st July 2016: IGRP Approved.  
August 2016: SAIL data available for download.   
Standard cost recovery 
structure applied: 
 
£500 Base cost 
£291 Data transfer to SAIL 
£1455 Individual level data 
processing 
£500 Data transfer 
The Clinical Practice 
Research Network 
(CPRD) 
November 2014: First request regarding feasibility of the study, response received broadly confirming feasibility. 
August 2015: Further contact regarding feasibility and quote. Estimated quote received. Informed by CPRD that the Confidentiality 
Advisory Group and Ethical approvals need to be updated to permit identifiable, linked data release and the timelines to resolve 
these are unclear. Furthermore, informed that compliance with NHS Digital’s governance framework needs to be approved. No 
further contact as the issues with linked data release, cost and population coverage make CPRD unfeasible for this study.  
Standard cost recovery 
structure applied: 
 
£7500 CPRD GOLD for 
<1000 patients 
£4250 Linked HES inpatient 
£850 Linked HES Outpatient 
£3-5000 Extraction, 
specification, assurance 
QResearch | 
The Health Improvement 
Network (THIN) Database |  
ResearchOne 
September 2015: All organisations contacted via email or telephone call. Confirmed that data is de-identified only, with no facility to 
re-identify patients as would be needed for this study. Data sources are therefore not feasible for inclusion in this study.   
N/A 
NorthWest eHealth October 2015: First contact regarding study. Telephone call to discuss the study outline and confirm feasibility in principle. 
November 2015: Correspondence via email to request review of the updated protocol and PIS / Consent Form. Further 
correspondence to determine the methodology, refine the protocol and determine provisional costings. Advice also provided on PIS 
/ Consent Form. Face to face meeting at the end of November clarified the methodological details. All feedback and correspondence 
prompt and detailed.  
December 2016: Correspondence via email and telephone discussion with Apollo regarding the development of the data query to 
allow the extraction of data. Response received confirming the existing data query can be used for GP practices in Salford already 
holding a data sharing agreement with NWEH.   
January 2016: Final review of PIS / Consent Form requested and received.  
May 2016: <5 participants consented to inclusion in the study are registered in eligible GP practices, therefore accessing data 
through NWEH is not cost effective for this study.   
Bespoke NWEH costing: 
£11027 Data handling 
£1575 Data check 
£1326 Project manager 
 
Apollo Medical costing: 
£7200 Data query 
development 
 
CK Aspire costing: 
£6800 GP Recruitment 
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The Driver and Vehicle 
Licensing Agency 
(DVLA) 
October 2014: Multiple points of contact (emails and telephone calls) regarding the feasibility of accessing DVLA data for this study. 
No response received. 
February 2015: Following discussion with a member of a DVLA expert committee, a DVLA medical advisor was contacted. The study 
was discussed with the DVLA Data Sharing Team and the response indicated that the DVLA would not have the capacity to assist 
with the study and the data security requirements are ‘over and above the NHS or University’.   
N/A 
The Department for Work 
and Pensions  
(DWP) 
 
HM Revenue and Customs 
(HMRC) 
November 2014: First contact via email regarding feasibility of accessing DWP and HMRC data for this study. The email was 
forwarded to the DWP External Data Sharing and Advice Centre. 
December 2014: External Data Sharing Advice Centre responded. Data access directly with the DWP or HMRC would not be possible 
and my query should be redirected to the ADRN.  
N/A 
The Administrative Data 
Research Network 
(ADRN) 
December 2014: First contact via email regarding feasibility for this study. No response received. 
Feb 2015: Following a telephone call and further email acknowledgement of the query was received. General guidance provided via 
email and telephone conference arranged.  
March 2015: Teleconference to discuss the study. ADRN confirmed that the study is eligible for their service and they can request 
access to DWP / HMRC linked to clinical datasets such as HES provided by NHS Digital. They would begin contacting the relevant 
data sources. 
April 2015: Further teleconference, no significant progress. 
May 2015: Further teleconference, HMRC have declined participation, DWP remains pending. I was informed that if the DWP do not 
permit access to their data I cannot apply through the ADRN solely for clinical datasets and independent applications must be 
submitted to the relevant organisations.  
July 2015: Informed via email that the DWP have not been forthcoming but negotiations are on-going and they are unlikely to have 
a confirmed response until September. They provided no further feedback.  
N/A 
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Abstract 
Background: In the UK, routinely recorded data may benefit prospective studies including randomised controlled 
trials (RCTs). In an on-going study, we aim to assess the feasibility of access and agreement of routinely recorded 
clinical and non-clinical data compared to data collected during a RCT using standard prospective methods. This 
paper will summarise available UK routinely recorded data sources and discuss our experience with the feasibility of 
accessing routinely recorded data for participants of a RCT before finally proposing recommendations for improving 
the access and implementation of routinely recorded data in RCTs. 
Methods: Setting: the case study RCT is the Standard and New Antiepileptic Drugs II (SANAD II) trial, a pragmatic, UK, 
multicentre, phase IV RCT assessing the clinical and cost-effectiveness of antiepileptic drug treatments for newly 
diagnosed epilepsy. 
Participants: 98 participants have provided written consent to permit the request of routinely recorded data. 
Study procedures: routinely recorded clinical and non-clinical data were identified and data requested through 
formal applications from available data holders for the duration that participants have been recruited into SANAD II. 
The feasibility of accessing routinely recorded data during a RCT is assessed and recommendations for improving 
access proposed. 
Results: Secondary-care clinical and socioeconomic data is recorded on a national basis and can be accessed, 
although there are limitations in the application process. Primary-care data are recorded by a number of 
organisations on a de-identified basis but access for specific individuals has not been feasible. Access to data 
recorded by non-clinical sources, including The Department for Work and Pensions and The Driving and Vehicle 
Licensing Agency, was not successful. 
Conclusions: Recommendations discussed include further research to assess the attributes of routinely recorded 
data, an assessment of public perceptions and the development of strategies to collaboratively improve access to 
routinely recorded data for research. 
Trial registration: International Standard Randomised Controlled Trials, ISRCTN30294119. Registered on 3 July 2012. 
EudraCT No: 2012-001884-64. Registered on 9 May 2012. 
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Background 
There is a plethora of individual-level, routinely re- corded 
data in the UK. These data are recorded to fulfil specific, 
defined purposes and are regulated for security, 
confidentiality and disclosure by The Data  Protection Act 
1998 [1] and The Freedom of Information Act 2000 [2]. 
Access to routinely recorded data for ‘secondary purposes’, 
such as clinical research, is permitted provid- ing that there 
is demonstrable secondary benefit. 
The potential for routinely recorded data to inform clinical 
research and Health Technology Assessment (HTA) has 
long been recognised [3]. Presently, there are a number of 
sources of routinely recorded primary and secondary-care 
clinical data with regional or national coverage. However, 
limitations with accuracy of coding, confidentiality, 
ownership and data access have been previously identified 
as significant barriers to using rou- tinely recorded data in 
research [4]. 
There are numerous examples of retrospective, observa- 
tional, record-linkage population studies where routine 
sources have proved a valid and efficient method for 
providing data for clinical  research  [5].  In  the  context of 
prospective research, such as randomised controlled trials 
(RCTs), routinely  recorded  data  have  been  used to 
inform judgements about the feasibility of sample size and 
recruitment targets [6] and measuring participant 
outcomes [3, 7]. Pragmatic cluster RCTs have been co- 
ordinated through routine data sources including pa- tient 
recruitment,  randomisation,  and   administration of 
intervention and trial assessments, such as  through the 
Clinical Practice Research Datalink (CPRD)  [8]. The 
majority of RCTs incur costs as clinicians assess 
participants, record outcomes and complete Case Report 
Forms – hence, using routinely recorded data may provide 
an efficient alternative method for data collection in 
addition to reducing the burden on participants. Further- 
more, data from non-clinical routine sources may inform 
outcomes beyond the standard RCT assessments of clinical 
efficacy and effectiveness. For example,  cost data (such as 
use of health care resources) and socio- economic data 
(such as employment and means-tested benefits data) may 
inform health  economic  analyses  and the assessment of 
the broader societal impact of health care interventions. 
The potential benefits of using routinely recorded data in 
clinical research have resulted in a political drive to 
increase implementation, detailed in The Plan for Growth 
[9] and The NHS Constitution [10], where research is pre- 
sented as a core activity making the link explicit between 
the provision of NHS services and research. Consequently, 
initiatives, such as the Administrative Data Research Net- 
work [11], have been established to provide a method of 
access to individual-level data, linking clinical and non- 
clinical sources of routinely recorded data. 
The objective of this paper is to review  relevant sources of 
routinely recorded data for England, Scotland and Wales 
and to discuss our experience with the feasi- bility of 
accessing individual-level data for a subgroup of 
participants enrolled into a RCT before finally proposing 
recommendations for improving the access and imple- 
mentation of routinely collected data in RCTs. This is an 
on-going study and in a future publication we aim to as- 
sess the agreement of routinely recorded data compared to 
paired data collected in a RCT using standard pro- spective 
methods. 
 
Methods 
The case study RCT is the Standard and New Antiepi- 
leptic Drugs (SANAD) II trial. SANAD II is a pragmatic, 
UK, multicentre, phase IV RCT funded by the National 
Institute for Health Research (NIHR) Health Technology 
Assessment (HTA) programme, assessing the clinical  and 
cost-effectiveness of a number of antiepileptic drugs as 
first-line treatments for newly diagnosed epilepsy. Data for 
clinical outcomes, including seizure freedom and adverse 
events, are recorded on Case Report Forms by the treating 
clinical team during outpatient appointments. Data to 
inform cost-effectiveness analyses, including health care 
resource use and quality of life, are re- corded through 
participant completion of questionnaires. SANAD II is 
currently recruiting and is expected to report in 2019. 
Following research ethics and governance approvals, 470 
participants enrolled in SANAD II were invited to provide 
written consent to permit the request of routinely recorded 
data for the duration of their participation in SANAD II. 
Ninety-eight (20.9%) participants provided consent and 
were included in the study. Relevant sources of routinely 
recorded data were identified and detailed scoping 
discussions ensued. Subsequently, where access- ible, 
routinely recorded data for participants recruited into 
SANAD II were requested through formal applications. The 
routinely recorded data sources included in this study are as 
follows: 
 
● Clinical routine data sources: secondary care: 
◦ The Health and Social Care Information Centre 
(HSCIC) 
◦ The NHS Wales Informatics Service (NWIS) 
◦ The NHS National Services Scotland; Information 
Services Division (ISD) 
● Clinical routine data sources: primary care: 
◦ The Clinical Practice Research Datalink (CPRD) 
◦ ResearchOne 
◦ QResearch 
◦ The Health Improvement Network (THIN) 
database 
◦ North West eHealth (NWEH) 
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● Non-clinical routine data sources: 
◦ The Office for National Statistics (ONS) 
◦ HM Revenue and Customs (HMRC) 
◦ The Department for Work and Pensions (DWP) 
◦ The Driver and Vehicle Licensing Authority 
(DVLA) 
● ‘Linked’ routine data sources: 
◦ The Secure Anonymised Information Linkage 
(SAIL) databank 
◦ The Administrative Data Research Network 
(ADRN) 
 
In a future publication, the agreement between routinely 
recorded data and data collected using standard prospect- 
ive methods will be assessed for baseline variables such as 
gender, age and date of first seizure, and for outcome mea- 
sures relevant to SANAD II such as time to 12-month 
remission from seizures. To assess agreement between 
paired continuous data, Bland-Altman methods will be 
employed. Acceptable clinical limits of agreement for each 
variable or SANAD II outcome will be specified a priori 
and compared to the 95% confidence limits of agreement. 
To assess agreement between paired, nominal categorical 
datasets, cross tabulations will be constructed followed by 
calculation of Cohen’s Kappa. 
 
Results 
Clinical routine data sources: secondary care 
Electronic medical records of patients’ use of secondary- care 
services in the UK are routinely managed on a national basis. 
A number of public service organisations provide na- tional 
information, data and IT systems for commissioners, analysts 
and clinicians in health and  social  care.  Data are recorded 
to inform patient care, provide the data for remuneration for 
hospital trusts and are subsequently used to monitor and 
improve clinical services through clinical research. Table 1 
summarises the data sources where access to individual-
level data is possible. 
 
Clinical routine data sources: primary care 
Electronic medical records of patients’ use of primary- care 
services in the UK are recorded routinely by the general 
practitioner to inform patient care and remuner- ation, but 
are not currently available for clinical research on a 
national basis. A number of organisations represent 
collaborations between governmental bodies or academic 
institutions and providers of primary-care IT systems. Ac- 
cess on a regional basis is possible through a number of 
data sources summarised in Table 2. 
 
Non-clinical routine data sources 
Non-clinical, individual-level data are routinely recorded 
by a number of UK governmental departments for a var- 
iety of indications. Selected organisations record data that 
 
Table 1 Example sources of routinely recorded secondary-care 
data 
 
 
The Health and Social Care Information Centre (HSCIC) [21] 
Data access for clinical research: 
The Data Access Request Service provides a method of access to a 
number of routinely collected datasets for England. Hospital Episode 
Statistics (HES) provides clinical, health and socioeconomic data for all 
secondary-care attendances in England. Datasets include Accident and 
Emergency, Admitted Patient, Outpatient, Adult Critical Care, Maternity and 
selected Patient Reported Outcome Measures. 
Previous experience in clinical research: 
HES data have been accessed for retrospective linkage studies [22] and 
to provide data for prospective studies; for example, estimation of 
health care resource use or measuring outcomes such as long-term 
mortality [23] 
The NHS Wales Informatics Service (NWIS) [24] 
Data access for clinical research: 
Data access can be facilitated through The Public Health Wales Observatory. 
The Patient Episode Database for Wales (PEDW) provides clinical, health and 
socioeconomic data for all secondary-care attendances in Wales and is 
broadly comparable to the Admitted Patient HES dataset, with data 
regarding elective and emergency admissions and maternity care 
recorded. Additional datasets of relevance to this study include the 
Emergency Department and Outpatient Datasets. Previous 
experience in clinical research: 
PEDW data have been accessed for retrospective analyses; for example, 
analysis of the incidence of obstetric complication rates [25] 
The NHS National Services Scotland; Information Services Division (ISD) [26] 
Data access for clinical research: 
The electronic Data Research and Innovation Service (eDRIS) provides a 
method of access to ISD datasets including Outpatient, General Acute/ 
Inpatient, Emergency Department, Unscheduled Care, GP Out of Hours and 
The Prescribing Information System. Clinical, health and socioeconomic 
data are recorded and datasets are largely comparable to HSCIC HES. 
Previous experience in clinical research: 
ISD data have been accessed for retrospective linkage studies; for 
example, analysis of the incidence of gastrointestinal bleeding and 
complications including mortality [27] 
 
 
 
 
would be informative to prospective clinical research in 
epilepsy and other diseases, summarised in Table 3. 
 
‘Linked’ routine data sources 
In order to provide a ‘complete’ dataset of the informa- tion 
required to meet research objectives, data from a number of 
organisations may need to be accessed. This   is typically 
accomplished by linking data sources using identifiers such 
as patients’ name, date of birth, National Insurance number 
or NHS number. In response to the growing recognition of 
the potential of routinely re- corded data, initiatives have 
been established to assist with the provision of linked, de-
identified, aggregate data between data sources: 
 
● The Secure Anonymised Information Linkage (SAIL) 
Databank is an initiative developed by Swansea 
University and funded by the Welsh  Government. 
SAIL provides a method of access to individual-level, 
routinely recorded, de-identified electronic data for 
patients across Wales  to  support  research  [12]. 
Access to clinical datasets provided by NWIS is 
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Table 2 Example sources of routinely recorded primary-care data 
 
 
The Clinical Practice Research Datalink (CPRD) [28] 
Data access for clinical research: 
CPRD is a governmental research service jointly funded by the NHS 
National Institute for Health Research and the Medicines and Healthcare 
products Regulatory Agency. Following approval by the Independent 
Scientific Advisory Committee, CPRD provides access to de-identified pri- 
mary-care clinical, health and socioeconomic data for a geographically rep- 
resentative 13 million patients in England for health care research. 
Previous experience in clinical research: 
CPRD data have been used in retrospective studies for estimating health 
care resource use, prescription medicines and clinical outcomes [22]. 
Gulliford conducted two cluster-randomised trials using CPRD: one aimed to 
reduce inappropriate antibiotic prescribing for acute respiratory 
infection; the other aimed to increase physician adherence with 
secondary prevention interventions after first stroke [8] 
ResearchOne [29] 
Data access for clinical research: 
ResearchOne is a collaboration between The University of Leeds and 
The Phoenix Partnership (TTP), developers of the SystmOne clinical 
database and IT system. De-identified clinical, health and socioeconomic 
data are available from primary, secondary and out-of-hours care settings 
for approximately 26 million patients in the UK. 
Previous experience in clinical research: 
ResearchOne data have been used in public health surveillance studies, 
retrospective studies [29] and, currently, in combination with CPRD data 
to measure the outcomes of a cluster RCT [30] 
QResearch [31] 
Data access for clinical research: 
QResearch is a collaboration between The University of Nottingham and 
the developers of the EMIS IT systems. De-identified clinical, health and 
socioeconomic data are available for approximately 18 million patents in 
the UK. 
Previous experience in clinical research: 
QResearch data have been used to measure clinical outcomes in 
case-control and cohort studies [32] 
The Health Improvement Network (THIN) Database [33] 
Data access for clinical research: 
THIN is a collaboration between IMS Health and In Practice Systems, 
developers of the IT software Vision. De-identified clinical, health and so- 
cioeconomic data are available for approximately 11.1 million patients in 
the UK. 
Previous experience in clinical research: 
THIN data have been accessed to measure clinical outcomes in cohort 
and case-control studies [34] 
North West eHealth (NWEH) [35] 
Data access for clinical research: 
NWEH is a collaboration between The University of Manchester, Salford 
Royal Foundation Trust and Salford Clinical Commissioning Group. 
NWEH has developed the methodology and governance framework to 
implement the Salford Integrated Record, an integrated primary- and 
secondary-care electronic medical record, into research as part of the 
Salford Lung Study [14]. The infrastructure permits access to secondary- 
care electronic medical records accessed through the HSCIC Secondary 
Uses Service. With participant and GP practice enrolment and consent, 
the Apollo [36] and Graphnet [37] data-extraction tools are employed to 
extract participant primary-care electronic medical records that can then 
be linked to data regarding secondary care. North West eHealth is unique 
in that data are not de-identified and, therefore, participant consent is 
required. Furthermore, GP practice enrolment and consent is required 
to permit the installation of third-party software on their systems and 
subsequent extraction of data. 
Previous experience in clinical research: 
NWEH offers a number of primary-care research tools including a 
randomised controlled trial (RCT) recruitment feasibility assessment, but 
does not currently routinely provide a bespoke primary-care 
data-extraction service for research. However, the methodology for 
this process has been demonstrated [14] 
 
 
 
Table 3 Example sources of routinely recorded non-clinical data 
 
 
The Office for National Statistics (ONS) [38] 
Data access for clinical research: 
The ONS records individual-level mortality data and aggregate economic and 
societal statistics that may inform clinical and health economic 
analyses. Mortality data can be requested through application to the 
HSCIC DARS. Aggregate data can be accessed via services provided by 
ONS such as NOMIS [39] and Data for Neighbourhoods and Regeneration 
[40]. The smallest reported level is the Lower Layer Super Output Area 
(LSOA) consisting of a population of 1000–3000. 
Previous experience in clinical research: 
ONS mortality data have been accessed to measure mortality in 
retrospective and prospective studies [23] 
HM Revenue and Customs (HMRC) [41] 
Data access for clinical research: 
HMRC is the UK’s national tax authority and responsible for taxation 
including National Insurance and student loan repayments and the 
administration of tax credits, child benefit and statutory sick and maternity 
pay. Individual-level data on employment and tax contributions are 
recorded and likely to inform health and socioeconomic analyses. The 
HMRC Datalab provides a means to access de-identified, aggregate 
HMRC data for research. An application, once ‘approved researcher’ 
status has been gained, must benefit the listed functions of the HMRC. 
Previous experience in clinical research: 
There was no evidence of individual-level, HMRC data being accessed 
for clinical research in a scoping search performed in MEDLINE via OVID 
The Department for Work and Pensions (DWP) [42] 
Data access for clinical research: 
The DWP is responsible for welfare including the provision of state 
pensions, benefits and child maintenance. Individual-level data regarding 
employment and welfare are likely to inform health and socioeconomic 
analyses and de-identified, aggregate data are available for social research. 
Previous Experience in Clinical Research: 
There was no evidence of individual-level, DWP data being accessed for 
clinical research in a scoping search performed in MEDLINE via OVID 
The Driver and Vehicle Licensing Authority (DVLA) [43] 
Data access for clinical research: 
The DVLA is responsible for the licensing of drivers and vehicles in the 
UK and issuing, reviewing and maintaining guidance regarding driving 
licence status in the context of medical diagnoses. The legal 
requirement for driving licence holders to inform the DVLA of the 
occurrence of seizures and, subsequently, to regain normal driving 
privileges after a specified period of seizure freedom raises the 
possibility of DVLA providing an accurate data source to inform the 
clinical outcome measures in epilepsy research. 
Previous experience in clinical research: 
The DVLA publish limited de-identified, aggregate datasets for research, 
usually involving driving restrictions. There was no evidence of individ- 
ual-level, DVLA data being accessed for clinical research in a scoping search 
performed in MEDLINE via OVID 
 
 
 
complemented with numerous non-clinical 
administrative datasets including births, deaths and 
demographic data. Following the scoping process a formal 
application is submitted to the Information Governance 
Review Panel before access to data is 
granted. SAIL data have been accessed to measure clinical 
outcomes in retrospective research [13] 
● The Administrative Data Research Network (ADRN) 
is a UK-wide partnership between universities, 
government departments, national statistics 
authorities, funders and researchers, funded by the 
Economic and Social Research Council. ADRN provides a 
method of access to a number of 
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non-clinical administrative routine datasets in- cluding 
employment, socioeconomic, crime and 
education data [11] in addition to clinical datasets 
detailed previously such as those recorded by HSCIC. 
Following development of a project proposal a formal 
application is reviewed by the Approvals Panel before 
access to data is granted 
 
Challenges and feasibility of access 
We have requested access to routinely recorded data for 
individuals enrolled in the SANAD II RCT, resident in 
England and Wales, who have provided written consent. 
There were insufficient participants meeting the eligibility 
criteria resident in Scotland. Data sources were identified 
and scoping discussions informed the initial assess- ment 
of feasibility. Data sources were deemed feasible  if 
individual-level data could be provided for specified 
individuals providing consent. Resources required in- 
cluding cost and researcher time were also factors im- 
portant in the assessment of feasibility. Including the 
preparation, research ethics and governance approval and 
submission of the applications for data access, sig- 
nificant researcher time and a period  of 18  months were 
required. The feasibility, timeline and key mile- stones 
involved for each data  source are  summarised  in Table 
4. 
 
Clinical routine data sources 
Routinely recorded secondary-care data can be requested 
on an individual-level, identifiable basis for patients in 
England and Wales through HSCIC and NWIS, accessed 
through SAIL and in our experience this process is feas- 
ible as part of a RCT, yet there are notable limitations. In 
England, HSCIC has set a target time to data access of sixty 
working days following submission for a complex ap- 
plication, involving bespoke data linkage from multiple 
datasets. From the date of submission of the Data Access 
Request Service online application, we have been granted 
access to the data within this timeframe. However, this 
positive experience following submission of the applica- 
tion is countered by limitations in the pre-application 
process. Acknowledging the significant update to online 
application and approval procedures that occurred during 
this period, there remains a considerable period of time 
required in the development of the application. The na- ture 
of the request for identifiable data necessitated participant 
consent as the valid legal basis. HSCIC re- quire ethical 
and governance approval to be in  place  prior to DARS 
review and to prevent future amendments and delays, it was 
rational to ensure the consent materials had been reviewed 
by the HSCIC’s Information Govern- ance Team, prior to 
submitting the documents for ethical and governance 
approval. HSCIC provide written guid- ance regarding the 
consent materials and advise that 
 
documents should be reviewed. However, in our experi- 
ence there is no formalised process for providing this 
review. Following significant correspondence the con- sent 
materials were reviewed by the Data Access and 
Information Sharing Team. However, this feedback was 
provided following a formal submission and review by the 
Data Access Request Service. Formalising the process for 
the review of consent materials would likely improve the 
time and resource efficiency for both HSCIC and the 
researcher. 
For participants in Wales, we have requested secondary- 
care data and, for a proportion of participants, primary- care 
data through SAIL databank. SAIL provided a streamlined 
pre-application service, including  engaging in multiple 
discussions and completion of a scoping document 
outlining the study methods and costs in- volved. Consent 
materials were also promptly reviewed by a member of 
the Information Governance Team. 
Common to both sources of secondary-care, routinely 
recorded data; there are stringent information govern- ance 
requirements that must be in place prior to appli- cation. 
These include information security measures and 
assessments, specific inclusion regarding the ‘processing of 
health care data for the subjects of research’ in the in- 
stitutional Data Protection Act registration and, in  the case 
of HSCIC, an institutional Data Sharing Framework 
Contract. Adequate guidance is provided by the data 
sources and, if not addressed by the researcher, may cause 
delay. Furthermore, there is a time lag of approxi- mately 
3–6 months before data become available within each data 
source. This delay potentially limits the utility of such 
sources in prospective clinical research, such as drug trials, 
where prompt reporting is clinically import- ant and a 
regulatory requirement. 
Routinely recorded primary-care data for specific par- 
ticipants in England are less accessible. The majority of 
providers of primary-care data, such  as  ResearchOne and 
QResearch, provide data on a de-identified  basis  with no 
facility to re-identify individuals. Therefore, where specific 
participants need to be identified, as for RCTs such as 
SANAD II, these sources are not applicable. Fol- lowing 
our correspondence, CPRD confirmed it may be possible to 
retrieve identifiable individual-level data linked to HSCIC 
data in the future, but the required approvals were not in 
place and the timescale to resolution was un- clear. 
Furthermore, such primary-care sources provide data for 
only a proportion of the population and can be expensive. 
North West eHealth employs an alternative method- 
ology whereby primary-care data are extracted directly 
from the GP through a third party. This process requires 
participant and GP consent and installation of the re- 
quired software but is an effective data-extraction method 
[14]. NWEH offers a number of primary-care research 
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Table 4 Summary of key application milestones 
Routine data source Summary of key application milestones Cost structure 
The Health and Social Care Information Centre 
(HSCIC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Secure Anonymised Information Linkage 
Databank (SAIL) 
August 2015: first request to review Participant Information 
Sheet (PIS) and Consent Form. Sent by enquiries desk to 
the Data Access Request Service (DARS) 
4 November 2015: second request to review PIS and 
Consent Form. Sent by enquiries desk to Data Access and 
Information Sharing Team (DAIS) 
23 November 2015: no feedback yet received. PIS and 
Consent Form discussed with a member of the DARS 
team in person at a HSCIC engagement event. Informed 
that a full, formal application would be required in order 
for HSCIC to provide feedback on the PIS and Consent 
Form. This was completed and submitted on 26 November 
7 December 2015: response regarding PIS and Consent 
Form. Informative teleconference with a member of the 
DARS team 
22 December 2015: response from the DAIS team in 
response to the second request on 4 November 2015. 
Teleconference provided feedback, in agreement with that 
received from the DARS team on 7 December 
29 February 2016: as directed by HSCIC, submission of a 
new formal application using the existing application 
process 
18 April 2016: formal acknowledgment of submission. 
Requested to submit the application via the DARS Online 
Portal 
22 April 2016: formal application submitted via DARS 
Online Portal 
24 May 2016: Data Access Advisory Group (DAAG) review. 
Caveats to be addressed before approval 
26 May 2016: caveats addressed, application updated and 
re-submitted 
13 July 2016: DAAG approved. Hospital Episode Statistics 
(HES) data available for download 
22 April 2015: first contact regarding application process 
and association with the Administrative Data Research 
Network (ADRN) 
June 2015: informative teleconference regarding the SAIL 
application process and scoping procedure 
7 July 2015: protocol regarding methods specific to SAIL 
submitted 
August 2015: request to review PIS and Consent Form. 
Sent to information governance officer for review 
September 2015: feedback on PIS and Consent Form from 
information governance officer. Scoping document issued 
by SAIL 
January 2016: final review of PIS/Consent Form requested 
following revisions required for the other data sources 
February 2016: submission of full, formal application 
March 2016: feedback received following internal review 
with amendments suggested 
April 2016: application re-submitted for formal Information 
Governance Review Panel (IGRP) review, outcome pending 
Standard cost recovery structure applied: 
£1000 new application 
£900 release fee 
£500 3-year agreement 
£300 per dataset per year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Standard cost recovery structure applied: 
£500 base cost 
£291 data transfer to SAIL 
£1455 individual-level data processing 
£500 data transfer 
The Clinical Practice Research Network (CPRD) November 2014: first contact regarding feasibility of the 
study, response received broadly confirming feasibility August 2015: following protocol development, 
further contact regarding feasibility. Informed by CPRD that the Confidentiality Advisory Group and 
ethical approvals with HSCIC need to be updated to permit identifiable, linked data release and the 
timelines to resolve these are unclear. Furthermore, informed that compliance with HSCIC’s 
governance framework needs to be approved. No further contact as the issues with linked data release, 
cost and population coverage make CPRD not feasible for inclusion in this study 
Standard cost recovery structure applied: 
£7500 CPRD GOLD for <1000 patients 
£4250 linked HES inpatient 
£850 linked HES outpatient 
£3000–5000 extraction, specification, 
assurance 
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Table 4 Summary of key application milestones (Continued) 
QResearch | ResearchOne 
The Health Improvement Network (THIN) 
Database 
September 2015: all organisations contacted. Confirmed 
that data are de-identified only, with no facility to 
 
re-identify patients as would be needed for this study. 
Data sources are, therefore, not feasible for inclusion in 
this study 
N/A 
North West eHealth October 2015: first contact, the service is not routinely 
offered but feasibility of the process broadly confirmed November 2015: correspondence via email to 
request review of the protocol, PIS and Consent Form, confirm the methodology and determine provisional 
costings. Further discussion during a face-to-face meeting at NWEH December 2016: discussion 
with the third party, Apollo Medical Software Solutions, regarding the development of the data query to 
permit the extraction of data. Response received confirming the structure of the existing data query 
can be used for GP practices in Salford already holding a data-sharing agreement with NWEH, but a 
bespoke query would be required for this study 
January 2016: final review of PIS/Consent Form requested and received 
May 2016: < participants consented to inclusion in the study are registered in eligible GP practices; 
therefore, accessing data through NWEH is not feasible for this study 
Bespoke NWEH costing: 
£11027 data handling 
£1575 data check £1326 project manager 
Apollo Medical costing: 
£7200 data query development 
CK Aspire costing: 
£6800 GP recruitment 
The Driver and Vehicle Licensing Agency 
(DVLA) 
 
 
 
 
 
 
 
The Department for Work and Pensions (DWP) 
HM Revenue and Customs (HMRC) 
 
 
 
 
 
The Administrative Data Research Network 
(ADRN) 
October 2014: multiple attempts at contact to discuss the 
feasibility of the study, including telephone calls and email 
correspondence. No response received 
February 2015: following discussion with a member of a 
DVLA expert committee, the DVLA medical advisor was 
contacted. The study was discussed with the DVLA data- 
sharing team and the response indicated that the DVLA 
would not have the capacity to assist with the study and 
the data-security requirements are ‘over and above the 
NHS or university’ 
November 2014: first contact regarding feasibility of 
accessing DWP and HMRC data for this study. Request 
transferred to the DWP External Data Sharing and 
Advice Centre 
December 2014: External Data Sharing Advice Centre 
responded. Data access directly with the DWP or HMRC 
would not be possible and my request should be 
redirected to ADRN 
December 2014: first contact regarding feasibility for this 
study. No response received 
Feb 2015: further contact regarding feasibility of the study. 
General information provided via email 
March 2015: informative teleconference to discuss the 
study. ADRN confirmed that the study is eligible for their 
service and they can request access to the DWP/HMRC 
linked to clinical datasets, such as HES, provided by HSCIC. 
They agreed to contact the relevant data sources to 
determine the feasibility 
April 2015: further teleconference, no significant progress 
May 2015: further teleconference, HMRC have declined 
participation, the DWP remains pending. I am informed 
that if the DWP does not permit access to its data I cannot 
apply through ADRN solely for clinical datasets and 
independent applications must be submitted to the 
relevant organisations such as HSCIC 
July 2015: informed that the DWP have not been 
forthcoming but negotiations are on-going and they are 
unlikely to have a confirmed response until September. No 
further feedback received 
N/A 
 
 
 
 
 
 
 
 
N/A 
 
 
 
 
 
 
N/A 
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tools for the wider research community but does not 
currently routinely provide a bespoke primary-care data- 
extraction service for research. 
 
Non-clinical routine data sources 
Aggregate economic and societal statistics, provided by 
Lower Layer Super Output Area (LSOA), can be accessed 
through the ONS and are in the public domain. Such data 
may have additional benefits to the analyses of health and 
socioeconomic outcomes in RCTs. Individual-level, eco- 
nomic data from sources such as the DWP and HMRC 
would likely be informative to prospective clinical research 
as such data are often poorly or incompletely recorded 
using standard methods [15]. However, relevant to this 
study, there is no previous evidence of access to DWP    or 
HMRC individual-level or aggregate data for clinical 
research. 
During scoping discussions with DWP and HMRC, we 
were directed to ADRN but this network has not been 
successful in negotiating data access. 
Finally, the outcomes of selected clinical studies may be 
measured using DVLA data. However, the DVLA de- 
clined the request for access, citing insufficient internal 
resources to process the request and more stringent data 
protection requirements than those employed in the NHS 
or academic institutions, without providing explicit 
details regarding these requirements. 
 
Discussion 
Routinely recorded data are valid for use in retrospective 
clinical research [3, 4] and have the potential to be used in 
prospective research including measuring the outcomes of 
RCTs [7] and providing additional benefits such as a 
method to address missing RCT data. Limitations, specif- 
ically with respect to accuracy and access have been recog- 
nised for some time. Academic, political [9] and health 
service [10] interest in UK sources of routinely recorded 
data has resulted in expansion and improvements, notably 
in the access to linked datasets. However, our experience 
with accessing individual-level data for specific partici- 
pants providing written consent, to inform the outcomes of 
a RCT, highlights persisting limitations. 
Clinical routine data  sources are numerous and there   is 
comprehensive national coverage of secondary-care data. In 
our experience, accessing individual-level data is feasible. 
However, inefficiencies in the application pro- cesses 
persist, particularly during the informal ‘pre-appli- cation’ 
phase. The notable limitation encountered was obtaining 
feedback on the Patient Information Sheet and Consent 
Form prior to ethical and governance review. Formalising 
an explicit review process for consent materials would 
improve the efficiency for both the data holders and the 
research team. 
 
Table 5 Recommendations to improve access to routinely 
recorded data for research 
 
 
General 
Routinely recorded data are being used to measure randomised 
controlled trial (RCT) outcomes with the agreement, additional benefits 
and cost-efficiency of such data compared to data recorded through 
standard RCT methods being unknown 
Further research should be performed to assess the agreement, additional 
benefits and cost-efficiency of accessing routinely recorded data to measure 
RCT outcomes compared to data collected through standard RCT methods 
The costs required for data access from routine data sources vary 
widely, although all reportedly operate on a cost recovery, not-for-profit 
basis 
Costs should be standardised and rationalised between routine data 
sources 
The time lag before data are available in routine data sources represents a 
significant limitation to the access of routinely recorded data for 
prospective research, including RCTs 
The infrastructure and procedures should be developed to reduce the time 
lag seen in routinely recorded data sources 
The requirement for linkage between sources of routinely recorded data 
has been observed and improvements are on-going; for example, with 
the establishment of the Administrative Data Research Network (ADRN) A 
standardised set of identifying variables could be recorded by all (clinical and 
non-clinical) data sources to improve the accuracy of data linkage, similar 
to a Core Outcome Set for clinical trials [44] 
The public mistrust in the sharing and linking of routinely recorded data 
will hamper future efforts to develop routinely recorded databases, 
despite the likely benefits to individual patients and the population 
Further research and public engagement should be undertaken to define 
the issues of most importance to the public and develop strategies to 
address these 
Clinical routine data sources 
There are numerous requirements prior to application, and criteria to 
fulfil on submission, of an application, yet the guidance and support 
during development of an application remains limited 
Formalise and improve access to guidance and review of study materials 
during the ‘pre-application stage’ 
There is national coverage of routinely recorded secondary-care data, 
yet primary-care coverage remains patchy, based on geographical area 
or GP IT system 
Develop the primary-care data sources to provide national coverage, either 
through collaboration of existing sources and data linkage or development 
of national data sources, such as the General Practice Extraction Service 
Non-clinical routine data sources 
Access to non-clinical data sources to inform clinical research was not 
possible during this study, despite the significant potential to inform 
Health Technology Assessment and the increasing importance of such 
assessments in a health care system where resources are increasingly 
limited 
To assist with Health Technology Assessment, and particularly the analysis 
of health economic outcomes, urgent research is required to consider 
facilitating access to individual-level, identifiable data from non-clinical 
sources. This would include: 
1. Research regarding the public perception and acceptability of using their 
personal economic data for clinical research 
2. Internal review within non-clinical sources, such as the DWP and HMRC, 
to assess the feasibility and limitations of permitting access to data for 
clinical research 
3. Formalisation of the approval processes through the independent party, 
the ADRN for access to non-clinical administrative data – currently, following 
internal approval the ADRN then negotiates access to administrative data on 
a project-by-project basis 
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Access to routinely recorded, individual-level, primary- 
care data has not been feasible. Each primary-care data 
source has limited geographical coverage, often based on 
GP IT systems, which usually process de-identified data 
and may incur significant expense. The  inception  of the 
HSCIC General Practice Extraction Service, which 
records primary-care data nationally for England, rep- 
resents the most optimistic national source; however, 
access is currently restricted to Department of Health 
initiatives such as research involving screening proce- 
dures [16]. 
The access to non-clinical data sources for clinical re- 
search has not been possible. ADRN has been estab- lished 
to act on behalf of the researcher in negotiating access to 
de-identified, linked, routinely recorded data from a 
number of organisations and the study proposal was 
promptly directed to ADRN. However, the decision 
whether to release data remains with the data holder. 
Ideologically, the next step would be the storage of de- 
identified linked data from participating organisations in a 
single repository, similar to those established for RCT data 
[17]. This would create a single point of access and remove 
the burden for each organisation  to  consider each study 
individually. This would, however, require significant 
information governance and security barriers to be cleared 
and, in light of recent developments within the research 
climate, individual consent. Including pa- tients as 
stakeholders in the development of such data sources is 
essential [18]. 
Although there are examples of pragmatic RCTs being 
coordinated through routine data sources [8], there are 
likely to be limitations when accessing routinely recorded 
data to measure the outcomes of RCTs. Quality assurance is 
unclear and the level of agreement of routinely recorded 
data with data recorded through standard RCT methods 
remains uncertain, particularly when measuring clinical 
outcomes. The time delay before routinely recorded data 
become available may have implications for RCTs where 
prompt reporting is both clinically important and a regula- 
tory requirement. Furthermore the pre-application and 
application process may introduce further delays. This will 
have implications for RCTs relying on routinely recorded 
data. The cost-efficiency of accessing routinely recorded 
data, compared to standard methods, is unclear. Further 
research is required to assess the agreement, additional 
benefits and cost-efficiency of routinely recorded data 
compared to data collected through standard RCT methods; 
it may be in the additional benefits, such as addressing 
missing RCT data, where routinely recorded data is most 
useful. 
 
Conclusions 
The failure of access to routinely recorded data for a 
purpose, such as this study with clear secondary benefit 
 
to clinical research methodology, seems inappropriate when 
the ‘public purse’ funds the research, the re- searcher and 
the public body holding the data. Perhaps a significant 
cause or contributor to the current limita-  tions is the 
Care.Data initiative in 2014. The proposal to extract 
primary-care records from all patients was op- posed 
publicly by a number of groups and, for example, resulted 
in an internal inquiry within HSCIC. Data appli- cations 
were suspended during this period and  our current 
experience may be explained by the concurrent revision of 
the HSCIC application and approval proce- dures. 
However, in the medium term, of more  concern   is the 
harm in public perception that resulted. Currently, more 
than 1.2 million individuals in the UK have sub- mitted a 
‘Type 2 objection’, meaning that their data will not be shared 
for purposes other than direct care [19]. Although the 
application procedures may improve,  and  in time we may 
be able to access data more  efficiently, the loss of 2.2% of 
the population’s data will have impli- cations for the 
routinely recorded data that will then be made available for 
research. Involving patients as im- portant stakeholders and 
re-gaining their trust will be an essential factor in realising 
the individual and population health care benefits of 
routinely recorded data [20]. 
 
Recommendations 
We propose recommendations to improve access and 
implementation of routinely recorded data during a RCT, 
summarised in Table 5. 
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